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Abstract 
Background: Cardiovascular diseases (CVDs) are the leading cause of disability 
and mortality globally. Although there has been substantial medical advancement 
in treating and managing CVDs, surviving CVD patients are at a greater risk of 
mortality and morbidity. Thus, preventative approaches aiming to identify, 
manage and control CVD risk factors remain the highest priority.  
Depression is a leading cause of disability worldwide, and it has been considered 
a relevant emergent, non-classical risk factor for the onset and poor prognosis of 
CVDs. Several systematic reviews have been published on this subject, providing 
evidence that depression is associated with an increased risk of CVD incidence. 
However, these reviews were limited by incorporating poor study designs and by 
focusing predominantly on a single CVD outcome. This previously fragmented 
investigation masked the overall picture of how strongly depression impacts each 
CVD subtype. 
At the same time, hypertension is one of the biggest risk factors for CVD; hence, 
the management and control of hypertension is of the utmost importance. 
Hypertensive patients mainly rely on antihypertensive treatment with a high 
dosage regimen and/or a combination of several antihypertensive drugs for the 
long term to control blood pressure and to consequently prevent the development 
or complication of CVD. Emerging evidence has investigated the effect of 
antihypertensive drugs in relation to depression onset, though the exact 
relationship remains unclear. Given that both hypertension and depression are risk 
factors for CVD, it becomes important that therapeutic agents to control blood 
pressure not have deleterious effects toward triggering depressive disorders, as 
both conditions will have a relevant big impact on patient’s health particularly 
those at high CVD risk. Objectives: This thesis has two main objectives: (1) 
updating the evidence of the association between depression and the risk of major 
subtypes of CVDs and (2) to investigate the association between exposure to 
antihypertensive drugs and risk of depression incident. 
Method: For the first objective, I conducted a systematic review and meta-
analyses. Depression in the review referred to depressive symptoms or clinical 
depression and main outcomes of interest were incidence of fatal/non-fatal 
coronary heart diseases (CHD), heart failure (HF) and stroke, each measured as a 
single endpoint and reported as hazard ratio (HR) and 95% confidence interval (CI). 
The results for the systematic review were divided into three main results 
chapters based on the main outcomes (4-6). For the second objective, a secondary 
analysis of existing data held in the Glasgow Blood Pressure Clinic (GBPC) was 
conducted. Exposure was antihypertensive drugs which involves the five major 
classes including calcium channel blocker (CCB), beta-blocker (BB), angiotensin 
converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) and 
thiazide diuretic (TZD). The primary outcome was depression as indicated by the 
first prescription of antidepressants drug. Main findings of this analysis are 
presented in chapter 7. 
Results: Chapter 4 evaluated the relation between depression and risk of stroke. 
The meta-analysis included 19 studies enrolling 3,154,290 participants, with an 
average follow-up of 11.2 years. The pooled estimated risk revealed that baseline 
depression is associated with a 22% (HR = 1.22, 95% CI, 1.11-1.33) increased risk 
of developing first-ever stroke, with evidence of substantial statistical 
heterogeneity between studies (I2 = 67%). The magnitude of risk presented in this 
study is more modest than that previously reported in past systematic reviews for 
stroke outcomes. Sensitivity analyses were carried out to assess for a possible 
reverse causality (i.e. depression manifested as an acute sickness response to a 
subclinical stroke). This was achieved by restricting the analysis to four studies 
that considered a lag period, excluding stroke events occurring during the first 
years of follow-up. The results showed that depression remains a statistically 
strong predictor of stroke incidents with a more pronounced effect, and a wider 
95% CI was obtained, which might indicate uncertainty (HR = 1.39, 95% CI, 1.11, 
1.74). The statistical positive association remained significant after further 
restricting the analysis to five studies that measured depression over multiple 
instants over the follow-up period and modelled depression as a time-varying 
exposure (HR = 1.33, 95% CI, 1.10, 1.59). This finding suggests that elevated 
lifetime depressive symptoms among adults can be used as a reliable measure to 
predict future risk of stroke; however, due to the limited number of studies 
included to derive these findings, the result should be considered with caution 
and more work is required to confirm this finding. Subgroup analysis was also 
performed, and the findings showed that depressed elderly participants aged 65 
years or above were at a lower risk of developing stroke than depressed 
participants at a younger age (< 65 years). However, the group difference showed 
only a borderline significance (p = .5). The results of this analysis may indicate 
that depression occurring at an early age might have a more devastating effect 
than late-life depression, though this finding should be considered with caution 
given the good heart health condition of elderly patients at baseline. Future 
epidemiological studies should be carried out on a large-scale to identify the 
clinical characteristics of participants that make them more prone to developing 
depression at an early age. 
Chapter 5 examined the association between depression and incident CHD. The 
meta-analysis incorporated 23 studies with 33,786299 participants and an average 
follow-up of 12.4 years. The pooled summary effect showed that the risk of CHD 
incident increased with depression by 22% (HR= 1.22, 95% CI, 1.13-1.32, p < .000) 
with evidence of substantial statistical heterogeneity between studies (I2 = 77%). 
The estimated risk presented in this study is almost identical to the latest review. 
This study also found that depression is associated with a 24% higher risk of 
developing myocardial infarction (HR = 1.24, 95% CI, 1.19, 1.29) with no evidence 
of statistical heterogeneity between studies (I2 = 0%). Sensitivity analyses 
comprising five cohort studies that considered a lag period provided similar risk 
estimates (HR = 1.22, 95% CI, 1.01, 1.48). Five studies modelled depression as a 
time varying exposure; a meta-analysis of these studies revealed an increased risk 
of incident CHD for depression, though a slightly lower magnitude was observed 
(HR = 1.17, 95% CI, 1.07, 1.28). Subgroup analysis by type of depression measures 
showed that the effect of clinical depression is more pronounced (HR = 1.26, 95% 
CI, 1.20, 1.32; I2 = 0%) than depressive symptoms (HR = 1.17, 95% CI, 1.10, 1.25; 
I2 = 0%) on risk of CHD incidence. 
In Chapter 6, I investigated the association between depression and incident HF 
in a CVD-free population. The meta-analysis was based on only four cohort studies 
with 2,200,308 participants and an average follow-up of 10.13 years. The main 
finding revealed that depression was associated with a 17% (HR = 1.17, 95% CI, 
1.08, 1.38) increased risk of HF in the absence of CVD events at baseline, with no 
statistically significant amount of heterogeneity (I2 = 0%). 
The hypothesis of a dose-response relation was also assessed. Overall, this review 
identified 12 cohort studies that assessed a dose-response relation between 
depression and CVD outcomes. For stroke outcomes, four studies suggested a dose-
response relation, and two did not confirm this finding (chapter 4). For CHD 
events, four studies showed no evidence of a dose-response relation and four 
found that depression increased the risk of CHD incident in a dose-response 
manner (chapter 5). Importantly, there was substantial heterogeneity in terms of 
how the studies defined ‘a dose of depression’, which seriously hampered the 
meta-analysis and drawing of conclusions. Future studies should establish 
guidance for researchers on the optimal measures of ‘a dose of depression’ to 
investigate such a relation. 
Chapter 7 covered the investigation of the association between antihypertensive 
drugs and the risk of incident depression. This was a retrospective cohort study in 
which I analysed data of hypertensive patients attending the GBPC, providing 
secondary and tertiary care service, between January 2005 and March 2013. All 
patients aged between 18 and 80 years who were newly commenced on 
antihypertensive drugs were included in this cohort. Exposure to ACEI, ARB, BB, 
CCB, and diuretics was assessed. Patients were prospectively followed up to the 
outcome, death, or end of the study. Depression as an outcome in this cohort was 
defined as patients who filled at least two prescriptions of antidepressants during 
the study period. Two analyses were performed. The first analysis was on patients 
who were on antihypertensive monotherapy. Eligible patients had no known 
history of depression and were on an antihypertensive monotherapy of the same 
drug class within a 12-month window defined as the exposure period. Patients who 
died or developed the outcome during the exposure period were excluded. The 
association between antihypertensive drug classes and depression incidence was 
investigated using Cox proportional hazards models to estimate HR, and patients 
who received ACEI therapy were set as the reference group. In this analysis, a 
dose-response relationship was also investigated, whereby the cumulative defined 
daily dose (cDDD) of antihypertensives during the exposure period was stratified 
into tertiles and the lowest tertile was set as the reference group. The second 
analysis was on patients who were either on antihypertensive monotherapy or 
polytherapy. In this analysis, eligible patients had an exposure period of 6 months 
preceded by 6 months of no antihypertensive or antidepressant prescription 
records. Patients who developed the outcome or died within the six months of the 
exposure period were excluded. Studied antihypertensive drug classes were 
additionally included alpha-blocker and centrally acting antihypertensive drugs. 
CCB and diuretic classes were divided into dihydropyridine CCB and non-
dihydropyridine CCB, diuretics, and mineralocorticoids diuretic, correspondingly. 
Both Cox proportional hazards models and the generalised estimating equation 
(GEE) were used to investigate the association between antihypertensive drugs 
and incident depression. The reference group in this analysis was also patients on 
ACEI therapy. Findings of the monotherapy analysis showed that, among the five 
major classes of antihypertensive drugs, CCB had the highest risk of developing 
depression after adjusting for covariates, compared to the ACEI group (HR = 1.39; 
95% CI: 1.07, 1.82). Consistence results derived from the polytherapy analysis 
showed that dihydropyridine CCB was associated with a significantly increased risk 
of incident depression in comparison to ACEI (HR = 1.38; 95% CI: 1.03, 1.86). The 
GEE analysis further confirmed this finding (OR = 1.32 95% CI: 1.06, 1.64). The 
dose-response analysis demonstrated that higher cDDD of ARB was associated with 
a greater risk of depression, although the association was marginally significant (p 
= 0.055). Conclusion: This thesis provided evidence that depression imposes a 
similar level of risk across different CVD subtypes. Future epidemiological studies 
should examine the dynamic aspects of depressive symptoms in relation to CVD 
and subclinical CVD, whether the risk of CVD is related to a specific subtype of 
depression, and the role of antidepressant drugs in this association. 
The present thesis showed that among population with complicated hypertension, 
CCB is associated with an increased risk of depression incidence compared to ACEI, 
supporting findings of previous studies. The risk of developing depression is also 
linked to ARB, although it might be dose dependent. A well-designed randomised 
control trial is the optimal study design to validate these findings, and up to that 
time when a clear association is established, these medications should continue 
to be used as recommended by the current guidelines for hypertension treatment 
and CVD prevention. 
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 Depression and Cardiovascular diseases (CVD) 
 CVD definition and prevalence 
According to the World health organsiation (WHO), CVD is a general term for a 
group of diseases affecting the heart and blood vessels, which refers to coronary 
heart diseases (CHD), stroke and trainset ischemic attack (TIA), heart failure (HF), 
peripheral vascular disease (PVD), rheumatic heart diseases, congenital heart 
diseases and deep vein thrombosis and pulmonary embolism (WHO, 2017a) 
CVD is the leading cause of death worldwide, accounting for more than 17 million 
deaths in 2016, which corresponded to 31% of all global deaths (WHO, 2017a). This 
figure is expected to increase to more than 23.6 million by 2030 (AHA, 2015), 
meaning CVDs are projected to remain the single largest cause of death 
worldwide. Among the different types of CVD, CHD and all forms of stroke are the 
main cause of death, and one-third of these deaths occur prematurely in people 
under the age of 70. The risk of CVD is not limited to mortality; it can also cause 
severe disabilities, particularly among patients who survived a stroke or a 
myocardial infarction (MI) event.  
 Depression definition and prevalence 
The definition of depression relies on identifying several symptoms that form a 
syndrome causing functional impairment (Malhi and Mann, 2018). Key symptoms 
that are relatively specific to depression include anhedonia and depressed mood. 
Other symptoms involve cognitive and somatic symptoms (Figure 1-1). However, 
it should be noted that, none of the symptoms are pathognomonic of depression, 
and do feature in other psychiatric and medical illnesses. For example, somatic 
symptoms including fatigue, appetite disturbance and sleep disturbance are very 
common in other medical illness. The two main classificatory diagnostic systems 
used to diagnose clinical depression are the International Classification of Diseases 
(ICD) and the Diagnostic and Statistical Manual of Mental Disorders (DSM), but the 
DSM is widely used for research. In order to qualify as major depressive disorder 
(MDD) based on the DSM, an individual should be presented with five or more 
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depressive symptoms including anhedonia and depressed mood, for nearly every 
day during a 2-week period. Depressive symptoms that do not meet the above 
criteria often regarded as subthreshold depressive symptoms, which could serve 
as early indicator of a major depressive episode. A depressive episode can be also 
described in a greater depth using a specifier which defines the pattern of the 
illness (e.g. a single or a recurrent episode), the severity (e.g. mild, moderate or 
severe), time of onset (e.g. early, late life or postpartum) and whether it has 
remitted. 
Based on the spectrum view of mood disorders, there is no distinct qualitative 
differences between MDD and mild episode of sadness. Instead, they lie along a 
continuum of depressive states. The only exception is melancholic depression, 
which does seem to differ qualitatively from normal sadness in some respects. 
A recent epidemiological survey stated that more than 322 million people of all 
ages are living with depression, accounting for 4.4% of the global population 
(WHO, 2017b). Between 2005 and 2015, there was an 18.4% increase in the number 
of people living with depression, and by 2015, depressive disorders were the single 
largest contributor to nonfatal health loss globally (GBD 2015 Disease and Injury 
Incidence and Prevalence, 2016).  
The burden of depressive disorder extends far beyond the disorder. The WHO 
describes depression as a leading cause of disability worldwide and the major 
contributor to the overall global burden of diseases. Depression can become a 
serious health condition threatening patients’ life and quality of life. Evidence 
shows that depression increases risk of all-cause and specific-cause mortality, 
traumatic death and suicide in the general population, especially with long-lasting 
moderate to severe symptoms (Melhem et al., 2019). Cardiovascular mortality is 
the most common cause-specific mortality in depressed individuals after an initial 
cardiac or neurological event; this risk also relates to the severity of the 
depressive episode (Bartoli et al., 2018, May et al., 2017). 
 Identification of depression 
Accurate identification of depression is a crucial step for providing effective 
treatment for depressed patients. It has been recognised that general 
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practitioners (GPs) fail to make accurate diagnoses of depression. Studies have 
shown that about 50% of primary care cases of depression go undetected and 
therefore untreated (National Collaborating Centre for Mental Health, 2010b). 
However, it is more likely that mild to moderate symptoms go underdiagnosed 
compared to severe or clinically important symptoms (National Collaborating 
Centre for Mental Health, 2010b). Diagnosing depression is even more complicated 
in depressed patients suffering from other physical health conditions. One study 
reported a detection rate by GPs of 95% for patients with depression alone, but a 
much lower rate of 23% was reported for patients exhibiting depression alongside 
other physical health problems (Bridges and Goldberg, 1985). This low rate is 
mainly because it is difficult to distinguish somatic symptoms related to 
depression from those related to the physical health problem. Depressive 
symptoms can be categorised into somatic symptoms, such as fatigue, appetite 
disturbance and sleep disturbance, and non-somatic symptoms, which include 
affective and cognitive impairments (Figure 1-1). Previous studies have therefore 
suggested a simplified method of diagnosis criteria using only non-somatic 
symptoms to identify depression in patients with a physical condition to overcome 




Figure 1-1 Depressive symptoms dimensions 
Information modifie from (O’Shea et al., 2018) 
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Overall, evidence from the literature regarding depression and CVD can be 
summarised in three points: (1) depression and CVD are highly comorbid 
(Khandaker et al., 2019); (2) depression can increase CVD incidence (and vice 
versa), either directly or indirectly, by increasing the incidence of CVD classical 
risk factors, such as hypertension , obesity and diabetes; and (3) depression is a 
potential predictor of poor health prognosis in CVD patients. 
 Depression and CVD as comorbid diseases 
 Depression in CVD patients 
Patients with established CVD are at a higher risk of developing depression 
compared to the general population, and depression prevalence in CVD patients 
varies based on the type and severity of the CVD. Studies that have investigated 
the prevalence of depression in CHD patients reported considerably varied 
estimates. For example, Ziegelstein (2001) showed that approximately 15% to 20% 
of CHD patients have depression and up to two-thirds of MI patients experienced 
depressive symptoms during the index admission. Another study reported that up 
to 40% of CHD patients met the diagnostic criteria of MDD (Huffman et al., 2013). 
Among patients with PVD, the prevalence of depression was found to be up to 48% 
(Brostow et al., 2017). Regarding HF, data from two large meta-analyses showed 
an approximate prevalence of depression of 20%-30%, and this rate is similar across 
different HF aetiologies (Sbolli et al., 2020). Epidemiological studies investigating 
the prevalence of post-stroke depression have reported widely variable estimates 
ranging from 10% to 81%, though the occurrence of depression in stroke patients 
is more likely to relate to the level of functional disability after the stroke event 
(Vojtikiv-Samoilovska and Arsovska, 2018).  
 CVD in depressed patients  
Epidemiological and observational studies investigating the prevalence of CVD in 
depressed patients reported varied estimates of prevalence. For example, the 
results from the Medical Outcomes Study in a sample of outpatients with MDD or 
depressive symptoms showed that 5% of these patients were diagnosed with CHD 
and 4% reported having angina (Wells et al., 1989, Air et al., 2017). Another study 
reported a prevalence of 12% for CHD and 5% for HF in depressed patients (Lyness 
et al., 1993). Higher prevalence estimates were reported in a case-control study, 
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which found that 46.1% of patients suffering from recurrent depression also had 
CVD, compared with 13.9% in the control group (Topic et al., 2013). 
 Depression and risk of CVD incidence  
The association between depression and CVD has long been recognised. The 
impact of mental health on the pathogenesis of CVDs was first described by 
William Harvey in 1628. Harvey proposed that mental distress can negatively 
affect the heart and impair its function (Rumsfeld and Ho, 2005). However, this 
potential association was largely ignored until the 1930s, when an epidemiological 
study found that institutionalised psychiatric patients with melancholia had a 
mortality rate eight times higher than the general population and that heart 
diseases accounted for almost 40% of these deaths (Malzberg, 1937). Further 
support for this suggestion came from Dreyfuss and colleagues in the late 1960s. 
The authors found that depressed patients had a six times higher risk of MI 
compared to patients with other psychiatric diseases and, as depressive symptoms 
usually preceded the MI event, they concluded that depression may cause MI 
(Dreyfuss et al., 1969). Despite this early evidence, the interest in the role of 
depression in CVD only surged in the late 1980s, and since then, hundreds of 
prospective studies and reviews have been published. 
However, the inconsistent findings of prospective studies (Almas et al., 2015, 
Kyrou et al., 2017, van Marwijk et al., 2015, Penninx et al., 1998, Vinkers et al., 
2004) highlighted the need for an objective meta-analysis of this literature. 
Between 2002 and 2016, 10 meta-analyses were published, all of which identified 
depression as an independent risk factor for incidence of CVD (Van der Kooy et 
al., 2007) and CVD subtypes, including CHD (Rugulies, 2002, Wulsin and Singal, 
2003, Nicholson et al., 2006, Gan et al., 2014, Wu and Kling, 2016) and strokes 
(Pan et al., 2011b, Dong et al., 2012, Barlinn et al., 2015, Li et al., 2015a). As 
illustrated in Table 1-1Error! Reference source not found., the quantified risk of 
depression varied considerably across the studies, particularly those focused on 
CHD outcomes, which ranged from 20% to 90%. Meta-analysis of studies that 
assessed the risk of depression in relation to strokes reported an approximately 
stable risk estimated in the range of 40%-50% (Barlinn et al., 2015, Li et al., 2015a, 
Pan et al., 2011b, Van der Kooy et al., 2007), though one reported a lower risk 
(34%) (Dong et al., 2012). The meta-analysis conducted by Van der Kooy et al. 
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(2007) showed that depression was associated with a 57% increased risk of CVD in 
initially healthy individuals. A recent prospective cohort study reported a more 
modest effect of depression on overall CVD incident. Rajan et al. (2020) enrolled 
145,862 participants from 21 countries with different levels of economic 
development to identify the association between depression and incidences of 
CVD and all-cause mortality. Over a median follow-up of 9.3 years, they found 
that participants who had experienced at least four depressive symptoms before 
study entry had a 14% increased risk for a future CVD event (HR, 1.14; 95% CI 1.05-
1.24) compared to participants who had not. Their findings also showed that 
depression is associated with an increased risk of future MI (HR = 1.23; 95% CI 
1.10-1.37) but not stroke (HR = 1.05, 95% CI 0.91-1.21) or HF (HR = 1.09, 95% CI 
0.86-1.39). 
Depression may confer different degrees of risk for each CVD subtype. However, 
based on the previously conducted meta-analysis, the magnitude of risk for each 
CVD subtype cannot be determined with confidence for several reasons. First, 
early studies did not adjust properly for potential confounders, especially those 
that were proposed to be in the causal pathways between depression and CVD, 
which may have led to an overestimation of the estimated risk. This problem was 
first identified by Nicholson et al. (2006), who conducted a meta-analysis to 
estimate the risk between depression and CHD. Their findings showed that about 
50% of the eligible studies did not adjust for potential confounders. After 
stratifying the analysis based on the degree of confounder adjustment, they found 
a 12% lower risk of CHD in an adjusted risk estimate (RR = 1.90, 95% CI 1.49-2.42) 
compared with an unadjusted risk estimate (RR = 2.08, 95% CI 1.69–2.55). Another 
possible reason is that the majority of the previously conducted meta-analyses 
have not focused on CVD-free participants as the target population. Of the 10 
meta-analyses, only two considered excluding studies that enrolled patients with 
a previous history of CHD or stroke at baseline. Evidence shows that stroke 
patients are at a high risk of having another major vascular event, such as CHD 
(Amarenco and Steg, 2008). Observational studies and RCT suggest that the risk 
of having a second stroke decreases within the first two years following the first 
stroke event, whereas the risk of MI increases continuously over time (Amarenco 
and Steg, 2008, Vickrey et al., 2002). Likewise, CHD patients are at a higher risk 
of developing stroke than the general population (Matthews, 2006). Based on this 
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evidence, it is plausible to expect that the results from the majority of previous 
meta-analyses may be driven by the pre-existence of clinically apparent CVD, and 
it remains unclear whether depression can be considered a pre-morbid risk factor 
for stroke and/or CHD, which may also affect the magnitude of the true 
association between depression and CVD.  
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Excluding CVD at 
baseline (other than the 
outcome of interest) 
HR or RR (95% CI) of 
CVD 
(Rugulies, 2002) 1887-2000 
Prospective cohort 
studies 
11 CHD No 1.64 (1.29-2.08) 
(Wulsin and Singal, 2003) 1966-2000 
Prospective cohort 
studies 
10 CHD Yes 1.64 (1.41-1.90) 
(Nicholson et al., 2006) 1966–2003 
Prospective cohort 
studies 
11+ CHD No 1.90 (1.49-2.42) 




16 CHD No 1.48 (1.29, 1.69) 
16* CVD Yes 1.57 (1.36-1.81) 
10 Stroke No 1.43 (1.17-1.75) 
(Pan et al., 2011b) Up to 2011 
Prospective cohort 
studies 
24‡ Stroke No 1.44 (1.26–1.65) 
(Dong et al., 2012) Up to 2010 
Prospective cohort 
studies 
17 Stroke No 1.34 (1.17-1.52) 
(Gan et al., 2014) Up to 2014 
Prospective cohort 
studies 
30 CHD No 1.30 (1.22-1.40) 
(Barlinn et al., 2015) Up to 2014 
Prospective cohort 
studies 
15* Stroke Yes 1.43 (1.19-1.72) 
(Li et al., 2015a) Up to 2014 
Prospective cohort 
studies 
30‡ Stroke No 1.48 (1.30–1.67) 
(Wu and Kling, 2016) 1966-2015 
Prospective cohort 
studies 
19 CHD No 1.22 (1.13-1.32) 
CHD, coronary heart disease. CVD, cardiovascular disease. HR, hazard ratio. RR, relative risk. +studies with adjusted HR. *Included only those studies of 




 Common hypothesised pathways linking depression to CVD 
The mechanisms by which depression leads to CVD are most widely investigated 
in relation to CHD, but they are strikingly similar across other CVD subtypes Figure 
1-2 summarises the most common pathways proposed to explain the depression-
CVD relationship, which include neurohormonal and autonomic dysfunction, 
dysregulation of the immune system, coagulation abnormalities and vascular 
endothelial dysfunction, and behavioural mechanisms.. 
Neurohormonal and autonomic dysfunction caused by depression are associated 
with an overactivation of the hypothalamic pituitary adrenal (HPA) axis and 
sympathetic nervous system (SNS)(Huffman et al., 2013). Hyperactivation of the 
HPA axis triggers the hypersecretion of the adrenocorticotropic hormone (ACTH) 
and the subsequent elevation of cortisol and catecholamine plasma levels. Chronic 
elevated levels of cortisol or hypercortisolism increase the risk of the development 
and progression of metabolic syndrome which ultimately cause CVD. 
Hypercortisolism also mediates a sustained increase in the immune response 
mechanism. Further, it has been suggested that depression is associated with 
enhancing SNS activity, creating an autonomic imbalance between the SNS and 
the parasympathetic nervous system (PSN) activity. The result is an increase in 
heart rate, a vasoconstriction of blood vessels and event 
ually high blood pressure (BP). Additionally, hyperactivation of the SNS causes a 
reduction in baroreflex sensitivity response and heart rate variability (HRV), 
resulting in cardiac autonomic dysfunction and arrhythmia, which have a 
substantial role in HF pathology (Shi et al., 2017). 
Depression promotes increased levels of proinflammatory cytokines and reduced 
levels of anti-inflammatory cytokines in the immune mechanism, causing an 
insufficient control of the immune response (Baune et al., 2012). Proinflammatory 
cytokines, including interleukins (IL), such as IL-1, IL-2, IL-6, tumour necrosis 
factor (TNF-α) and C-reactive protein (CRP), have been linked to CVD. Prolonged 
activation of inflammatory mediators leads to oxidative stress and endothelial 
damage, which may accelerate and amplify the progression of atherosclerosis, 




Evidence from genetic studies showed that pleiotropic genes are likely to be 
shared with depression and CVD further expanded the possible biological pathways 
linking these two diseases. Amare et al. (2017) identified 24 overlapping genes 
between mood disorders and cardiometabolic disorders and linked them to 10 
molecular pathways encoded by these genes.  
While behavioural mechanisms can play an important role in mediating the CVD 
risk associated with depression, they do not on their own account for the link 
between the two disease entities (Stapelberg et al., 2011). Depressed patients are 
likely to adopt and maintain poor health behaviours, such as poor diet, smoking, 
low physical activity and poor medication adherence, placing them at a higher risk 







Figure 1-2 Pathways linking depression with CVD 
Figure modified from (Baune et al., 2012, Hare et al., 2014, Stapelberg et al., 2011). a) Behavioral mechanism. b) Inflammatory mechanism. c) 
and d) Autonomic dysfunction. Abbreviation: CRH, Corticotrophin releasing hormone; HTN, hypertension; HPA-axis; hypothalamic-pituitary-





 Antidepressants medication and risk of CVD 
Antidepressants is one of the first-line treatment for depression and it should be 
considered for treating patients showing moderate to severe depressive symptoms 
or those patients with mild symptoms but with a history of moderate or severe 
depression.  
When discussing the role of antidepressant medications, particularly in the 
context of CVD, it is important to determine whether (1) antidepressants are 
associated with an increased or reduced risk of CVD incidence in healthy 
individuals and (2) treating depressive symptoms with antidepressant medication 
can reduce the risk of poor health outcomes in CVD patients with depression. 
The major classes of antidepressants are tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine re-
uptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs). Of these 
classes, TCAs and MAOIs have fallen out of favour in clinical practice and are 
rather reserved for treating resistant depression cases mainly due to their side 
effects profile and safety concerns. TCA is known to cause cardiotoxicity through 
affecting normal cardiac contractility and HRV, which are linked to worsening CHD 
and sudden cardiac death. By contrast, SSRIs have shown to have a positive effect 
on specific pathophysiological disturbances whereby depression increases the risk 
of CVD. For example, SSRIs may inhibit platelet aggregation (Halperin and Reber, 
2007) which in turn reduces atherosclerosis risk and thrombotic events and 
eventually decreases the risk of CVD incidences. Several meta-analyses and 
observational studies have evaluated the association between antidepressant 
medication and CVD in healthy depressed patients. Hamer et al. (2011) conducted 
a prospective cohort study of 14,784 adults with no known history of CVD using 
data from the Scottish Health Survey. They showed that TCAs were associated 
with a 35% increased risk of CVD but not CHD incidences, but SSRIs were not 
associated with a greater CVD risk. These findings were confirmed by a later meta-
analysis of 16 observational studies enrolling CHD-free patients (Oh et al., 2014). 
The results from the study provided no evidence that TCAs and SSRIs are 
associated with an increased risk of CHD incidence in this population. More 
recently, Almuwaqqat et al. (2019) proposed that SSRIs are not superior to other 





patients with no previous CVD. The exact relation between different 
antidepressants drug classes and CVD incident remain to be established.  
The question of whether poor cardiac prognosis can be improved in depressed 
patients by treating depressive symptoms remains controversial. In the literature, 
the following three major randomised control trials (RCTs) attempted to answer 
this question: the Enhancing Recovery in CHD Patients (ENRICHD) trial (Berkman 
et al., 2003), the Myocardial Infarction and Depression–Intervention Trial (MIND-
IT) (van Melle et al., 2007) and the Sertraline Antidepressant Heart Attack 
Randomized Trial (SADHART)(Glassman et al., 2002b). In brief, the trials failed to 
detect any significant differences in cardiac outcomes between the 
antidepressant and control groups in cardiac patients. However, in a post-hoc 
subgroup analysis, findings from the ENRICHD trial demonstrated that patients 
who did not respond to antidepressant treatment were at higher risk for late 
mortality (over 29 months follow-up) than patients who responded, but that was 
only observed within the active treatment arm (Carney et al., 2004). A post-hoc 
subgroup analysis from the MIND-IT trial reached the same conclusion regrading 
poor prognosis in non-respondent depressed patients in relation to cardiac 
outcomes (either new cardiac event or cardiac mortality) (de Jonge et al., 2007). 
Similarly, a supplementary report from the SADHART trial showed that the failure 
to improve depression within the first six months after a cardiac event, in both 
the intervention and control arms, was significantly associated with all-cause 
mortality over 6.7 years of follow-up (Glassman et al., 2009). More encouraging 
findings had reported by recent studies. Kim et al. (2018), conducted an RCT 
among 300 patients with recent acute coronary syndrome and depression. Patients 
were assigned for either flexible doses of escitalopram or a placebo for 24 months 
and followed up for a median of 8.1 years. The primary outcome was major 
adverse cardiac events (MACE). For the first time, the findings from this RCT 
showed that escitalopram significantly reduced the risk of MACE (HR= 0.68, 95% 
CI 0.49–0.96, P-value= 0.03) over the follow-up duration; however, of the four 
secondary endpoints, the difference was significant only for the MI incidence (HR= 
0.54; 95% CI, 0.27-0.96; P = 0.04). With respect to the association between 
depression remission status and MACE incident, the study investigators further 





cardiac outcomes; they showed that the remitted group was at a significantly 
lower risk of developing MACE than the non-remitted group (Kim et al., 2018).  
 Cardiovascular medication and risk of depression: an 
overview 
A host of cardiovascular medication have been historically linked to 
neuropsychiatric disorders such as anxiety, mood syndromes, psychosis and 
cognitive disturbances. Some drugs had suggested to induce neuropsychiatric 
symptoms, while others may have anti-manic or anti-depressants activity 
(Huffman and Stern, 2007). In the following section I briefly summarised evidence 
of the most common cardiac medications suggested to have an effect on 
depression. These medications involve, antihypertensive drugs, lipid lowering 
agents, antiplatelets and cardiac glycoside.  
Perhaps the most extensively studied cardiovascular medications in relation to 
depression were the antihypertensive medications. There has been a long debate 
about the capacity of antihypertensive medications to produce depression as a 
side effect and more recently whether they can be repurposed as a new 
therapeutic agent to treat depression (Shaw et al., 2019). The relationship 
between the five major classes of antihypertensive drug including calcium channel 
blocker (CCB), beta-blocker (BB), renin angiotensin system (RAS) antagonist, 
thiazide diuretics (TZD) and risk for depression are described in section 1.2.5. 
Other antihypertensive agent that has been linked to depression is reserpine. 
Reserpine is an alkaloid extract from the root of Rauwolfia serpentine. In 1931, it 
was first described in Indian literature as an herbal remedy for insanity and 
hypertension, though it was not introduced to modern medicine until the mid-
1940s (Mashour et al., 1998). Between 1960s and 1990s several RCTs had 
conducted in western countries and consistently reported that reserpine is a 
powerful BP lowering agent when combined with other antihypertensive 
treatment including diuretics or diuretics and vasodilators (Zhu et al., 2019). 
Despite its effectiveness in lowering BP, the clinical uses of reserpine have been 
declined dramatically due to safety concerns. It has been linked to severe 
depression that resulted in suicide and hospital admission and other serious health 
problem such as breast cancer and gastric bleeding (Lavorato and Patten, 1999, 





Digoxin is a cardiac glycoside derived from the foxglove plant, Digitalis lanata. It 
has been used in the treatment of HF and as a rate control agent for atrial 
fibrillation and atrial flutter. In general, mental adverse effect of digoxin are very 
uncommon or rare (Celano et al., 2011). Few case reports and small trials had 
suggested a link between digoxin and depression, however, larger prospective 
trials have not supported a strong association between digoxin and the 
development of depression (Huffman and Stern, 2007). As inflammation is one of 
the potential mechanisms that has been implicated in depression etiology, agents 
with anti-inflammatory properties have been proposed as a treatment for 
depression. For example, statins are lipid lowering agents that have been used to 
reduce the risk of CVD. Meanwhile, they were suggested to have a possible 
therapeutic benefit in depression as they possess immunomodulatory, anti-
inflammatory, and antioxidant properties (Kim et al., 2019b). Several studies had 
evaluated the efficacy of statin either as an adjunctive therapy or as a primary 
therapy for depression, however, findings are largely contradicting (Agustini et 
al., 2019, Dave et al., 2018, Kessing et al., 2019, Köhler-Forsberg et al., 2019, 
Mansi et al., 2013, Parsaik et al., 2014, Salagre et al., 2016). Another example is 
aspirin, also known as acetylsalicylic acid, which belongs to the non-steroidal anti-
inflammatory drugs. Aspirin is an antiplatelet agent that prevents thrombus 
formation and therefore it has been used in the prevention and treatment of CVD. 
At low doses aspirin inhibits cyclooxygenase-1 enzyme whereby produced 
neuroprotective effect. A small open RCT with 24 non -responder depressed 
patients showed that adding aspirin to SSRI for 4 weeks led to rapid and sustained 
response of over 50% of the patients (Mendlewicz et al., 2006). Subsequent 
epidemiological and RCT studies have produced inconsistent results when 
evaluated aspirin as a primary therapeutic agent for depression (Berk et al., 2020, 
Glaus et al., 2015, Kessing et al., 2019).  
 Depression and hypertension 
 Hypertension 
Hypertension, also known as high BP, is a condition in which the blood exerted a 
high force against the artery walls of the systematic circulation. The overall BP is 
maintained by cardiac output and peripheral vascular resistance. Cardiac output 





is a function of the viscosity of blood and rigidity of the blood vessel walls. The 
determinants of BP are regulated by several physiological mechanisms, including 
cardiac contractility, homeostasis of extracellular fluids and tone of vascular 
musculature.  
BP consists of two determines: systolic pressure (SBP), which represents the 
maximum pressure during contraction of the ventricles, and diastolic pressure 
(DBP), which is the minimum pressure recorded just prior to the next contraction. 
There is a cut-off BP value that has been universally accepted to facilitate 
diagnostic approach and clinical decisions about treatment initiation. As a general 
guide, BP is considered to be normal or optimal when SBP is 80-120 mmHg and 
DBP is 60-90 mmHg. Conventionally, hypertension is diagnosed when a clinic SBP 
is 140 mmHg or higher and/or DBP is 90 mmHg or higher. However, recently, there 
have been some differences in defining and classifying hypertension stages 
between guidelines. For example, according to the European Society of Cardiology 
(ESC)/European Society of Hypertension (ESH) guidelines, hypertension is a BP of 
(SBP/DBP) ≥140/90 mmHg (Williams et al., 2018), while the American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines changed the 
definition of hypertension to a lower BP (SBP/DBP) ≥130/80 mmHg (Whelton et 
al., 2018) (Table 1-2). In terms of the classifications, the ESH/ESC guideline 
continues to classify BP ≥140/90 as stage 1 hypertension (140-159/90-99 mm Hg), 
while the ACC/AHA guideline classifies this as stage 2 hypertension. On the other 
hand, the ACC/AHA guideline considers a BP of ≥130/80 (130-139/85-89 mm Hg) 
mmHg as stage 1 hypertension and the ESH/ESC considers it a high normal BP. 
 Prevalence and global burden of hypertension 
According to an estimation from a multinational statistical survey derived from a 
135 population-based study enrolling 968,419 adults from 90 countries, the global 
age-standardised prevalence of hypertension was 31.1% in 2010 (Mills et al., 2016). 
This estimate of age-standardised hypertension prevalence was almost consistent 
with sex (31.9% in men and 30.1% in women). However, the study showed that 
large global disparities exist in the prevalence of hypertension depending on 
economic development (Mills et al., 2016). The most recent report from the Global 
burden diseases (GBD) had updated estimates of SBP changes from 1990 to 2015 





al., 2017). The GBD demonstrated that the prevalence of high SBP, defined as 
≥140 mmHg, increased by 3.2% from 17.3% in 1990 to 20.5% in 2015.  
Hypertension is known as the strongest risk factor for all CVD acquired during life. 
In 2015, Forouzanfar and colleagues estimated that the number of deaths 
attributed to elevated SBP (≥ 140 mmHg) was 7.8 million, which represents 14.0% 
of all deaths. The risk was not limited to high levels of SBP, as the number of 
deaths linked to lower levels of SBP ≥110–115 mmHg was 10.7 million (19.2% of all 
deaths) (Forouzanfar et al., 2017). The authors also showed that at all levels of 
SBP, CHD is the largest contributor to SBP-related deaths, followed by ischemic 
stroke and haemorrhagic stroke (Forouzanfar et al., 2017). Hypertension is also 
associated with an increased risk of diseases other than CVD, such as kidney 
disease, diabetes and dementia. A systematic review and meta-analysis of six 
prospective cohort studies showed that prehypertensive patients had a 1.5X 
increased risk of end-stage renal disease compared to normotensive patients 
(Huang et al., 2014). The risk carried by high BP is not limited to hypertensive or 
prehypertensive patients. Evidence showed that the risk of CVD increased 
exponentially as BP increase even within the normal range of BP, suggesting that 
SBP may not need to exceed the clinic BP threshold to be considered a risk factor 






Table 1-2 Definitions of BP categories according to the American and European guidelines 
Blood pressure category  ACC/AHA 
(SBP/DBP) mm Hg 
ESC/ESH 
(SBP/DBP) mm Hg 
Normal range of BP <120/80  <120/80 
Elevated BP  120-129/<80 130-139/85-89 
Hypertension stage 1 130-139/80-89 140-159/90-99 
Hypertension stage 2 ≥140/90 160-179/100-109 
Hypertension crises ≥180/120 ≥180/110 
Abbreviations: AHA/ACC, American College of Cardiology/ American Heart Association; 
ESH/ESC, European Society of Hypertension/ European Society of Cardiology; SBP, systolic 






As co-existing conditions, depression and hypertension have a far more 
detrimental effect on health than as individual conditions. As previously 
mentioned, both conditions are associated with an increased risk of CVD and 
mortality. Moreover, studies suggest that the impact of depression as a comorbid 
condition in hypertensive patients may have a major bearing upon physical 
functioning, quality of life, treatment compliance and healthcare utilisation 
(Wiehe et al., 2006). 
 Hypertension and risk of depression 
Depression is highly prevalent among hypertensive patients. Li et al. (2015b) 
conducted a meta-analysis of 41 studies comprising 30,796 participants and 
reported that approximately 27% of hypertensive patients had depressive 
symptoms. More recent studies conducted in low- and middle-income countries 
reported an even higher prevalence of depression among hypertensive patients, 
ranging from 25%-40% (Mahmood et al., 2017, Valladares-Garrido et al., 2020, 
Gebre et al., 2020). 
Overall, studies that have investigated whether hypertension is associated with 
an increased risk of depression are limited, and most have examined hypertension 
in relation to late-life depression. Two systematic reviews have been conducted 
in this regard with consistent findings. First, Valkanova and Ebmeier (2013) 
conducted a meta-analysis of 14 studies, including cross-sectional and prospective 
studies, and found no association between hypertension and depression (OR= 1.14; 
95% CI 94–1.40; P-value =0.19). Second, Long et al. (2015) conducted a meta-
analysis of five prospective cohort studies and found no evidence of an association 
between hypertension and depression incidence (RR = 1.16, 95% CI 0.91, 1.42). 
However, there is also evidence suggesting that low BP could lead to depression 
(Licht et al., 2009, Hildrum et al., 2007, Ng et al., 2010, Kim et al., 2010) 
Some evidence has linked the increased prevalence of depression in hypertensive 
patients to the perception of being a chronically ill patient. They proposed that 
elevated BP levels may have no direct effect on depression and that depressive 
symptoms may be a consequence of the psychological effect accompanied by a 





 Depression and risk of hypertension 
The hypothesis that depression may increase the risk of hypertension has been 
studied for more than a century. In 1898, Maurice Craig observed that during a 
depressive episode, BP was always elevated and returned to normal after 
remission (Friedman and Bennet, 1977). Since that time, several clinical studies 
have attempted to establish the nature of the relationship between these two 
diseases. So far, only one meta-analysis of this literature has been published (Meng 
et al., 2012), which comprised nine prospective studies; the main finding showed 
that depressed patients had a 42% (RR= 1.42; 95%CI 1.09 ,1.86, p = 0.009) higher 
risk of developing hypertension than non-depressed patients.  
 Antihypertensive drug class and risk of depression 
The following section closely describes the relationship between the major five 
classes of antihypertensive drugs, including CCBs, BBs, RAS antagonists, TZDs and 
risk for depression. Table 1-6 summarises epidemiological studies that had 
investigated the association between different classes of antihypertensive drugs 
and depression. 
 CCBs and risk of depression 
 Calcium channels  
Calcium channels are present in most cell types of mammalian bodies and have 
critical functions in various cellular processes. There are several types of calcium 
channels regulating calcium ions (Ca+2) influx through cell membranes, including 
voltage-gated channels, ligand-gated channels and/or sodium (Na+)/Ca+2 
exchanger pumps. Since most of the available CCBs act on the voltage-gated 
calcium channel (VGCC) to produce their therapeutic effect in cardiovascular 
tissue, the next section focuses on the molecular structure of VGCC, particularly 
the L-type Ca+2 channel, different subtypes and their distinct function in various 
tissues. 
VGCCs are transmembrane ion channel proteins that act as key signal transducers 
of electrical excitability, transforming electrical signalling derived from 





Ca+2 entering the cell serves as a second messenger initiating different cellular 
events depending on the type and location of the VGCC. VGCCs are grouped into 
three families – CaV1, CaV2 and CaV3 – which form 10 isoforms; each has a distinct 
physiological and pharmacological effect. Table 1-3 summarises information on 
each member of the VGCC families. Among the three channel families, the L-type 
VGCC (L-VGCC) channel possess a crucial role in cardiovascular tissues, making 
them a specific target for therapeutic agents, namely CCB, for the treatment of 
CVDs. L-VGCC is composed of the heteromultimeric protein complex consisting of 
a central pore forming α1 and the auxiliary channel α2/δ, β and, in some tissues, 
γ subunits, which bind tightly but non-covalently to α1. This Ca+2 channel family 
consists of four isomers, including CaV1.1, CaV1.2 , CaV1.3,  and CaV1.4. CaV1.2 
and CaV1.3 isomers are localised in various tissues and are often expressed in the 
same cells, including the cardiac muscle, smooth muscles, neurons and endocrine, 
but their contribution to the L-type current varies depending on the region. In 
cardiac myocytes, CaV1.2 is more predominant and Ca+2 influx through this 
channel initiates excitation-contraction coupling. By contrast, the CaV1.3 channel 
is more predominant in the sinoatrial node, where it is required for a regular 
cardiac pacemaking function in atrioventricular node (Zamponi et al., 2015). 
Unlike CaV1.2 and CaV1.3, the tissue expression of CaV1.1 and CaV1.4 is limited 
to certain tissues. skeletal muscle and retina (Zamponi et al., 2015). 
 Molecular role of L-VGCC in depression 
The critical role of Ca+2 signalling pathways through L-VGCC channels in the brain 
contributing to neurodevelopmental disorders, depression and other 
neuropsychiatric diseases has been established by several lines of evidence from 
both animal models and human studies. Among the four isoforms of L-VGCC, 
CaV1.2 and CaV1.3 were the strong candidates contributing to these pathological 
conditions. In the brain, CaV1.2 and CaV1.3 are much more complex than those 
presenting in the cardiac tissue in terms of structure considering the additional 
diversity of the auxiliary subunits and the fact that all α 1 subunits seem to be 
capable of assembling with all β and α 2 δ isoforms (Pichler et al., 1997, Schlick 
et al., 2010). CaV1.2 and CaV1.3 are mainly localised post-synoptically to 
dendrites in neurons, particularly in soma, shafts and spines (Zamponi et al., 
2015). The Ca+2 currents conducted by these channels regulate neuronal 





gene expression, which is referred to as the excitation-transcription coupling 
(ETC). In brief, perhaps what we can conclude from the literature is that the 
importance of Cav1.2 and Cav1.3 in modulating depressive-like symptoms lies in 
their potential regulation of the neurogenesis process and synaptic plasticity. 
These neurobiological functions are essential for a broad range of psychiatric 
diseases, making them a possible therapeutic target for depression, bipolar 
depression (BD), schizophrenia, attention deficit hyperactivity disorder and 
autism disorders. CaV1.2 and CaV1.3 are involved in the regulation of gene 
transcriptional events controlling neurogenesis and synaptic plasticity, each with 
a distinct function based on their brain location (Kabir et al., 2017, Lee et al., 
2016, Marschallinger et al., 2015, Kim et al., 2017a, Nanou and Catterall, 2018). 
The precise mechanism by which CaV1.2 and CaV1.3 influence the neurogenesis 
process remains unknown. One potential mechanism is via regulating gene 
transcription, hence, the release of the brain-derived neurotrophic factor (BDNF) 
from the hippocampal neurons. BDNF is a member of the neurotrophin family 
polypeptides, which is vital to the regulation of neural processes in neurogenesis, 
such as proliferation, differentiation and modification of synaptic plasticity, 
including the establishment of hippocampal long-term potentiation (LTP) 
(Martinowich et al., 2007). Ca2+ influx through L-VGCC serves as a primary source 
for the transcriptional up-regulation of BDNF through the activation of cyclic 
adenosine monophosphate (cAMP) response element-binding protein (CREB) and 
major Ca2+ response elements (Aimone et al., 2014, Kabir et al., 2017). BDNF 
enhances synaptic plasticity and neurogenesis through activating Tropomyosin-
Related Kinase B Receptors (TrkB) signalling. 
 Genetic variation in L-VGCC and depression 
Studies attempting to link depression with genetic variations in CACNA1C and 
CACNA1D genes (coding CaV1.2 and CaV1.3, respectively) provide additional 
evidence. Rao et al. (2016) conducted a systematic review and meta-analysis to 
explore the association between CACNA1C variants and depression. Pooling the 
results from six studies, including one GWAS, showed that CACNA1C is strongly 
associated with depression. The authors also identified potential single nucleotide 
polymorphisms (SNPs) thought to increase the risk of depression. Among these 





SNPs, significantly associated not only with depression but also with broad 
neuropsychiatric disease (Rao et al., 2016). This SNP has also been found to affect 
the clinical response to antidepressant treatment in a biphasic manner (Fabbri et 
al., 2019). Similar to CACNA1C, genetic variants in CACNA1D (non-coding SNP 
rs893363) were found in GWAS to be associated with depression and other 
neuropsychiatric diseases(Cross-Disorder Group of the Psychiatric Genomics 
Consortium, 2013). 
 CCBs 
Based on the chemical structure, CCBs were divided into three subclasses: 
phenylalkylamines (e.g. verapamil), benzothiazepines (e.g. diltiazem) and 
dihydropyridines (e.g. nifedipine, amlodipine and isradipine). The 
phenylalkylamine and benzothiazepine CCBs are also known as non-
dihydropyridine CCBs. All CCBs induce a vasodilatation effect to reduce BP as their 
primary mechanism of action. The vasodilator potency of CCBs varied considerably 
according to the subclass, with dihydropyridine-type compounds being comparably 
more potent than the phenylalkylamine and benzothiazepines groupings(Sica, 
2006). The main cardiovascular indications for CCB include hypertension, coronary 
spasm, angina pectoris, supraventricular dysrhythmias, hypertrophic 
cardiomyopathy and pulmonary hypertension. CCB have also been used in other 
conditions involving peripheral vasospasm (i.e. Raynaud’s phenomenon).  
Mechanism of action: CCBs primarily act by inhibiting the influx of Ca+2 through 
the L-VGCC, resulting in lowering the peripheral resistance and subsequently 
enhancing vascular smooth muscle relaxation and reducing myocardial 
contractility.  
Regarding tissue selectivity, unlike dihydropyridine, diltiazem and verapamil are 
more selective to cardiac muscle than vascular smooth muscle, reducing cardiac 
contractility and heart rate. CCB is generally considered selective to cardiac and 
vascular smooth muscle because L-VGCC in other tissues, such as skeletal, 
bronchial and tracheal muscle, are relatively insensitive to CCB. Studies have 
shown that dihydropyridine has a minimal effect on neuronal tissue, suggesting 
that these tissues are also less sensitive to CCB and are therefore associated with 





from human data demonstrated that dihydropyridine CCB can affect the LTP and 
L-term depression at the therapeutic dose, indicating that dihydropyridine CCB 
may also induce adverse CNS effects (Ortner and Striessnig, 2016). In general, the 
three subclasses of CCB have comparable pharmacokinetics properties (Sica, 
2005). They have low and variable bioavailability, rapid onset of action, high 
protein binding (70%–98%) and high first pass metabolism. Most CCBs have a half-
life between 1.3 and 6 hours, except for amlodipine, which has a half-life of 35-
50 hours. Most CCBs are primarily excreted renally after metabolism. 
 Role of CCBs in depression 
The putative association between CCB and depression has been contentious. In 
the late 1980s, several case reports and case series were published of substantial 
depression among patients treated with CCBs (Hullett et al., 1988, Biriell et al., 
1989). These were followed by a cross-sectional ecological study conducted by 
Lindberg and colleagues with 152 Swedish patients. The authors revealed that CCB 
users faced a significantly higher risk of suicide (relative risk for suicide of 5.4, 
95% CI 1.4–20.5) compared to non-users (Lindberg et al., 1998). Nonetheless, the 
study was extensively criticised in the literature because of the limited number 
of observations used to draw the conclusion. In another study, Hallas (1996) used 
a technique known as prescription sequence symmetry to analyse a large 
computerised prescription database. The author also analysed data from other 
antihypertensive classes, including CCBs and angiotensin converting enzyme 
inhibitors (ACEIs). The main findings of the study showed that CCBs and ACEIs, but 
not BBs, have a depression-provoking effect (Hallas, 1996). Rathmann et al. (1999) 
carried out a case-control study to identify an association between CCBs, BBs, 
ACEI and depression in diabetic patients. The study enrolled 972 diabetic cases 
who were newly diagnosed with MDD and matched with 972 diabetic controls for 
age, sex and index date. Eligible patients were newly exposed to antihypertensive 
medication for six months prior to the index date. Their findings showed that CCBs 
(OR = 2.2, 95% CI 1.2–4.2) and BBs (OR = 2.6, 95% CI 1.1–7.0) were strong predictors 
for depression occurrence. In an additional analysis, the authors assessed whether 
the association could be explained by the level of the daily prescribed dosage and 
they found that patients exposed to a high level of CCBs and BBs during the 
previous six months were at a four-fold higher risk of developing depression than 





al. (2000) followed 1,660 elderly patients for two years after a one-year exposure 
to antihypertensive treatment. and found a significant association between CCBs 
and depression On the other hand, several studies with different designs failed to 
detect any association between CCBs and depression (Agustini et al., 2020, 
Gerstman et al., 1996, Johnell and Fastbom, 2008, Patten and Lavorato, 
2001).(Agustini et al., 2020) 
Owing to the recent advanced knowledge about the biological role, the 
pharmacological effect and the genetic variation of L-VGCC in modulating some 
major psychiatric diseases, it was worth considering repurposing CCBs as a 
therapeutic agent in the psychiatric field. In general, the efficacy of CCBs was 
predominantly investigated in relation to BD. In the context of BD, the available 
evidence for CCB efficacy showed mixed results. To date, one comprehensive 
meta-analysis has examined the effects of CCBs on BD. However, the results of 
this study comprising six RCTs and 17 observational studies failed to provide 
evidence of any beneficial effect of CCBs on BD (Cipriani et al., 2016). 
Nonetheless, a more recent meta-analysis studying the cellular Ca+2 signalling in 
patients with BD showed that unmedicated BD patients had an excessive elevation 
of basial intracellular Ca+2 (Harrison et al., 2019), providing strong evidence for 
the plausible use of CCBs for this condition. Thus, until recently, CCBs have 
continued to be an experimental treatment for BD (Atkinson et al., 2019). CCBs 
have also been studied in depression treatment as a monotherapy or as adjunct 
therapy, but the results were largely inconsistent. An early trial found that in 
depressed patients receiving electroconvulsive therapy, there was greater mood 
improvement among those taking nicardipine compared with a placebo (Huffman 
and Stern, 2007). Tully et al. (2018) supported this finding after conducting a 
prospective cohort study of 269 depressed patients treated with SSRI and anti-
hypertensive medication. The findings revealed that patients taking SSRIs and 
CCBs showed greater improvements in their depression scores compared to 
patients taking SSRIs and other antihypertensives; however, the effect was not 
statistically significant at 10-year follow-ups. Resent study also support this 
finding suggesting that CCBs may reduce the risk of developing depression (Kessing 
et al., 2020). Nonetheless, the results from other observational studies were 
discouraging, showing that CCBs could increase the risk of depression (Boal et al., 





To date, the risk of depression related to CCBs is inconclusive, and study findings 
fail to consistently support a single view of their association; thus, further studies 
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  BBs and risk of depression 
 β-adrenergic receptors (βARs) 
βARs are essential components of the SNS mediating the effect of endogenous 
catecholamines, including adrenaline (A) and noradrenaline (NA). There are 
distinct subtypes of βARs; each has a unique pharmacological function based on 
their tissue localisation. β1AR is. predominantly located in the heart and kidney 
facilitating myocyte contraction and renin release, whereas β2AR is more 
predominant in the lung and blood vessels mediating smooth muscle relaxation. 
β1AR and β2AR are also located in the liver. β3AR is predominant in adipose tissue 
and exclusively in brown adipose tissue present in rodents and new-born humans. 
βARs have also been detected in several brain areas, such as the hippocampus, 
cerebellum, thalamic nuclei, basal ganglia, midbrain and cerebral cortex 
(Reznikoff et al., 1986). β1AR and β2AR may coexist in the same tissue and 
facilitate the same physiological functions. For example, in the hippocampus, 
β1AR and β2AR were found to regulate synaptic plasticity. All βARs belong to the 
G-protein coupled receptor (GPCR) family, which utilises a variety of second 
messengers in response to a binding ligand to provoke a cellular function. βARs 
can signal via stimulatory G-protein activating adenylyl cyclase (AC), which 
mediates the conversion of adenosine triphosphate (ATP) into cAMP (Frishman, 
2007). Elevating the levels of cAMP triggers further downstream signal 
transduction, resulting in a functional response. 
 Role of βARs in depression  
The locus coeruleus (LC) is a cluster of NA-containing neurons that are located in 
the dorsal pontine tegmentum. Hyperactivation of these neurons is thought to be 
associated with depression induced by stress (Sara, 2009). Under stress conditions, 
acute activation of the LC results in the secretion of NA and subsequently 
stimulates the adrenergic receptors in the PVN in the hypothalamus, which in turn 
aggravates stress by activating the HPA axis (Seki et al., 2018). Therefore, the 
noradrenergic innervation from the LC to the hypothalamus is important for 
activating the critical step (i.e. the HPA axis) related to stress. However, long-
term stress can cause a prolonged activation of the HPA axis and eventually lead 





response to these neurological alterations (i.e. impairment of the LC), changes in 
βARs in terms of the functionality and number of receptors may occur (Brunello 
et al., 2003). Recent studies have illustrated that βARs play a critical role in 
regulating potential brain functions, such as cognition and memory, and they 
contribute to the pathogenesis of Alzheimer's Disease, Parkinson's disease and 
depression (Gannon et al., 2015, Hagena et al., 2016, Seki et al., 2018). The 
stimulation of βARs following the activation of noradrenergic neurons may 
enhance hippocampal synaptic plasticity and hippocampal neurogenesis, which 
are thought to be important therapeutic components of antidepressants. Several 
studies have confirmed the role of β1AR and β2AR in promoting synaptic plasticity 
(Hagena et al., 2016). Antidepressants and rapid acting antidepressants have 
shown some efficacy in reversing stress-induced neural remodelling and 
hippocampal shrinking through the upregulation of BDNF(Lee and Kim, 2008, Sun 
et al., 2016a) This antidepressant effect is thought to be mediated through βAR 
activation, which stimulates cAMP/PKA/CREB/BDNF downstream signalling (Seki 
et al., 2018, Hagena et al., 2016). The proposed mechanism of action might be 
restricted to antidepressants that increase synaptic NA levels by blocking the 
action of NA transporters at the presynaptic side and sustain synaptic plasticity, 
particularly LTP, which is considered an important beneficial effect of 
antidepressants (Seki et al., 2018) (Figure 1-3). Qian et al. (2017) proposed that 
stimulated β2AR can interact with both the Cav1.2 channel and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) postsynaptically, 
forming two distinct complexes supporting the generation process of the LTP in 
response to brain wave frequency (Figure 1-4). Genetic studies provide another 
line of evidence that emphasises the role of βAR in depression. The ADRB1 gene 
coding the β1AR has been the most investigated candidate gene. ADRB1, mediating 
the effect of A and NA, has been linked to the regulation of mood, memory, 
autonomic function, neuro endocrine activity, BP, and response to anti-
depressants treatment (Amare et al., 2017, Fabbri et al., 2013). 
 BB 
BBs were one of the first-line therapies for primary hypertension dating back to 
1977, as recommended by the first report of the Joint National Committee on 
Detection, Evaluation and Treatment of High Blood Pressure (JNC 1) (Ripley and 





recommendation suggests using BBs as an add-on therapy with other 
antihypertensive medications (Hackam et al., 2013). BBs are now mainly indicated 
for patients suffering from CHD, especially after an MI event, stroke or HF. BBs 
can be classified according to their pharmacological properties into three 
generations of agents. Propranolol is the prototype of the first generation, which 
exerts equal blockades of β1AR and β2AR and is thus characterised as a non-
selective BB. The second generation is termed a selective BB, as it possesses a 
higher affinity towards β1AR than β2AR, though the extent of the selectivity varies 
among the agents of this generation, which includes metoprolol, bisoprolol and 
atenolol. In most cases, non-selective BBs are effective as selective BBs; however, 
selective BB agents have the advantage of fewer side effects associated with 
blocking β1AR, such as bronchospasm. The third generation includes labetalol, 
carvedilol and bucindolol, which are distinguished from the two previous 
generations by their ability to block α1-adrenergic receptors inducing 
vasodilatation. Furthermore, some BBs, such as pindolol, exhibit intrinsic 
sympathomimetic activity (ISA), meaning they can act as an agonist mimicking the 
transmission of SNS signalling; however, the clinical significance of this effect is 
uncertain. 
Table 1-4 displays some pharmacodynamic and pharmacokinetic properties 
possessed by an individual BB, which include bioavailability, lipophilicity, ISA, 
elimination half-life and route of elimination. In terms of lipophilicity, BB can be 
divided into lipophilic and hydrophilic agents. Hydrophilic agents, such as atenolol 
and nadolol, are advantageous over hippophilic agents, such as propranolol, since 
they have lower CNS side effects (e.g. depression, psychosis and sleep 
disturbances). The mechanism by which BBs reduce BP is not fully understood. 
However, it is thought that BBs mainly act by inhibiting β1AR located in the heart 
and reducing cardiac output, though a reduction in peripheral resistance may 
occur with long-term use. As the third generation of BBs can antagonise α1AR, this 
class can also reduce the peripheral resistance, thus mediating vasodilatation. By 
blocking the β1AR in the juxtaglomerular apparatus, BBs decrease the release of 
renin by the kidney, resulting in decreased circulating angiotensin II (Ang II) and 
aldosterone and subsequently enhancing sodium and water excretion and further 





 BB and risk of depression 
After the introduction of propranolol for clinical uses in 1967, several studies 
reported its association with the onset of clinical depression. An early frequently 
cited study conducted by Waal (1967) reported that 50% of patients treated with 
propranolol hydrochloride (12mg/day) for more than three months developed 
depression. This kind of association was replicated by later case reports and RCT 
studies (Steiner et al., 1990). An increase in antidepressant usage among BB users 
was also observed (Avorn et al., 1986). It was hypothesised that BB decreases the 
noradrenergic activity in the brain(Patten and Love, 1993). Thus, highly lipophilic 
BBs, such as propranolol, that are more likely to cross the blood brain barrier (BBB) 
were considered more likely to cause depression. Thiessen et al. (1990) conducted 
the first longitudinal study in this regard to investigate the relation between BBs 
and the incidence of antidepressant prescription. They recruited 3,218 patients 
who were free of a BB prescription for six months prior to the study. Over a 12-
month follow-up period, they found that propranolol in particular, but not other 
lipophiliic or hyprophilic BBs, was associated with an increased risk of 
antidepressant prescription, proposing that the depressogenic activity is a unique 
feature restricted to propranolol that is irrelevant to its lipophilicity property 
(Thiessen et al., 1990). However, this finding was refuted by Sørensen and 
colleagues, who examined the association between different classes of 
antihypertensive medications and risk of suicide, which was considered in this 
study as a specific indicator for severe depression. In a six-year follow-up, they 
found a significant increase in suicide risk among new BB users (standardised 
mortality ratio = 1.6 95% CI 1.2, 2.1) compared to non-BB users, especially during 
the first year of treatment. After stratification by the degree of lipid solubility, 
the risk of suicide was confined to BBs with medium and high lipid solubility, and 
no significant association was observed with low lipid solubility, suggesting a dose-
response association (Sørensen et al., 2001). This was contradicted by other 
studies suggesting a null association between BB and depression (Crane et al., 
2006, Patten and Lavorato, 2001). Dhondt et al. (2002) showed that BBs are 
significantly associated with an increased risk of depression; however, after 
performing an additional analysis, the significant positive association remained 
only for non-selective BBs (OR = 1.08, 95% CI 1.08–3.10) and not for selective BBs 





findings regarding the association between BBs and depression is a matter of how 
depression is measured. 
Two meta-analyses summarised studies investigating the association between BBs 
and depression, but they provided inconsistent evidence. The findings from the 
first meta-analysis of 11 RCTs suggested an increased risk of depression in users 
of propranolol (Patten, 1990). However, the results obtained a decade later by Ko 
et al. (2002), who pooled the results from seven RCTs with a maximum follow-up 
duration of four years and a total number of 100,662 patients, showed that neither 
BBs (RR = 1.12, 95% CI 0.89, 1.41) nor high lipid soluble BBs were significantly 
associated with depressive symptoms. Contradictory results have been continued 
to publish on this subject in recent years showing either positive or negative effect 
of BBs on depression. Researches with different study designs including cross-
sectional (Agustini et al., 2020), case-control (Cao et al., 2019) and prospective 
studies (Boal et al., 2016, Shaw et al., 2019) reported a positive association 
between BBs and risk of depression. Nonetheless, in a large case-control study 
with more than 3 million subjects, Kessing et al. (2020) have strongly challenged 
these results, suggesting that BB as a class is associated with a reduced risk of 
depression. Certain BBs have been suggested to augment the treatment of 
depression. Pindolol, in particular, has been found to accelerate antidepressant 
responses during therapy for refractory depression (Sokolski et al., 2004). This 
finding is mainly due to its structural homology to serotonin that underlies its 
capacity to act as an antidepressant-augmenting agent at the level of the 
serotonin receptor (Barowsky and Schwartz, 2006). Several studies have evaluated 
pindolol as an augmentation agent of antidepressants in treatment-resistant 
depression; however, data from the largest studies failed to detect any significant 
effects (Anderson et al., 2008). 
As shown, these studies spanning five decades report conflicting results and the 
long-standing concern about whether BBs increase the depression risk has not been 






Table 1-4 Pharmacodynamic/pharmacokinetic properties of BB 
Generation BB Bioavailability Lipid 
solubility 




Propranolol 49-60% High - 3-4 Hepatic  
Penbutolol >90% High - 1-3 Hepatic 
Nadolol 20-30% Low - 14-24 Hepatic ± 
renal 
Oxprenolol 24-60% High - 1-3 Hepatic ± 
renal 
Timolol 50-75% Low - 5.5 Hepatic ± 
renal 
Sotalol 75-90% Low - 15 Renal ± 
hepatic 




Atenolol 50% Low + 6-9 Hepatic + 
renal 
Metoprolol 50% Moderate + 3-4 Hepatic 
Bisoprolol 88% Low + 10-12 Renal + 
Hepatic 
Acebutolol 40-60 Low + 7-13 Hepatic ± 
renal 
3rd generation 
B – with alpha  
Carvedilol 25 Moderate - 7 Hepatic 
Nebivolol 12 Low + 22 Hepatic 
Betaxolol 80 Low + 14-20 Hepatic ± 
renal 
Carteolol 90 Low - 7 Renal+-
Hepatic  
Abbreviations: ±, elimination is less than 30%; BB, Beta blocker; E t1/2, elimination half-life; 
h, hour; ISA, Intrinsic sympathetic activity  








Figure 1-3 Role of βAR inducing hippocampal synaptic plasticity and neurogenesis 
mediating antidepressants effect 
Figure modified from [(Hagena et al., 2016, Seki et al., 2018). Stimulation of βAR coupled to Gs 
protein by adrenaline or noradrenaline results in activation of adenylyl cyclase and formation of 
cAMP. cAMP activates PKA and subsequently ERK/MAPK which eventually activates the CERB 
which in turn enhances the expression of the BDNF and other proteins promoting neurogenesis. In 
a second pathway, PKA phosphorylates the GluA1 subunit of the AMPAR at Ser845 and Ser 831 
facilitating membrane insertion of the Glu1 and consequently maintains LTP. Abbreviations: AMPAR, 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ATP, adenosine triphosphate; βAR, 
beta adrenergic receptors; BDNF, brain derived neurotrophic factor; cAMP, cyclic adenosine 
monophosphate, C-Raf, RAF proto-oncogene serine/threonine kinase; CREB, cAMP-responsive 
element-binding protein; ERK, extracellular signal-regulated kinase; Glu1, glutamate receptor 
subunit 1; Glu2, glutamate receptor subunit 2; Gs, stimulatory G protein; LTP, long-term potentiation; 








Figure 1-4 Role of βAR mediating postsynaptic calcium channel signalling in LTP 
Figure reproduced with permission from (Qian et al., 2017). Stimulation of βAR that are specifically 
bound to AMPAR and Cav1.2 results in activation of these receptors through phosphorylation of 
Ser1928 on Cav1.2 and Ser845 on AMPA by the PKA. The phosphorylated AMPAR cause Na+ influx 
and depolarisation during synaptic transmission in response to theta stimulation., while the 
phosphorylated Cav1.2 enhances Ca+2 entry and therapy cause an increase in synaptic strength LTP. 
Abbreviations: AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ATP, 
adenosine triphosphate; β2AR, beta adrenergic receptors type 2; cAMP, cyclic adenosine 
monophosphate; Cav1.2; calcium channel receptor; Gs, stimulatory G protein; LTP, long-term 






 The RAS antagonists and risk of depression 
 The RAS 
It is now well accepted that all components of the RAS are present within the 
brain. The central and peripheral pathways of RAS in the brain play a potential 
role in regulating different functions and patterns, including cerebral circulation, 
cerebroprotection and other neuropsychiatric diseases, such as depression 
(Jackson et al., 2018b, Labandeira-Garcia et al., 2014, Vian et al., 2017, Wright 
and Harding, 2011). The main peripheral pathway of RAS is the forebrain pathway 
comprising the circumventricular organs (CVOs) that are connected to the 
peripheral RAS via fenestrated capillaries. Brain structures surrounding the 
forebrain pathway have access to the peripheral RAS component. However, the 
BBB restricts the peripheral RAS from accessing the majority of the brain regions, 
making local synthesis of the cerebral RAS components essential. The central 
pathway integrates the hypothalamus and medulla, being the primary source of 
local angiotensin synthesis. 
The RAS can exert its main biological functions through the traditional pathway, 
also named classic RAS and through the non-classic pathway (Romero et al., 2015). 
Figure 1-5 (a), schematically presents the components of the RAS illustrating its 
common pathways. The classical pathway of RAS begins with the synthesis of renin 
from the pro-renin, which then cleaves angiotensinogen to angiotensin I (Ang I) 
and subsequently Ang I is converted by Ang converting enzyme (ACE) into Ang II, 
which is the most powerful biologically active product of RAS (Unger, 2002). 
Studies of the adult human brain revealed that Ang II actions in the CNS are 
mediated by the activation of angiotensin 1 (AT1) and angiotensin 2 (AT2) 
receptors. The classic effects of Ang II are predominantly mediated by the AT1 
receptor, which is a GPCR that initiates signal transduction and regulates gene 
transcription (Wright and Harding, 2011). In the brain, the AT1 receptor is 
particularly dense in the HPA axis, the anterior pituitary, the CVOs, the PVN, the 
preoptic and the supraoptic nuclei of the hypothalamus (Wright and Harding, 
2011). 
In the circulation, activation of AT1 receptor results in vasoconstriction, 





2015). Stimulation of the AT1 receptor is also implicated in multiple pathways, 
including stress response and the release of inflammatory biomarkers (Benicky et 
al., 2011). Recently, a non-classical RAS pathway was discovered and is considered 
a counterregulatory pathway of the classical RAS actions formed by ACE, Ang II 
and the AT1 receptor (Santos et al., 2013). The identification of ACE 2, a homology 
to ACE, unravels the existence of a distinct enzymatic pathway for the degradation 
of Ang I and Ang II (Patel et al., 2016). This enzyme can convert Ang II into 
angiotensin 1-7 (Ang 1-7). It can also transform Ang I into angiotensin 1-9 (Ang 1-
9), which is then converted to Ang 1‑7 by ACE (Patel et al., 2016). Ang 1‑7 binds 
to the MAS1 receptor, a G‑protein‑coupled receptor, and elicits a vasodilation of 
blood vessels by an endothelium-dependent release of nitric oxide (Brosnihan et 
al., 1998).  
 The classical RAS antagonist 
The classical inhibitors of the RAS can be classified into four groups: renin inhibitor 
, ACEIs, angiotensin receptor blockers (ARBs), and mineralocorticoid receptor 
blockers (Figure 1-5 [a]). The following section focuses on the two main types of 
RAS, including ACEIs and ARBs, considering their mechanisms of action, 
pharmacokinetics, and pharmacological and clinical effects. 
ACEIs: In the early 1980s, captopril was proposed as the first oral ACEI after 
proving its effectiveness in controlling BP and improving clinical outcomes of 
patients with HF (Dzau et al., 1980). Since then, ACEI has been proven as a 
treatment for a wide range of CVD and kidney-related conditions, including 
hypertension, HF, left ventricular dysfunction, MI and diabetic nephropathy 
(Brown and Vaughan, 1998). ACEIs have been classified according to the chemical 
structure of their active moiety into three groups: sulfhydryl, carboxyl and 
phosphinyl. Captopril is the prototype of the sulfhydryl-containing ACEIs; the 
other members of this group are fentiapril, pivalopril, zofenopril and alacepril. 
The carboxyl-containing group represents the majority of ACEIs, which include 
enalapril, benazepril, lisinopril, ramipril, quinapril, perindopril and trandolapril. 
Fosinopril is the only phosphinyl-containing ACEI that has been approved by the 
Food and Drug Administration (FDA) (Brown and Vaughan, 1998). The main 
differences between the three groups are not limited to the chemical structure, 





lives, distribution and binding affinity. Table 1-5 summarises the 
pharmacokinetics properties of ACEIs. Of all the ACEIs, fosinopril has the greatest 
lipophilicity, meaning it can cross the BBB, while lisinopril has the least. Other 
ACEIs that are able to cross the BBB are ramipril, captopril, quinapril and 
trandolapril. The potency of ACEIs measures the amount of ACEIs required to 
inhibit 50% of ACE plasma activity. The relative potency and ability to bind tissue 
ACE of ACEIs is quinaprilat = benazeprilat > ramiprilat > perindoprilat > lisinopril 
> enalapril > fosinopril > captopril (Lala and McLaughlin, 2008). Regarding the 
route of elimination, the majority of ACEIs are cleared by the kidney except for 
fosinopril, trandolapril and spirapril. The most common adverse effects are a 
cough (6%–20% of patients) and angioedema (1% of patients) (Romero et al., 2015, 
Sánchez-Borges and González-Aveledo, 2010). 
ACEIs act mainly by blocking ACE, preventing the conversion of Ang I to Ang II and 
resulting in the vasodilatation of blood vessels. Blocking ACE may also shift the 
balance of RAS towards the ACE2–Ang (1‑7) MAS1 axis (Figure 1-5 [a]) and suppress 
the degradation of Ang (1-7) to an inactive metabolite. This causes an increase in 
the plasma level of Ang (1‑7)–MAS1, thus producing a cardioprotective effect 





















Captopril None 30 75-91 2 Renal 
Carboxyl-
containing 
Benazepril Benazeprilat 90-97 37 10-11 Renal ± 
Hepatic 
Enalapril Enalaprilat 13-50 60 11 Renal 
Lisinopril None 3-10 6-60 12  Renal 
Moexipril Moexiprilat 50 13 2-9 Renal + 
Hepatic 
Perindopril Perindoprilat 10-20 74 3-10 Renal 
Quinapril Quinapril 
diacid 
97 >60 2 Renal 
Ramipril Ramiprilat 56 50-60 9-18 Renal + 
Hepatic 






89-100 36 12 Renal + 
Hepatic 
Abbreviations: ±, less than 30% hepatic elimination when renal function normal; ACE, 
angiotensin-converting enzyme inhibitors; E t1/2, elimination half-life; h, hour. 







ARBs: Losartan is the first oral ARB that has been approved for clinical use since 
1995 (Ripley and Hirsch, 2010). At present, nine orally active ARBs are available 
on the market: losartan, candesartan, irbesartan, olmesartan, telmisartan, 
valsartan, eprosartan, fimasartan and azilsartan. Generally, the clinical indication 
for ARBs is the same as that for ACEIs, and both have shown comparable efficacy 
(Messerli et al., 2018). In terms of tolerability, ARBs are better tolerated than 
ACEIs as they are associated with fewer side effects than ACEIs (Toh et al., 2012). 
Theoretically, as both ACEIs and ARBs supress the RAS activity, it is anticipated 
that a combination therapy would produce a pronounced beneficial cardiac effect. 
Nonetheless, studies have shown that a combination therapy achieves no 
additional benefit over single agent approaches and it could even lead to a harmful 
effect (Abraham et al., 2015, Phillips et al., 2007).  
Most ARBs have long plasma elimination half-lives. Candesartan cilexetil and 
losartan potassium are prodrugs requiring further metabolism to elicit their 
therapeutic effect, while most ARBs are inherently active (Vallerand et al., 2019). 
The absolute bioavailability of ARBs is quite varied, ranging from a low of 13% for 
eprosartan to a high of 80% for irbesartan (Israili, 2000). Most ARBs are highly 
bound to plasma protein (>90%), but they differ substantially in their volume of 
distribution. ARBs are predominantly cleared from the circulation by the biliary 
system, while only a small proportion are eliminated through the kidney (Sica, 
2001).  
ARBs were specifically designed to inhibit Ang II from binding to the AT1 receptor, 
thus preventing the negative consequences after AT1 receptor activation. Similar 
to ACEIs, ARBs can increase the plasma level of Ang (1‑7) by producing a reflexive 
increase in the production of ineffective Ang II, thus shunting the Ang II 
metabolism towards Ang (1‑7) formation (Miller and Arnold, 2019). There is 
evidence that not all ARBs share the same pharmacological effects; some ARBs 
possess a unique molecular effect independent of AT1 receptor inhibition (Kurtz 
and Pravenec, 2008, Miura and Saku, 2010). For example, Wang et al. (2013) 
assessed six ARBs ability to slow the progression of Alzheimer diseases by reducing 
the accumulation of β-amyloid protein in primary cortico-hippocampal neuron 
cultures derived from the Alzheimer mouse model expressing human amyloid 





extent losartan can cause a significant reduction of β-amyloid levels with no 
evident cell toxicity (Wang et al., 2013). 
 Role of the RAS in depression 
As described previously (See section 1.2.8.1), there are several subtypes of Ang 
and Ang receptors; however, it appears that the neurotoxic effect, particularly in 
depression, is predominantly ruled by the Ang II/AT1 receptor cascade. This 
section thus focuses mainly on this pathway, presenting evidence that investigates 
the functional relevance of the Ang II/AT1 receptor in depression. Ang II is 
considered a stress hormone based on several observations showing that Ang II can 
stimulate the stress response systems (i.e. HPA axis and SNS) through activating 
AT1 receptors centrally and peripherally (Saavedra and Benicky, 2007, Yang et al., 
1993, Yang et al., 1996). Multiple pathways have been identified in the brain 
linking Ang II to stress; however, the Subfornical organ (SFO)–PVN connection is 
the best studied pathway (Bains and Ferguson, 1995, Ferguson, 2009). Studies on 
animal models have demonstrated that different types of stress can increase the 
formation of brain Ang II and the expression and transcription of AT1 receptors, 
particularly in the hypothalamic PVN and SFO areas (Saavedra and Benicky, 2007). 
In the PVN, AT1 receptors are highly expressed in the parvocellular corticotrophin-
releasing neurons controlling the release of the corticotropin-releasing hormone 
(CRH). In response to stress, the HPA axis is activated and then stimulates the 
release of ACTH from the anterior pituitary gland, which in turn activates the 
immune system and signalling of other hormones, such as catecholamines and 
vasoactive peptides. The regulation of ACTH synthesis and secretion is governed 
by a number of neurotransmitters and peptides, such as Ang II. (Spinedi and Negro-
Vilar, 1983). Ang II can stimulate ACTH secretion, either directly by acting on the 
pituitary corticotrophs (Aguilera et al., 1995) and/or indirectly by activating AT1 
receptors in the PVN and subsequently enhancing the expression and secretion of 
the CRH and adrenal glucocorticoids, which eventually initiate the stress response 
cascade (Figure 1-5 [b]). 
Furthermore, there is evidence that even circulating Ang II can act centrally after 
altering BBB permeability to produce Ang II as a neurotransmitters, resulting in 
initiating the stress response (Calvillo et al., 2019). Additionally, since the AT1 





suggests that Ang II also enhances central sympathetic activity, thus regulating 
the secretion of catecholamines from the adrenal medulla and sympathetic nerves 
that are characteristic of stress (Saavedra and Benicky, 2007, Saxena, 1992). 
Overall, evidence generated from these studies correlates well with one of the 
major neuroendocrine alterations characterising major depression, the HPA axis 
and SNS dysfunction. 
There is strong evidence of the major involvement of the Ang II/AT1 receptor in 
the initiation and regulation of inflammatory cascades centrally and peripherally, 
which has been implicated in the pathological process of depression (Figure 1-5 
[c]). Ang II activates the AT1 receptor mediating the inflammatory process through 
several mechanisms. In the circulation, Ang II can induce proinflammatory effects 
on leucocyte, endothelial cells and the vascular smooth muscle through 
stimulating inflammatory mediators such as the reduced nicotinamide adenine 
dinucleotide phosphate dehydrogenese (NADPH), tumour necrosis factor-a (TNF-
a), IL-6 and nuclear factor-kB (NF-kB) (Figure 1-5 [c]) (Dandona et al., 2007) 
predisposing to inflammation (Zhang et al., 1999, Dandona et al., 2007). The 
peripheral inflammatory response has been shown to trigger the development of 
atherosclerosis (Verdecchia et al., 2008); thus, since Ang II contributes to 
increased inflammation, it can also be considered a mediator of atherosclerosis, 
which has been linked to depression (Tiemeier et al., 2004). Evidence shows that 
primary inflammation that has occurred peripherally can further sustain and/or 
strengthen the pathophysiological cascades causing neuroinflammation, which has 
been linked to depression (Troubat et al., 2020). Research also shows that brain 
Ang II can induce a proinflammatory effect through stimulating oxidative stress, 
apoptosis and neuroinflammation causing neurodegenerative disorders (Abiodun 
and Ola, 2020) and mood disorders (Bakunina et al., 2015). Furthermore, Ang II 
can act directly on the microglial cells, which are one of the potential brain cells 
that have been recently linked to depression (Singhal and Baune, 2017) and 
hypertesion pathology (Shen et al., 2015). In the brain, microglial cells are 
considered the resident macrophage inducing a neural immune response (Lenz and 
Nelson, 2018). They are a major source of Ang II production, which can directly 
act on AT1 receptors on microglial cells, activating a neuronal and inflammatory 
effect (Gong et al., 2019). Researchers have observed that stressful conditions 





chronic neuroinflammation and consequently causing depressive-like symptoms in 
animal models (Qin et al., 2007). More recently, Zhang et al. (2018) demonstrated 
that inhibiting microglial activation can be a possible target for treating 
depression. There is strong evidence that ACEIs and ARBs can act as anti-
inflammatory agents, ameliorating brain and peripheral inflammation by blocking 
the Ang II/AT1 receptor cascade in animal models (Benicky et al., 2011, Benicky 
et al., 2009, Pang et al., 2012, Saavedra, 2012, Gong et al., 2019). This evidence 
shows that Ang II mediates peripheral and central inflammation, which correlates 
highly with the inflammatory hypothesis of depression. 
Furthermore, genetic studies have linked several functional polymorphisms of 
RAS-related genes to depression and suicidal behaviour. For example, the AT1 
receptor genotype (A1166C) CC, which results in greater responses to Ang II at 
lower concentrations, has been shown to be associated with an increased risk of 
depression (Saab et al., 2007). Additionally, there is evidence that the ACE 
polymorphisms associated with enhanced ACE serum activity are able to influence 
responses to antidepressants (Bahramali et al., 2016) and could even be a risk 







Figure 1-5 Components of RAS, main RAS cascades correlated with depressive-like 
symptoms, and RAS drugs interfering with Ang II/AT1 signaling. 
Figure modified from [(Benicky et al., 2009, Guimond and Gallo-Payet, 2012, Riet et al., 2015, 
Romero et al., 2015, Saavedra and Benicky, 2007)]. (a) Renin cleaves angiotensinogen to 
angiotensin I which is the rate limiting step of the RAS and it can be blocked by RI. Angiotensin I is 
then converted to Angiotensin II by ACE which can be inhibited by ACEI. Angiotensin II acts directly 
on AT1R and AT2R receptors or undergoes further metabolism by APA producing Angiotensin III 
which further processed by APN to Angiotensin IV. Angiotensin IV inhibit the activity of IRAP receptor. 
Angiotensin II can be also metabolized by ACE2 producing angiotensin (1-7) activating MAS 
receptor. In a second pathway, Angiotensin I can be cleaved by ACE2 into angiotensin (1-9) and 
eventually to angiotensin (1-7) by ACE. (b) Stress is associated with autonomic dysfunction including 
hyperactivation of HPA-axis function; increased brain Angiotensin II formation and upregulation of 
AT1 receptors in the PVN in the hypothalamus. Angiotensin II enhance the activation of ACTH either 
indirectly through activating AT1R in the PVN mediating CRH secretion which in turn enhances 
ACTH production or directly through stimulating AT1R in the pituitary gland resulting in formation of 
ACTH. ACTH hormone stimulates adrenal gland to release glucocorticoids which regulates negative 
feedback inhibition of HPA-axis which is impaired under stress resulting in a sustain activation of 
HPA-axis function and depressive-like symptoms. (c) Ang II/AT1R also promotes inflammatory 
cascades centrally and peripherally; In the circulation, Angiotensin II activates AT1R in endothelial 
cell enhancing immune response signaling. Angiotensin II/AT1R stimulates the production of 





factors including but not limiting to cytokines (TNF-a, IL-B, IL-6), Adhesion molecules (ICAM-1, 
VCAM-1), Inducible enzymes (iNOS, Cox-2) and chemokines (MCP-1). Pro-inflammatory cytokines 
and angiotensin II can penetrate BBB activating microglial cells inducing cell injury and 
neuroinflammation. Angiotensin II within brain can act directly on AT1R resulting in microglial 
activation and initiation of inflammatory signaling inducing depressive-like symptoms. 
Abbreviations: ACE, angiotensin converting enzyme; ACE2, angiotensin converting enzyme 2; 
ACEI, angiotensin converting enzyme inhibitor; Ang II, angiotensin II; ANS autonomic nervous 
system; APA, aminopeptidase A; APN, Aminopeptidase N; ARB, angiotensin receptor blockers; 
AT1R, type-1 angiotensin receptor angiotensin; AT2R, type-2 angiotensin receptor; AT4R/IPRA, 
type-4 angiotensin receptor/insulin-regulated membrane aminopeptidase or insulin-responsive 
aminopeptidase; BBB, blood brain barrier; COX-2, cyclooxygenase 2; HPA-axis, hypothalamus- 
pituitary adrenal axis; ICAM-1, intercellular adhesion molecule 1; IL-6, interleukin-6, IL-B, interleukin-
B; iNOS, inducible nitric oxidase; MAPKs, mitogen activated protein kinases; MCP-1 - monocyte 
chemotactic protein-1; NADPH, nicotinamide adenine dinucleotide phosphate; NFκB, nuclear factor 
κB; PVN, paraventricular nucleus; RI, renin inhibitor; ROS, reactive oxygen species; TNF-a, tumor 






 RAS antagonist and depression  
In the 1980s, several case reports from clinical studies revealed that depressed 
patients using ACEIs experienced a substantial mood elevation (Germain and 
Chouinard, 1988, Hertzman et al., 2005, Zubenko and Nixon, 1984). However, the 
study conducted by Patten et al. (1996) was the first epidemiological study 
reporting an association between ACEIs and depression risk. The authors 
conducted a case-control study to evaluate the associations between CCBs, BBs, 
digoxin, ACEI and clinical diagnoses of depressive disorders in hospitalised 
patients. They showed that hypertensive patients, particularly, female and 
elderly patients who had exposed to ACEI were more likely to exhibit depressive 
symptoms, an association that was not found with the other drugs (Patten et al., 
1996). Meanwhile, Gerstman et al. (1996) refuted any evidential links between 
ACEIs and depression following their prospective cohort study to determine the 
relationship between BBs and depression as the primary objective. Patients who 
were newly exposed to antihypertensive medication, including ACEIs, BBs and 
CCBs, were followed up for six months for new incidences of depression or 
recurrent depression (Gerstman et al., 1996). Although the results obtained from 
this study had obvious limitations since they were not adequately adjusted for 
possible confounders, they presented a comparable rate of depression cases 
among the three antihypertensive groups indicating that ACEIs may confer no 
greater or lesser risk than other antihypertensive drug classes. This finding was 
replicated by a later cross-sectional study conducted by Feng and colleagues 
(2008), where they demonstrated a null association between ACEIs and depressive 
symptoms after adjusting for potential confounders (Feng et al., 2008). A 
Norwegian cross-sectional study investigated the association between the 
different classes of antihypertensive medications (ACEIs, CCBs, BBs and diuretics) 
and depressive symptoms in a large sample of 55,472 patients (Johansen et al., 
2012). Among the four groups of antihypertensive drugs, the ACEI group showed 
less frequent depressive symptoms compared to the untreated systemic 
hypertension group, though with no statistical significance (OR = 0.54, 95% CI 0.28–
1.08). In a five-year retrospective study, Williams et al. (2016) followed-up 836 
patients for the first depressive episode. They showed that among 80 patients who 
were on ACEI treatment, the incidence of depression was zero, while among the 
756 patients who were not on ACEI, the incidence of depression was 5.3%, 





further supported the later suggestion. They examined mood related hospital 
admissions of 144,660 patients treated with antihypertensive monotherapy for a 
five-year follow-up. Their results showed that ACEIs and ARBs were associated 
with the lowest risk of mood disorder admissions comparing to other 
antihypertensive drug classes. Similar findings were revealed by Kessing et al. 
(2020) showing that ACEI and ARB associated with decreased risk of depression 
incident. By contrast, Cao et al. (2019) followed 181,709 newly diagnosed 
hypertensive patients for four years to detect the first antidepressant prescription 
as a proxy for depression. The results showed that ACEIs had the second-highest 
risk of depression among participants in all five main classes of antihypertensive 
drugs compared to ARBs (HR = 1.35, 95% CI 1.28–1.42).  
Recently, it has been suggested that medications targeting the RAS system, 
including ARBs and ACEIs, may have a beneficial effect as therapeutic agents for 
mood disorders (Vian et al., 2017). However, even without mentioning the large 
inconsistencies between the clinical studies, evidence supporting this theory was 
largely based on early case reports, observational studies that were poorly 
designed and small trials. More recent data, however, have been published from 
adequately powered and well-designed clinical studies, although it remains 






 TZD and TZD related diuretics 
TZDs have been considered a cornerstone in the treatment of hypertension 
since their introduction in 1958 (Moser and Feig, 2009). Apart from the UK, 
most recent European and American guidelines continue to recommend this 
class as a first-line treatment for essential hypertriton (McNally et al., 2019). 
TZDs are also used to manage oedema as a result of HF, hepatic cirrhosis and 
kidney diseases. They are grouped into TZD and TZD-like diuretics according 
to their molecular structure. Members of the TZD class derive from 
benzothiadiazide, while TZD-like diuretics lack this structural derivative, but 
both groups share a similar mechanism of action. In general, TZDs and TZ-
related diuretics exert their BP lowering effect by promoting diuresis through 
restricting sodium reabsorption and enhancing Na+ and water excretion. They 
were specifically designed to inhibit the action of the Na+/Cl- co-transported 
(NCC) at the distall convoluted tubule, where about 7%-10% of the daily 
filtered NaCl is returned into the circulation (Ives, 2012). The resulting low 
intracellular Na+ in turn lowers intracellular Ca2+ mediated by the Na+/Ca-
exchanger (NCX1). This triggers a compensatory mechanism at the proximal 
tubule that enhances the reabsorption of Ca2+ through a passive diffusion into 
the luminal epithelial cells inducing a hypocalciuric effect. For this reason, 
TZDs can also be used as a treatment for kidney stones produced by 
hypercalciuria (Ives, 2012).  
 TZD and depression  
Overall, the CNS side effects of TZDs, such as fatigue, confusion and lethargy, are 
reported to be 5% to 10% (Gengo and Gabos, 1988). Compared to the other four 
main classes of antihypertensive agents, TZDs show no frequent association with 
depression and have not been used as a therapeutic agent in this context. One 
study suggested a link between TZD and depression based on a case series of eight 
patients (Okada, 1985), though further evidence confirming this finding is lacking. 
Subsequent studies that have investigated the relation between TZDs and 
depression have almost consistently reported a null association (Table 1-6) (Boal 
et al., 2016, Kessing et al., 2020, Pająk et al., 2013, Shaw et al., 2019). A 





suggested to be through an electrolyte imbalance rather than a direct action on 





Table 1-6 Antihypertensive drugs and risk of depression 
Study Study population N EM 
FU 
Yrs 
Studies antihypertensive drugs 
Index Effect size 
CCB1 BB2 ACEI3 ARB4 DIT5 










(Dhondt et al., 
2002) 
Elderly participants 




(Feng et al., 
2008) 
Elderly participants 
2804 DS  -/+ -/+ -/+ NA -/+ OR 
1.07 (0.70, 1.63)1 
1.01 (0.67, 1.52)2 
1,56 (0.95, 2.57)3 































Aged 18 or older 












Study Study population N EM 
FU 
Yrs 
Studies antihypertensive drugs 
Index Effect size 
 CCB1 BB2 ACEI3 ARB4 DIT5 
Case-control (cases/controls) and retrospective studies 
(Cao et al., 
2019) Newly diagnosed 
with HTN 





























226/471 DD - -/+ -/+ -/+ NA NA OR 
1.09 (0.70-1.71)1 
0.29 (0.14-0.56)2 
1.23 (0.82 -1.87)3 
(Rathmann et 
al., 1999) 




Prospective cohort studies   
















(Ried et al., 
2000) Hypertensive 
elderly patients 




(Shaw et al., 
2019) 
New user of AHT 
with no previous 

















Abbreviations: AD, antidepressants; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; BB, β-blocker; CCB, calcium channel blocker; DD, depressive disorders; DS, 
depressive symptoms; FU, follow-up; HR, hazard ratio; MDD; major depressive disorders; OR, odd ratio; PR, Prevalence ratio; RR, risk ratio; SMR, standardised mortality ratio TZD, thiazide diuretics.* 





 Summary of literature review and rationale for the 
present study 
 Depression and risk of future CVD event 
Over the past several decades, there has been notifiable progress in our 
understanding of the complex networks of interacting pathways linking depression 
with CVD. Several meta-analyses that have been conducted on this topic have 
provided robust evidence indicating that depression is an independent risk factor 
for CVD. However, as previously described (section 1.1.5), early observational 
studies that examined the association between depression and CVD had poorly 
adjusted for potential confounders, and therefore their results are likely to be 
biased, posing threats to the accuracy of the estimated risk. Further, apart from 
Van der Kooy et al.’s study (2007), the main outcomes of previous meta-analyses 
were a single subtype of CVD, either CHD or stroke. There are now accumulating 
numbers of observational studies that have assessed a depression risk in relation 
to stroke, CHD and HF simultaneously; subsequently, these studies have detected 
the first outcome of the CVD subtype and provided a separate risk estimate for 
each outcome. A previous meta-analysis that focused mainly on one outcome 
failed to provide a full picture of the relation between depression and different 
CVD subtypes. Thus, it remains unclear whether depression is associated with an 
excessive risk for a specific subtype or whether it imposes an equivalent risk across 
different types of CVD. Moreover, most of the previous meta-analyses had pooled 
the risk estimate from observational studies that had measured depressive 
symptoms at a single time point and extrapolated the results to lifetime exposure. 
To overcome this problem and provide more valid estimates for CVD risk attributed 
to depression, more recently published prospective studies have measured 
depression at multiple instances over the follow-up time. Therefore, one of the 
questions that remains to be answered is how changes in depressive symptoms 
over time may affect the risk of developing CVD and whether the magnitude of 
risk increases as the number of depressive episodes increases. 
Hypertension is the strongest risk factor for CVD (Fuchs and Whelton, 2020), which 
is the leading cause of morbidity and mortality worldwide. Meanwhile, as an 
established risk factor for CVD, depression is as important and independent of the 





have a large and relevant impact on public health and clinical context. A large 
body of evidence shows pathophysiological overlaps between hypertension and 
depression and, accordingly, the pathways of commonly used antihypertensives 
drugs may also play a role in the pathogenesis of depression. Indeed, there has 
been a long-standing debate on whether antihypertensive drugs are associated 
with an increased or decreased risk of depression and which of the drug classes 
are most likely to cause such an effect. Early epidemiological studies conducted 
on this matter were constrained by methodological limitations, including cross-
sectional designs, small sample sizes, short follow-up duration, lack of a control 
group and inadequate adjustment for potential confounders. Further, the main 
objective of most previous studies was to look for a relation between a specific 
drug class of antihypertensive and depression. However, these studies did not 
clearly enable clinicians to discern how each drug class may impact depression. 
More recent epidemiological studies have revealed that each class of 
antihypertensive drug might have a distinct effect on mood disorders. Therefore, 
as an antihypertensive drug is one of the core medications in a CVD therapeutic 
plan, it is crucial to determine the exact relation of each individual class with 
depression and evaluate the possible impact of medication-related factors, such 







 Aim and objectives of the thesis 
This study has two main objectives. First, to conduct an updated systematic 
review and meta-analysis to assess the association between depression and new-
onset CVD event (defined as CHD, stroke and HF) among CVD free patients to 
answer the following questions: 
1- Whether the magnitude of depression risk is similar across different CVD 
subtypes.  
2- How changes in depressive symptoms over time may affect the risk of 
developing CVD. 
The Second objective is to investigate the association between the exposure to 
the five major classes of antihypertensive agents including CCB, BB, ACEI, ARB and 
TZD and risk of depression and determine whether there is a dosage relation. 
 
81 
Chapter2: Methods  
 
 Methods 
 Systematic review  
This section describes the strategies and methods applied to systematically review 
the association between depression and CVDs. The research methods of this 
review were performed in accordance with the Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) guidelines (Stroup et al., 2000), with reference 
to the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
Protocols (PRISMA-P)(Shamseer et al., 2015). The protocol for this review is 
registered in the open access online registry, PROSPERO, University of York, York, 
United Kingdom (CRD42018094605) and is available at 
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=94605 
(See Appendix 1). 
 Eligibility criteria 
The criteria for considering and excluding studies for this review were conducted 
in accordance with the Population Exposure Comparison Outcome Study design 
(PECOS) framework (Morgan et al., 2019). 
 Population 
Adult men and women aged 18 years old and over, and free of stroke and CHD at 
study entry. Studies focusing on men and women aged younger than 18 years or 
with existing CHD or stroke at study entry were excluded from this analysis. 
 Exposure and comparators 
The exposure and comparators were evaluated based on the following criteria: (1) 
the eligible type of exposure is depression, which refers to MDD, clinical 
depression, depressive disorder and depressive mood; (2) the screening or 
diagnosis strategies used to measure depression include a valid standard SRS, 
structured clinical diagnostic interview, physician/clinical diagnosis and/or anti-
depressant medication use; (3) depression should be reported as a binary variable 
by grouping participants by depression status based on the presence or absence of 
depressive symptoms (yes/no); (4) depression should be assessed and reported 
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separately if the study examined other mood disorders within the same 
population; (5) as a measure of the association between depression and the main 
outcomes (CVDs incidences and/ or CV mortality), an adjusted RR with 95% CI or 
HR with 95% CI should be reported or at least sufficient information provided to 
compute effect size 6) eligible studies should have a control group with no 
depression.  
Studies that measured depression combined with other mood disorders, such as 
anxiety and did not report depression separately, were excluded. Further 
exclusions included screening or diagnostic strategies that non-specifically 
measured depression (e.g. measured anxiety alone or other generalised 
psychological distress), studies that analysed depression as a continuous variable 
or did not provide enough information to abstract RR or HR, and studies without 
a control group of participants with no depression diagnosis. 
 Outcome measures 
Endpoints for decision-making were evaluated based on the following: (1) 
Outcome: defined as diseases of the circulatory system based on the 10th/11th 
Revision of the ICD-10. In this review, the outcome of interest was divided into 
three groups: (a) CHD (ICD-10 code I20-I25, or ICD-11 code BA40-BA60), (b) 
cerebrovascular disease (stroke) (ICD-10 code I60-I69 or ICD-11 code 8B00- 8B03, 
8B10, 8B11 and 8B20), and (c) HF (ICD-10 code 150 or ICD-11 code BD10-13, BD1Y 
and BD1Z). Transient ischemic attack (TIA) has been also considered as part of the 
stroke outcome (defined by the ICD-10 code G45). (2) Outcome measures: CVD 
events defined by hospital admission or medical records with diagnoses of CVDs, 
or death certificates with CVD as underlying cause of death. (3) Type of outcome: 
Primary outcome is the incidence of CVDs including fatal or non-fatal CVDs 
observed among depressed individuals compared with those who were free of 
depression. The following outcome measures were excluded: (1) Outcomes of 
other CVDs not mentioned in the list of outcomes or (2) a composite CVD endpoint. 
 Study design 
Studies were included if they met the following criteria: (1) a prospective cohort 
study design; (2) provided estimates as a measure of the association between 
depression and the main outcomes– an adjusted RR with 95% CI or HR with 95% CI 
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should be reported and (3) adjusted for potential confounders or at least for age 
and gender. Observational studies that had retrospective, case-control, cross-
sectional or case series study designs or clinical review papers, letters to the 
editor and editorials without data were all excluded. Further, studies that did not 
adjust for potential confounders (age and sex) were also excluded. 
 Language  
Only articles written in the English language were considered. 
 Information sources 
A comprehensive search strategy was applied to ensure more complete coverage 
of relevant studies including published and unpublished studies. The search 
strategy was developed by examining existing systematic reviews on depression as 
a risk factor for incidence of various heart diseases, to identify relevant electronic 
database and search terms (Gan et al., 2014, Nicholson et al., 2006, Rugulies, 
2002, Van der Kooy et al., 2007, Wu and Kling, 2016). 
 Search strategy for identifying relevant studies 
 Electronic searching 
The search was applied to four databases: Medical Literature Analysis and 
Retrieval System Online (MEDLINE (OVID), from 2005 onwards), the Excerpta 
Medica Database (EMBASE (OVID) from 2005 onwards), Psychological Information 
Database (PsychINFO, from 2005 onwards) and Web of science database from 2005 
onwards. 
Literature search strategies were developed using medical subject headings 
(MeSH) and text words related to depression and CVDs, including the following: 
the umbrella term ‘depress*’ was used to capture all studies that had a title 
related to depression disorder or depressive symptomatology. ‘Depress*’ was 
combined with other keywords such as ‘myocardial infarction’, ‘cardiovascular 
disease’, ‘cardiovascular disorder’, ‘cerebrovascular disease’, ‘cerebrovascular 
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disorder’, ‘stroke’, ‘ischemic heart disease’, ‘heart failure’, ‘cohort’, 
‘hyperten*’1, ‘longitudinal’ and ‘prospective’ on human beings.  
Table 2-1 shows the search strategy used in more detail. The literature search in 
the current review spanned the last 15 years because the latest comprehensive 
systematic review covering depression and CVDs was performed in January 2005 
(Van der Kooy et al., 2007). 
 
 
1 High blood pressure key words were also included to make the search comprehensive enough to 
encompass hypertension, the strongest risk factor of CVD for a better understanding of the 
relation between depression and hypertriton and how the association, if exist, will influence the 
relationship between depression and CVD and antihypertensive drugs and depression. 
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Table 2-1 Keywords use for electronic database search 
# Keyword search 
1 exp depression/  
2 depress*.mp.  
3 low mood.mp.  
4 depress* symptom*.mp.  
5 (symptom* of adj3 depress*).mp 
6 major depress*.mp.  
7 1 or 2 or 3 or 4 or 5 or 6  
8 hypertension/  
9 (elevated blood pressure or high blood pressure).mp.  
10 hyperten*.mp.  
11 blood pressure.mp.  
12 8 or 9 or 10 or 11  
13 ischemic heart disease/ or angina pectoris/ or 
coronary artery atherosclerosis/ or coronary artery 
constriction/ or coronary artery obstruction/ or 
coronary artery thrombosis/  
14 (ischemic heart or cardiac disease*).mp.  
15 myocardial infarction.mp.  
16 (coronary adj2 disease*).mp.  
17 infarc*.mp.  
18 or/13-17  
19 cerebrovascular disease/ or cerebrovascular disorder/  
20 (cerebrovascular disease* or cerebrovascular 
disorder*).mp.  
21 stroke.mp.  
22 or/19-21  
23 (cardiovascular disease* or cardiovascular 
disorder*).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword, 
floating subheading word]  
24 heart failure.mp.  
25 exp cohort studies/  
26 cohort*.tw.  
27 exp longitudinal study/  
28 exp prospective study/  
29 cohort.mp.  
30 or/25-29  
31 (animal$ not human$).sh,hw.  
32 30 not 31  
33 12 or 18 or 22 or 23 or 24  
34 7 and 32 and 33  
35 limit 34 to yr="2005 -Current"  
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 Searching other resources 
To ensure literature saturation, screening was performed on the references list of 
the included studies based on the aforementioned criteria. Previous reviews and 
meta-analyses were also screened for eligible studies (Barlinn et al., 2015, Dong 
et al., 2012, Li et al., 2015a, Meng et al., 2012, Nicholson et al., 2006, Pan et al., 
2011b, Rugulies, 2002, Van der Kooy et al., 2007, Wu and Kling, 2016).  
 Study records 
 Data management 
The electronic database citations, studies retrieved from the references list of 
past reviews and studies retrieved from relevant articles were imported and 
collated into a reference manager software (Endnote).  Endnote X9 was used to 
manage and delete duplicate records. All imported references from the searched 
electronic databases in Research Information Systems, Inc. (RIS) or endnote export 
(.enw) format were then grouped into smart groups labelled according to the 
source of every reference (MIDLINE, EMBASE, Web of Science and PsychINFO). 
Then, all references were exported to Rayyan, a screening software, using 
endnote the export (.enw) output style. Rayyan is a free Web and mobile app 
designed to speed-up the initial screening of abstracts and titles through a semi-
automation process facilitating a rapid exploration and filtering search for eligible 
articles (Ouzzani et al., 2016). Further identification of duplicates was carried out 
in Rayyan. 
 Selection process  
After uploading the citations to Rayyan, screening was performed in two stages: 
(1) the title and abstracts were screened and (2) all studies that met the inclusion 
criteria were exported to endnote using the export (.enw) output style. The full 
text-articles for all titles that appeared to meet the predefined eligibility criteria 
were then retrieved and screened. As the primary reviewer, I conducted an initial 
screening of the titles and abstracts of all retrieved articles. The full texts of 
potentially eligible studies were retrieved and assessed independently for 
eligibility by two reviewers (myself and Mohammed Ba-zuhair). Any disagreements 
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between the reviewers were resolved through discussions with the supervising 
authors (Prof Sandosh Padmanabhan and Prof Daniel Smith). 
 Data collection process 
Data extraction from all selected articles was carried out by the primary reviewer 
(Anwar Mansour Alnakhli) (i.e. 100%). Mohammed Ba-zuhair crosschecked all 
articles for accuracy and independently extracted the data.  
 Data extraction 
The data extraction form was designed after considering how much information 
should be collected. A standardised Microsoft Excel 2010 worksheet was used to 
extract data from the included studies for assessment of study quality and 
evidence synthesis.  
The extracted study population data included (1) characteristics of the study 
population at baseline (i.e. mean age in years and percentage of male), (2) overall 
number of study participants and (3) the health condition of enrolling participants 
before study entry, including history of CVDs. 
The extracted data for exposure were (1) definition of depression (cut-off point), 
(2) measurement of depression, (3) how frequently depression was measured 
throughout the study period, (4) whether a study defined a minimum period that 
depressive symptoms should last to make a proper diagnosis (e.g. for the past two 
weeks) and (5) type of depressive symptoms assessed by a SRS. 
For the outcome of interests, the following data were extracted: (1) main type of 
outcomes and other subtypes if reported, (2) measurement method of the 
outcomes and (3) number of cases. 
The extracted study design data were (1) name of the first author, (2) year of 
publication, (3) name of the cohort, (4) study design, (5) study location, (6) 
duration of follow-up, (7) covariates that were adjusted in the multivariable 
analysis and (8) most fully adjusted RR or HR with the corresponding 95% CI. 
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 Dealing with missing data 
When data were missing, the original authors of the study were contacted with a 
maximum of two email attempts to obtain the relevant missing data. If there was 
no response, studies with insufficient information were excluded from this review 
and analysis. 
 Assessment of methodological quality  
To evaluate the risk of bias within eligible studies, the methodological quality of 
potential studies was assessed using the Newcastle-Ottawa scale (NOS) for cohort 
studies (Wells et al., 2014). The NOS is a validated eight-item scale for assessing 
the quality of non-randomised studies in meta-analyses. This scale uses a ‘star 
system’, assigning a maximum of nine stars for the eight items. The stars are 
allocated based on three domains. The first domain refers to the selection of the 
study groups and assesses four items each worth one star: (a) representativeness 
of the exposed cohort, (b) selection of non-exposed cohort, (c) ascertainment of 
exposure, and (d) demonstration that the outcome of interest was not present at 
the start of the study. The second domain, which is allocated a maximum of two 
stars, evaluates the comparability of the groups based on the study design or 
analysis, meaning that either exposed or non-exposed individuals were matched 
in the design or confounders were adjusted for in the analysis. The third domain 
allocates a maximum of three stars to evaluate how the study ascertained the 
outcome. Stars are awarded for the method used to assess the outcome, whether 
the follow-up was long enough for the outcome to occur and the adequacy of the 
cohort follow-up regarding titration rate.  
Studies were rated as good, fair or low quality for scores of 7-9, 4-6 or 0-3 stars, 
respectively based on the most common cut-offs score applied in epidemiological 
studies (Lo et al., 2014). A justification for the judgement of each item is reported 
in a risk of bias table.  
 Criteria used in the quality assessment of the included studies 
The NOS tool often needs to be adapted by the study author commensurate with 
the review question of interest. Therefore, criteria were set for each assessment 
item as an indication of what would be considered acceptable to earn a star. 
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To gain four stars in the first domain, (1) participants should be representative of 
the general population and not a select group, (2) the non-depressed group should 
be selected from the same setting as the depressed group, (3) depression should 
be assessed either by a standardised psychometric tool specifically designed for 
depression screening or by a structured interview for clinical diagnosis and (4) the 
study should state that the enrolled participants were free of stroke andCHD at 
baseline. In the second domain, to earn one star, the cohort should take into 
account the most important confounders, including age and sex. To gain two stars, 
the cohort should additionally adjust for at least for five of the following 
confounders: CVD risk factors (HTN, diabetes mellitus, hyperlipidaemia, obesity, 
family history of CVD); behavioural risk factors (smoking, alcohol consumption, 
physical inactivity, medication adherence); other psychological or mental health 
problems that may also increase the risk of CVD, e.g. (anxiety); and medication 
abuse. To earn three stars in the third domain, the study outcome should be 
measured directly or through a review of secure medical records or self-reported 
scales, and studies should have a minimum follow-up duration of 10 years and a 
dropout rate of less than 20%. A guidance of how each item defined in order to 
allocate a star is presented in Table 2-2.
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Table 2-2 Criteria for the NOS to allocate stars for the quality of studies (out of 9 stars) 











Representative of cohort 
  
Selection of non-exposed 
cohort 





Ascertainment of exposure A valid psychometric tool 
for depression screening or  
a structured clinical 
interview 





outcome of interest was 
not present at start of 
study 
Stating that patients with 
stroke or IHD at baseline 















Adjusting for most 
important confounders 
Adjusted for age and sex No adjustment or 
adjusted only for 
sex or only for age 
Adjusting for other 
important confounders 
Adjusting for at least any 
five of the following: 
hypertension, diabetes 
mellitus, hyperlipidaemia, 






disorders, medication use 
such as anti-depressants and 
lipid-lowering agent 









Assessment of outcome Secure records or direct 
measure 
Self-reporting 
Was Follow-Up Long 
Enough for Outcomes to 
Occur? 
10Years Less than 10years 
Adequacy of follow-up of 
cohorts 
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 Meta-analysis 
 Meta-analysis software 
I used RevMan 5 (Review Manager, 2014) to perform the meta-analysis in this 
review. RevMan 5 is a software recommended for preparing and maintaining 
Cochrane Reviews developed by the Cochrane Collaboration Group. It is available free 
for Cochrane authors and academic use. 
 Data synthesis 
For this review, data synthesis in RevMan was conducted using a generic inverse-
variance approach, as most studies reported their main outcomes as time-to-event 
data presented as HR 95% CI. I extracted the HR, upper limit and lower limit of CI 
from all studies reflecting the impact of depression on CVDs and entered them 
into the RevMan 5 (version 5.3.5) calculator. The calculator automatically 
computes the natural logarithm of the HR and the standard error (SE) of the 
natural logarithm for the HR. 
 Choosing between the ifxed effect  and the random effect models for 
meta-analysis 
Meta-analyses are based on one of two statistical models the fixed effect model 
(FEM) and the random effect model (REM). The assumptions under the FEM are 
that all studies in the meta-analysis share a common effect size and the variation 
in the effect size from one study to another is only due to sampling error 
(Borenstein et al., 2010). Therefore, the summary effect size is the estimate of 
this common effect size. The null hypothesis being tested in this model is that the 
effect size of each study is zero for a difference or one for a ratio (Borenstein et 
al., 2010). Distribution of points observed in the meta-analysis indicates sampling 
error only and can be reduced by assigning weights to each study in the analysis. 
Under the REM, it is assumed that the true effect size varies from one study to 
the next, and the studies included in the meta-analysis represent a random 
sampling of effect sizes (Borenstein et al., 2010). Thus, the summary effect under 
the REM is the mean of these effects. The null hypothesis under this model is that 
the mean effect is zero if  no difference exists and one for a ratio. The variation 
between effect sizes in this model can be explained by sampling error and 
variation in the true effect size across studies. The variation could also be 
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minimised by assigning weight to each study in the analysis. Given the differences 
between the two models, it is not always appropriate to conduct the analysis using 
both FEM and REM. In this review, I assessed whether REF or FEM should be 
performed to avoid misleading inferences. Ideally, FEM can be used under two 
conditions: (1) if all included studies in the meta-analysis were functionally 
identical, meaning that the subject or exposure/intervention was equivalent 
among the studies, and (2) if all studies used an identical, narrowly defined 
population whereby the common effect size cannot be generalised to other 
populations. In this review, there was a minor diversity across the included studies 
with respect to the methodological approaches used. Additionally, the goal is to 
compute the summary effect size with the purpose of extrapolating the results to 
a wide range of scenarios. Therefore, REM was adopted across all analyses to 
compute the summary effect size. Under the REM, computing a summary effect is 
based on assigning more weight to studies that yield a more precise estimate of 
the effect (Borenstein et al., 2010).  
 Assessment of heterogeneity 
Heterogeneity in a systematic review is defined as any kind of variability between 
included studies (Borenstein et al., 2010). This variability may be due to clinical 
diversity (e.g. variability in participants, exposures and outcomes) and/or 
methodological diversity (e.g. variability in study design). Statistical 
heterogeneity is a consequence of clinical or methodological variabilities, or both 
(Higgins and Thompson, 2002, Higgins, 2011).  
To determine the extent of variation in the true effect size between studies, tests 
of heterogeneity were performed. One common test used is the Chi-squared (X2, 
or Chi2), also known as Q-statistic test (Higgins and Thompson, 2002), which tests 
the null hypothesis that all the included studies share a common effect size. This 
review considers a p-value of <.05 statistically significant for the presence of 
heterogeneity. The Higgins (I2) statistic test was also applied to quantify the 
variability in effect estimates that is due to true heterogeneity rather than chance 
(sampling error). The I2 value ranges between 0% (indicates no observed 
heterogeneity) and 100% (larger values indicate increasing heterogeneity). I2 can 
be interpreted as follows (Higgins, 2011): 
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• 0% to 40%: might not be important; 
• 30% to 60%: may represent moderate heterogeneity; 
• 50% to 90%: may represent substantial heterogeneity; 
• 75% to 100%: considerable heterogeneity. 
Significant heterogeneity is typically considered if I2 is 50% or more. In the 
presence of statistically significant heterogeneity, one analytical approach is to 
incorporate it into an REM. The REM does not fix heterogeneity, but it allows for 
differences in the treatment effect from study to study (Riley et al., 2011) as it 
assumes that there is a distribution of true effect sizes. Furthermore, 
heterogeneity is explored with reference to the characteristics of the studies 
included in the meta-analysis by performing sensitivity and subgroup analysis. 
 Publication bias assessment 
Failing to include all relevant studies in the meta-analysis because they were not 
published is known as publication bias. Several tests can detect and/or estimate 
the impact of publication bias on a meta-analysis. In this review, I used the funnel 
plot method. The funnel plot is a simple scatter plot of the intervention/exposure 
effect estimates from individual studies against the standard error (Sterne et al., 
2006, Higgins, 2011). The effect estimates of the studies were plotted on the 
horizontal axis while the measure of standard error was plotted on the vertical 
axis. The results from the small studies were scattered at the bottom of the graph, 
and the spread narrowed for the larger studies. In the absence of bias, the studies 
were distributed symmetrically around the mean effect size, while in the presence 
of the bias, the model appeared symmetrical at the top (reflecting large studies) 
and more studies absence (small studies) near the bottom. This approach cannot 
be used to estimate the extent of the impact of publication bias on the meta-
analysis or the effect size in the absence of publication bias. 
 Sensitivity analysis  
Sensitivity analysis was performed to assess the robustness of the obtained results. 
The criteria followed for excluding or restricting certain studies are described in 
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detail in the methods section of each outcome results chapter (Sections 4.2.1 and 
5.2.1). 
 Subgroup analysis 
Subgroup analyses are typically undertaken to explore possible sources of 
heterogeneity. Full details on stratification for the subgroup analysis are provided 
in each outcome results chapter (Sections 4.2.1 and 5.2.1). 
 The Cohort study 
 The Glasgow Blood Pressure Clinic database (GBPC) 
 Study setting and study population 
The study population are all patients attending the GBPC (Williamson et al., 2013), 
which is the largest and the main specialist hypertension clinic in Glasgow 
providing secondary and tertiary level service to individuals with hypertension 
from the West of Scotland. Patients are referred to GBPC if their BP is not well-
controlled in primary care with at least three drugs, or if there is evidence of high-
risk factors such as early-onset hypertension, features of secondary hypertension, 
or family history of premature CVD. Structured instruments are used to collect 
data from all patients attending the clinic and are stored electronically in a single 
computerised database, which contains information on more than 16,000 patients 
attending the clinic from 1969 until 2011. All patients were treated at the clinic 
until their BP control was stabilised, with continuing follow-up at the clinic or in 
primary care. Use of the anonymized database for analyses is approved by the 
West of Scotland research ethics service of the National Health Service 
(11/WS/0083). 
2.2.1.1 Laboratory and clinical measurements 
A structured format was used to enter clinical details for patients including age, 
gender, the presence of existing CVD, tobacco use (any versus none), body weight, 
cholesterol level, renal function and family history of hypertension or premature 
CVD. Method for data collection and prescription was described in detail on 
previous work 
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• Blood pressure measurement  
The patient was placed in either a supine or sitting position for five minutes 
prior to BP measurement. Maintained, and calibrated mercury 
sphygmomanometers (Accoson Dekamet MK3,UK) were used for reading 
blood pressure. The tight clothing was removed, and arm was supported at 
heart level position. The appropriate cuff size was taken. The cuff was 
inflated above the brachial artery until the pulse disappeared. When the 
pulse appeared again by deflating the cuff, the SBP was recorded as an 
estimation. The cuff was then re-inflated to 30 mm Hg over the SBP 
estimation, a stethoscope was placed and the cuff was deflated at the rate 
of 2 mm Hg per second. The SBP was recorded when the rhythmic sound 
appeared, and diastolic blood pressure (DBP) was recorded when the sound 
disappeared by continuing the deflation. BP measurements were obtained 
manually two times. Third measurement was taken if the second reading 
was significantly lower. The mean of the last two measurements were 
recorded. The difference between the SBP and DBP was defined as pulse 
pressure. SBP < 140 mm Hg and DBP < 90 mm Hg were the therapeutic target 
of blood pressure. 
• Smoking status 
Specialist nurses or physicians interviewed patients during their first visit 
to obtain smoking status information. A copy of this information was kept 
in the case notes as well as transferred to the GBPC electronic database. 
• Body weight and hight 
Calibrated weighing machines were used to measure body weight (Seca 955 
chairscale). A height stick was used to measure height. Both body weight 
and hight used to calculate body mass index (BMI). According to the WHO, 
a BMI equal to or more than 30 kg/m2 defined as obesity. Overweight or 
pre-obesity defined as a BMI between 25 and 29.99 kg/m2. A BMI between 
18.5 and 24.99 kg/m2 defined as an optimal weight. 
 
• Blood samples were collected at baseline and at regular intervals for 
estimation of routine hematologic and biochemical indices, including renal 
function tests and cholesterol level. All biochemical investigations were 
96 
Chapter2: Methods  
 
performed at the Western Infirmary clinical laboratory service on blood 
samples obtained at the first visit as part of routine screening.  
•  Family history 
Records of patients who attended the GBPC from 1969 to 2011 were 
extracted from the database and reviewed. Each patient attending the 
clinic completed a structured questionnaire on health details of firstdegree 
relatives (parents and siblings): alive/dead, number of full brothers and full 
sisters, history of hypertension, myocardial infarction and stroke, age at 
death, age at heart attack/stroke, and age at diagnosis of hypertension. 
• The Charlson comorbidity index score 
The Charlson comorbidity index (CCI) score was defined using the enhanced 
ICD-9 codes and ICD-10 codes as described in Quan et al. (2005). The CCI 
score was calculated for the time of study start date using data on all 
preceding hospital admissions upto 1990. (meaning between 1990 and 
2005). 
• Renal function 
Estimated glomerular filtration rate (eGFR) was used to evaluate renal 
function.eGFR was calculated from the baseline serum creatinine values. 
Modification of Diet in Renal Disease Study Group (MDRD) equation was used 
to calculate eGFR. The three variable modification were included with 
serum creatinine values in this equation. These variable are age, race, and 
sex as shown in equation below (461). 
eGFR= 32788 × serum creatinine (in μmol/L) -1.154 × age -0.203 *(1.212 if 
black) ×(0.742 if female) 
Based to the National Kidney Foundation Kidney Disease Outcomes 
QualityInitiative (NKFKDOQI) and based on eGFR, kidney function was 
classified intonormal or 3, 4, and 5 stages (Levey et al., 2003). While a 
normal kidney was considered as having an eGFR ≥ 60 mL/min/1.73 m2, 
CKD stage 3 was determined if the eGFR was between 30 and 59 
mL/min/1.73 m2. The eGFRs between 15–29 mL/min/1.73 m2 and < 15 
mL/min/1.73 m2 were considered as CKD stages 4 and 5, respectively. 
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 The Information Services Division database 
Pharmacy refill data were obtained from the Prescribing Information System (PIS), 
an electronic database of all National Health Service (NHS) prescriptions dispensed 
to individuals across Scotland, which is maintained by NHS National Services 
Scotland (NSS) (Ahmed et al., 2015) and linked to the hospitalisation using the 
unique patient Community Health Index (CHI) number. The PIS is created from 
information supplied by the Practitioner Services Division of the NSS, which is 
responsible for the processing and pricing of all NHS prescriptions dispensed in 
Scotland (Ness et al., 2015). Data on private (non-NHS) prescriptions are not 
routinely collected and were therefore unavailable for analysis; however, as 
prescription charges were abolished in Scotland in 2011 and the NHS is free at the 
point of use for the entire population, the relative contribution of these 
prescriptions is expected to be low. 
The PIS contains fields for a variety of metrics, including prescriber and dispenser 
information (e.g. location and organizational structure) and prescription details 
(e.g. the name, strength, formulation and cost of the medicine). Data fields 
included date of dispensation, the class and name of the medicine, and the 
number of items. Medicines were categorized by both British National Formulary 
(BNF) subsection and approved name. Antihypertensive drugs were classified as 
alpha blockers, ACEI, ARB, BB, CCB, centrally acting antihypertensive, non-
thiazide diuretic and thiazide diuretic drugs. 
The number of items referred to those items processed and paid for under 
NHS Scotland, excluding those from GP10A (Stock Order) forms and hospital-based 
prescription forms. Prescription data and outcome data was obtained from the 
Information Services Division (ISD) Scotland which provided data for all patients 
attending the Glasgow Blood Pressure Clinic during the period of 31/12/2003 to 
31/03/2013. The CHI number had been used to connect the ISD prescription data 
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• Daily defined dose of antihypertensive and antidepressants drugs 
Data on refilled prescription for patients extracted from the ISD were 
converted into defined daily dose (DDD) as illustrated below, to enable 
comparison of different drug classes. 
➢ The number of days covered by a specific drug in the study period 
was calculated. Then, the total quantity of the drug dispensed over 
the study period – was calculated from the number of 
tablets/capsules dispensed and the strength of each. The DDD for 
each drug was obtained from the WHO ATC table (WHO, 2020). The 
total quantity dispensed was converted into total DDD (equal total 
quantity dispensed/DDD). 
Table 2-3presents the extracted information for each eligible patient. 
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Table 2-3 Extracted data for patients from the GBPC and ISD from Dec 2003 up to Mar 2013 
Demographic information Classification Coding 
Gender Categorical Male (1) and female (2) 
Year of birth Continuous  
Risk factors   
SBP and DBP Continuous   
BMI Continuous  
Cholesterol Continuous  
eGFR Categorical ≥60ml/min and 
 <60ml/min 
Smoking status Categorical Non-smoker, currently 
smoker 
Comorbidities at 
baseline for each subject 
were determined using 
CCI score 
Continuous No comorbidity (0), having 
one comorbid condition (1), 
having more than one 
comorbid conditions (2) 
Antihypertensive and antidepressants drugs 
Drug class Categorical ACEI, ARB, CCB, BB, 
alpha-blocker, diuretics, 
centrally acting 




Daily dosage Categorical Based n tertiles (low, 
moderate and high DDD) 
Other data   
• Date of death 
• Date of hospital 
admission due to CVD 
•  •  
BMI, body mass index; CCI, Charlson comorbidity index score eGFR, estimated glomular 
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 Statistical analysis and packages used for cohort analysis 
2.2.3.1 Statistical package  
Microsoft Excel 2016, and IBM SPSS statistics 26.0 were used for data analyses. 
2.2.3.2 Summary of statistics 
Categorical data was summarised using counts and percentage. Whereas 
continuous data was summarised using median and standard deviation (SD). 
2.2.3.3 Comparison of categorical data 
A chi-square (X2) test was carried out to assess the associations of the categorical 
data. The chi-square (X2) test for trend was performed to evaluate the linear 
relationship between the ordered variables (i.e. CCI categories and DDD) and the 
outcomes. Significance was set at P<0.05. 
2.2.3.4 Comparison of continuous data 
Continuous variables were examined using the Students’ T-test, which was applied 
for comparing the mean of two groups, and the one-way analysis of variance 
(ANOVA), which was used to compare means of more than two groups. The 
normality of the continuous data was tested visually (Normal Q-Q plot and 
histogram) and statistically (Shapiro-Wilk test). 
2.2.3.5 Survival analysis 
Survival analysis was performed using the Kaplan-Meyer univariate analysis to 
determine the risk of incident depression among different classes of 
antihypertensive drugs. A log-rank test was used to compare depression rate 
between antihypertensive drugs classes. Cox proportional hazards models were 
used to perform multivariate analysis and coefficients were reported as HR and 
95%CI. 
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2.2.3.6 Generalised estimating equation (GEE) 
The GEE was also used to examine the relation between antihypertensive drugs 
and risk of depression. GEE is a type of general linear model used for clustered 
data which adjusts for the within-subject correlation present among repeated 
observations over time (Liang and Zeger, 1986). This test was performed to 
analyse data of patients on antihypertensive polytherapy by treating each newly 
introduced antihypertensive drug as a cluster data for each subject. In this context 
each newly introduced antihypertensive drugs was considered as a repeated 
admission for each patient. To determine which of the antihypertensive drugs is 
independently associated with developing depression, a univariate and a 
multivariate binary logistic model were constructed that simultaneously included 
all antihypertensive drugs and coefficients were reported as OR and 95%CI. 
As there was no control group (i.e. non-users of antihypertensive drugs), the 
reference group in both analyses (i.e. Cox regression and GEE analysis) 
investigating the association between different antihypertensive drug classes and 
incident of depression was determined based on the total number of participants. 
The ACEI group contains the largest number of participants compared to the other 
antihypertensive groups and was therefore set as the reference group. 
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 Depression and Risk of CVDs: Systematic 
Review – Screening, Eligibility and Quality 
Assessment 
3.1  Aim 
This chapter describes the results of the systematic review search for cohorts 
studying depression and risk of CHD, stroke and HF. The following sections present 
the literature search, excluded and included studies, and risk of bias.of the 
included cohorts. 
3.2 Results of the search 
As shown in Figure 3-1, the initial search for published studies was carried out 
from January 2005 to October 2017 using four databases and updated in July 2020. 
Overall, 21,779 citations and/or abstracts were screened for eligibility. Of these, 
just over 97% (21,193) were excluded based on the title or abstract, as pre-
determined by this review’s PECOS criterion. The full texts of the remaining 586 
publications were assessed for eligibility. Of these, 467 were excluded and the 
full texts of the remaining 120 articles were further assessed. 
Finally, 32 cohorts were included in this review and 30 were included in the meta-
analysis. All included studies were full-length articles except for one study, which 
was a conference abstract (Sico et al., 2018). Sections 3.2.1 and 3.2.2 describe 
the details of the excluded and included studies, respectively. 
3.2.1 Description of the excluded studies 
Overall, 88 cohorts were excluded after screening their full texts for eligibility. 
Table 3-1 presents the reasons for exclusion for each cohort. Fourteen studies 
were excluded for different reasons Twenty-two studies had an outcome of 
interest that was a composite of cardiovascular events, 14 studies did not provide 
information about whether participants were with stroke and/or CHD at study 
entry, and 26 enrolled participants with CVD at baseline.  
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3.2.2 Description of the included studies 
This review included 31 studies and 47 reports (Table 3-2). All included studies 
used a prospective cohort design to investigate the association between 
depression and the outcomes of interest, which are stroke, CHD and HF. A 
description of the characteristics of the included studies is supplemented in an 
individual outcome chapter of the results section (Chapter 4 for stroke outcome,  
chapter 5 for CHD outcome and chapter 6 for HF outcome). 
 
104 
Chapter3: Systematic review and meta-analysis 
 
 
Figure 3-1 PRISMA study flow diagram 
BD, bipolar depression; CHD, coronary heart diseases; CVD; cardiovascular diseases; HF; heart 
failure; MDD, major depressive disordere. 
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Table 3-1  Reason for exclusion of cohorts 
Reference   Elaboration 
(Ahto et al., 2007) Participants with CHD or stroke at baseline  
(Almas et al., 2019) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Almeida et al., 2019) Participants had CVD at study entry 
(Appleton et al., 2013) 
Outcome of interest was a composite end point of cardiovascular 
event   
 
Participants had CVD at study entry 
(Avendano et al., 2006) Participants had CVD at study entry 
(Azevedo Da Silva et al., 
2014) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Batty et al., 2014) Exposure Not depression 
(Berecki-Gisolf et al., 2013) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Bos et al., 2008) Participants had CVD at study entry 
(Boyle et al., 2006) Participants with CHD or stroke at baseline  
(Burns et al., 2013) Participants with CHD or stroke at baseline  
(Canoui-Poitrine et al., 2017) Exposure measured as a continuous variable 
(Case et al., 2018) Outcome was a composite end point of cardiovascular event 
(Chi et al., 2014) Participants had CVD at study entry 
(Chichetto et al., 2019) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Cho et al., 2019) A Duplicate survey 
(Choi et al., 2014) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Azevedo Da Silva et al., 
2015) 
Participants had CVD at study entry 
(Deschênes et al., 2020) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Egeberg et al., 2015) Participants had CVD at study entry 
(Egeberg et al., 2016) Participants had CVD at study entry 
(Egede et al., 2005) Participants had CVD at study entry 
(Gaspersz et al., 2018) Outcome was not incidence of CVD 
(Gillespie et al., 2019) No data available on participants cardiac health condition at baseline 
(Gilsanz et al., 2017) Participants had CVD at study entry 
(Gilsanz et al., 2015) Participants had CVD at study entry 
(Glymour et al., 2010) Participants had CVD at study entry 
(Goldstein et al., 2015)  
Outcome of interest was a composite end point of cardiovascular 
event   
(Gromova et al., 2007) No data available on participants cardiac health condition at baseline 
(Graham et al., 2019) Participants with CHD or stroke at baseline 
(Haaf et al., 2017) Participants had CVD at study entry 
(Hamano et al., 2015) Participants had CVD at study entry 
(Hamieh et al., 2020) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Haukkala et al., 2009) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Haukkala et al., 2013) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Hawkins et al., 2014) A duplicate survey 
(Hazuda et al., 2019) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Henderson et al., 2013) Participants had CVD at study entry 
(Higueras-Fresnillo et al., 
2018) 
Exposure Not depression 
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Reference   Elaboration 
(Hiles, 2015) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Huang et al., 2013) Participants with CHD or stroke at baseline  
(Jackson and Mishra, 2013) Participants had CVD at study entry 
(Jackson et al., 2018a) Exposure Not depression 
(Jakobsen et al., 2008) Exposure mixed of Bipolar and unipolar depression 
(Forouzanfar et al., 2016) Participants had CVD at study entry 
(Joyce, 2015) Thesis 
(Kamphuis et al., 2006) Depression not measured as a binary variable 
(Kawada, 2017) Woring publication type 
(Khodneva et al., 2019) No data available on participants cardiac health condition at baseline 
(Klabbers et al., 2009) Participants aged < 18 years 
(Köhler et al., 2013) Participants had CVD at study entry 
(Kouvari et al., 2019) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Kubzansky et al., 2006) 
Depression was not measured as a binary variable (categorical 
classification) 
(Langvik, 2015) Participants with CHD or stroke at baseline  
(Lankarani and Assari, 2016) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Lee et al., 2008) Participants with CHD or stroke at baseline  
(Li et al., 2012) Participants with CHD or stroke at baseline  
(Liebetrau et al., 2008) Participants had CVD at study entry 
(Liu et al., 2016) Depression measured retrospectively 
(Marzari et al., 2005) Participants had CVD at study entry 
(May et al., 2014) No full data available on risk of CVD 
(Mittag and Meyer, 2012) No data available on participants cardiac health condition at baseline 
(Nabi et al., 2010b) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Nicholson et al., 2005) Participants had CVD at study entry 
(Norton et al., 2020) 
Outcome of interest was a composite end point of cardiovascular 
event   
(O'Brien et al., 2015) Participants with CHD or stroke at baseline  
(Ortega et al., 2017) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Pan et al., 2011a) Participants had CVD at study entry 
(Patten et al., 2009) Participants were aged <18 years old 
(Polanka et al., 2018) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Poole and Jackowska, 2019) No data available on participants cardiac health condition at baseline 
(Poole and Steptoe, 2020) Exposure was mixed of depression and inflammatory biomarker 
(Pössel et al., 2015) Participants with CHD or stroke at baseline  
(Rantanen et al., 2020b) Exposure was stratified by depression subtypes  
(Rowan et al., 2005) Participants with CHD or stroke at baseline  
(Rutledge et al., 2009) Participants had CVD at study entry 
(Salaycik et al., 2007) Participants had CVD at study entry 
(Scherrer et al., 2015) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Seldenrijk et al., 2015) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Sims et al., 2015) Participants with CHD or stroke at baseline  
(Sun et al., 2013) Participants had CVD at study entry 
(Sun et al., 2016b) Depression measured retrospectively 
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Reference   Elaboration 
(Surtees et al., 2008b) Participants with CHD or stroke at baseline  
(Tully et al., 2015) Outcome was not incidence of CVD 
(Vaccarino et al., 2007) Participants with CHD or stroke at baseline  
(Wiehe et al., 2006) Study design (cross-sectional) 
(Xiang and An, 2015) 
Outcome of interest was a composite end point of cardiovascular 
event   
(Zahodne et al., 2017) Participants had CVD at study entry 
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Table 3-2 Name of included cohorts, main studies outcomes and summary of studies quality 
Study Nama of cohort Outcome NOS evaluation 
CHD Stroke HF Selection Comparability Outcome 
(Brown et al., 2011) NA ✔   *** ** ** 
(Brunner et al., 2014) The Whitehall study ✔ ✔  * * *** 
(Daskalopoulou et al., 
2016) 
The Cardiovascul-ar research using Linked Besposoke 
studies and Electronic Health Records (CALIBER) 
✔ ✔ ✔ **** ** ** 
(Davidson et al., 2009) The Coronary Artery Risk Development in Young Adults 
(CARDIA) study 
✔   *** ** *** 
(Everson-Rose et al., 
2014) 
The Multi-Ethnic Study of Atherosclerosis (MESA) 
 ✔  *** ** ** 
(Gafarov et al., 2013) The WHO MONICA-psychosocial (MOPSY) Programme ✔ ✔  ** * *** 
(Gump et al., 2005) The Multiple Risk Factor Intervention Trial (MRFIT) ✔ ✔  ** ** *** 
(Gustad et al., 2013) The Nord-Trøndelag Health (HUNT) study ✔   *** ** ** 
(Gustad et al., 2014b) The HUNT study   ✔ *** ** ** 
(Hamieh et al., 2019)  The GAZEL cohort (GAZEL stands for GAZ and ELectricité) ✔   ** ** ** 
(Janszky et al., 2010) NA ✔   *** ** ** 
(Jee et al., 2019) National Health Insurance Service (NHIS) Database of 
Korea 
✔ ✔  **** ** ** 
(Karlsen et al., 2020) The Osteoporotic Fractures in Men (MrOS) study ✔ ✔  ** ** ** 
(Khambaty et al., 
2016) 
The Veterans Aging Cohort Study (VACS) 
✔   *** ** ** 
(Krishnan et al., 2005) NA  ✔  ** ** ** 
(Ladwig et al., 2006b) Multinational MONItoring of trends and determinants in 
CArdiovascular disease (MONICA) 
✔   *** ** ** 
(Li et al., 2012) Nationwide National Health Institute (NRI) Databse of 
Taiwan 
 
✔  **** ** ** 
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 Study Nama of Cohort/Database 
  
Outcome NOS evaluation 
CHD Stroke HF Selection Comparability Outcome 
(Li et al., 2019) China Health and Retirement Longitudinal Study 
(CHARLS). 
 ✔  **** ** ** 
(Majed et al., 2012) Prospective Epidemiological Study of Myocardial 
Infarction (PRIME) Study 
✔ ✔  ** ** *** 
(Mathur et al., 2016) The East London Primary Care Database ✔ ✔  *** ** *** 
(Mejia-Lancheros et 
al., 2014) 
PREvención con DIeta MEDiterránea (PREDIMED) 
✔ ✔  *** ** * 
(Moise et al., 2016) Reasons for Geographic And Racial Differences in Stroke ✔ ✔  *** ** ** 
(Nabi et al., 2010a) Health and Social Support study (HeSSup) ✔ ✔  *** ** * 
(Péquignot et al., 
2016) 
Three City Study 
✔ ✔  *** ** ** 
(Rahman et al., 2013) The Screening Across the Lifespan Twin Study (SALT) 
Interview 
✔ ✔  **** ** * 
(Rajan et al., 2020) The Prospective Urban Rural Epidemiological (PURE)  ✔ ✔ ✔ **** ** ** 
(Scherrer et al., 2011) The Veterans Health Administration (VHA) Database ✔   *** * * 
(Sico et al., 2018)a Veterans Aging Cohort Study (VACS)  ✔     
(Whang et al., 2009) The Nurses’ Health Study (NHS) ✔   ** ** * 
(White et al., 2015) Veterans Aging Cohort Study (VACS)   ✔ *** ** * 
(Wouts et al., 2008) Longitudinal Aging Study Amsterdam (LASA)  ✔  *** ** ** 
(Wulsin et al., 2005) The Framingham Heart Study (FHS) original and offspring 
cohort  
✔   *** ** ** 
CHD, coronary heart diseases; HF, heart failure; NOS, New castle-Ottawa Scale; a Conference abstract 
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3.3 Discussion 
3.3.1 Depression screening tools 
3.3.1.1  The validity of screening tools and the cut-off scores used to 
identify depression cases 
As several types of SRS instruments are available for depression screening, the 
most suitable one should be selected based on the evidence-based literature 
about these assessments, especially regarding their intended use and appropriate 
populations. The cohort studies included in this review used various types of 
validated SRS for depression screening (Table 3-3). In the following section, I 
describe and identify tool performance for depression screening and the optimal 
cut-off score commonly used to identify depression cases based on the best 
evidence available in the literature. 
The 20-item CES-D scale is among the most widely used SRS to measure depressive 
symptoms (Carleton et al., 2013); The scale has high levels of validity and 
reliability to detect both clinical depression (defined by DSM criteria) and 
subthreshold depression within a wide range of populations (Andresen et al., 
1994). The original 20-item CES-D scale has a score ranging from 0 to 60 and 
patients are categorised into one of the following four groups: not depressed (0–9 
points), mildly depressed (10–15 points), moderately depressed (16–24 points) and 
severely depressed (more than 25 points). A cut-off score of 16 or higher is 
recommended as an optimal score to identify depression cases (Andresen et al., 
1994). Most of the studies included in this review that used the CES-D scale used 
the original 20-item version and a cut-off point of 16 to classify persons as having 
‘depressive symptoms’. Davidson et al. (2009) and Gump et al. (2005) used lower 
cut-off scores (10 and 13 respectively) to identify individuals with depression, 
which may have resulted in overestimating the number of depression cases and 
increasing the number of false positives of depression. Li et al. (2019) used the 
10-item CES-D, a short version of the original scale, with a cut-off score of 12 
indicating elevated depressive symptoms. The CES-D 10 has excellent screening 
properties for MDD, particularly in older adults, and has sufficiently identified 
depressive cases as those diagnosed by clinician (Irwin et al., 1999). Irwin et al. 
(1999) recommended a cut-off score of 4 for older individuals. However, evidence 
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shows that a higher score such as 12 would be more appropriate for different 
population including elderly (Baron et al., 2017, Björgvinsson et al., 2013). The 
cohort by Moise et al. (2016) used a 4-item short version of the CES-D. The 4-item 
CES-D asks whether patients over the past week (1) felt depressed, (2) felt lonely, 
(3) had crying spells, and (4) felt sad, which corresponded with items 6, 14, 17 
and 18 on the original version. This shortened version with a cut-off point of 4 was 
validated in a heterogeneous community population of 411 women who were at 
high risk of contracting and transmitting human immunodeficiency virus (Melchior 
et al., 1993). The 4-item CES-D was found to correlate (r= 0.89) with the full CES-
D version. Recently, researchers have questioned the validity and psychometric 
properties of several items on the CES-D, including item number 17 (i.e. ‘I had 
crying spells’) (Carleton et al., 2013). Previous studies suggest robust sex 
differences in response to item 17 due to cultural norms regarding emotional 
expression rather than true differences in depressive symptoms, leading to 
potentially invalid cut-off scores, an overestimation of women’s CES-D score and 
an underestimation of men’s scores (Carleton et al., 2013, Rivera-Medina et al., 
2010). Given that the Moise et al. (2016) cohort was 41.2% male and the validity 
of 4-item CES-D has only been assessed among female population, this study may 
not have accurately captured depression in the sample. 
Majed et al. (2012) reported that depression was assessed using the 13-item 
modified CES-D, and the fourth quartile was used to identify depression cases. 
This study used data from the Prospective Epidemiological Study of Myocardial 
Infarction (PRIME); a review of the original protocol indicates that the PRIME study 
used a 13-item modification of the Welsh depression subscale which derived from 
the Minnesota Multiphasic Personality Inventory (Empana et al., 2005, Sykes et 
al., 2002). 
The 21-item BDI is a multiple-choice inventory used widely to assess the level of 
depressive symptoms in adults. Each item is scored from 0 to 3 points, giving a 
total score in the range of 0-63. The scale was constructed in 1961 and has since 
been employed in numerous empirical studies (Beck et al., 1961). The internal 
consistency of this tool has been confirmed by several studies in psychiatric and 
non-psychiatric samples and, on average, they report alpha-coefficients higher 
than 0.75 (Richter et al., 1998). Further, the BDI has good content validity, as it 
reflects six of the nine DSM-III criteria for major depression (Moran and Lambert, 
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1983). Previous studies have suggested that the range of scores from 0 to 9 can be 
considered normal (Kendall et al., 1987). The Centre for Cognitive Therapy 
distributed the following guidelines for BDI cut-off scores: a score of < 10 indicates 
none or minimal depression; 10-18 indicates mild to moderate depression; 19-29 
indicates moderate to severe depression; and 30-63 indicates severe depression 
(Beck et al., 1988). The appropriateness of the BDI cut-off scores depends on the 
nature of the sample and the purpose for which the instrument is being used (Beck 
et al., 1988). For example, if the purpose is to include the maximum number of 
depressed cases, then the cut-off score is lowered to minimise false negatives. 
However, if ‘pure’ depressive cases are included, then a higher cut-off score is 
used to minimise false positive (Beck et al., 1988). In this review, Nabi et al. 
(2010a) used the 21-item BDI screening tool to define depression cases with a BDI 
cut-off score of 10, which includes even mild cases of depression. 
The General Health Questionnaire (GHQ) (Goldberg, 1972) was developed as a 
general measure of psychiatric disorders and common mental health problems 
including depression, anxiety, somatic symptoms and social withdrawal (Jackson, 
2007). The reliability coefficients of the GHQ range from 0.78 to 0.95 in various 
studies (Jackson, 2007). The original version of the GHQ contains 60 items (GHQ-
60) covering four main areas: depression, anxiety, social performance and somatic 
complaints. Other short versions are available that include 12, 28 or 30 items. 
Brunner et al. (2014) used existing data from the Whitehall II cohort, an 
occupational study, to examine the impact of depression on the incidence of CHD 
and stroke. Depression was assessed using the 30-item GHQ (Stansfeld and 
Marmot, 1992). Theoretically, the GHQ-30 removes all questions related to 
somatic symptoms and captures the remaining three factors: depression, anxiety, 
and social performance; this version is perceived to be a stronger measure of 
psychological symptoms and can be used when circumstances demand, with only 
slight penalties in reliability and validity (Goldberg, 1972). The main concern with 
Brunner et al. (2014) study is that it used a nonspecific screening instrument for 
a common mental disorder, capturing depressive symptoms as well as anxiety, 
which is not the focus of my review. The study further measured depression using 
the 20-item CES-D scale and reported a moderate agreement between the two 
screening tools. The performance of 30-item GHQ were also tested against the 
revised Clinical Interview Schedule, which is a valid measure of mental disorders 
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as a criterion for detecting a depressive episode; the findings showed a sensitivity 
of 0.78 (0.40–0.96) and a specificity of 0.83 (0.78–0.87), which are reassuring of 
the ability of GHQ to detect depression cases in their cohort (Head et al., 2013). 
One study used the 15-item Geriatric Depression Scale (GDS) with a cut-off score 
of 5 to identify depression cases in an older population (Krishnan et al., 2005). 
The GDS was the first depression screening tool designed specifically to identify 
late-life depression in older people (Yesavage et al., 1982). The original version 
comprised 30 items with a yes/no format and a cut-off of 10 indicating depression 
cases (Yesavage and Sheikh, 1986). A shorter version of 15 items (cut-off score of 
5) was developed and validated against the original 30-item version and the DSM-
III criteria for depression. The 15-item version can be successfully used as a 
screening device for depression in the elderly (Yesavage and Sheikh, 1986), with 
specificity and sensitivity scores of 79%–100% and 67%–80%, respectively (Watson 
and Pignone, 2003). 
Whang et al. (2009) used the 5-item Mental Health Index scale (MHI-5) with a cut-
off score of 52 to identify depressed individuals. This tool is a subscale of the 
Short-Form 36 Health Status Survey designed to capture psychological distress 
versus wellbeing (Ware et al., 1993). The survey was originally constructed from 
the long version of the 38-item MHI, and it includes one or more items from each 
of the four major mental health dimensions: depression, anxiety, loss of 
behavioural/emotional control and psychological wellbeing (Ware et al., 1993). 
Although the MHI-5 scale is not specific to depression it performs better as a 
measure of depression than as a measure of these other disorders (Cuijpers et al., 
2009, Rumpf et al., 2001, Thorsen et al., 2013). The MHI-5 has been shown to have 
high sensitivity and specificity for major depression, with an area under the 
receiver-operating characteristic curve of 0.88 to 0.91 for the detection of mood 
disorders or major depression (Berwick et al., 1991). The MHI-5 scale is scored 
from 0 to 100, with lower scores indicating more depressive symptoms. No optimal 
cut-off score was used for predicting depressed cases (Hoeymans et al., 2004, 
Strand et al., 2003). Some authors have recommended a cut-off score of 52 
(Holmes, 1998), whereas others recommend a score of 60 (Rumpf et al., 2001). 
Overall, the literature shows that the MHI-5 has good performance at this cut-off 
score of 52 for detecting major depression (Berwick et al., 1991, Holmes, 1998). 
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Ladwig et al. (2006b) assessed depressed symptomatology using the DEpression 
and EXhaustion subscale (DEEX scale). This scale combines eight items 
(fatiguability, tiredness, irritability, loss of energy, difficulty concentrating, inner 
tension, nervousness, anxiety) rated from 0 to 3, leading to a score of 24. 
Clinically, the DEEX scale identifies symptoms of reduced vitality, weakness and 
‘vital exhaustion’, but without the assessment of negative self-concept 
and feelings of guilt; it is thus used as a proxy for measuring depression in a large 
population-based epidemiological study but is not limited to major depressive 
disorder. Ladwig et al. (2006b) reported that the internal consistency of the 
subscale was high (Cronbach’s alpha = 0.88). In their cohort, the cut-off score was 
derived statistically where subjects in the top third of the depressive symptom 
distribution were considered the index group with depressed mood Ladwig et al. 
(2006b), (Ladwig et al., 2006a). 
Two cohorts in this review conducted by the same authors used the 14-item 
Hospital Anxiety and Depression Scale (HADS) (Gustad et al., 2013, 2014b). The 
HADS is a well-recognised assessment instrument comprising 14 items – 7 
measuring depression and 7 measuring anxiety (Zigmond and Snaith, 1983). It has 
good concurrent validity, performing well as a psychiatric screening device 
(Bjelland et al., 2002, Lipman, 1982) and has been shown to have acceptable 
psychometric properties. The depression subscale in the HADS emphasises 
anhedonia and excludes somatic items. Items are scored on a 4-point scale, 
ranging from 0–3; the higher the score, the greater the depression and anxiety 
(each subscale ranges from 0-21). There is no single generally accepted cut-off 
score for the HADS and choosing between the score ranges depends on the 
intended use of the scale. In the original study, two cut-off scores for depression 
subscales were suggested: 8-10 for possible and 11 or more for definite cases of 
depression (Zigmond and Snaith, 1983). The latter score is likely to produce the 
best result with one false positive and no false negatives (Zigmond and Snaith, 
1983). Gustad et al. presented the HR results for the two score ranges (8-10 and 
≥11) and I extracted the HR for participants scoring ≥11 on the HADS to include 
only those patients with a high probability of suffering from depressive symptoms 
(i.e. a low proportion of false positives). 
Evidence suggests that there tend to be no major differences in performance 
among depression screening tools (Siu et al., 2016). Accordingly, no single SRS is 
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recommended over another, and the most practical one for the clinical setting 
can be used (Alexopoulos et al., 2014, Siu et al., 2016). Some authors 
recommended using both observer-rating scales, such as the Hamilton Rating Scale 
for Depression and Montomery–Asberg Depression Rating Scale, in addition to an 
SRS for a complete assessment of depression (Uher et al., 2012). In addition to the 
variability in the screening tools, the time frame of the questions also varies 
between tools. For a depressive episode, a minimum duration of two weeks is 
required for a diagnosis following the gold standard criteria (ICD-10 and DSM-IV) 
(NICE, 2009), although shorter durations may also be reasonable if the symptoms 
are unusually severe (WHO, 1993). In this review, the SRS tools measured 
depressive symptoms each within a certain time frame (i.e. today, past week, 
past weeks and past month) (Table 3-3). The validity of these differences in the 
recall period for depressive symptoms has not yet been examined in the general 
population (Maske et al., 2015). Further, as shown in Table 3-3, the SRS used by 
cohorts in this review differ widely in the symptoms they ask about. As previously 
mentioned, symptoms of depression are composed of different categories 
involving somatic, cognitive and affective symptoms (see Section 1.1.3). However, 
some SRS more dominantly focus on one or another category. For example, in the 
Gustad et al cohort, depression subscale in the HADS emphasises anhedonia (a 
subset of affective symptoms) and excludes somatic items. The 13-item subscale 
modified from the Welsh focuses solely on affective symptoms. The 10-item short 
version of the CES-D focuses predominantly on somatic symptoms, while the 4-
item CES-D predominantly focuses on affective symptoms. The GDS excludes 
somatic symptoms and focuses on cognitive and affective symptoms. Among the 
19 cohorts, only few studies justified the use of the selected SRS (Gustad et al., 
2014b, Karlsen et al., 2020, Krishnan et al., 2005). In this section, I do not intend 
to discuss the type of symptoms addressed by each tool and its suitability for the 
targeted population in each cohort, as this is beyond the scope of my research. 
This information is included only to present the symptoms heterogeneity between 
studies which can exert a significant impact on identifying depression cases and 
determining the severity of depressive symptoms as they depend on gaining scores 
on the SRS. 
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Table 3-3 Summary table of the depression screening instruments used by the included cohorts 
 












used in this 
review 
Refrence 
20-item BDI 1 Yes 
Cognitive, affective, somatic and 
vegetative symptoms 
Today 0-63 10 10,16 





Positive affect, negative affect, 
somatic problem, activity level, and 
interpersonal items 
Past week 






Three items on negative affect, five 
items on somatic symptoms, and two 
on positive affect 
   
(Li et al., 
2019) 
4-item CESD 
1  Negative affect  4 4 
(Moise et al., 
2016) 
DEEX sub-scale 1 No 
Fatigability, tiredness, irritability, 
loss of energy, difficulty in 
concentrating, inner tension, 
nervous-ness, anxiety symptoms 
Not reported 0-24 - Third tertiles 





Common mental health 
problems/domains of depression, 
anxiety, somatic symptoms and 
social withdrawal 






Affective and cognitive symptoms 
common in elderly 











(Whang et al., 
2009) 
13-item modified subscale of the 
Welsh depression subscale derived 




Negative perceptions of life  
(e.g. ‘I feel helpless’) 






(Majed et al., 
2012) 
15-item MONICA-psychological 











Past week 0-21 7,8 or 10,11 8 
(Gustad et al., 
2013, 2014b) 
BDI, Beck Depression Inventory; CES-D, Centre for Epidemiologic Study Depression Screen, DEEX, DEpression and EXhaustion subscale; GHQ, General Health Questionnaire; GDS; Geriatric 
Depression Scale; K, number of studies; MHI, Mental health Index scale; MONICA, Multinational Monitoring of Trends and Determinants of Cardiovascular Disease 
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3.4 NOS for assessment of the quality of included cohort 
studies 
A full description of the NOS instruments and how stars awarded for each study 
are summarised in chapter2 (section 2.1.5). From the 31 cohort studies, around 
60% (20) of the studies were considered good and 30% (10) were fair. One was not 
assessed because it was an abstract (Sico et al., 2018). Figure 3-2 presents the 
results of the 30-study quality analysis by domain. The major drawbacks were 
identified in the selection and outcome assessment. The following section 
describes the quality of the studies based on each domain of the NOS. Justification 
for how each studies has been evaluated is presented in Appendix 2. 
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Figure 3-2 Results from the Newcastle-Ottawa risk assessment tool for cohort studies 
It presented the results for each domain as well as the overall evaluation of the 30 cohort studies 
included in this review 
 
 






Good Quality Fair Quality Poor Quality
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3.4.1 Selection 
3.4.1.1 Representativeness of the exposed cohort 
Thirteen studies had sampled cohorts that were conducted among selected group 
of particpants (Brunner et al., 2014, Gafarov et al., 2013, Gump et al., 2005, 
Janszky et al., 2010, Karlsen et al., 2020, Khambaty et al., 2016, Krishnan et al., 
2005, Majed et al., 2012, Mathur et al., 2016, Mejia-Lancheros et al., 2014, 
Scherrer et al., 2011, Whang et al., 2009, White et al., 2015), while the remaining 
studies were represented to the general population and each therefore gain one 
star.  
3.4.2 Selection of the non-exposed cohort 
As all included studies drew their exposed and non-exposed groups from the same 
population, all of them are awarded one star for this domain. 
3.4.2.1 Ascertainment of exposure  
In this domain, star allocation is restricted to studies that used medical records or 
structured interviews to identify the exposure which was 12 studies.  
3.4.2.2 Demonstration that the outcome of interest was not present at the 
start of the study 
Under this domain, it is sufficient for a study to report a clear statement defining 
their population to be free of both stroke and CHD before study entry to earn a 
star. This is regardless of the method used to assess the participant’s medical 
history. In my review, apart from Brunner et al. (2014) and Gump et al. (2005), 
all included studies defined their population to be free of stroke and CHD at 
baseline with a clear statement either by using medical records or self-reported 
questionnaires; therefore, each earned a star. However, for Brunner’s and Gump’s 
studies, I relied on a previous meta-analysis (Barlinn et al., 2015) because the 
authors performed an additional analysis that included studies with participants 
free of cardiac diseases. Accordingly, I assumed that these two cohorts had 
excluded patients with stroke and CHD at baseline, and I therefore assigned a star 
to each. 
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3.4.3 Comparability 
In this domain, a maximum of two stars could be allocated. Comparability assesses 
cohorts based on the design or analysis. Confounders are divided into two 
categories, as shown below, and each category merits one star. 
3.4.3.1 Adjusting for most important confounders 
As stated in the method (section 2.1.5.1), age and gender were potential 
confounding variables. Cohort studies had to adjust for both age and gender to be 
allocated a star. All cohorts were awarded a star for this category. 
3.4.3.2 Adjusting for additional confounders (a second important factor) 
Studies that adjusted for at least five of the previously mentioned additional 
confounders (section 2.1.5.1) earned a star. Only three studies did not adjust for 
these confounders (Brunner et al., 2014, Gafarov et al., 2013, Scherrer et al., 
2011). 
3.4.4 Outcome 
3.4.4.1 Assessment of outcome 
In this domain, the allocation of stars depends on the method used to confirm 
outcome occurrence. Blind, independent assessment, reference to secure records 
and linkage to medical records were considered acceptable assessment methods 
to earn a star. Apart from Li et al. (2019) and Rajan et al. (2020), all included 
studies reported the outcome using these criteria and were thus all awarded one 
star. 
3.4.4.2 Sufficient follow-up duration for outcomes to occur  
An acceptable length of follow-up was set at 10 years. Eleven studies had a follow-
up duration less than this period (Li et al., 2012, Li et al., 2019, Mejia-Lancheros 
et al., 2014, Moise et al., 2016, Nabi et al., 2010a, Rahman et al., 2013, Scherrer 
et al., 2011, Sico et al., 2018, Whang et al., 2009, Wulsin et al., 2005, White et 
al., 2015), but the remaining cohorts were each awarded one star. 
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3.4.4.3 Adequacy of follow up of cohorts 
In this domain, the follow-up of the exposed and non-exposed cohorts was 
assessed to ensure that losses were unrelated to either the exposure or the 
outcome. One star was assigned to cohorts that achieved complete follow-up for 
their subjects or if the proportion lost to follow-up was less than 20%. Eight studies 
stated that follow-up was completed for 100% of their participants and each were 
allocated one star (Gafarov et al., 2013, Majed et al., 2012, Mathur et al., 2016, 
Davidson et al., 2009, Gump et al., 2005, Jee et al., 2019, Krishnan et al., 2005, 
Ladwig et al., 2006b). Five studies reported a small proportion of lost to follow-
up (<20%) and were allocated one star each (Gump et al., 2005, Moise et al., 2016, 
Pequignot et al., 2013, Wulsin et al., 2005, Rajan et al., 2020). The remaining 
cohorts did not provide any proportion or description of those lost to follow-up.  
3.5 Discussion 
This chapter describes the protocol for identifying studies used in this systematic 
review and discusses the main methodological challenges that might explain the 
high diversity observed between the included studies.  
Many studies in this review have issues that may introduce bias, leading to an 
underestimation or overestimation of the true effect of exposure. The NOS is an 
easy and convenient instrument recommended by the Cochrane Collaboration to 
assess the risk of bias in observational studies (Reeves BC et al., updated March 
2011). Further, I chose this tool because it would be easier to compare my 
assessment with previous reviews in this area that had used the same instrument 
(Barlinn et al., 2015, Gan et al., 2014, Wu and Kling, 2016). 
The first item in the NOS tool assesses the representativeness of the cohort’s 
population. About 30% of the included cohorts were not representative of the 
general population as they were conducted on selected groups of patients. This 
means that important baseline imbalances probably existed across studies and can 
be considered a potential source of bias. However, the NOS tool defined the 
representativeness of the cohort with respect to the community, meaning that 
even enrolling a group of patients that is unrepresentative of the general 
population but still representing their community is sufficient to meet this 
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criterion. Nevertheless, doing so might affect the exposure-outcome association 
since there is a high chance that some factors associated with the selection also 
determine the outcome of interest (Pizzi et al., 2013). The impact of selecting 
individuals that are not representative to the general population can be observed 
in Scherrer et al. (2011) study, which showed that the risk of future CHD is 
significantly high among patients with a high risk, such as diabetic patients, 
compared to those without. 
Further, a valid ascertainment of exposure based on the NOS can occur via secure 
records or a structured interview. The psychiatric field is different from other 
medical areas, as the diagnostic process relies exclusively on clinical evaluation 
(Luchini et al., 2017). Therefore, it is important to determine whether a study 
identified cases through a structured interview or an SRS. Although the two 
methods showed moderate to strong agreement, an SRS is likely to be affected by 
the patient’s interpretation of the questions and their cultural conception of 
depression. Additionally, not all aspects of depression can be self-assessed 
(Sartorius et al., 1986). In this review, approximately 60% (n = 19) of the included 
studies had a potentially inadequate measure of depression, as they used an SRS 
to identify cases. On balance, the nature of depression makes it difficult to 
diagnose and distinguish it from other psychological disorders, even when using 
the ‘gold standard’ diagnostic criteria. Other psychiatric illness, particularly BD, 
may also be mistakenly diagnosed as depression (Hantouche et al., 1998, Smith et 
al., 2011). These issues could all affect the risk estimate in this review in either 
direction, leading to an under- or overestimation of depression risk. 
The second item in the NOS tool relates to the comparability of cohorts, which is 
based on study design and analysis. In this review, 90% of the studies (n = 28) were 
awarded the maximum score (2 stars) for this item despite the idiosyncratic list 
of adjustable covariates. However, awarding the maximum score does not 
necessarily mean that those studies had properly adjusted for the relevant 
covariates. It has been suggested that determining an appropriate set of 
covariates is important because it can help to reduce the risk of bias in 
observational studies (Steiner et al., 2010). I prepared a comprehensive list of 
what I considered the ‘most important covariates’ in the protocol based on my 
knowledge and what I have read in the literature. However, it is recommended 
that this step be done with the assistant of subject-matter experts to ensure only 
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related covariates were adjusted for (Bero et al., 2018). Frasure-Smith and 
Lesperance (2005) summarised studies linking depression and cardiac disease and 
proposed that the majority of studies failed to explain the reasons behind their 
choice of covariates and that the variables selected were idiosyncratic, making 
comparisons of the adjusted outcomes difficult. In addition, some crucial 
covariates considered to be a risk factor for the outcome of interest were not 
measured; thus, residual confounding cannot be ruled out, which may therefore 
contribute to finding a positive association between depression and incident CVD. 
For example, family history of premature CHD is a well-known risk factor for CHD 
incidence (Schildkraut et al., 1989, Snowden et al., 1982) and recently it has also 
been suggested as a risk factor for depression incidence (Khandaker et al., 2019). 
In this review, of the 22 studies examining the association between depression 
and CHD, only three (Janszky et al., 2010, Mejia-Lancheros et al., 2014, Whang et 
al., 2009) adjusted for this risk factor. The same problem applies to studies 
examining the relationship between depression and stroke. A recent case-control 
study found that low physical activity was the most important risk factor, 
accounting for 59.7% of all strokes (Aigner et al., 2017). Nevertheless, this 
covariate was rarely considered by studies examining the relationship between 
depression and stroke (Everson-Rose et al., 2014, Majed et al., 2012, Karlsen et 
al., 2020, Moise et al., 2016). 
The selection of covariates is one of the main issues when studying the association 
between depression and CVD because the positive relation is, in some cases, a 
bidirectional relation between depression and some classical risk factors, such as 
hypertension, diabetes and obesity (Pan et al., 2010, Rotella and Mannucci, 2013, 
Pan et al., 2012, Skilton et al., 2007), making it difficult to determine whether 
depression is an independent risk factor for CHD and stroke. Carney and Freedland 
(2017) and Penninx (2017) previously discussed this kind of challenge in relation 
to the association between depression and CHD. Hypertension is a good example 
of the covariate selection challenge in the depression-stroke relation. A summary 
meta-analysis suggested that depression increases the risk of hypertension 
incidence (Meng et al., 2012). At the same time, hypertension is one of the most 
important established risk factors for stroke, accounting for 27.1% of all strokes 
(Aigner et al., 2017). Accordingly, it is possible to include hypertension as a 
covariate in the predictive model, but it might mediate rather than confound the 
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association between depression and stroke. Thus, the scenario would be as 
follows: depression as the first exposure may lead to hypertension, which in turn 
leads to the earlier development of stroke. In this case, covariate adjustment for 
hypertension would be inappropriate because this covariate would be on the 
causal pathway between depression and stroke. In a matched cohort study, Li et 
al. (2012) followed 5,015 participants, who were free of metabolic syndrome and 
stroke at the study entry, for nine years. The authors found that a large proportion 
of depressed patients suffered from major comorbidities, most frequently 
hypertension, before stroke onset and thus concluded that a history of clinical 
depression would not directly increase the risk for stroke, but rather acted 
indirectly through known stroke risk factors such as metabolic diseases. However, 
it is unlikely that this completely explains the increased stroke risk, as the results 
are rather consistent across studies examining the association between depression 
and stroke, even after excluding hypertensive patients (Gafarov et al., 2013). 
The third item in the NOS tool relates to the outcome of interest, which includes 
three domains. The second domain is whether the follow-up duration was long 
enough for the outcome to occur. I selected a cut-off point of 10 years as an 
acceptable length of follow-up, but that was based on past reviews (Barlinn et al., 
2015, Li et al., 2015a). Further, the average length of follow-up in the stroke and 
CHD review was around 12 years. Thus, I have tried to see the effect of depression 
on the average follow-up period of the included studies. 
Authors using the NOS assessment tool can develop and apply their own criteria 
and assign different quality scores for the same study. Indeed, there was a low 
agreement and considerable diversity in the overall quality score when comparing 
my evaluation to the previous reviews using the same tool (Barlinn et al., 2015, 
Gan et al., 2014, Wu and Kling, 2016) and none described their detailed criteria 
used to assess the risk of bias. A sensitivity analysis can be done to investigate the 
impact of study quality on the effect size. However, the scoring approach is 
subjective and a study with a high score does not necessarily mean that it is high 
quality. Thus, a sensitivity analysis based on study quality was not performed to 
avoid obtaining a misleading conclusion. 
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 Depression and risk of incident stroke: An 
updated systematic review and Meta-analysis 
 Introduction  
 Stroke prevalence and burden 
Overall, the incidence of stroke is declining worldwide, although it remains one 
of the leading causes of death globally in the last 15 years (World health 
Organisation, 2018). In 2016, the GBD provided a systematic review analysis of the 
global, regional and national burden of stroke from 1990 to 2016 regarding 
prevalence, incidence, deaths, years lived with disability, years of life lost and 
disability-adjusted life-years (DALYs) (G.B.D. Stroke Collaborators, 2019). 
According to this report (G.B.D. Stroke Collaborators, 2019), there were around 
80 million prevalent cases of stroke and 13.7 million new stroke cases globally in 
2016. Of the total number of prevalent strokes, an average of 84.4% (82.1%–86.4%) 
were ischaemic. The prevalence of stroke cases was slightly higher in women 
(41.1%) than in men (39.0%). Between 1990 and 2016, a decline in the age-
standardised incidences was reported in most regions globally, with the largest 
decreases in Latin America. The number of deaths due to stroke and the age-
standardised DALY rates for stroke reduced by 36.2% and 34.2%, respectively, over 
the same period. Despite these improvements, it was recorded that stroke 
accounted for 5.5 million deaths globally and remained the second largest cause 
of death after CHD in 2016 (G.B.D. Stroke Collaborators, 2019). Several risk factors 
contribute to the increased risk of stroke, most of which are modifiable. An 
international case control study of 3,000 stroke patients found that the majority 
of strokes (90%), particularly ischemic stroke, can be explained by 10 risk factors 
(O'Donnell et al., 2010): hypertension, current smoking, waist-to-hip ratio, diet 
risk score, lack of physical activity, alcoholism, cardiac disease, diabetes mellitus, 
psychosocial stress and depression, and ratio of apolipoprotein B to A1. Depression 
based on this report accounted for a 35% (OR 1.35, 1.10–1.66) increased risk of 
stroke. 
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 Stroke and depression: A bidirectional link 
The association between depression and stroke is well established and is 
considered bidirectional, although it is unclear how each condition acts as a risk 
factor for the other.  
 Depression in stroke patients 
Depression is one of the most common psychiatric disorders occurring in stroke 
survivors (Chemerinski and Robinson, 2000). A systematic review and a meta-
analysis comprising 61 studies demonstrated that 3 out of 10 stroke survivors are 
likely to manifest depressive symptoms (Hackett and Pickles, 2014). In stroke 
patients, depression as a complication may exert a significant negative impact on 
stroke recovery and impair outcomes, resulting in significant disability (Paolucci 
et al., 2019), increased mortality and lower quality of life (Ayerbe et al., 2013). 
According to the meta-analysis by Ayerbe et al. (2013), which examined studies 
published up to 2011, the pooled prevalence of depression among stroke patients 
at any point after stroke was 29% (95% CI, 25–32). The researchers attempted to 
identify the major risk factors predicting post-stroke depression stroke (PSD), and 
they concluded that in addition to stroke severity, pre-stroke depression and 
cognitive impairment are associated with PSD (Ayerbe et al., 2013). 
 Depression and risk of stroke 
The association between depression and risk of stroke incidence is well 
established. The first meta-analysis to detect an association between depression 
and stroke was conducted by Van der Kooy et al. (2007). Pooled data from 10 
observational studies before 2005 revealed that depression is associated with a 
43% (OR 1.43, 1.17-1.75) increased risk of new stroke onset, but with significant 
heterogeneity among the studies (Van der Kooy et al., 2007). Many other studies 
were subsequently conducted, which have been summarised in four detailed 
meta-analyses (Barlinn et al., 2015, Dong et al., 2012, Li et al., 2015a, Pan et al., 
2011b). The most recent meta-analysis pooled data from 28 studies and revealed 
an increased risk of an incident stroke for depression by 40% (overall RR 1.40, 95% 
CI, 1.27–1.53; p = .0001) (Barlinn et al., 2015). Description and main limitations 
of these previous reviews were discussed in section 4.5.7 of this chapter. Briefly, 
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most past reviews enrolled patients with a history of stroke and/or CHD; thus, the 
association between depression and stroke may arise due to reverse causation. 
Although evidence suggests that the effect of depression on cardiac diseases and 
stroke is independent of the presence of either disease since the aetiologies are 
likely to be different (Widimský et al., 2013), evidence also suggests that cardiac 
diseases moderate the association between depression and stroke (Wouts et al., 
2008). This suggestion is logical, given that the prevalence of vascular risk factors 
are high in cardiac patients and they therefore have a greater burden of 
subclinical cerebrovascular diseases that in turn may increase the possibility of 
residual confounding in longitudinal cohort studies (Barlinn et al., 2015). 
Additionally, the past reviews have evaluated the association between baseline 
depression and stroke incidents, assuming without confidence that this 
prospective relation is stable over a long duration. Therefore, I aimed to update 
and expand the prior knowledge of the depression-stroke relation by performing 
a systematic review and meta-analysis of cohort studies. 
 Aim 
This chapter conducts a systematic review and reports the meta-analysis of 
prospective cohort studies that have examined the effect of depression on the risk 
of stroke in individuals with no known history of stroke or CHD. 
 Hypothesis 
1- Depression is associated with an increased risk of overall stroke incidence. 
2- Depression increases the risk of first-ever stroke in a dose-response 
manner. 
3- Baseline depression predicts future stroke as well as depression measured 
on a multiple instant.  
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 Methodology 
 Search strategy and selection criteria 
Chapter 2, Section 2.1 provided a full description of the methods used for this 
systematic review and meta-analysis, and Chapter 3 described risk of bias of the 
studies included in this review. 
 Statistical analysis and data synthesis 
HR was used as the parameter of interest to study the association between 
depression and stroke. One study used OR to report the estimated risk (Krishnan 
et al., 2005) and was excluded to maintain consistency across studies. One study 
provided HRs for women and men separately (Majed et al., 2012) and I pooled 
both risk estimates using the FE model to obtain one overall estimate for the 
primary analysis. Two studies provided more than one stroke outcome (i.e. 
outcomes divided by stroke subtypes) (Daskalopoulou et al., 2016, Majed et al., 
2012), and one provided HRs for stroke in relation to different measures of 
depression (e.g. using self-reported scales [SRS] or clinical interviews). In these 
cases, I only pooled HRs that corresponded with the largest number of events to 
obtain a study level HR for the primary analysis. Other reports were included in 
subgroup analysis. 
 Data synthesis 
I performed sensitivity analysis by first excluding the studies by Gump et al. (2005) 
and Mejia-Lancheros et al. (2014) because, although the study populations were 
free from CVD at baseline, they had a high cardiovascular risk. In addition, I 
excluded the study by Rahman et al. (2013) because it used an early version of 
the ICD (ICD-7), which used a broad classification of depression that was different 
from the definition of MDD in later versions of ICD. I also excluded the studies by 
Brunner et al. (2014) and Gafarov et al. (2013) because they reported only 
demographic-adjusted HR and did not adjust for other health-related 
confounders, as previously discussed in section 2.1.5. I restricted the analysis to 
studies that excluded incident stroke cases in the first year of follow-up (Brunner 
et al., 2014, Majed et al., 2012, Pequignot et al., 2013, Rahman et al., 2013) to 
minimise reverse causality. I also restricted the analysis to include studies that 
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measured depressive symptoms at multiple instances over the follow-up period 
and modelled depression as a time-dependent variable in Cox’s proportional 
hazard model (Everson-Rose et al., 2014, Moise et al., 2016, Wouts et al., 2008, 
Péquignot et al., 2016). Furthermore, I restricted the inclusion criteria to include 
only studies that evaluated incident stroke and CHD as their primary outcomes 
and provided a separate risk estimate for each. Finally, I examined the influence 
of a single study on the overall risk estimate by excluding one study and combining 
the remainders in turn (one-study-removed meta-analysis). I also performed 
subgroup analyses to investigate the heterogeneity and to determine whether the 
effect of depression varied with different characteristics of studies and the 
included participants in the following groups: (1) type of depression assessment 
stratified based on SRS, clinical diagnosis, antidepressants combined with clinical 
diagnosis and antidepressants alone; (2) age 65 and older or below 65; (3) studies 
with follow-up of less or more than 10 years; (4) stroke subtypes including 
fata/non-fatal stroke or IS; and (5) studies where participants were free of CHD 
or free from CHD and other CVD conditions; (6) sample size and (7) study location. 
 Results 
The findings below are based on 20 cohort studies enrolling 3,154,290 
participants, with an average follow-up of 11.2 years (ranging from 4 to 24 years). 
Nineteen of these studies were included in the quantitative synthesis. 
Table 4-1 summarises the details of the 20 studies included in this review, 
including the first author’s, location, sample size of the cohort, proportion of 
male, mean of age or age range of study population (where applicable), duration 
of follow-up, measurement method of depression, main outcome, method used to 
identify the outcome, number of incident cases registered during the follow-up 
period in both exposed and unexposed groups and variables included in the final 
adjusted model. The study carried out by Daskalopoulou et al. (2016) was the 
largest study in this review with nearly 2 million participants (1,937,360), followed 
by that of Mathur et al. (2016) with 524,952 participants. The majority of the 
included cohort studies (10 studies) were conducted in Europe, followed by five 
in the U.S, three in Asia and one was a multinational study. Most of the studies 
recruited females and males, either in equal or different proportions, with the 
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exception of four studies. The cohort examined by Gafarov et al. (2013) was 
exclusively female, while those of Gump et al. (2005), Majed et al. (2012) and 
Karlsen et al. (2020) included only males. The mean or median age of participants 
varied across all studies, with five studies targeting elderly populations (Karlsen 
et al., 2020, Krishnan et al., 2005, Mejia-Lancheros et al., 2014, Péquignot et al., 
2016, Wouts et al., 2008). The diagnosis of depression was largely based on SRS (n 
= 9), with CES-D being the most commonly used assessment scale (n = 7). Screening 
for depressive symptoms in seven studies was based on clinical diagnosis that 
originated from a direct evaluation through healthcare professionals according to 
ICD or DSM criteria (Krishnan et al., 2005, Li et al., 2012, Mathur et al., 2016, 
Mejia-Lancheros et al., 2014, Rahman et al., 2013, Rajan et al., 2020, Sico et al., 
2018). One of the three remaining studies used both SRS and clinical diagnosis 
(Wouts et al., 2008) and the other two included antidepressant medication as a 
component of the depression definition in addition to a clinical diagnosis 
(Daskalopoulou et al., 2016, Jee et al., 2019). Most of the studies reported the 
outcome either as a composite or single endpoint of fatal or non-fatal ischemic or 
haemorrhagic stroke (n = 11). Three studies captured different stroke types 
(ischemic, haemorrhagic and TIA) (Daskalopoulou et al., 2016, Everson-Rose et 
al., 2014, Jee et al., 2019) and two restricted the endpoint to ischemic stroke 
(Rahman et al., 2013, Sico et al., 2018). The number of incident stroke cases 
observed during a total follow-up was reported by all studies except two (Sico et 
al., 2018, Wouts et al., 2008). Adjustment for confounders was mostly consistent 
across studies. Apart from Brunner et al. (2014) and Gafarov et al. (2013), all 
cohorts adjusted for most of the prespecified confounders previously described in 
Chapter 2 (see Section 2.1.5).  
Table 4-2 shows the selected characteristics of interest extracted from the 
individual studies, comprising the type of population, frequency of measuring 
depression over the study period, whether the study excluded incident stroke 
cases that occurred in the first years of follow-up, and the proportion of 
participants lost to follow-up during the study. On the whole, the studies defined 
their population as free of stroke and IHD at baseline. However, nine studies 
extended this definition to exclude individuals with other CVD subtypes a priori 
or in additional analyses (Daskalopoulou et al., 2016, Everson-Rose et al., 2014, 
Jee et al., 2019, Li et al., 2019, Mejia-Lancheros et al., 2014, Moise et al., 2016, 
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Rahman et al., 2013, Sico et al., 2018, Rajan et al., 2020). Five studies made 
frequent assessments of participants’ depression status during the study period 
(Brunner et al., 2014, Everson-Rose et al., 2014, Moise et al., 2016, Péquignot et 
al., 2016, Wouts et al., 2008), while the remaining studies relied on the baseline 
assessment only. Six studies excluded incident stroke cases that occurred in the 
first years of follow-up (Brunner et al., 2014, Jee et al., 2019, Majed et al., 2012, 
Nabi et al., 2010a, Péquignot et al., 2016, Rahman et al., 2013); however, one 
had not reported the data (Nabi et al., 2010a) and another study provided HRs for 
combined stroke and CHD outcomes (Péquignot et al., 2016). Seven studies 
examined the relation between depression severity and risk of stroke (Brunner et 
al., 2014, Everson-Rose et al., 2014, Gump et al., 2005, Jee et al., 2019, Li et al., 
2012, Nabi et al., 2010a, Péquignot et al., 2016). In terms of attrition rate, six 
studies did not lose any patients during the study follow-up period (Gump et al., 
2005, Jee et al., 2019, Krishnan et al., 2005, Majed et al., 2012, Mathur et al., 
2016, Nabi et al., 2010a), four studies reported patients lost to follow-up at a rate 
of 0.1% to 8% (Brunner et al., 2014, Moise et al., 2016, Péquignot et al., 2016, 
Rajan et al., 2020), and ten studies failed to report the proportion of loss to 
follow-up (Daskalopoulou et al., 2016, Everson-Rose et al., 2014, Gafarov et al., 
2013, Karlsen et al., 2020, Li et al., 2012, Li et al., 2019, Mejia-Lancheros et al., 
2014, Rahman et al., 2013, Sico et al., 2018, Wouts et al., 2008). 
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Table 4-1 Characteristics of the included cohort studies 















(Brunner et al., 
2014) 
EU 10,036 67.2 44.4 
24 years 
1985-2009 
GHQ-30≥ 5 F/NF IS and HS 
Self-reported 
confirmed be using 
medical records, GP 
confirmation and 
death certificate 
(ICD-9 codes 430–438 
or ICD-10 codes I60–
I69). 
168 Age, sex, and ethnicity 
(Daskalopoulou et 
al., 2016) 




of CD and/or 
prescription of 
AD 
F/NF IS, HS and 
TIA 




Age, sex, smoking, SBP, diabetes, 
cholesterol, and socio-economic status 
(Everson-Rose et 
al., 2014) 











Age, race, sex, education and study 
site, SBP, alcohol use, smoking status, 
moderate and vigorous physical 
activity, BMI, height, use of anti-
hypertensives, diabetes/fasting blood 
glucose status, HDL- cholesterol, and 
triglycerides 
(Gump et al., 
2005) 
US 11,216 100 46 18.4 years 
20-item CES-D 
≥16 
F/NF IS and HS 
Death certificates 
According to the 
ICD-9 codes 
167 
Age, intervention group, race, 
educational attainment, 
smoking at baseline and visit 6, trial 
averaged SBP, alcohol consumption, 
and fasting cholesterol, as well as the 
occurrence of nonfatal cardiovascular 
events during 
the trial 
(Gafarov et al., 
2013) 







F/NF IS and HS 
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(Jee et al., 2019) Korea 481 355 54.15 52.8  
13 years 
2002-2013 






AD at >3 out-
patients visits 
F/NF IS and HS 
Mediacl records 
(ICD-10 codes I60-
I69), divided into IS 
and HS 
17102 
Age, smoking status, HTN, 
hypercholesterolaemia, diabetes and 
chronic renal failure 
(Karlsen et al., 
2020) 
US 3135 100 76.38 
12 years 
2003-2015 
9-item GADS ≥2 









hospital record or 





Age, education, race/ethnicity, 
diabetes, antidepressant use, BMI, 
cholesterol/oxidised LDL, smoking 
status, drinking habit, physical activity 
and sleep quality 
(Krishnan et al., 
2005) 
US 110 31 84.4 







F/NF IS and HS Physician diagnoses 24 
Age, Sex, level of education, marital 
status, Mini-Mental State Examination, 
BMI, HTN, CHF, arterial fibrillation, 
diabetes, hyperlipidaemia, and 
smoking 
(Li et al., 2012) China 5015 36.3 ≥18 






F/NF IS and HS Hospital records 150 
Age, sex, diabetes mellitus, HTN, 
hyperlipidaemia, substance 
comorbidities 





F/NF IS and HS Self-reported 190 
Age, sex, residence, marital status, 
educational level, smoking status, 
drinking status, BP,BMI; history of 
diabetes, HTN, dyslipidaemia, chronic 
kidney disease; use of anti-
hypertensive medications, diabetes 
medications, and lipid-lowering 
therapy 
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(Majed et al., 
2012) 








F/NF IS and HS 
Hospital or general 
practitioner records 




Age, study centres,socioeconomic 
factors (marital status, education 
level, employment status) physical 
activity, smoking status, daily alcohol 
intake, SBP, use of anti-hypertensive 
drugs, BMI, total and HDL- cholesterol, 
treatment for diabetes, and use of 
antidepressant treatment 
(Mathur et al., 
2016) 
EU 524,952 52.8 35.9 
10 years 
2005- 2015 
CD, read code 
used in general 
practice across 
the UK 
F/NF IS and HS 
CD Read code used 
in general practice 
across the UK 
987 
Age, sex, and ethnic group, diabetes, 
HTN, hyperlipidaemia, and smoking 
anti-depressant prescribing at baseline, 
obesity, and Townsend deprivation 
score, presence of co-morbid anxiety 
(Mejia-Lancheros 
et al., 2014) 








DSM-IV or other 
mental health 
scales BDI 




annual revisions of 
medical records, 
data from GPs, and 
consultation of the 
National Death Index 
136 
Age, sex, smoking, alcohol 
consumption, BMI, HTN, type 2 
diabetes, dyslipidaemia and family 
history of premature CHD, and type 
mediterranean diet intervention 
(Moise et al., 
2016) 





F/NF IS and HS 
Self-administered 
questionnaires with 





Age, sex, region, income, health 
insurance, education, and traditional 
CHD risk factors (SBP, total 
cholesterol, HDL- cholesterol, 
medication use (aspirin, statins, any 
antihypertensive medications), BMI, 
albumin: creatinine ratio, diabetes 
mellitus, pack-years of cigarette 
smoking, self-reported alcohol use, 
physical inactivity, medication 
adherence, high-sensitivity C-reactive 
protein, antidepressant use, QT 
interval corrected for heart rate, atrial 
fibrillation and left ventricular 
hypertrophy 
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(Nabi et al., 
2010a) 
EU 23, 282 41 20-54 




F/NF IS and HS 
Hospital discharge 
register or mortality 





Age, sex, education, alcohol 
consumption, sedentary lifestyle, 
smoking, obesity, HTN or diabetes and 
incident CHD or incident CBVD 




7,313 36.6 ≥65  10 years  
20-item CES-D 
≥16 




interviews with the 
patient’s physician 
or family, death 
certificates and 
autopsy reports. All 
possible event were 




Age, gender, city, education level (>12 
years), living alone, current smoking,>3 
glasses of alcohol a day, diabetes 
mellites, HTN, hypercholesterolemia, 
Mini Mental State Examination at 
baseline examination 




145 862 58 35-70 
14 years  
2005-2019 
Short form of 
the CIDI-SF; 













ICD-10 I60- I64, I69) 
3317 
Age, sex, urban/rural residence, 
educational attainment, use of statins, 
disabilities  
former and current smoking and 
alcohol use, HTN, diabetes, and social 
isolation index 
(Rahman et al., 
2013) 
















(ICD-10 codes I63-64) 
833 
Birth year, sex, smoking status, 
educational level, HTN, diabetes, 
alcohol intake and BMI 
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(Sico et al., 2018) USA 106,363 NR NR 9.2 years 
Medical records 
of CD according 
to the ICD-9 
IS 
Medical records of 
clinical diagnosis 
according to the ICD-
9 
NR 
Age, sex, race, LDL, HDL, triglyceride, 
SBP, DBP, diabetes, smoking, BMI, 
eGFR, haemoglobin, hepatitis C, 
arterial fibrillation, statin use, cocaine 
abuse, dependence and alcohol abuse 
dependence  
(Wouts et al., 
2008) 







F/NF IS and HS 
Self-reported 
confirmed by GP or a 
cardiac specialist 
confirming the GP 
diagnosis of stroke, 
death certificates 
(according to the 
ICD-10 codes I-61, I-
63, and I-64.) 
NA 
Age, sex, Mini-Mental State 
Examination score, smoking, functional 
limitations, HTN, diabetes mellitus, 
and obesity 
Abbreviations: AD; antidepressants; BDI, Beck's Depression Inventory; BMI, body mass index; BP, blood pressure; CBVD, cerebrovascular disease; CD, clinical diagnosis; CES-D, Centre for 
Epidemiological Studies Depression scale; CHD, coronary heart disease; CHF, congestive heart failure; CIDI; Composite International Diagnostic Interview; DBP, diastolic blood pressure, DIS, diagnostic 
interview schedule; DSM, Diagnostic and Statistical Manual of Mental Disorders; EU, Europe; F, fatal; GADS; Goldberg Anxiety and Depression Scale; GDS, Geriatric Depression Scale; GHQ, General 
Health Questionnaire; GP, general practitioner; HDL, high density lipoprotein, HTN, hypertension; HS, haemorrhagic stroke; ICD, International Classification of Diseases; IS, ischemic stroke; LDL, low 
density lipoprotein, MOPSY; MONICA-psychosocial programme; NA; not available; NR, not reported; NF, non-fatal;SBP, systolic blood pressure; TIA, transit ischemic attack; UK, United Kingdom; US, 




Recently published studies that were not included in previous meta-analysis are shaded 
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Free of CHD 
and stroke 
6 times Yes (5) 
Yes 




ulou et al., 
2016) 




Free of CVD  3 times No 
Yes/ points on CES-











Baseline No No No NR 
(Gump et 
al., 2005) 
Free of CHD 
and stroke 





Yes/ points on CES-




(Jee et al., 
2019) 
Free of CVD  Baseline Yes (2) 
Yes/Number of 
outpatients visit 











Free of CHD 
and stroke 
Baseline No No No 0 










number of visits 




(Li et al., 
2019) 
Free of CVD Baseline No 
Yes / points on 





Free of CHD 
and stroke 
Baseline Yes (5) No No 0 
(Mathur et 
al., 2016) 
Free of CHD 
and stroke 






at high risk 
but free of 
CVD 




free of CVD  




free of CHD 
and Stroke 










































free of CHD 
and stroke 
4 times Yes* 
Yes/ 





Free of CVD 
and cancer 





free of CVD  









free of CVD  
3.4 (mean) No No No NR 
Abbreviations: AD; antidepressants; BDI, Beck's Depression Inventory CES-D, Centre for Epidemiological 
Studies; CHD, coronary heart diseases; CVD, cardiovascular diseases; GHQ, General Health Questionnaire; HIV, 
human immunodeficiency virus; HTN, hypertension NR, not reported; Yrs, years, -ve; negative* Outcome 
reported as a combined endpoint 
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 Depression and risk of incident stroke 
  Overall 
To generate a consistent analysis, I excluded Krishnan et al. (2005), which 
reported the risk estimate as an OR. Therefore, the primary analysis included 19 
studies. Figure 4-1 demonstrates the results from REM for depression and risk of 
incident stroke. Of the 19 studies, 11 showed a non-statistically significant 
association between depression and stroke risk, and nine suggested a statistically 
significant positive association. At the meta-analysis level, the diamond 
representing the pooled effect estimates was entirely to the right of the line-of-
no-effect, indicating a positive association between depression and stroke 
incidence. The pooled HR was 1.22 (95% CI, 1.11, 1.33, p < .0001) and there was 
a considerable amount of heterogeneity (p < .0001, I2 = 67%). The observed 
statistical heterogeneity can be partly explained by the methodological and 
clinical diversity of Sico et al. (2018) (see Section 4.4.2). Three studies (Jee et 
al., 2019, Péquignot et al., 2016, Sico et al., 2018) carried more than 30% of the 
overall weight and are thus likely to influence the summary effect. 
Finally, a visual inspection of the funnel plot, as shown in Figure 4-2 indicates a 
slight asymmetry in the distribution of studies at the bottom of the graph. There 
is a study missing from the bottom left-hand side of the plot (the area of the non-
significance), which may indicate the presence of publication bias.  
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Figure 4-1 Forest plot showing the adjusted HR of stroke incidence for depressed participants 
compared with non-depressed individuals, overall and in 19 stroke cohorts [RE model]. 
*, adjusted HR for depressive symptoms; CI, confidence interval; IS, ischemic stroke; IV, inverse 
variance; SE, standard error 
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Figure 4-2 Funnel plot from 19 cohorts investigated publication bias 
SE, standard error.
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 Sensitivity analysis 
Table 4-3 shows the results for the sensitivity analysis according to the 
prespecified criteria (Section 4.2.2). As shown in Figure 4-3, the exclusion of 
studies enrolling participants with a high CVD risk (Gump et al., 2005, Mejia-
Lancheros et al., 2014) did not significantly affect the pooled risk estimate for 
stroke (HR = 1.22, 95% CI, 1.12, 1.34). By excluding cohorts that used tools or 
criteria that were not specifically designed to measure depression (Brunner et al., 
2014, Rahman et al., 2013), the magnitude of the estimated effect was slightly 
attenuated (HR = 1.18, 95% CI, 1.08, 1.30, Figure 4-4). Similarly, there was a slight 
reduction in the estimated effect (HR = 1.19, 95% CI 1.09, 1.31) after excluding 
cohorts that were not adjusted for important covariates (Figure 4-5). When 
restricting the analysis to studies that excluded incident stroke occurring within 
the first years of follow-up (Figure 4-6), only four studies remained in the analysis 
and the statistical association between depression and first-ever stroke was more 
evident (HR = 1.39, 95% CI, 1.11, 1.74). Additionally, I restricted the analysis to 
include cohorts that treated depression as a time-dependent variable. As shown 
in Figure 4-7, five studies remained in the analysis, yielding a slight increase in 
the summary effect compared to the one obtained from the primary analysis with 
a wider CI (HR = 1.33, 95% CI, 1.10, 1.59, p = 0.003) and a moderate amount of 
heterogeneity (p of Chi-square test = .25, I2 = 47%). Notably, the study by 
Péquignot et al. (2016) greatly influenced the direction of this analysis because it 
carried about 40% of the total weight. Figure 4-8 demonstrates the results for a 
meta-analysis of 13 studies that examined the association between depression, 
CHD and stroke. Compared with the primary analysis, the pooled effect estimate 
was slightly higher (HR = 1.23, 95% CI, 1.10, 1.37), whereas the heterogeneity 
between studies was slightly lower (Chi-square test p = 0.06, I2 = 59%). Additional 
analyses that examined the influence of a single study on the findings (by omitting 
a study in each turn) yielded a range of HRs from 1.20 to 1.26 (Table 4-4). None 
of the studies had a large impact on the estimated risk. However, by excluding 
Sico et al. (2018) study, the heterogeneity dropped to a moderate estimate, 
resulting in an I2 of 56% and a chi-square p-value of 0.002. Likewise, excluding the 
study conducted by Jee et al. (2019) also reduced the between-study 
heterogeneity to a similar estimate (I2 = 50%, Chi-square p = 0.008).  
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Table 4-3 Depression and risk of stroke: Sensitivity analysis summary 
Sensitivity analysis K HR (95%CI) P-value for 
heterogeneity 
I2 
Overall effect REM 19 1.22 (1.11, 1.33) <0.000 67% 
Excluding studies enrolling 
participants at high risk of CVD  
(Gump et al., 2005, Mejia-Lancheros et al., 
2014) 17 
1.22 (1.12, 1.34) 
0.000 67% 
Excluding studies used unspecified 
diagnosis of depression 
(Rahman et al., 2013, Brunner et al., 2014) 
17 
1.18 (1.08, 1.30) 
0.000 68% 
Excluding studies not controlling for 
important covariates  
(Brunner et al., 2014, Gafarov et al., 2013) 
17 
1.19 (1.09, 1.31) 
0.0007 70% 
Studies excluding events occurred 
with 1st years 
(Brunner et al., 2014, Jee et al., 2019, Majed et 
al., 2012, Rahman et al., 2013) 4 
1.39 (1.11, 1.74) 
0.005 58% 
Studies reported risk of time-varying 
depression  
(Everson-Rose et al., 2014, Moise et al., 2016, 
Péquignot et al., 2016, Wouts et al., 2008) 
5 1.33 (1.10, 1.59) 0.02 42% 
Studies examined CHD and stroke 
outcomes simultaneously within the 
same population 
(Brunner et al., 2014, Daskalopoulou et al., 
2016, Gafarov et al., 2013, Jee et al., 2019, 
Karlsen et al., 2020, Majed et al., 2012, Mathur 
et al., 2016, Mejia-Lancheros et al., 2014, Moise 
et al., 2016, Nabi et al., 2010a, Péquignot et al., 
2016, Rahman et al., 2013, Rajan et al., 2020) 
13 1.23 (1.10,1.37) 0.003 59% 
Abbreviations: CI, confidence interval; CHD; coronary heart diseases; CVD; cardiovascular diseases; HR, hazard ratio; I2, I-square test; K; number of studies; MDD, major 
depressive disorders; REM, random-effect model. 
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Table 4-4 Depression and risk of stroke: Sensitivity analysis excluding studies in turn 
(leave-one-out approach) 
Study  HR (95%CI) P-value for 
heterogeneity 
I2 
Overall effect (REM) 1.22 (1.11, 1.33) <0.000 67% 
(Brunner et al., 2014) 1.20 (1.09,1.32) 0.000 68% 
(Daskalopoulou et al., 2016) 1.22 (1.11, 1.34) 0.000 68% 
(Everson-Rose et al., 2014) 1.20 (1.10, 1.32) 0.000 68% 
(Gafarov et al., 2013) 1.21 (1.11, 1.32) 0.000 67% 
(Gump et al., 2005) 1.21 (1.10, 1.33) 0.000 68% 
(Jee et al., 2019) 1.20 (1.09, 1.31) 0.008 50% 
(Karlsen et al., 2020) 1.23 (1.12, 1.34) 0.000 68% 
(Li et al., 2012) 1.21 (1.10, 1.33) 0.0000 69% 
(Li et al., 2019) 1.20 (1.10, 1.32) 0.000 68% 
(Majed et al., 2012) 1.21 (1.10, 1.33) 0.000 69% 
(Mathur et al., 2016) 1.21 (1.10, 1.33) 0.000 69% 
(Mejia-Lancheros et al., 2014) 1.23 (1.13, 1.34) 0.000 65% 
(Moise et al., 2016) 1.21 (1.10, 1.34) 0.000 69% 
(Nabi et al., 2010a) 1.23 (1.12, 1.35) 0.000 67% 
(Péquignot et al., 2016) 1.22 (1.11, 1.35) 0.000 68% 
(Rahman et al., 2013) 1.20 (1.10, 1.32) 0.000 67% 
(Rajan et al., 2020) 1.23 (1.12, 1.36) 0.000 64% 
(Sico et al., 2018) 1.24 (1.13, 1.35) 0.002 56% 
(Wouts et al., 2008) 1.23 (1.12, 1.34) 0.000 67% 
HR, hazard ratio; REM, random effect model 
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Figure 4-3 Forest plot showing the adjusted HR of stroke for depressed participants 
compared with non-depressed individuals [Sensitivity analysis: Excluding studies enrolled 
participants at high risk of developing CVD] 
CI, confidence interval; IV, inverse variance; SE, standard erorr 
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Figure 4-4 Forest plot showing the adjusted HR of stroke for depressed participants 
compared with non-depressed individuals [Sensitivity analysis: Excluding studies used 
unspecified diagnostic or screening tools to identify cases of depression] 
CI, confidence interval; IV, inverse variance; SE, standard erorr 
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Figure 4-5 Forest plot showing the adjusted HR of stroke for depressed individuals compared 
with non-depressed individuals [Sensitivity analysis: Excluding studies not adequately 
adjusted for potential confounders] 
CI, confidence interval; IV, inverse variance; SE, standard erorr 
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Figure 4-6 Forest plot showing the adjusted HR of stroke for depressed participants 
compared with non-depressed individuals [Sensitivity analysis: studies excluded stroke 
incident occurred within the first years]. 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 4-7 Forest plot showing the adjusted HR of stroke for depressed individuals compared 
with non-depressed individuals [Sensitivity analysis: studies assessed depression as a time-
dependent exposure] 
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Figure 4-8 Forest plot showing the adjusted HR of stroke for depressed participants 
compared with non-depressed individuals [Sensitivity analysis: Including cohorts that 
examined risk of developing stroke and CHD simultaneously as their primary outcomes and 
calculated the HRs for each outcome separately]  
CI, confidence interval; IV, inverse variance; SE, standard error 
151 
Chapter 4: Depression and risk of stroke 
 
 Depression and risk of incident stroke: Subgroup analysis 
Table 4-5 summarises the results for the subgroup analyses for depression and 
stroke risk. Altogether, seven subgroups were categorised by type of depression 
assessment, study follow-up duration, mean age groups, stroke subtype, CVD 
condition at baseline, sample size and geographical location of the study. The 
results from the primary overall analysis are included for reference. 
 By type of depression assessment 
Eleven studies reported data for depression assessment using SRS, enrolling 
108,069 participants. Data synthesis of these studies resulted in an HR of 1.28, a 
95% CI between 1.12 and 1.46 and a p-value of 0.004 (Figure 4-9). None of the 
studies principally influenced this analysis. Heterogeneity between studies was 
markedly reduced, evident by the I2 statistic, which was observed at 35% and a 
chi-square test resulted in a p-value of 0.12, indicating no statistically significant 
heterogeneity between the studies. Data for depression assessment using clinical 
diagnosis were available from seven studies, enrolling 794,919 participants (Figure 
4-9). The combined HR from this analysis was 1.13, with a 95% CI between 0.98 
and 1.31 (p = 0.10). The direction of this finding was greatly driven by Sico et al. 
(2018) and Rajan et al. (2020) because their studies carried more than 50% of the 
total weight. There was a substantial amount of heterogeneity between studies, 
as indicated by the chi-square test (p = .04) and the I2 test, which was observed 
at 54%. Data for depression assessment relying on valid prescriptions of 
antidepressants and/or combined with a clinical diagnosis were available for three 
studies with 2,455,369 participants. Pooling the effect estimates yielded an HR of 
1.34 (95% CI, 1.16-1.55) with a p-value of < .0001 (Figure 4-9). The I2 test for 
heterogeneity was observed at 56%, and the chi-square test yielded a p-value of 
0.1. Three studies investigated the relationship between antidepressants and 
stroke with 584,888 participants. The summary effect estimate was an HR of 1.11, 
with a 95% CI between 0.96 and 1.28 and a p-value of .17 (Figure 4-9). Mathur et 
al. (2016) and Rahman et al. (2013) studies both had a large impact on the 
direction of this analysis (total weights of 48% and 46.9%, respectively). Testing 
for heterogeneity resulted in a chi-square p-value of 0.37 and an I2 statistic of 1%, 
indicating no significant difference between the studies. The test for subgroup 
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differences indicated that no statistically significant subgroup effect existed (p = 
.18). 
 By duration of follow-up 
Studies with a follow-up duration of 10 years or longer were available from 12 
cohorts (3,135,614 participants). Combined effect estimates resulted in an HR of 
1.24 with a 95% CI between 1.12 and 1.37 and a p-value of < .0001 (Figure 4-10). 
Assessment of heterogeneity revealed substantial differences between studies 
confirmed by I2 statistics test, which observed at 59% and chi-square test p-value 
of .01. Meanwhile, data for studies with a follow-up of less than 10 years were 
available from 1,80,116 participants enrolled in seven cohorts. The pooled HR was 
1.18 with a 95% CI between 0.98 and 1.41 and a p-value of .08 (Figure 4-10). 
Moderate to high heterogeneity was detected with an I2 statistics test result of 
62% and a p-value of .01 for the chi-square test. No statistically significant 
differences exist between the two groups (p = 0.63). 
 By mean age groups 
Data for studies with a younger mean age (<65 years) were available from 
3,227,725 patients enrolled in 14 cohorts. Figure 4-11 shows the estimated HR 
(1.30, 95% CI, 1.18-1.42; p < .00001). A moderate heterogeneity was found with 
an I2 = 44% and a chi-square test p-value of 0.04. However, for studies of patients 
with a mean age of 65 years or older, data were available from four studies 
comprising 18,805 participants. These studies yielded a non-significant association 
between depression and incident stroke. The pooled HR, as shown in Figure 4-11 
was 0.92 (95% CI, 0.67-1.27, p =0.63). Moderate heterogeneity was evident by an 
I2 of 43% and a chi-square test p-value of 0.16. The test for subgroup differences 
was borderline statistically significant (p =0.05). 
 By stroke subtypes 
Fifteen studies with 791,161 participants reported a combined endpoint for 
fatal/non-fatal stroke. Analysing these studies produced a pooled HR of 1.23 (95% 
CI, 1.08-1.39, p = .002 (Figure 4-12). Assessment of heterogeneity by the chi-
square test resulted in a p-value of 0.02. I2 statistics test results showed 47%, 
detecting moderate to substantial heterogeneity. Data for ischemic stroke were 
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available from six cohorts enrolling 2,544,528 patients. The combined estimate of 
HR was 1.16 with a 95% CI between 1.02 and 1.31, p = 0.02 (Figure 4-12). 
Heterogeneity between studies was substantial (I2 = 70%, chi-square test p = 
0.006). Two studies with 2,418,715 participants provided data for haemorrhagic 
stroke and pooling effect estimates from these studies yielded an HR of 1.09 (95% 
CI, 0.98, 1.22) and a p-value of 0.11 (Figure 4-12). A heterogeneity assessment 
showed a chi-square p-value of 0.87 and I2 statistics of 0%, indicating a trivial 
difference between studies. Visually, the influence of Jee et al. (2019) study in 
the analysis was apparent, as it was represented by the largest box corresponding 
to its weight (86%). No statistically significant subgroup effect (p = 0.41). 
 By CVD status at baseline 
Nine studies enrolling 594,329 participants defined their population as free of both 
CHD and stroke. As shown in Figure 4-13, pooling the effect estimate from the 
nine studies resulted in an HR of 1.29 (95% CI, 1.09, 1.53, p = .003). The results 
from all cohorts included in this analysis are relatively homogenous (p = .15, I2 = 
33%). However, 10 studies with 2,725,020 extended this definition to exclude 
patients with CVD conditions. The combined effect estimates resulted in a lower 
HR compared to the above group (HR = 1.19, 95% CI, 1.06, 1.34, p = .004). There 
was, however, considerable statistical heterogeneity between these studies (p < 
.00001, I2 = 80%). Test for subgroup differences showed no statistically significant 
group effect (p = .43). 
 By sample size 
Figure 4-14 illustrates meta-analyses results stratified based on studies sample 
size. Eight studies enrolled less than 10,000 of individuals and results showed non 
statistically significant association between depression and risk of stroke (HR= 
1.19 95%CI 0.92,1.54). Pooling results from six studies with total participants 
between 10,000 and 100,000 yielded a statistically significant association but with 
a larger magnitude comparing to the primary results (HR= 1.37 95%CI 1.15, 1.62). 
Finally, a subgroup analysis of five studies with extremely large sample size 
enrolling more than or equal to 100,000 showed a statistically significant 
association with a HR of 1.17 and a 95%CI between 1.01 and 1.35 with considerable 
amount of heterogeneity (I2= 85%). It should be noted that among the five studies 
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only Jee et al.’s showed a statistically significant association result with a 95%CI 
that not included one. It also had the largest weight comparing to other four 
studies (25%). To ensure that the overall meta-analysis result was not driven by 
this study I excluded Jee et al., study and the results obtained showed that 
depression remained statistically significantly associated with incident stroke 
(HR= 1.08, 95%CI 1.00, 1.17; p= 0.04).Despite the discrepancy in the results in 
terms of the magnitude, results from large studies were consistently in the same 
direction showing positive association. 
 By study location 
Figure 4-15 shows data stratified according to the study location. Ten cohorts were 
conducted in Europe, enrolling 2,559,375 participants. The combined estimate of 
HR was 1.21 (95% CI, 1.02-1.44, p = .03). Substantial heterogeneity was observed 
as indicated by an I2 statistic test (51%) and a chi-square test (p = .03). Five studies 
were conducted in the United States with 115,325 patients. As shown in Figure 
4-15 a meta-analysis of these studies resulted in an HR of 1.19 (95% CI, 0.99-1.42, 
p = .06) with moderate heterogeneity (I2 = 50%, p = .06). This result was mainly 
influenced by the Sico et al. (2018) study, which accounted for 40% of the total 
weight. Data for studies in Asia were available from 498,787 participants enrolled 
in three studies. The effect of depression in this subgroup was more pronounced 
compared to the European and American populations (HR = 1.34, 95% CI, 1.29, 
1.40, p < .000). The result was mostly driven by Jee et al. (2019) study, which 
carried the most weight (96.7%). The results of the subgroup analysis suggested 
that no statistically significant subgroup effect existed (p = .25). 
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Table 4-5 Depression and risk of stroke: Subgroup analysis summary 










Overall effect REM 19 3,314,334 1.22 (1.11, 1.33) 0.000 67%  
Type of depression 
assessment 
SRS 11 108,069 1.28 (1.12, 1.46) 0.12 35% 
0.18 
Clinical diagnosis 7 794,919 1.13 (0.98,1.31) 0.04 54% 
Combined clinical diagnosis and AD 
use 
3 2,455,369 1.34 (1.16,1.55) 0.10 56% 
AD 3 584,888 1.11 (0.96,1.28) 0.37 1% 
Duration of follow-up 
< 10 years 7 1,80,116 1.18 (0.98, 1.41) 0.01 62% 
0.63 
≥ 10 years 12 3,135,614 1.24 (1.12, 1.37) 0.004 59% 
Mean age 
< 65 years 14 3,227,725 1.30 (1.18,1.42) 0.04 44% 
0.05 
≥ 65 years 4 18,805 0.92 (0.67,1.27) 0.16 43% 
Stroke subtypes 
Fatal/non-fatal stroke 15 791,161 1.23 (1.08, 1.39) 0.002 47% 
0.41 IS 6 2,544,538 1.16 (1.02, 1.31) 0.006 70% 
HS 2 2,418,715 1.09 (0.98, 1.22) 0.87 0% 
CVD status at 
baseline 
Free of CHD and stroke 9 594, 329 1.29 (1.09, 1.53) 0.15 33% 
0.43 
Free of CVD  10 2,725,020 1.19 (1.06, 1.34) 0.000 80% 
 ≥ 100,000 5 3162348 1.17 (1.01,1.35) 0.0001 86% 0.36 
Sample size 
≥ 10,000 and <100,000 6 116271 1.37 (1.15, 1.62) 0.000 30% 
0.21 
< 10,000 8 40,730 1.19 (0.92, 1.54) 0.03 55% 
Study location 
EU 10 2,559,375 1.21 (1.02, 1.44) 0.03 51% 
0.51 US 5 115,325 1.19 (0.99, 1.42) 0.09 50% 
Asia 3 498,787 1.34 (1.29, 1.40) 0.88 0% 
Abbreviations: AD, antidepressants; CI, confidence interval; CHD, coronary heart disease; CVD, cardiovascular disease; EU; Europe; HR, hazard ratio; HS; 
Haemorrhagic stroke; K; number of studies; IS, ischemic stroke; SRS, self-reported scale; N; number; REM, random effect model; US, United states. 
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Figure 4-9 Forest plot showing the adjusted HR of stroke incidence for depressed individuals 
compared with non-depressed individuals by type of depression assessment 
AD, antidepressants; CD, clinical depression; CI, confidence interval; IV, inverse variance; SE, 
standard error; SRS, self-reported scale 
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Figure 4-10 Forest plot showing the adjusted HR of stroke incidence for depressed individuals 
compared with non-depressed individuals by duration of follow-up 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 4-11 Forest plot showing the adjusted HR of stroke incidence for depressed individuals 
compared with non-depressed individuals by study population’s mean age 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 4-12 Forest plot showing the adjusted HR of stroke incidence for depressed individuals 
compared with non-depressed individuals by stroke subtypes 
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Figure 4-13 Forest plot showing the adjusted HR of stroke incidence for depressed individuals 
compared with non-depressed individuals by CVD status 
CHD; coronary heart diseases; CI, confidence interval; CVD, cardiovascular diseases; IV, inverse 
variance; SE, standard error 
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Figure 4-14 Forest plot showing the adjusted HR of stroke incidence for depressed 
participants compared with non-depressed individuals by study sample size 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 4-15 Forest plot showing the adjusted HR of stroke incidence for depressed 
participants compared with non-depressed individuals by study geographical location 
CI, confidence interval; IV, inverse variance; SE, standard error 
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 Discussion 
This study investigates the association between depression and first-ever stroke 
in patients free of stroke and CHD at baseline. The findings from 19 prospective 
cohort studies suggested that depression was associated with a 22% increased risk 
of stroke. This was demonstrated in the REM (HR 1.22, 95% CI, 1.11-1.33) with 
evidence of a substantial heterogeneity between studies (I2 = 67%, p < .0001). 
Overall, the main findings did not significantly change in most of the subgroup and 
sensitivity analyses. The association between depression and stroke derived from 
studies that measured CHD and stroke outcomes simultaneously within the same 
population yielded a very close estimate effect (HR = 1.23, 95% CI, 1.10, 1.37, I2 
= 59%). Nevertheless, in some analysis there were studies shifted the trend 
towards non-significance. The following sections discuss the results obtained from 
these analyses. 
 Dose response relationship 
I investigated the dose-response relationship between depression and stroke, 
which is often a function of both the level and duration of exposure. However, 
few studies in this review investigated a possible dose-response relationship. If 
depression is considered a traditional risk factor for stroke, then we should expect 
an incremental increase in the risk of future stroke as depression 
severity/chronicity increases. This review tested six studies for a dose-response 
effect between depression and stroke (Brunner et al., 2014, Everson-Rose et al., 
2014, Gump et al., 2005, Jee et al., 2019, Li et al., 2012, Péquignot et al., 2016), 
which adopted various methodological differences, including different measures 
of depression, different risk indexes and different ranges of scores within the same 
scale used to generate multiple categories of increasing severity. Therefore, since 
there was no standardised approach among the studies, it was impossible to pool 
the data results. Thus, in the following section, I only describe and discuss their 
results narratively. To measure the severity of depressive symptoms, Gump et al. 
(2005) and Everson-Rose et al. (2014) used the 20-item CES-D (score range 0-60) 
in their studies to measure depressive symptoms and examine the dose-response 
association related to symptom severity. They divided the CES-D score into five 
groups, but each used distinct cut-off points. Gump et al. (2005) used 0-1 and 13-
60 scores to represent the lowest and highest risk groups, respectively, while 
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Everson-Rose et al. (2014) classified the lowest risk group as having a 0-2 score 
and the highest risk group as having a score of more than or equal to 16. Gump et 
al. (2005) presented a significant linear association between depressive symptoms 
quartiles and risk of stroke (p-value for trend = .002), though after modelling 
depression as a binary variable (<16 and ≥16), the statistically significant 
association between depression and stroke did not survive. Correspondingly, 
Everson-Rose et al. (2014) found a gradient of increasing stroke risk as the severity 
of depressive symptoms increases (p-value for trend = .03). Notably, this approach 
addresses dose-response associations of stroke with depressive symptoms but not 
clinical depression. Further, the trend of association in both studies was presented 
only for minor symptoms (i.e. a score of <16 indicates nil or mild symptoms) and 
did not present how the dose-response relationship looked beyond that point to 
evaluate the stability of this relation over higher levels of depressive symptoms. 
In contrast to these two studies, Nabi et al. (2010a) measured depressive 
symptoms with the BDI tool and used standardised cut-off scores to incorporate 
different levels of severity; however, no evidence was found of a dose-response 
association between depression and stroke. Li et al. (2019) used the 10-item CES-
D scale (score range of 0-30) to quantify depressive symptoms. The scores were 
then split into quintiles, where the first quintile (score of 0-2) represented the 
lowest risk group and the fifth quintile (score of 15-30) represented the highest 
risk group. The results showed a linear and positive association between the CES-
D total score and risk of incident stroke, although a statistical significance 
association with stroke risk was only observed for the highest quintile. Li et al. 
(2012) applied two different approaches to explore a dose-response relationship 
in terms of symptoms severity. First, they categorised depressed patients based 
on their baseline response to antidepressant medication into three groups: easy 
to treat, intermediate to treat and difficult to treat. Their results showed no 
statistically significant differences between the three groups in terms of stroke 
rate. However, antidepressant refractoriness may not be an ideal marker to 
evaluate depression severity, as this may reflect individual differences. The 
second approach was to retrospectively measure the levels of depressive 
symptoms before the stroke index date using the average number of psychiatric 
visits as an indicator. They found that the average number of psychiatric visits 
within the last six months before stroke onset was significantly higher among 
stroke patients compared to the control depressed patients. Although this method 
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has the advantage of avoiding recall bias, as they had relied on hospital records 
to extract information rather than patient interviews, it measured depressive 
symptoms’ intensity over a short period (six months prior to the event), which 
might also originate from subclinical CVD; thus, reverse causality cannot be ruled 
out. Regarding depression chronicity, Jee et al. (2019) used the number of 
outpatients visits, up to 10 visits, due to MDD as a proxy for severity of depression 
and showed a gender differences response. The results showed that the risk of 
stroke incidence was more profound with 3-4 visits; however, this risk was no 
longer statistically significant after 10 or more visits. With regards to women, they 
showed that the risk of stroke incidents increases with the increasing number of 
outpatient visits. On the contrary, Brunner et al. (2014) measured depressive 
symptoms seven times over the follow-up period, and using the frequency of 
exhibiting clinically related depressive symptoms, they provided no evidence for 
a dose-response relationship. Péquignot et al. (2016) measured depressive 
symptoms at four study visits and found that the risk of first-ever stroke was 
evident with both transient and cumulative exposure to depressive symptoms. 
Previous meta-analyses have not examined whether depression follows a dose-
response relationship to stroke risk. On balance, the results of this analysis are 
inconclusive in relation to a dose-response relationship due to the relatively small 
number of studies included and substantial methodological heterogeneity. 
However, based on what is known to date, I can conclude that even one episode 
of mild depression cannot be considered safe, as the probability of having a first-
ever stroke might be the same with mild-to-moderate depression as it is with 
severe depression and with one episode as it is with multiple episodes of 
depression. 
 Depression as a time-varying exposure 
The nature of depression is complex. Symptoms can improve and deteriorate over 
time, and patients can switch between categories (Gilchrist and Gunn, 2007). 
However, this fluctuating course can be missed in studies with short follow-up 
duration and in the case of a lack of repeated measures over the study period. 
This variation was noticed in my subgroup analysis based on the follow-up duration 
as I found that depression is associated with a significant increased risk of 
developing stroke in the group of more than or equal to 10 years of follow-up but 
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not in the group with less than 10 years follow-up, though the difference was not 
statistically significant (p = .63). This finding may be partially explained by the 
number of stroke events, as a longer follow-up will inevitably lead to more events. 
More importantly, not all studies accounted for time-varying risk factors. As 
mentioned, depression as a cluster of symptoms as well as other risk factors 
confounding the associations between depression and stroke (e.g. health-related 
variables) are likely to change throughout a long study duration. Therefore, in this 
subgroup, the significant observation over a long follow-up period may not be due 
to an actual ‘strengthening’ of the association but may be due to the decreased 
accuracy of baseline data. One possible solution is to analyse depression as a time-
varying variable because it is more likely to afford robust findings compared to 
baseline depression. As a secondary aim, I sought to evaluate the stability of the 
association between depression and stroke over time. I performed a sensitivity 
analysis incorporating fivestudies measured depressive symptoms at least three 
times over the follow-up period interval and modelled depression as a time-
varying variable in Cox’s proportional hazard model. I found that depressive 
symptoms are associated with a 27% (HR = 1.27, 95% CI, 1.05, 1.53; I2 = 42%) 
increased risk of stroke. Although the magnitude was slightly higher and the CI 
was wider compared to the primary result, which may increase the uncertainty, 
the association was similar to that obtained in the primary analysis. The present 
finding is relatively novel because none of the prior reviews investigated the 
stability of the depression–stroke association over time. My result to a certain 
extent agrees with the findings from the Pan et al. (2011a) study, which was one 
of the few that investigated the association between time-dependent depression 
and stroke. The authors followed up 80,574 women aged between 54 and 79 years 
without a history of stroke for six years as part of a nurses’ health study. Pan et 
al. (2011a) assessed depression biennially and found that depressed women had a 
29% (HR = 1.13, 95% CI, 1.13, 1.48) increased risk of a future stroke. Though 
obviously their finding was limited to specific gender data and depression in this 
study was measured using a combination of mixed indictors (antidepressants, 
clinical diagnosis and SRS). The consistency of the summary effects validates my 
hypothesis that baseline depression can predict the risk of stroke incidence as well 
as time-varying depression, although further studies are warranted to confirm this 
finding. 
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 Reverse causality 
To explore the impact of possible reverse causation, I restricted the analysis to 
studies that accounted for residual confounding by excluding the initial follow-up 
period. The positive significant association became more pronounced (HR = 1.39, 
95% CI, 1.11, 1.74) after synthesising this analytic ‘lag period’ approach based on 
four cohorts. However, the small study number (n=4) and the moderate 
heterogeneity between studies (I2 = 58%) render the results meaningless. Among 
the past reviews, only Barlinn et al. (2015) assessed for possible reverse causation 
by adopting the same analytical approach. Their synthesised sub-analysis data 
consisted of six cohorts and provided similar findings that depression is associated 
with a 41% increased risk of stroke incidence (HR = 1.41, 95% CI, 1.27–1.57). 
Nevertheless, one of the included studies in their analysis was ineligible 
(Pequignot et al., 2013) as it reported an HR for a combined endpoint (fatal and 
non-fatal CHD or stroke). 
 Types of depression assessment tools and stroke  
When comparing different types of assessment methods used to identify 
depression, my subgroup analysis found a 21% increased risk of stroke incidence 
for studies that used SRS, which is consistent with the primary results and previous 
reviews (Barlinn et al., 2015, Dong et al., 2012, Li et al., 2015a, Pan et al., 2011b). 
However, combining the HR from the seven studies that relied on a clinical 
diagnosis resulted in a lower estimate (HR = 1.13, 95% CI, 0.98, 1.31), which 
contradicts the above finding. This result also differed from Li et al. (2015a) and 
Pan et al. (2011b) meta-analyses which found that patients diagnosed with clinical 
depression are at a twofold increased risk of a future stroke; however, comparing 
my results to these reviews is somewhat complicated because both studies 
enrolled populations with a history of stroke and/or CHD. Nevertheless, this 
subgroup analysis highlighted some methodological limitations in two of the six 
studies that failed to detect an association. Sico et al. (2018), the largest study 
influencing the estimated risk in this subgroup, was a conference abstract that did 
not contain adequate information, so I was unable to closely assess its quality. 
Further, Wouts et al. (2008) had a relatively few participants with an MDD at 
baseline (n = 58), which may have limited the ability to find an association 
between depression and stroke risk. Nevertheless, the results from the subgroup 
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cohorts that used clinical diagnosis and/or antidepressants to identify cases of 
depression demonstrate that depression is associated with a 34% increased risk of 
stroke incidence. In most cases, depression identified through a structured clinical 
interview and/or through a valid prescription of antidepressants reflects severe 
depression status. Thus, this pronounced effect of depression on risk of incident 
stroke may support a dose-response theory. Alternatively, as these studies used 
antidepressants as an indicator of depression, it is possible that they suffer from 
misclassification, and their results may not necessarily reflect the independent 
association of depression with stroke. Further, statistically, combining different 
depression indicators can enhance statistical power and thus obtain significant 
findings. The findings suggest that depressed individuals defined based on the use 
of antidepressant medication did not have an increased risk of stroke. Similarly, 
Li et al. (2012), whose study was excluded from this analysis, retrospectively 
reviewed the pattern of antidepressant prescriptions prior to stroke onset in 
depressed patients and showed that no clinically relevant associations existed 
between antidepressants and stroke. This may be a true indication that 
antidepressants are not associated with an increased risk of stroke in a CVD-free 
population. However, each individual class of antidepressants has a different 
safety profile with respect to different CVD outcomes (Hamer et al., 2011, 
Glymour et al., 2019) and my finding is not informative from this prospect. In 
contrast to my results, Barlinn et al. (2015) and Pan et al. (2011b) explored the 
independent effect of antidepressants in a sub-analysis of six studies, and both 
found that antidepressant medication is associated with an elevated risk of stroke. 
However, both reviews included cohorts with previous incidences of CHD/stroke, 
which may explain the possible relationship. A recent nested case-control study 
of 344,747 individuals showed that antidepressants are significantly associated 
with an increased risk of stroke in patients who previously suffered from CVD 
compared to those who did not (Biffi et al., 2020). Although the interpretation is 
limited by a few included studies and the large heterogeneity between them, the 
divergent results obtained from this subgroup analysis may indicate that different 
depression measures tend to have different predictive values for stroke risk, 
although it is unclear how strongly and how valid each separate approach predicts 
stroke. Therefore, I conclude that we do not yet have sufficient evidence to 
determine which type of depression assessment tool is best for predicting stroke 
risk among depressed individuals in clinical settings and would encourage future 
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research to examine different measurements or indictors of depression in parallel 
with this regard. 
 Age factor  
I stratified the analysis according to the participants’ mean age to investigate the 
sources of heterogeneity and explore possible modifiers of the depression-stroke 
relationship. My subgroup showed that no statistically significant association 
existed between depression and risk of stroke in elderly patients aged 65 years 
and above (HR = 0.92, 95% CI, 0.67, 1.27). However, younger patients (aged <65 
years) were at a significantly greater risk of developing stroke in relation to 
depression (HR = 1.30, 95% CI, 1.18, 1.42). The test for subgroup differences 
indicates a marginal statistically significant subgroup effect (p = .05). However, 
far smaller cohorts and participants contributed data to the subgroup with a mean 
age of ≥65 years (four cohorts with 18,805 participants) than to the subgroup with 
a mean age of <65 years (14 cohorts with 3,227,725 participants), meaning that 
the finding from this subgroup analysis cannot be relied on to produce a valid 
conclusion. However, this trend has been observed in the past reviews, as both 
Barlinn et al. and Pan et al. reported a lower risk of stroke in depressed patients 
aged ≥65 years than in those aged <65 years. In the Framingham Heart Study, 
Salaycik et al. (2007) examined elderly and non-elderly groups separately and 
found that depressive symptoms were statistically significantly associated with a 
fourfold increase in the risk of future stroke in patients younger than 65 years but 
not in those aged 65 years or older. Some other studies that did not meet my 
eligibility criteria also proposed similar findings that depression may not be an 
independent risk factor for stroke in the elderly (Colantonio et al., 1992, Köhler 
et al., 2013), although other positive findings suggesting a strong association 
between depression and stroke in this targeted population also exist (Gilsanz et 
al., 2015, Krishnan et al., 2005, Liebetrau et al., 2008). Polypharmacy is known 
to be common among elderly individuals. Accordingly, it is highly plausible that 
some medication prescribed as a primary prevention for stroke, such as 
antihypertensive medications, may mask the effect of depression on stroke. 
Frasure-Smith and Lesperance (2006) summarised evidence linking depression and 
cardiac disease. The authors suggested an alternative interpretation that might 
also be applicable to stroke outcomes. They proposed that a group of individuals 
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who managed to achieve more than 80 years without CVD manifestation are likely 
to be both genetically and behaviourally advantaged in some way compared to 
most individuals. Although the result from this analysis was not very useful to draw 
a clinically meaning conclusion with respect to the age factor, it calls for future 
studies to investigate the pathological mechanism linking depression to stroke in 
the young population with no known history of stroke or cardiac diseases and to 
determine whether late-life depression can be considered a true risk factor for 
incident stroke in this elderly population. 
 Depression and risk of stroke subtype 
Analysing studies by stroke subtypes showed that depression is associated with an 
increased risk of ischemic stroke (HR = 1.16, 95% CI, 1.02, 1.31) but not 
haemorrhagic stroke (HR = 1.09, 95% CI, 0.98, 1.22), although no statistically 
significant subgroup effect exists (p = .41). Although interpretation is limited by 
the lack of sufficient numbers in each subgroup, these findings are in line with 
reviews by Li et al. (2015a) and Pan et al. (2011b), which showed no statistically 
significant association between depression and haemorrhagic stroke (HR = 1.16, 
95% CI, 0.80,1.70). Their results derived from two studies (Pan et al., 2011a, Ohira 
et al., 2001) enrolling 1,912 participants. The results herein were also pooled from 
two cohorts, albeit with a much larger sample size (2,418,715). Several studies 
have shown that each stroke subtype is likely to have a different risk factor profile 
(Price et al., 2018, Hägg et al., 2014, Zhang et al., 2011). Future studies 
investigating whether depression imposes different effects across stroke subtypes 
and the possible mechanisms by which depression is linked to different stroke 
subtypes are needed. 
 Comparison with other reviews 
Although the main finding is consistent with previous meta-analyses in terms of 
the direction of the estimated risk, the magnitude of the pooled adjusted HR in 
the current study was about half that of the estimated risk in past reviews (Barlinn 
et al., 2015, Dong et al., 2012, Li et al., 2015a, Pan et al., 2011b, Van der Kooy 
et al., 2007), which ranged from 35% to 45%. Nevertheless, the quantified risk of 
depression in my study is similar to the findings from a recent large prospective 
cohort conducted by Cho et al. (2019) in South Korea. Cho et al. (2019) used 
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nationwide health insurance claims data to enrol 2,705,090 participants who were 
free of stroke and CHD at baseline and found that depression was associated with 
a 24% (HR = 1.24, 95% CI, 1.21-1.27) increased risk of first-ever stroke. However, 
the risk is likely to differ across different populations. In a multicentre cohort 
involving 145,862 participants from 21 economically diverse countries, Rajan et 
al. (2020) showed that adults with four or more depressive symptoms were at a 
20% higher risk of death and developing a cardiovascular event compared to 
people without depressive symptoms, although the risk was more than twice as 
high in urban areas as in rural areas. Wium-Andersen et al. (2020) recruited 
participants from 10 Danish population-based cohorts studied between 1981 and 
2015 and suggested that depression increased the risk of first-ever stroke by 94% 
(HR = 1.94, 95% CI, 1.63, 2.30). The following section provides a detailed 
description and critical appraisal of past reviews. As previously stated, Van der 
Kooy et al. (2007) published the first review on this subject, although they 
evaluated and quantified the risk of depression on stroke incidents as a secondary 
analysis. The reviewer included both case-control and prospective cohort studies 
that were published before 2005. Pooling the effect size from 10 studies showed 
that depression is associated with a 43% increased risk of stroke onset (OR = 1.43, 
95% CI, 1.17, 1.75, I2 = 45%). Notably, in the case of stroke outcomes, the case-
control study design is not the proper design to obtain information on prior 
depressive episodes because stroke victims may suffer from serious complications, 
such as cognitive dysfunction, making them vulnerable to recall bias, which results 
in imprecise findings. In 2011, Pan et al. (2011b) updated and enlarged the earlier 
work with a primary focus on stroke outcomes. They searched three databases, 
including MEDLINE, EMBASE and PsychINFO. Only prospective cohort studies were 
eligible with participants either with or without a history of stroke. Eventually, 
they ended up with 28 studies enrolling 317,540 participants. The quality 
assessment in this review was performed based on eight aspects, including study 
design, response rate, follow-up rate, follow-up years, exposure and outcome 
measurements, statistical analysis, and generalisability to other populations, 
which are comparable with the NOS tool assessment criteria. The primary result 
of their meta-analysis demonstrated that depression significantly increased the 
risk of stroke development by 45% (HR = 1.45, 95% CI, 1.29, 136) with a 
considerable statistical heterogeneity (I2 = 66%). The relatively larger number of 
included studies compared to the previous review enabled Pan et al. (2011b) to 
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test the association in further subgroup analyses and showed a consistent positive 
association across different subgroups. The reviewers demonstrated that no 
statistically significant differences existed between studies that excluded past 
stroke cases and those that did not (p =.21). Nevertheless, since there was uneven 
covariate distribution arising from the unbalanced number of studies across this 
subgroup (24 studies vs 7 studies), the validity of their results is restricted. Dong 
et al. (2012) carried out a subsequent review with stricter inclusion criteria. The 
authors used only one search engine, PubMed database, to obtain potentially 
relevant studies. Only population-based studies enrolling stroke-free participants 
with a prospective cohort design were included. However, owing to the limited 
number of database resources, the authors omitted several eligible studies 
(Avendano et al., 2006, Arbelaez et al., 2007, Kawamura et al., 2007, May et al., 
2002, Stürmer et al., 2006). Further, this publication did not supplement readers 
with the quality assessment of the included studies; hence, it is difficult to 
determine the burden of study quality to compare with my review. A total of 17 
cohorts involving 206,641 participants were ultimately included. The pooled 
effect size demonstrated that participants with depressive symptoms experienced 
a 34% (HR = 1.34, 95% CI, 1.17, 1.54) higher risk for developing a stroke event with 
moderate statistical heterogeneity (I2 = 55%, p = .003). Notably, the risk estimate 
reported by this review was the lowest compared to four reviews answering the 
same research question (Van der Kooy et al., 2007, Li et al., 2015a, Barlinn et al., 
2015, Pan et al., 2011b). Li et al. (2015a) performed the largest review to date on 
this subject. The reviewers used three databases, including PubMed, Embase and 
the Cochrane Library, to identify 36 studies enrolling 399,791 participants. Quality 
assessment of the included articles was based on the guideline developed by the 
US Preventive Task Force, which is composed of eight criteria resembling those in 
the NOS assessment tool. The pooled risk estimate demonstrated that depression 
was associated with a 45% increased risk of stroke onset (HR = 1.45, 95% CI, 1.31, 
1.61) – a considerable statistical heterogeneity was detected between studies (I2 
= 66%, p < .000). Around the same time, Barlinn et al. (2015) published a similar 
review but with stricter inclusion criteria, as their search primarily focused on the 
stroke-free population. They searched PubMed and Medline for eligible studies. 
However, as the Medline database is a subset of PubMed database (≈98%) 
(Williamson and Minter, 2019), the output is greatly similar. To achieve an 
acceptable recall, a combination of four databases is recommended (Bramer et 
173 
Chapter 4: Depression and risk of stroke 
 
al., 2017), in addition to using the PsycINFO database, which provides unique 
references to this relevant topic. Barlinn et al. identified 28 eligible studies with 
681,139 participants. The assessment of the methodological quality of the 
included studies was performed in accordance with the NOS tool. Although Barlinn 
et al. adopted stricter inclusion criteria than Li et al., their quantified estimated 
risk was comparable (HR = 1.40, 95% CI, 1.27, 1.53, I2 = 48.6%). Compared to the 
other reviews, Barlinn et al. was the only review that also performed a sensitivity 
analysis, restricting the data synthesis to 15 studies excluding cardiac patients; 
however, their pooled risk estimate was 43% (RR = 1.43, 95% CI, 1.19–1.72), which 
was similar to their main result.  
In my study, I updated the review conducted by Van der Kooy et al. (2007), which 
covered a search period up to 2005. Thus, the period of my study considered only 
studies published after 2004. I employed a similar search strategy to Pan et al.’s 
review, although I also searched the Web of Science database and hand-searched 
the bibliography of related reviews and all relevant articles. Additionally, I 
extended the search to July 2020. The selection criteria in my review were 
modified based on the conclusion and recommendations of the latest review 
conducted by Barlinn et al. (2015) to reduce heterogeneity and risk of bias. 
Briefly, two aspects were not considered in the past reviews that may influence 
the estimated risk of depression: types of population and a clear definition of 
acceptable measures of depression. In terms of the population, the majority of 
past reviews did not focus on a stroke-free population (Li et al., 2015a, Pan et al., 
2011b, Van der Kooy et al., 2007) and did not consider the role of the other 
vascular comorbidities such as cardiac disease in the depression-stroke relation, 
which can increase the possibilities of reveres causality or exaggerate the effect 
of depression on stroke outcome. In terms of exposure measures, none of the past 
reviews clearly defined how clinically related depression symptoms should be 
measured for a study to be eligible (Barlinn et al., 2015, Dong et al., 2012, Li et 
al., 2015a, Pan et al., 2011b, Van der Kooy et al., 2007). They combined 
depression data, which were presented as either binary or ordinal variables. For 
example, if the studies categorised depressed individuals as having low, moderate 
or severe depressive symptoms based on the SRS (Kamphuis et al., 2006, Stürmer 
et al., 2006, Vogt et al., 1994), they considered only those individuals with high 
or severe symptoms. This approach is likely to be subjected to selection bias. 
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Further, as this approach is not equivalent to the binary dichotomous response to 
SRS thresholds or to clinical diagnosis, it may have affected the consistency of the 
reported risk and the accuracy of their estimated effect. My inclusion criteria are 
narrower compared to all reviews on this topic, as I only included studies that 
enrolled patients with no known history of stroke and CHD at baseline and I 
attempted to minimise the impact of selection bias on the estimated risk by 
including studies that clearly defined depression as a dichotomous variable where 
participants were classified as depressed and not depressed. I used a similar 
approach to Barlinn et al. to assess the methodological quality of each included 
cohort. My review is composed of fewer studies, 19 studies, compared to previous 
reviews, which may in part explain the lower estimated risk. However, I included 
seven new prospective cohorts (Daskalopoulou et al., 2016, Jee et al., 2019, Li et 
al., 2019, Mathur et al., 2016, Moise et al., 2016, Karlsen et al., 2020, Rajan et 
al., 2020) with larger sample sizes than previous reviews, adding more than 
3,000,000 participants, thus substantially increasing the power. Further, I 
identified two studies (Krishnan et al., 2005, Mejia-Lancheros et al., 2014) that 
were omitted by recent reviews. Ten studies (Arbelaez et al., 2007, Avendano et 
al., 2006, Glymour et al., 2010, Hamano et al., 2015, Jackson and Mishra, 2013, 
Kamphuis et al., 2006, Liebetrau et al., 2008, Pan et al., 2011a, Salaycik et al., 
2007, Surtees et al., 2008b) published after 2004 and included in the latest review 
were excluded from my study for reasons described in Section 3.2.1. Therefore, 
to my knowledge, the present meta-analysis includes all qualified studies, 
including those omitted by previous meta-analyses and most recent studies 
assessing the effect of depression on risk of incident stroke. 
 Conclusion 
Overall, evidence from this study shows that baseline depression is associated with 
elevated risk for new-onset stroke in patients with no known history of CHD and 
stroke. Similarly, a positive association was also observed for depression assessed 
over time. Future studies should investigate whether age modifies the relation 
between depression and stroke and, if so, the pathological mechanisms underlying 
early and late-life depression leading to stroke. Further, more studies are 
warranted to examine whether depression confers a greater risk for ischemic 
stroke than for haemorrhagic stroke. 
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 Depression and risk of CHD first event: An 
updated systematic review and Meta-analysis 
 Introduction  
 CHD prevalence and burden 
In 2015, CHD was reported to be the leading cause of death worldwide accounting 
for 9 million deaths (Roth et al., 2017). The estimated age-standardised CHD death 
rate was highest in Central Asia (336 per 100,000) and Eastern Europe (326 per 
100,000). Further, there were an estimated 110.55 million prevalent cases of CHD 
and 7.29 million acute MI in 2015. Eastern Europe had the highest estimated age 
standardised prevalence of CHD (4,140 cases per 100,000) followed by Central Asia 
and then Central Europe, while the sub-Saharan Africa, southern Latin America 
and high-income Asia Pacific regions had the lowest estimated rate (622 per 
100,000) (Roth et al., 2017). In 2017, it was estimated that more than 126 million 
people were living with CHD, and it was more prevalent in males than in females. 
Mortality rates were generally lower than 150 per 100,000 for most of the world 
but remain the highest in Eastern Europe and Central Asia (Virani Salim et al., 
2020). According to a recent statistical report by the AHA, a decline in the 
incidence of CHD has been observed over the past decades; however, the number 
of cases is projected to increase because of population ageing, which means that 
CHD will continue to be a leading cause of death and prevention of CHD should be 
a continuing priority (Benjamin et al., 2019). Several prevention approaches have 
been put forward to reduce the incidence of CHD. Potential strategies include 
controlling and addressing risk factors to reduce the risk of developing CHD and 
make significant health gains. Risk factors associated with an increased risk of 
CHD involve nonmodifiable risk factors, such as age, gender, family history and 
race, and modifiable risk factors, such as hypertension, smoking, sedentary 
lifestyle, abnormal lipid profiles, inflammatory markers, diabetes and metabolic 
syndrome (Khawaja et al., 2009). Additionally, evidence shows that psychological 
factors, such as depression, can be as big a risk factor for CHD as smoking, high 
cholesterol levels and high BP (Dhar and Barton, 2016). 
176 
Chapter 5: Depression and risk of CHD 
 
 Bidirectional relationship between depression and CHD 
 Depression and established CHD 
Numerous studies have reported the prevalence of major depression or clinically 
significant depression in patients with established CHD (Carney and Freedland, 
2017). In a comprehensive review, Thombs et al. (2006) proposed that depression 
is about three times more common in patients recovering from an acute MI than 
in the general population. An estimated 15% to 20% of patients hospitalised after 
MI found to meet the DSM-diagnostic criteria for MDD (Lespérance and Frasure-
Smith, 2000) with an even greater proportion (40%) of patients reporting elevated 
levels of depressive symptoms (Bush et al., 2005). Spijkerman et al. (2005) 
reported that a history of MI is an independent predictor of both in-hospital and 
post-discharge depressive symptoms. Together, these findings suggest that CHD 
can cause depressive symptoms and depression following MI (Khawaja et al., 2009, 
Spijkerman et al., 2005). Research has extensively documented the association 
between depression and poor health prognosis in patients with established CHD. 
As noted above, depression is highly common in post MI patients and it has been 
linked to recurrent cardiac events (van Melle et al., 2004), cardiac-related death 
(Frasure-Smith et al., 1993, van Melle et al., 2004, Whang et al., 2009) and all-
cause mortality (Barth et al., 2004, van Melle et al., 2004). These links prompted 
the AHA to elevate depression to the status of a risk factor for adverse medical 
outcomes within this population (Lichtman et al., 2008). 
 Depression as a risk factor for CHD incident 
Studies have also found that depression increases the risk of cardiac events in 
people without a history of CHD. So far, six meta-analyses have evaluated 
depression as a risk factor for incident CHD (Table 5-1). The main objective of 
these studies was to quantify depression risk. Main limitations and detailed 
description of the past six previous reviews were discussed in section 5.6.7 of the 
current chapter. Briefly, past reviews relied on studies that were poorly designed. 
This was not surprising given that the depression-CHD hypothesis was relatively 
young in the last century compared to established risk factors for CHD such as 
smoking (Nicholson et al., 2006). Thus, complex interplay between depression and 
CHD had not considered. Therefore, I aimed to update and elaborate previous 
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work on depression-CHD relation by conducting a systematic review and meta-
analysis of cohort studies. 
 Aim 
By performing a systematic review and meta-analysis of cohort studies, this 
chapter aims to establish whether an independent association with CHD exists for 
depression (either measured at baseline or at multiple instances) within a study 
population that is free of both CHD and stroke disease. 
 Hypotheses 
1- Depression is associated with an increased risk of incident CHD in patients 
with no history of CHD or stroke. 
2- Depression increases the risk of CHD incidence in a dose-response manner. 
3- Baseline depression predicts future CHD as equally well as depression 
measured on a multiple instant. 
 
178 
Chapter 5: Depression and risk of CHD 
 
Table 5-1 Summary of meta-analysis examined depression as a risk factor for CHD incident 
Meta-analysis Search 
period 
K N  Outcomes 
 
Combined events of CHD MI CHD death 
N OR/RR (95%CI) N OR/RR (95%CI) N OR/RR (95%CI) 
(Rugulies, 2002) 1887-2000 11 36,549 11 1.64 (1.29–2.08) NA NA NA NA 
(Wulsin and Singal, 2003) 1966-2000 10 27,231 10 1.64 (1.41,1.90) NA NA NA NA 
(Nicholson et al., 2006) 1966–2003  21 124 509 11+ 1.90 (1.49–2.42) NA NA 9 1.69 (1.34–2.14) 
(Van der Kooy et al., 
2007) 
1966-2005 28 87,174 
16* 1.57 (1.36–1.81) 
8 1.60 (1.34–1.92) NA NA 
(Gan et al., 2014) Up to 2014 30 893 ,850 30 1.30 (1.22,1.40) 12 1.30 (1.18,1.44) 8 1.36 (1.14, 1.63) 
(Wu and Kling, 2016) 1966-2015 19 323,709 16* 1.20 (1.11–1.30) 9 1.31 (1.09–1.57) 8 1.36 (1.14–1.63) 
CHD, coronary heart disease; CI, confidence interval; K, nnumber of studies; MI, myocardial infarction; N, number of participants; NA, not applicable; RR, 
risk ratio; OR, odds ratio;*Includes only those studies of participants without CHD at baseline. +Adjusted analyses. 
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 Methodology 
 Search strategy and selection criteria 
Section 2.1 provided full descriptions of the methods used for this systematic 
review and meta-analysis, and Chapter 3 described the risk of bias of studies 
included in this review. 
 Statistical analysis and data synthesis  
Overall, I used the HR as the parameter of interest to study the association 
between depression and CHD. One study that used RR to report the estimated risk 
was excluded from the primary analysis for consistency. For the primary analysis, 
two studies provided HRs for women and men separately (Ladwig et al., 2006b, 
Jee et al., 2019). I obtained a study level HR by pooling risk estimates from both 
groups to obtain a single overall estimate. Where studies reported HRs for multiple 
CHD events, I pooled only one HR corresponding to the largest number of the 
multiple events (however, the other HRs were included in the subgroup analysis). 
Sensitivity analyses assessed the contribution of each study to the pooled estimate 
by excluding individual studies one at a time and re-calculating the pooled HR for 
the remaining studies (so-called ‘one-study removed meta-analysis’). Further 
exclusion was performed to exclude studies that had (1) not controlled for 
confounders, (2) enrolled participants with a high risk of developing CHD and (3) 
employed tools or diagnostic criteria that failed to clearly discriminate between 
different depressive disorders. I also restricted the analysis to studies that had 
excluded CHD events occurring within the first year of follow-up, which provided 
HRs for depression risk measured at multiple time points (i.e. depression modelled 
as a time-varying covariate) and that were looking for a first event of stroke or 
CHD outcomes within the same cohort. 
 Results 
My search identified 23 eligible studies that reported CHD outcomes enrolling 
3,786299 patients with an average follow-up of 12.4 years (range 4 to 37 years).  
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Table 5-2 shows the main characteristics of the 23 cohorts included in this review, 
encompassing the first author’s name and year of publication, total number of 
participants enrolled, proportion of males, mean age, mean or median duration 
of follow-up (where applicable), methods used to measure exposure (depression), 
main outcomes, methods used to identify outcomes, total number of cases and 
covariates that were adjusted within the multivariable analysis. The largest cohort 
was the one conducted by Daskalopoulou et al. (2016), followed by Mathur et al. 
(2016) and Jee et al. (2019). While The smallest study was conducted by Gafarov 
et al. (2013) with a sample size of 560. With regard to study location, most studies 
were conducted in European countries (n = 13), eight in the United States, one in 
Korea, and one was a multinational cohort. Gender ratios varied considerably 
between cohorts. Seven studies enrolled mainly male participants (>60%) (Brunner 
et al., 2014, Gump et al., 2005, Janszky et al., 2010, Karlsen et al., 2020, 
Khambaty et al., 2014, Majed et al., 2012, Scherrer et al., 2011) and four other 
cohorts included predominantly females (Brown et al., 2011, Gafarov et al., 2013, 
Pequignot et al., 2013, Whang et al., 2009). Depression screening was largely 
based on self-rating scales (n = 14). Two studies also used antidepressant 
prescriptions as a proxy for depression (Nabi et al., 2010a, Whang et al., 2009). 
The CES-D scale was used in nine cohorts; the other six studies each used a 
different scale. The remaining nine studies relied on clinical diagnosis based on 
ICD or DSM criteria. However, four studies also included patients with 
antidepressant medication (Daskalopoulou et al., 2016, Mathur et al., 2016, 
Rahman et al., 2013, Scherrer et al., 2011). A total of 26 reports were extracted 
from the included cohorts. Of those, 11 reported CHD outcomes associated with 
depressive symptoms as a combined endpoint, 13 reported incidence of MI, two 
reported incidence of angina (Daskalopoulou et al., 2016, Jee et al., 2019) and 
two reported CHD death (Daskalopoulou et al., 2016, Whang et al., 2009). The 
number of CHD cases diagnosed in the primary studies ranged from 15 to 23,735, 
with a total of 69,808 cases. Outcome ascertainment was from a variety of 
sources, including medical records, register databases, National Death Index, 
clinical diagnoses and death certificates. Apart from Brunner et al. (2014), 
Gafarov et al. (2013), the majority of the included studies adjusted for the pre-
specified confounding factors (see section 2.1.5). All studies calculated the effect 
estimate using HRs, except for one study that reported RR (Brown et al., 2011). 
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Table 5-3 summarises additional information for the 23 included cohorts, 
encompassing the first author’s name and year of publication, type of population, 
number of depression assessments over the study period and whether studies 
provided an additional analysis for the following: after excluding CHD events that 
occurred during first year of follow-up, severity/chronicity of depression and risk 
of CHD, independent association of antidepressants and risk of CHD, and 
proportion of patients who were lost to follow-up. All included studies defined 
their population as free of CHD and stroke at baseline. Two studies also excluded 
hypertensive patients (Gafarov et al., 2013, Scherrer et al., 2011). Three studies 
examined the association between depression and CHD in comorbid populations 
such as obese (Ladwig et al., 2006b), diabetic (Scherrer et al., 2011) and HIV 
patients (Khambaty et al., 2016) . Some studies (n = 6) excluded CHD events 
occurring in the first year of follow-up to reduce reverse causation (Gustad et al., 
2014a, Majed et al., 2012, Nabi et al., 2010a, Péquignot et al., 2016, Karlsen et 
al., 2020). Nine studies assessed whether a dose-response relationship existed 
between depression severity/chronicity and CHD, but with different methods 
(Brown et al., 2011, Brunner et al., 2014, Gustad et al., 2014a, Jee et al., 2019, 
Nabi et al., 2010a, Péquignot et al., 2016, Whang et al., 2009, Wulsin et al., 2005, 
Gump et al., 2005, Rajan et al., 2020). Five studies used the severity of depressive 
symptoms (i.e. higher score vs lower scores on the SRS), while the other four 
measured depression chronicity (i.e. how many times patients presented with 
clinically important depressive symptoms) during the follow-up period before the 
index date. Five studies measured depressive symptoms at multiple time points in 
addition to baseline, and treated depression as a time-dependent variable in their 
analyses (Moise et al., 2016, Péquignot et al., 2016, Whang et al., 2009, Brunner 
et al., 2014). Five studies investigated the independent association between 
antidepressants and CHD (Mathur et al., 2016, Nabi et al., 2010a, Rahman et al., 
2013, Scherrer et al., 2011, Whang et al., 2009). Finally, loss to follow-up ranged 
from nil to 8%, although one reported a 28% loss to follow-up, and 10 studies failed 
to report on this aspect. 
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Table 5-2 Characteristics of the included cohort studies 







Exposure measure Outcome Outcome measure Cases 
(n) 
Confounder adjustment 
(Brown et al., 
2011) 
US 2,728 28.6 60-102 
15 years 
1991-2006 
20-item CES-D ≥16 
MI and CHD 
death 
Medical record, NDI 
(ICD-9 codes 410–414 
and ICD-10 codes 120–
125) 
727 
Age, sex race, diabetes, HTN, 
history of smoking, 




UK, EU 10036 67 35-55 
24 years 
1985-2009 





be using medical 
records, GP confirmation 
and death certificate 
(ICD-9 codes 410–414 or 
ICD-10 codes I20– I25) 
454 Age, sex, and ethnicity 
(Daskalopoulo
u et al., 2016) 
UK, EU 1,937,360 NA ≥30 
13 years 
1997-2010 
Medical records of 
CD and/or 







(ICD-10 codes 120–125) 
23735 
Age, sex, smoking, SBP, 




Canada 1,794 49.9 18-98 
10 years 
1995-2005 
20-item CES-D ≥10 
Fatal/non-fatal 
CHD 
Health register records  
(ICD-9 codes (410.–414 
or the equivalent on 
ICD-10) 
152 












Medical records and 
death certificates 
15 Age 
(Gump et al., 
2005) 
US 11,216 100 46 18.4 years 20-item CES-D ≥13 Fatal CHD and MI 
Death certificate 
according to the ICD-9 
codes 
1248 
Age, intervention group, race, 
educational attainment, 
smoking at baseline and visit 
6, trial averaged SBP, alcohol 
consumption, and fasting 
cholesterol, as well as the 
occurrence of nonfatal 
cardiovascular events during 
the trial 










Clinical diagnosis, death 
registry 
(ICD-9 codes 410 and 
ICD-codes I21- I22). 
2,111 
Age, sex, marital status, 
education, smoking, physical 
activity, BMI, total 
cholesterol, diabetes mellitus 
and SBP 
183 
Chapter 5: Depression and risk of CHD 
 




















Medical records or self-
reported confirmed by 
medical records 
592 
Age, sex, HTN, diabetes, 
dyslipidemia, occupational 
grade, parental CHD history, 











interview by a 
psychologist and 
classified 
according to the 
(ICD-8; 29,300.4)  
CHD, MI Medical records 52 
Smoking, body length, 
diabetes, SBP, alcohol 
consumption, physical 
activity, father’s occupation, 
family history of CHD, and 
geographic area 
(Jee et al., 
2019) 
Korea 481,355 54.15 52.8  
13 years 
2002-2013 
≥ 1 out-patient 
visit diagnosed 
according to (ICD-
10 codes F32-F33) 
or prescription of 
AD at >3 out-
patients visits 
Fatal/ non-fatal 
CHD, angina, MI 
Mediacl records 16915 
Age, smoking status, HTN, 
hypercholesterolaemia, 




US 3135 100 76.38 
12 years 
2003-2015 




and/or phone conformed 
by medical records. 
Fatal event adjudicated 
by death certificate, 
hospital record or next 
of kin interview 
612 
Age, education, 
race/ethnicity, diabetes, AD 
use, BMI, cholesterol/oxidised 
LDL, smoking status, drinking 
habit, physical activity and 
sleep quality 
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according to ICD-9  
MI 
Medical records, death 
certificate 
(ICD-9 code 410 for MI) 
490 
Age, sex, race/ethnicity, 
HTN, dyslipidaemia, diabetes, 
statin use, CD4 cell count, 
HIV-1 RNA level, antiretroviral 
therapy regimen, hepatitis C 
infection, renal disease, 
history of abuse or 
dependence of alcohol and 
cocaine, and haemoglobin 
level Smoking, BMI, anti-
depressants  








24-item-DEEX scale MI and CHD 
Medical records, death 
certificates 
(ICD-9, 410–414, 798) 
229 
Age, total cholesterol, 
cigarette smoking and SBP, 
education, alcohol 
consumption and physical 
activity 









Fourth quartile of 
13-item-modified 
CES-D compared 
with first quartile 
CHD (stable and 
unstable angina, 
MI, and coronary 
death) 
Hospital or general 
practitioner records 





Age, study centres, 
socioeconomic factors, 
including marital status, 
education level, employment 
status, physical activity, 
smoking status, daily alcohol 
intake, SBP, use of anti-
hypertensive drugs, BMI, total 
and HDL cholesterol, 
treatment for diabetes, and 
use of AD 
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Exposure measure Outcome Outcome measure Cases 
(n) 
Confounder adjustment 
(Mathur et al., 
2016) 
UK, EU 524,952 52.8 ≥30 
10 years 
2005- 2015 
CD, read code used 
in general practice 
across the UK 
MI 
Clinically diagnostic 
Read code used in 
general practice across 
the UK 
3,390 
Age, sex, and ethnic group, 
diabetes, HTN, 
hyperlipidaemia, and smoking 
AD prescribing at baseline, 
obesity, and Townsend 





Spain, EU 7,263 42.5 55-80 
7 years   
2003-2010 
Self-reported by 
face to face 
interview and 
further confirmed 
in clinical records  
According to the  




Regular contacts with 
participants and/or 
families, annual 
revisions of medical 
records, data from GPs, 
and consultation of the 
NDI 
103 
Age, sex, smoking, alcohol 
consumption, BMI, HTN, type 
2 diabetes, dyslipidaemia and 
family history of premature 
CHD, and type Mediterranean 
diet intervention 
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Exposure measure Outcome Outcome measure Cases 
(n) 
Confounder adjustment 
(Moise et al., 
2016) 





(nonfatal or fatal 




retrieval of medical 
records 
895 
Age, sex, region, income, 
health insurance, education, 
and traditional CHD risk 
factors (SBP, total 
cholesterol, HDL- cholesterol, 
and medication use [aspirin, 
statins, any antihypertensive 
medications], BMI, log of 
albumin: creatinine ratio, 
diabetes mellitus, pack-years 
of cigarette smoking, self-
reported alcohol use, physical 
inactivity, medication 
adherence, log of high-
sensitivity C-reactive protein, 
AD use, QT interval corrected 
for heart rate, atrial 
fibrillation and left 
ventricular hypertrophy 




23, 282  40.8 20-54  
7 Years 
(1998-2005) 




register or mortality 
reports according to 
(ICD-10 codes I20–I25) 
203 
Age, sex, education, alcohol 
consumption, sedentary 
lifestyle, smoking, obesity, 
HTN, diabetes and incident 
CHD or incident CBVD 
(Péquignot et 
al., 2016) 
France, EU 7,313 36.6 
≥65  
(73) mean 
10 years  20-itemCES-D ≥16 
CHD (angina, MI, 
and CHD death) 
Self-reported further 
confirmed by medical 
reports, interviews with 
the patient’s physician 
or family, death 
certificates and autopsy 
reports. All possible 
event were adjudicated 
by two independent 
expert committees 




Age, gender, city, education 
level (>12 years), living alone, 
current smoking,>3 glasses of 
alcohol a day, diabetes 
mellites, HTN, 
hypercholesterolemia, MMSE 
(Mini Mental State 
Examination) at baseline 
examination 
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(ICD-10 codes I20, I22) 
850 
Age, sex, smoking status, 
educational level, HTN, 
diabetes, alcohol intake and 
BMI 




145,862 58 35-70 
14 years  
2005-2019 
Short form of the 
CIDI-SF; cut-off 








medical records, death 
certificates, and other 
sources(according to 
ICD-10 I60- I64, I69) 
3235 
Age, sex, urban/rural 
residence, educational 
attainment, use of statins, 
disabilities  
former and current smoking 
and alcohol use, HTN, 




US 345,949 88.3 25-80  
7 years 2000-
2007 
CD according to 
ICD-9 
MI 
Medical records and 
register database 




Age, sex, race, marital status, 
and insurance type 
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Exposure measure Outcome Outcome measure Cases 
(n) 
Confounder adjustment 
(Whang et al., 
2009) 
US 63,469 0 30-55 
8 years from 
1996-2004 
5-item-MHI <53, 
use of AD 
Fatal CHD, non-
fatal MI 
Medical records, death 
register or autopsy 
(according ICD-9 codes 
410- 412) 
1,724 
Age, beginning year of follow-
up, smoking status, BMI, 
alcohol intake, menopausal 
status and postmenopausal 
hormone use, usual aspirin 
use, multivitamin use, vitamin 
E supplement use, 
hypercholesterolemia, family 
history of MI, history of 
stroke, n-3-fatty acid intake 
(quintiles), alpha linoleic acid 
intake (quintiles), and 
moderate/vigorous physical 
activity, non-fatal CHD during 
follow-up, HTN and diabetes 
(Wulsin et al., 
2005) 
US 3,634 45 30-91  
6 years (a 
mean of 5.9) 
20-item CES-D ≥16 
CHD (MI and CHD 
death) 
Medical records 83 
Age, sex stratified, smoking, 
HTN, diabetes, BMI, total 
cholesterol, and alcohol 
consumption 
Abbreviations: AD, antidepressants; BDI, Beck's Depression Inventory; BMI, body mass index; BP, blood pressure; CBVD, cerebrovascular diseaseCD, clinical diagnosis; CES-D, Centre for 
Epidemiological Studies Depression scale; CHD, coronary heart disease; CHF, congestive heart failure; CIDI-SF; Composite International Diagnostic Interview- short form; DEEX, The DEpression 
and EXhaustion subscale; DBP, diastolic blood pressure, DIS, diagnostic interview schedule; DSM, Diagnostic and Statistical Manual of Mental Disorders;; EU, Europe; GADS; Goldberg Anxiety and 
Depression Scale; GDS, Geriatric Depression Scale; GHQ, General Health Questionnaire; GP, general practitioner; HDL, high density lipoprotein, HIV, human immunodeficiency virus; HTN, 
hypertension; ICD, International Classification of Diseases; LDL, low density lipoprotein; MI, myocardial infarction; MHI, Mental Health Index; MOPSY; MONICA-psychosocial programme; NDI, 
National death index; SBP, systolic blood pressure; UK, United Kingdom; US, United States. 
 
Recently published studies that were not included in previous meta-analysis are shaded 
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Free of CVD Baseline No 
Yes 
Symptoms severity / 









Free of CHD and 
stroke‡ 
Six waves Yes 
Yes 




ulou et al., 
2016) 








Free of CHD, 
stroke, HTN and 
diabetes mellitus 
Baseline No No No NR 
(Gump et 
al., 2005) 
Free of CHD and 
stroke but who 
had above 
average risk of 
CHD 
Baseline No 
Yes/ points on CES-D 










Free of CHD and 
stroke  
Baseline Yes Yes/ chronicity* No 28 
(Hamieh et 
al., 2019) 
Free of CVD 
Seven 
waves 
No No No NR 
(Janszky et 
al., 2010) 
Free of CVD Baseline No No No NR 
(Jee et al., 
2019) 
Free of CVD  Baseline Yes 
Yes/Number of 






patients free of 
CVD 






Baseline No No No NR 
(Ladwig et 
al., 2006b) 
Obese free of 
CHD, stroke and 
cancer  
Baseline No No No 0 
(Majed et 
al., 2012) 
Free of CHD and 
stroke 
Baseline Yes No No 0 
(Mathur et 
al., 2016) 
Free of CHD and 
stroke 
Baseline No No Yes 0 
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Individuals at high 
risk but free of 
CVD 
Baseline No No No NR 
(Moise et 
al., 2016) 
Free of CVD 
Three 
waves 
No No No 1.6 
(Nabi et 
al., 2010a) 




Symptoms severity / 









Free of CHD and 
stroke 
Four waves Yes** 
Yes 

















HTN and CVD at 
baseline 
Baseline No No Yes NR 
(Whang et 
al., 2009) 
Free of CHD, 

























BDI, Beck's Depression Inventory; CES-D, Centre for Epidemiological Studies Depression scale; CHD, coronary heart 
disease ; CVD; Cardiovascular diseases; HTN, hypertension; GHQ, General Health Questionnaire  HIV, human 
immunodeficiency virus ; MHI, Mental Health Index. *  Data calculated for mixed symptoms of depression and 
anxiety, ** Data presented only for a combined fatal event (CHD or stroke); † Data not provided, ‡ Information 
extracted from Barlinn et al. (2015) and Gan et al. (2014) 
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 Depression and risk of CHD 
  Overall 
The findings presented below are based on 23 studies with 3,786299 participants. 
Figure 5-1 demonstrates the forest plot and the summary effect using REM. 
Fourteen studies crossed the line of no effect (indicating no strong evidence that 
depression was associated with increased CHD risk). The pooled HR found a 22% 
increased risk of CHD in depressed patients (HR= 1.22, 95% CI, 1.13-1.32, p < .000) 
compared to patients without depression, with a substantial statistical 
heterogeneity (I2 = 77%, p < .00001). The observed statistical heterogeneity is most 
likely due to the clinical and methodological diversity of the Jee et al. (2019) 
cohort (see 5.5.1.2). None of the studies largely influenced this analysis, as each 
study weighed less than 10%. 
Visual inspection of the funnel plot shows a degree of asymmetry, which may 
indicate the presence of publication bias (Figure 5-2). However, poor 
methodological quality could be a source of asymmetry as well (Higgins and Green, 
2011). In the funnel plot, it is clear that the Gafarov et al. (2013) study, which is 
the smallest study in this meta-analysis, had a markedly different estimation 
compared to the other studies. This over-estimation of depression might reflect 
methodological shortcomings, such as inadequate accounting for confounders. 
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Figure 5-1 Forest plot showing the adjusted HR of CHD incidence for depressed participants 
compared with indivisuals with no depression, overall and in 22 CHD cohorts [RE model]. 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 5-2 Funnel plot from 22 cohorts investigated the association between depressions 
and first-incidence of CHD. SE, standard error
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 Sensitivity analysis 
Table 5-4 demonstrates the results for the one-study removed meta-analysis. 
Similar estimations of HRs were yielded across all meta-analyses, with HRs ranging 
from 1.21 to 1.23, suggesting that no single study affected the overall estimate. 
Nonetheless, sensitivity analyses excluding Jee et al. (2019) study resulted in a 
narrower 95% CI (HR = 1.21, 95% CI, 1.17, 1.26) and a marked reduction in I2 
statistics across studies, which was observed at 9%. These findings indicate that 
Jee et al. (2019) genuinely contributed to the whole statistical heterogeneity in 
my analysis.  
Table 5-5 summarises all sensitivity analysis performed based on pre-specified 
criteria (see Section 5.4.2). Exclusion of studies that enrolled patients with a high 
risk of developing CVDs yielded an HR of 1.24 with a 95% CI between 1.14 and 1.34 
and a p-value < .000 (Figure 5-4). Heterogeneity was substantial, as indicated by 
a chi-square test (p < .000) and I2 statistics, which were observed at 79%. As shown 
in Figure 5-5, excluding studies that had used broad nonspecific criteria to identify 
depressed cases did not significantly affect the main result (HR = 1.23, 95% CI, 
1.13, 1.33, I2 = 80%). Sensitivity analysis removing studies that did not control for 
potential confounders resulted in an HR of 1.22 and a 95% CI of 1.13-1.32, with 
substantial heterogeneity (p < .00001, I2 = 79%; Figure 5-6). Restricting the analysis 
to the five studies that had excluded CHD events occurring within the first years 
of follow-up yielded a similar estimated risk giving an HR of 1.22 with a marginally 
wider 95% CI ranging between 1.01 and 1.48. An important level of heterogeneity 
was observed (p < .000, I2 = 88%; Figure 5-7). Nabi et al. (2010a) reported a similar 
pattern of association (adjusted HR = 1.94, p < .001), though full data were not 
provided. 
I also examined the effect of depression measured at multiple time points on the 
risk of CHD (Figure 5-8). Pooling HRs from the five studies that analysed depression 
as a time-dependent variable showed a slight reduction in the estimated risk 
compared to the primary analysis (HR = 1.17, 95% CI, 1.07, 1.28). The chi-square 
test for heterogeneity yielded a p-value of 0.36 and I2 statistics were observed at 
8%, indicating trivial heterogeneity. The combined estimates are likely to be 
driven by the Péquignot et al. (2016) cohort which carried about 50% of the total 
weight. 
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Figure 5-9 illustrates the findings after restricting the analysis to studies 
investigating the association between depression and CHD or stroke within the 
same population. This resulted in a similar estimate (HR = 1.22, 95% CI, 1.10, 1.35) 
with substantial statistical heterogeneity (p < .000, I2 = 86%). 
 
196 
Chapter 5: Depression and risk of CHD 
 
Table 5-4 Depression and risk of CHD: Sensitivity analysis excluding studies in turn (leave-
one-out approach) 
Study  HR (95%CI) P-value I2 
Overall effect (REM) 1.22 (1.13,1.32) <0.000 77% 
(Brunner et al., 2014) 1.22 (1.13,1.33) <0.000 78% 
(Daskalopoulou et al., 2016) 1.23 (1.14,1.33) <0.000 75% 
(Davidson et al., 2009) 1.21 (1.12,1.31) <0.000 78% 
(Gafarov et al., 2013) 1.22 (1.13,1.32) <0.000 78% 
(Gump et al., 2005) 1.23 (1.13,1.33) <0.000 78% 
(Gustad et al., 2014a) 1.22 (1.12,1.32) <0.000 78% 
(Hamieh et al., 2019) 1.21 (1.12, 1.31) <0.000 78% 
(Janszky et al., 2010) 1.23 (1.13,1.33) <0.000 78% 
(Jee et al., 2019) 1.21 (1.16,1.26) 0.34 9% 
(Karlsen et al., 2020) 1.23 (1.13,1.33) <0.000 78% 
(Khambaty et al., 2016) 1.23 (1.13,1.33) <0.000 78% 
(Ladwig et al., 2006b) 1.22 (1.13, 1.32) <0.000 78% 
(Majed et al., 2012) 1.23 (1.13,1.33) <0.000 77% 
(Mathur et al., 2016) 1.22 (1.13,1.32) <0.000 78% 
(Mejia-Lancheros et al., 2014) 1.23 (1.14,1.33) <0.000 78% 
(Moise et al., 2016) 1.23 (1.13, 1.33) <0.000 78% 
(Nabi et al., 2010a) 1.21 (1.12,1.31) <0.000 78% 
(Pequignot et al., 2013)  1.23 (1.13,1.33) <0.000 76% 
(Rahman et al., 2013) 1.22 (1.13,1.32) <0.000 78% 
(Rajan et al., 2020) 1.22 (1.12, 1.32) <0.000 78% 
(Scherrer et al., 2011) 1.21 (1.11, 1.33) <0.000 78% 
(Whang et al., 2009) 1.23 (1.13,1.33) <0.000 78% 
(Wulsin et al., 2005) 1.23 (1.14,1.33) <0.000 78% 
Abbreviations: CI, confidence interval; HR, hazard ratio; I2, I-square test; REM, random-effect 
model. 
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Figure 5-3 Forest plot showing the adjusted HR of CHD for depressed participants 
compared with indivisuals with no depression [Sensitivity analysis: Leave-one-out meta-
analysis (excluding Jee et al. (2019)]
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Table 5-5 Depression and risk of CHD: Sensitivity analysis summary 




Overall effect RE model 23 1.22 (1.13,1.32) <0.000 77% 
Excluding studies enrolling participants 
at high risk of CVD  
(Khambaty et al., 2016, Gump et al., 2005, 
Mejia-Lancheros et al., 2014) 20 1.24 (1.14,1.34) <0.000 79% 
Excluding studies used unspecified 
diagnosis of depression 
(Rahman et al., 2013, Brunner et al., 2014, 
Janszky et al., 2010) 20 1.23 (1.13,1.33) <0.000 80% 
Excluding studies not controlling for 
important covariates  
(Brunner et al., 2014, Gafarov et al., 2013) 
21 1.22 (1.13,1.32) <0.000 79% 
Studies excluding events occurred with 
1st years 
(Brunner et al., 2014, Gustad et al., 2014a, Jee 
et al., 2019, Majed et al., 2012, Rajan et al., 
2020) 
5 1.22 (1.01, 1.48) <0.000 88% 
Studies reported risk of time-varying 
depression  
(Brunner et al., 2014, Hamieh et al., 2019, 
Moise et al., 2016, Péquignot et al., 2016, 
Whang et al., 2009) 
5 1.17 (1.07, 1.28) 0.36 8% 
Studies examined CHD and stroke 
outcomes simultaneously within the 
same population 
(Brunner et al., 2014, Daskalopoulou et al., 
2016, Gafarov et al., 2013, Gump et al., 2005, 
Jee et al., 2019, Karlsen et al., 2020, Majed et 
al., 2012, Mathur et al., 2016, Mejia-Lancheros 
et al., 2014, Moise et al., 2016, Nabi et al., 
2010a, Péquignot et al., 2016, Rahman et al., 
2013, Rajan et al., 2020) 
14 1.22 (1.10,1.35) <0.000 86% 
Abbreviations: CI, confidence interval; HR, hazard ratio; I2, I-square test; MDD, major depressive disorders; K, number of studies; REM, random-effect model. 
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Figure 5-4 Forest plot showing the adjusted HR of CHD for depressed participants compared 
with indivisuals with no depression [Sensitivity analysis: Excluding studies enrolled 
participants at high risk of developing CVD] 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 5-5 Forest plot showing the adjusted HR of CHD for depressed participants compared 
with indivisuals with no depression [Sensitivity analysis: Excluding studies used unspecified 
diagnostic or screening tools to identify cases of depression] 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 5-6 Forest plot showing the adjusted HR of CHD for depressed individuals compared 
with individuals with no depression [Sensitivity analysis: Excluding studies not adequately 
adjusted for potential confounders] 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 5-7 Forest plot showing the adjusted HR of CHD for depressed participants 
compared with indivisuals with no depression [Sensitivity analysis: studies excluded CHD 
incident occurred within the first years]. 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 5-8 Forest plot showing the adjusted HR of CHD for depressed individuals compared 
with indivisuals with no depression [Sensitivity analysis: studies assessed depression as a 
time-dependent exposure] 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 5-9 Forest plot showing the adjusted HR of CHD for depressed participants compared 
with indivisuals with no depression [Sensitivity analysis: Including cohorts that examined 
risk of developing stroke and CHD simultaneously as their primary outcomes and calculated 
the HRs for each outcome separately]  
CI, confidence interval; IV, inverse variance; SE, standard error 
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 Depression and risk of incident CHD: Subgroup analysis 
Table 5-6 summarises the results for subgroup analyses examining the stability of 
the primary results and exploring factors that likely modify the association. 
Overall, eight subgroups explore the impact of depression on first-onset CHD, 
stratified according to the type of depression measure, duration of follow-up, 
mean age at baseline, CHD subtypes, type of gender, patient’s CVD status at 
baseline, sample size and geographical location of study. Results from the primary 
overall analysis are included for reference. 
 By type of depression assessment 
Figure 5-10 depicts the meta-analysis of depression by type of assessment method. 
Fourteen studies enrolling 23,1439 participants used a validated SRS tool for 
depression screening. The combined effect estimate resulted in an HR of 1.19, 
with 95% CI of 1.11-1.27 (p = .001). Statistical heterogeneity was trivial (p = .40, 
I2 = 5%). The direction of this finding was affected mainly by Péquignot et al. 
(2016) study, which carried around 30% of the total weight. Seven studies 
identified depression via structured clinical diagnostic interviews or clinical 
diagnosis, with 1,136,145 patients combined. Pooling of effect estimates from 
these studies yielded an HR of 1.26 (95% CI, 1.20, 1.32, p < .0001). Assessment of 
heterogeneity showed a chi-square test p-value of 0.65 and I2 statistics of 0%, 
indicating no statistical heterogeneity between studies. Scherrer et al. (2011) 
study greatly influenced the direction of this analysis, as it carried more than 67% 
of the assigned weight. Three studies enrolling 2,455,369 participants identified 
depression cases by clinical assessments combined with the use of antidepressant 
medications. The summary effect estimates resulted in an HR of 1.18 (95% CI, 
0.86,1.63, p = .22) with evidence of substantial heterogeneity (p < .00001, I2 = 
95%). Finally, five studies with 994,306 participants determined the CHD risk 
associated with the use of antidepressants in additional analyses. Pooling the 
effect estimates showed an HR of 1.03 (0.63, 1.69, p = .91) with statistically 
considerable heterogeneity (p < .00001, I2 = 98%). Weight was evenly distributed 
across the studies. Scherrer et al. (2011) study explained 54% of the total variation 
between studies, perhaps due to population heterogeneity (diabetic population). 
No significant statistical difference was observed between studies (p = .47). 
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 By duration of follow-up 
A follow-up duration of 10 years, just below the average follow-up of the included 
studies, was set as a cut-off point for the group studies. Sixteen cohorts with 
3,283,382 participants had been conducted over 10 years or longer. The pooled 
HR, as demonstrated in Figure 5-11, showed a 23% increase in CHD risk among 
depressed patients (HR 1.23, 95% CI, 1.11, 1.36, p < .0001). Assessment of 
heterogeneity found considerable statistical variation between studies (p < .000, 
I2 = 80%). Data for studies with a follow-up duration of less than 10 years were 
obtained from seven studies enrolling 502,917 participants. The pooled effect 
estimate resulted in an HR of 1.23 and a 95% CI between 1.11 and 1.35 (p < .000). 
Low heterogeneity was detected by a chi-square p-value of < .28 and I2 statistics 
of 20%. The test for subgroup differences suggests no statistically significant group 
effect (p = .97). 
 By mean age groups 
For studies with patients’ mean age of less than 65 years, data were available 
from 3,768,588 participants enrolled in 19 cohorts (Figure 5-12). Combined effect 
estimates resulted in an HR of 1.24 with a 95% CI of 1.14-1.34 (p < .000). The chi-
square test resulted in a p-value of <.000 and the I2 statistics were observed at 
75%, indicating considerable statistical heterogeneity. None of the individual 
studies had a large influence on this analysis. Data for studies with an older mean 
age (≥ 65 years) were available from 17,711 patients enrolled in three cohorts. 
Pooling effect estimates showed an HR of 1.13 with a 95% CI between 1.02 and 
1.25 (p = .02). No statistical heterogeneity was observed between the studies (p 
= 0.42, I2 = 0%). The overall effect was strongly influenced by Péquignot et al. 
(2016) study which carried most of the assigned weight (86.5%). Testing for 
subgroup differences showed no statistically significant differences (p = .15).  
 By type of CHD endpoints 
Figure 5-13 demonstrates the impact of depression on CHD stratified by type of 
CHD endpoints, including fatal/non-fatal MI, composite CHD and angina.  
Results for MI were available from participants 3,651,404 enrolling in 12 studies 
with a pooled HR of 1.24 (95% CI, 1.19, 1.29, p < .00001). No statistical 
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heterogeneity was observed between studies (p = .48, I2 = 0%). This analysis was 
greatly influenced by Scherrer et al. (2011) study, which carried almost half of 
the overall weight (49%). Data for a composite endpoint of fatal and non/fatal 
CHD were obtained from 12 studies enrolling 616,250 patients. Pooling effect 
estimates resulted in an HR of 1.29 with a 95% CI between 1.16 and 1.57 (p = 
.002). Evidence for substantial heterogeneity was detected (p < .000, I2 = 78%). 
The two largest cohorts in this review provided data for risk of angina from 
2,418,715 patients. An analysis of these results showed an HR of 1.57 (95% CI 
1.40,75, p < .00001) with moderate to considerable heterogeneity (p = .08, I2 = 
68%). This analysis was mainly driven by Jee et al. (2019) study, which carried 60% 
of the total weight. Although the test for subgroup differences suggests that there 
is a statistically significant subgroup effect (p < .000), the number of studies in 
the angina subgroup (n = 2) was insufficient for an accurate comparison. 
Additionally, some of the studies’ participants contributed to more than one of 
the subgroups in the forest plot (Daskalopoulou et al., 2016, Jee et al., 2019). 
 By gender 
As shown in Figure 5-14, data were stratified based on gender. The first group 
comprised eight cohorts with 373,614 male participants. The pooled HR showed 
that depression increased the risk of incident CHD in men by 23% (HR 1.23, 95% 
CI, 1.06, 1.43, p = .007). Heterogeneity among these studies was substantial, as 
indicated by I2 = 67% and a chi-square p-value of .003. The second group for women 
consisted of five cohorts with 285,462 individuals and the HR showed a stronger 
effect of depression for female participants (HR 1.50, 95% CI, 1.25, 1.81, p = .001) 
with modest heterogeneity (p = 0.23, I2 = 29%). Jee et al. (2019) study carried the 
largest weight in both the male and female groups. 
 By sample size 
Studies were stratified based on sample size into less than 10,000, between 10 
and 100 thousand and those which have extremely large sample size more than 
100,000 thousand (Figure 5-16). The magnitude of HRs were roughly around 20 and 
results from all subgroup analysis are in the same direction indicating increased 
risk of CHD in depressed individuals compared to non-depressed individuals. 
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 By study location 
Stratification of studies according to their geographical regions resulted in two 
subgroups (Figure 5-17). A data synthesis of HRs obtained from 13 European studies 
showed that depression was associated with a 17% increase in first-onset CHD (HR 
1.17, 95% CI, 1.11, 1.24, p = .00001) with no evidence of heterogeneity (p = .57 
and I2 = 0%). This finding was primarily influenced by the Daskalopoulou et al. 
(2016) and Péquignot et al. (2016) cohorts because they carried 24.2% and 25.6% 
of the total assigned weight, respectively. Data from US studies were available 
from eight cohorts enrolling 478,007 patients. The pooled HR found that 
depression increased risk of first-onset CHD by 20% (HR 1.20, 95% CI, 1.10, 1.32, 
p = .002) with trivial heterogeneity (p = .22, I2 = 26%). Scherrer et al. (2011) drove 
the magnitude and direction of the combined estimate because it carried 42.2% 
of the total assigned weight. 
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SRS 14 23,1439 1.19 (1.11,1.27) 0.40 5% 
0.47 
Clinical diagnosis 7 1,136,145 1.26 (1.20,1.32) 0.65 0% 
Combined clinical diagnosis and 
AD 
3 2,455,369 1.18 (0.86,1.63) <0.000 95% 
AD 5 994,306 1.03 (0.63,1.69) <0.000 98% 
Duration of follow-
up 
< 10 years 7 502,917 1.23 (1.11,1.35) 0.28 20% 
0.97 
≥ 10 years 16 3,283,382 1.23 (1.11,1.36) <0.000 80% 
Mean age 
≥ 65 years 3 17,711 1.13 (1.02,1.25) 0.42 0% 
0.15 
< 65 years 20 3,768588 1.24 (1.14,1.34) <0.000 75% 
CHD subtypes 
MI 12 3,651,404 1.24 (1.19,1.29) 0.48 0% 
0.002 Composite endpoint (CHD and MI) 12 616,250 1.29 (1.16,1.57) <0.000 78% 
Angina 2 2,418,715 1.57 (1.40,1.75) 0.08 68% 
Type of gender 
Male 8 373,614 1.23 (1.06,1.43) 0.003 67% 
0.1 
Female 5 298,191 1.50 (1.25,1.81) 0.23 29% 
CVD status at 
baseline 
Free of CHD and stroke 11 737,287 1.18 (1.11,1.25) 0.85 0% 
0.41 
Free of CVD  13 3,071678 1.24 (1.11,1.38) <0.000 83% 
Sample size 
≥ 10,000 <100,000 10 253,329 1.20 (1.11,1.31) <0.000 0% 
0.39 < 10,000 8 39,539 1.15 (1.05,1.25) 0.41 3% 
≥100,000 5 3435478 1.28 (1.12,1.47) 0.0003 93% 
Study location 
EU 13 2,681075 1.17 (1.11,1.24) 0.57 0% 
0.66 
US, Canada 8 478,007 1.20 (1.10,1.32) 0.22 26% 
Asia 1 481,355 1.57 (1.50,1.64) NA NA  
Multinational 1 145,862 1.23 (1.10,1.38) Na NA  
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Abbreviations: AD, antidepressants; CI, confidence interval; CHD; coronary heart disease; CVD, cardiovascular disease; EU, Europe; HR, hazard 
ratio; K, number of studies; MI, myocardial infarction; N, number of participants; REM, random-effect model; SRS, self-reported scale; US, United 
states. 
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Figure 5-10 Forest plot showing the adjusted HR of CHD incidence for depressed individuals 
compared with indivisuals with no depression by type of depression assessment 
Abbreviations: AD, antidepressants medication; CHD, coronary heart diseases; SE, standard error; 
SRS, self-reported scale. 
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Figure 5-11 Forest plot showing the adjusted HR of CHD incidence for depressed individuals 
compared with indivisuals with no depression by duration of follow-up 
Abbreviations: CHD, coronary heart diseases; SE, standard error. 
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Figure 5-12 Forest plot showing the adjusted HR of CHD incidence for depressed 
individuals compared with indivisuals with no depression by study population’s mean age 
Abbreviations: CHD, coronary heart diseases; SE, standard error 
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Figure 5-13 Forest plot showing the adjusted HR of CHD incidence for depressed 
individuals compared with indivisuals with no depression by CHD outcomes 
Abbreviations: CI, confidence interval; CHD, coronary heart diseases; MI. myocardial infarction; 
SE, standard error 
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Figure 5-14 Forest plot showing the adjusted HR of CHD incidence for depressed individuals 
compared with individuals with no depression by gender 
Abbreviations: CI, confidence interval; CHD, coronary heart diseases; SE, standard error 
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Figure 5-15 Forest plot showing the adjusted HR of CHD incidence for depressed 
individuals compared with indivisuals with no depression by type of population 
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Figure 5-16 Forest plot showing the adjusted HR of CHD incidence for depressed 
individuals compared with indivisuals with no depression by study sample size 
CI, confidence interval; IV, inverse variance; SE, standard error 
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Figure 5-17 Forest plot showing the adjusted HR of CHD incidence for depressed individuals 
compared with indivisuals with no depression by location 
Abbreviations: CI, confidence interval; CHD, coronary heart diseases; EU, Europe; SE, standard 
error; US, United States
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 Discussion 
I sought to assess the relationship between depression and risk of CHD incident in 
patients with no known history of CHD or stroke prior to study entry. The primary 
analysis of the 23 studies using REM showed that participants with depression who 
were apparently free from stroke and cardiac diseases experienced a 22% 
increased risk of first-onset CHD events compared to non-depressed participants 
(HR = 1.22, 95% CI, 1.13, 1.32). My finding is in line with the latest systematic 
review and meta-analysis on this subject conducted by Wu and Kling (2016), who 
reported a 22% increased risk of CHD incident. A positive association was also 
found when analyses were performed for MI and angina: the corresponding 
estimated risks were 24% and 57%. The risk estimates yielded from the primary 
analysis, as well as the direction of the association, remained fairly stable when 
multiple exclusion criteria were applied within sensitivity analyses. There was, 
however, substantial variation between studies (I2 = 77%, p < .000). Most of the 
variability between the studies observed in the primary analysis, in the subgroups 
and sensitivity analyses can be explained by the Jee et al. (2019) study. Exclusion 
of this cohort based on a leave-out meta-analysis approach resulted in a narrower 
95% CI, an improvement on the overlaps between CI and a drastic decrease in the 
statistical heterogeneity (p = .44, I2 = 9%). Because the magnitude of the estimated 
risk did not change (HR = 1.21, 95% CI, 1.16, 1.26), the large heterogeneity in this 
review should not be a concern. The pooled effect estimates of HR for incident 
CHD obtained from the 14 cohorts that measured CHD and stroke outcome 
simultaneously within the same population yielded a very close estimate effect 
(HR = 1.22, 95% CI, 1.10, 1.35, I2 = 86%). 
 Dose response relationship 
In this review, I evaluate the dose–response hypothesis in relation to depressive 
disorder and its prospective association with CHD incidence. Of eight cohorts that 
examined the dose response relation (Brown et al., 2011, Brunner et al., 2014, 
Gump et al., 2005, Gustad et al., 2014a, Jee et al., 2019, Nabi et al., 2010a, 
Whang et al., 2009, Wulsin et al., 2005), four had previously discussed it in relation 
to stroke outcomes. There were considerable methodological diversities in terms 
of how studies measured the dose-response effect of depression, as discussed in 
section 4.5.1. Thus, generating a meta-analysis for those studies was not possible. 
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In the following section, I describe and discuss their results narratively. Of the 
eight cohorts, five investigated the relationship between the severity of 
depressive symptoms and the risk of developing CHD. Gump et al. (2005) divided 
the CES-D scores into quintiles and showed no statistically significant association 
between increasing the severity of depressive symptoms and risk of incident CHD. 
As described previously (See section 3.3.1), this study used uncommon cut-off 
scores (13) presenting the association for minor depressive symptoms (i.e. below 
a score of 13) and did not provide detailed data about the nature of the association 
beyond that point. Brown et al. (2011) applied the same screening tool and divided 
the CES-D scores into the following <16, 16–23 and ≥ 24. Their findings 
demonstrated a dose-response relationship between the CES-D score and CHD 
incidence. Compared to participants with a CES-D score < 16, participants with 
CES-D score ≥ 24 (RR = 1.61, 95% CI, 1.22, 2.11) and those with a CES-D score 
between 16–23 (RR = 1.36, 95% CI, 1.06, 1.74) had a higher RR of CHD risk. Wulsin 
et al. (2005) also used the CES-D screening tool and statistically derived three 
levels of severity based on gender-specific tertiles. The highest tertile of 
depressive symptoms was equivalent to scores above 9 for men and above 11 for 
women on the CES-D-scale. Their results showed no association between different 
levels of depressive severity and CHD risk for either gender (p for trend = .23), 
although it was likely underpowered to detect an association. Again, the dose-
response relationship in this study was not tested in relation to different severity 
levels of clinically relevant depressive symptoms. Nabi et al. (2010a) used the BDI 
scale divided into nil (0-9), mild (10-18), moderate (19-29) and severe symptoms 
(30-36) and found a dose-response association with CHD, but it was not 
statistically significant. They further examined the association between 
continuous BDI scores and risk of CHD and showed that a one-unit increase in the 
BDI score is associated with an excess CHD risk of 3% (HR = 1.03, 95% CI, 1.02–
1.05). Whang et al. (2009) utilised the MHI-5 screening tool and divided the 
participants into four categories of depressive symptoms according to their MHI-5 
score (77–100, 76–85, 53–75, 0–52). The findings from their study demonstrated a 
dose-response relation with fatal CHD (p=0.007) but not with MI (p-value for trend 
= .19). 
The other three cohorts examined the association between depression chronicity 
and risk of CHD. Two proposed a dose-response relationship between the 
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increasing number of depressive episodes experienced over the follow-up period 
and the risk of developing CHD (Brunner et al., 2014, Péquignot et al., 2016). 
Brunner et al. (2014) showed that compared to participants with no depressive 
symptoms, patients who experienced depressive symptoms 1-2 times during their 
lifetime were at a 12% increased risk of developing CHD, though with no statistical 
significance (HR = 1.12, 95% CI, 0.7–1.7), while those who experienced depressive 
symptoms 3 to 4 times had a twofold increased risk of developing CHD (HR = 2.06, 
95% CI, 1.2–3.7, p-value for trend = .01). As previously mentioned, results from 
Brunner et al. (2014) were presented without adjusting for CVD risk factors. In the 
Péquignot et al. (2016) cohort, the risk for future CHD was evident with transient 
and cumulative depressive episodes – a finding that is similar to stroke outcomes. 
In Jee et al. (2019) study, the risk of depression over 10 visits, irrespective of 
gender, did not show a dose-response relationship, although each visit due to 
depression was significantly associated with incident CHD. 
While these cohorts do not agree on a linear association between depression and 
CHD incidence, they all indicate that chronic depressive symptoms are associated 
with an increased risk of incident CHD. These findings contrast with one of the 
early studies that evaluated the effect of depression measured at multiple 
occasions on the risk of a new CVD event among elderly patients who were free of 
CHD (Penninx et al., 1998). The study found that chronic depression was not 
associated with an increased risk of incident CVD and concluded that chronic 
depression may not be a risk factor for CVD. The findings from these recent studies 
provide evidence that repeated exposure to depressive symptoms or chronic 
depression can indeed be a risk factor for CHD. Nonetheless, it should be noted 
that experiencing multiple depressive episodes over a period of time, however, 
predominantly reflects several depression subtypes (i.e. recurrent or persistent 
depression). There is a possibility that patients who have experienced recurrent 
depression may have a different genetic profile compared to those with single 
episodes. Studies suggest that recurrent depression reflects an underlying 
vulnerability that is largely based on genetic loading (Burcusa and Iacono, 2007, 
Shadrina et al., 2018). Further, it is well documented that depression and cardiac 
diseases share a common genetic background (Kendler et al., 2009, McCaffery et 
al., 2006, Scherrer et al., 2003). Thus, the significant association between 
depression and incident CHD in patients who experienced multiple depressive 
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episodes could be confounded by their distinct genetic variability and perhaps a 
unique disease profile. Consequently, the higher associated risk may mirror 
genetic predisposition rather than depression per se. 
 Depression as a time-varying exposure 
I also evaluated the risk of future CHD associated with depression assessed at 
multiple instants over the course of follow-up. A sensitivity analysis of five studies 
examined the cumulative effect of depressive symptoms for a minimum of three 
measures over an average follow-up of 12.7 years. The findings showed that the 
risk of time-varying depression was relatively stable (HR = 1.17, 95% CI, 1.07, 
1.28). Despite that no evidence of statistical heterogeneity being detected (p = 
.36, I2 = 8%), the result from this analysis should be considered with caution due 
to the small number of studies that were incorporated to pool the risk estimate. 
However, it has been suggested that, in REM, the minimum number required is 
five studies to reasonably achieve power to detect an effect of interest (Jackson 
and Turner, 2017). 
 Reverse causality 
One of the largest challenges that has been identified when studying the 
prospective association between depression and CHD is that both conditions are 
caused by  subclinical manifestations of atherosclerosis (Carney and Freedland, 
2003, Charlson and Peterson, 2002).  Thus, a positive association between 
depression and subsequent CHD may reflect a reverse causation (i.e. subclinical 
manifestation of CVD causing depression). In a meta-analysis, Nicholson et al. 
(2006) found that the impact of depression on CHD incidence was more 
pronounced in studies with relatively short follow-up durations compared to those 
with longer follow-up durations and suggested a possibility of reverse causality. 
Similarly, in a subgroup analysis, Gan et al. (2014) presented that depression 
increased the risk of CHD in the group with less than 15 years of follow-ups (RR = 
1.36, 95% CI, 1.24, 1.49), but no statistical significant association was found for 
the group with follow-ups equal to or more than 15 years (RR = 1.09, 95% CI, 0.96, 
1.23). However, there are some concerns about the reliability of these results. As 
previously mentioned, the review conducted by Nicholson et al. (2006).contains 
early observational literature that controlled poorly for potential confounders, 
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which may explain the profound effect in some of their findings. In Gan et al. 
(2014) cohort, it appeared that the subgroup analysis by the follow-up duration 
suffers from uneven covariate distribution as there was a large imbalance in the 
number of studies within the subgroup (30 vs 5 studies). In addition, some study 
participants contributed to both subgroups, limiting a proper examination and 
interpretation for a possible subgroup difference (Richardson et al., 2019). I 
performed a subgroup analysis dividing my eligible studies into a group with a 
follow-up duration of less than 10 years and to a follow-up duration of 10 years or 
longer. In contrast to the past reviews, the results from my subgroup analysis 
showed no significant impact of the follow-up duration on the estimated risk. I 
found that depression is associated with a 23% (HR = 1.23, 95 CI%, 1.11, 1.35) and 
21% (HR = 1.29, 95% CI, 1.14, 1.47) increased risk of CHD incident corresponding 
to studies with a follow-up duration of less than 10 years and those with 10 years 
or longer. These findings align with the results of Wu and Kling (2016) who found 
that depression significantly increases the risk of MI and CHD death based on 
studies that had a mean follow-up of eight years or longer. Although my review 
includes participants with no known history of CHD or stroke, the impact of reverse 
causality cannot be ruled out given that none of the included studies had measured 
the baseline level of subclinical atherosclerosis. 
Subclinical atherosclerosis, the pathological mechanism underlying CHD, is known 
to take decades to manifest as clinical symptoms (Janszky et al., 2010). In this 
review, the average follow-up was about 12 years, and most of the included 
studies enrolled middle-aged or older participants who may already have had 
atherosclerosis before study entry. On balance, atherosclerosis could also be a 
pathological consequence of depression (Khan et al., 2020). To minimise the 
possibility of reverse causality, I pooled the summary effect from five studies that 
considered a lag period with the exclusion of incident CHD in the first years of 
follow-up. The pooled HR was comparable to the primary meta-analysis showing 
that depression is associated with a 22% (1.22, 95% CI, 1.01, 1.48) increased risk 
of CHD incident, which may reassure that the main findings in this review are not 
biased by reverse causality. However, the wide 95% CI and the substantial 
heterogeneity (p <.000, I2 = 88%) limit drawing a firm conclusion.  
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 Types of depression assessment tools and CHD  
An evaluation of the different depression measurement types in a subgroup 
analysis showed that clinical depression had a stronger effect on incident CHD (HR 
= 1.26, 95% CI, 1.20, 1.32, I2 = 0%) relative to depressive symptoms (HR = 1.19, 
95% CI, 1.11, 1.27, I2 = 5%), although no statistically significant difference between 
the groups exists (p = .47). This finding suggests that depressive symptoms do not 
need to reach a clinical/diagnostic threshold to be associated with CHD risk, 
corroborating my findings regarding stroke in the previous chapters as well as 
reports from the past reviews (Rugulies, 2002, Nicholson et al., 2006), which fit 
well with a dose-response hypothesis. By contrast, Gan et al. (2014) found that 
the association was much stronger in studies that identified depression using SRS 
rather than structured clinical diagnostic interviews or clinical diagnosis. 
Nevertheless, the subgroup analysis in this review was incapable of producing valid 
results, partly due to the imbalanced number of studies across their subgroups (29 
studies vs 4 studies). Conversely, depressed patients identified through a clinical 
assessment and or usage of antidepressants yielded a null association. This result 
is contrary to those obtained from stroke analysis, which showed that depressed 
cases identified by clinical diagnosis and/or anti-depressants are associated with 
increased risk of stroke.  
In the last subgroup, I evaluated the independent effect of antidepressants on 
incident CHD and found no evidence that antidepressants were associated with an 
increased risk of developing CHD (p = .91). 
Overall, meta-analysis studies examining the effect of antidepressant use and risk 
of incident CHD among healthy individuals are limited. My finding is comparable 
with one of the few meta-analyses of observational studies enrolling participants 
with no history of CHD (Oh et al., 2014). This review of 7 case–control and 11 
cohort studies found that neither SSRIs nor TCAs were associated with an increased 
risk of a first-onset CHD event. More recently, a prospective cohort study of 
238,963 patients aged 20 to 64 years with a first diagnosis of depression and free 
of previous MI found no evidence of an association between antidepressant class 
and risk of MI over five years of follow-up (Coupland et al., 2016). The effect of 
antidepressants on CHD incidence was not studied in previous meta-analyses that 
examined the association between depression and CHD (Gan et al., 2014, 
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Nicholson et al., 2006, Rugulies, 2002, Wu and Kling, 2016, Wulsin and Singal, 
2003). My findings provide separate risk estimations which help to recognise the 
potentially distinct effect of depression and antidepressant use on incident CHD 
in individuals with no known history of CHD or stroke. The result from my subgroup 
analysis should be considered with caution due to the significant amount of 
heterogeneity between studies (I2 = 98%). Additionally, my result is limited by 
inadequate drug information on the type of antidepressants, dosage regimen and 
adherence. These findings clearly show how results may alter based on different 
diagnostic criteria used to identify depression, which could interfere with correct 
identification of CVD risk association or result in improper patient care plans. 
Altogether this evidence further supports my conclusion in previous chapter that 
current clinical practice lack evidence about the optimal methods for assessing 
depression and future studies should examine different diagnostic criteria and 
establish the possible optimal one. 
 Risk by type of CHD endpoint 
Two studies provided further information on angina pectoris as a CHD outcome 
(Daskalopoulou et al., 2016, Jee et al., 2019). The magnitude of the estimated 
risk provided by each study was much more profound compared to the risk 
estimates for other CHD endpoints within the same studies. The pooled HR showed 
that depression increased the risk of developing angina by 57% (HR = 1.57, 95% CI, 
1.40, 1.75, I2 = 68%). However, note that both cohorts that were used to pool the 
risk estimate identified the depressive cases by antidepressant usage in addition 
to clinical diagnosis (which are both subject to potential misclassification) and 
perhaps the potential bias of doing led to an overestimation of effect size. Another 
explanation for the larger effect observed in this subgroup is that the effect size 
obtained from the primary meta-analysis was based on studies that had mostly 
(80%) relied on hard primary endpoints (CHD death and MI), which are more likely 
to be less susceptible to manipulation or bias as soft endpoints (angina). Research 
has shown that an angina diagnosis is problematic as people with depression or 
other mood disorders are more likely than others to report angina-like chest pain 
in the absence of any narrowed coronary artery (Carter et al., 1997, Lantinga et 
al., 1988, Serlie et al., 1995, Kim et al., 2017b). Although results form this 
subgroup is limited due to the very small number of included studies, , it would 
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be expected that studies restricting their outcomes to hard endpoints as a 
conservative approach would underestimate the effect of depression on CHD. 
My subgroup analysis for MI outcome showed that depressed patients were at a 
24% higher risk of developing MI compared to non-depressed patients (HR = 1.24, 
95% CI, 1.19, 1.29, I2 = 0%). In the Wu and Kling (2016) review, only studies with a 
hard endpoint, including MI and fatal CHD, were eligible. The reviewers 
synthesised data from eight studies and reported that depression is associated 
with a 30% increased risk of MI. My subgroup result for MI outcome is highly 
consistent with those obtained from the primary analysis of the current study for 
all CHD events, including definite angina, leading to the conclusion that the result 
reported herein is not driven by ‘soft’ endpoints. 
 Gender differences 
Generally, men are known to have a higher propensity for developing CHD than 
women (Bots et al., 2017). Epidemiological studies have suggested that 
premenopausal women are at lower risk of developing CVD compared to age-
matched men. The reduced risk is attributed at least partly to oestrogen, which 
have been suggest to have protective mechanism against CVD (Iorga et al., 
2017).However, women are twice as likely as men to develop depression during 
their lifetime (Kuehner, 2017). Therefore, does that mean that depression 
increases the risk among women to develop CHD compared to men? Several studies 
suggest that gender, particularly younger women, could be a predictor of poor 
prognosis in patients with established CHD (Greenland et al., 1991, Vaccarino et 
al., 1998), which may partly explain why women with depression face higher 
mortality rates after a CHD event compared to men with depression (Mallik et al., 
2006). In this review, I examined whether depressed females compared to 
depressed males were at a higher risk of developing CHD by conducting a subgroup 
analysis. The results showed that depression significantly increased the risk of CHD 
in women by 50% (HR = 1.50, 95% CI, 1.25, 1.81, I2 = 29%) compared to 23% in men 
(HR = 1.23, 95% CI, 1.06, 1.43, I2 = 67%), but no significant between-group 
differences were observed (p = .1). My finding that depressed women experienced 
a higher risk of CHD is not completely congruent with previous meta-analyses. Wu 
and Kling (2016) found that depression increased the risk of CHD in men but not 
in women. Similarly, Gan et al. (2014) found that the depression effect on CHD 
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was more evident in men. Nonetheless, the risk estimations provided by both 
meta-analyses were inaccurate, as male proportions were between 30%-40% in 
more than 70% of the studies used to detect gender-based differences. My result 
also differs from that of a recent meta-analysis conducted by Smaardijk et al. 
(2019).In a systematic review, Smaardijk et al. (2019) assessed the association 
between different psychological factors, including depression and the 
development of CHD stratified by gender. The authors showed that the 
associations of depression with CHD did not differ between women and men 
(Smaardijk et al., 2019). They identified 34 studies provided data for men and, 
after pooling the risk estimate, they found that depression is associated with a 
23% increased risk of developing CHD, which is close to my effect size, though 
with a narrower 95% CI (HR = 1.23, 95% CI, 1.16, 1.31, I2 = 65%;(Smaardijk et al., 
2019)). For women, the result derived from 28 studies and showed a risk estimate 
of 24% (HR = 1.24, 95% CI, 1.15, 1.33, I2 = 68), which is about half that of my 
pooled effect size. One important reason for the discrepant findings is that in my 
review, the effect size in women subgroup was based on a very small number of 
reports (5) compared to Smaardijk et al. (2019) review. More recently, Bryant et 
al. (2020) examined whether age and gender modify the association between 
time-varying depressive symptoms and risk of all-cause and CVD mortality. In 
contrast to my results, they found that neither age nor gender moderate the 
association between depression and CVD mortality. but partly in line with Kouvari 
et al. (2019) results. Kouvari et al. (2019) conducted a prospective cohort study 
to examine the role of sex in the association between depressive symptomatology, 
incident and recurrent CVD events over 10 years period. The authors proposed 
that depressive symptomatology had an independent aggravating effect on the 
first and recurrent CVD events only in women. 
 
 Comparison with previous reviews 
Appraisals of the literature have shown several studies similar to this review that 
have assessed depression in relation to either all CHD or specific components of 
CHD. The first systematic review, which is the highly cited review on this topic, 
was conducted by Rugulies (2002) incorporating 11 prospective studies published 
in the 1990s with 36,549 participants. The reviewer used only two databases 
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(Medline and PsycINFO) to retrieve eligible studies with MI and CHD as their main 
outcomes of interest. Angina pectoris was excluded from the author’s criteria. 
Their main finding showed that depressed subjects had a 64% (RR = 1.64, 95% CI, 
1.29–2.08) higher risk of developing CHD than non-depressed subjects. As a 
fundamental step in any systematic review, reviewers should assess and report 
the methodological quality of the included studies to supplement the reader with 
information about the strength of the body of evidence used to generate the 
estimated effect. Rugulies (2002) did not use a quality assessment tool or compute 
a methodological quality score for each of the included studies; hence, the 
likelihood of the inaccuracy of the reported estimated effect is unknown. Further, 
this publication did not explore publication bias. Soon after, Wulsin and Singal 
(2003) published a systematic review addressing the same research question with 
10 studies and 27,231 participants. The reviewers had searched the same two 
databases as the previous review (i.e. Medline and PsycINFO). Since this 
publication synthesised evidence that spans around the same period (1993–2000) 
as Rugulies, it produced an identical effect estimate but with a narrower 95% CI 
(RR = 1.64, 95% CI, 1.41, 1.90). However, in contrast to Rugulies (2002), Wulsin 
and Singal (2003) explored the possibility of publication bias and suggested 
evidence of publication bias in their meta-analysis. Subsequently, Nicholson et al. 
(2006) performed a meta-analysis two times larger than the past reviews, 
incorporating 21 studies published before 2004 with 124,509 participants. The 
reviewers searched two search engines, including MEDLINE and Science Citation 
index citation tracking, without using relevant key databases, such as PsycINFO, 
which is specifically designed to access literature in psychology and related 
disciplines. Thus, potentially eligible papers may have been missed, which the 
authors acknowledged. As mentioned in the introduction, Nicholson et al. (2006) 
pointed out that about 50% of the studies conducted on this topic had poorly 
controlled for covariates and included crude RR or age-adjusted RR, resulting in 
an exaggeration of the estimated effect of depression on future CHD. After pooling 
the summary effect from 11 studies that had controlled for possible confounders, 
they found that depression was associated with a 90% (RR = 1.90, 95% CI, 1.49–
2.42) increased risk of developing CHD. Fewer studies were available when these 
three reviews were conducted; hence, further analytical stratifications to explore 
the effect of depression on different subgroups were limited. Additionally, 
because a meta-analysis is essentially restricted to the adequacy and quality of 
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the available evidence, perhaps these early meta-analyses on this topic would be 
better described as informative reviews providing suggestive evidence for a 
positive association between depression and onset of CHD rather than precisely 
quantifying the estimated risk. This was evident in the magnitude of the estimated 
risk obtained from all three meta-analyses with the wide associated 95% CI, 
meaning that their estimated risk of depression was filled with great uncertainty 
and further investigation was required. In 2007, Van der Kooy et al. elaborated 
the previous work and identified 28 eligible studies using Medline and PsycINFO 
databases(Van der Kooy et al., 2007). Their primary aim was to estimate the risks 
of depression for a wide range of CVDs, including CHD, MI, stroke and other CVD. 
For CHD outcome, 16 studies were eligible to pool the risk estimate, which 
resulted in an effect size of 1.57 (95% CI, 1.35, 1.81), with a lower magnitude and 
a narrower 95% CI than past reviews. Van der Kooy et al. (2007) were also able to 
quantify the inconsistencies between studies using the I2 test and provided 
evidence for statistical substantial heterogeneity between studies (I2 = 62%), an 
important step that past reviews had not considered as this kind of test had not 
previously been introduced. Van der Kooy et al. (2007) performed additional 
analyses to explore the effect of depression on CHD subtypes and were first review 
to quantify an effect size for an association between depression and MI (OR = 1.60, 
95% CI, 1.34, 1.92) based on eight studies with no evidence of statistical 
heterogeneity (I2 = 0%). Nonetheless, all four reviews (Nicholson et al., 2006, 
Rugulies, 2002, Van der Kooy et al., 2007, Wulsin and Singal, 2003) included 
studies enrolling participants with CHD at the study baseline, which did not clearly 
enable readers to discern the depression as a pre-morbid risk factor and affected 
the magnitude of the true association (Gan et al., 2014). In the last decade, two 
meta-analyses on this topic were published adopting more strict inclusion criteria, 
including studies that focused on CHD free patients (Gan et al., 2014, Wu and 
Kling, 2016). Gan et al. (2014) search strategy included PubMed, Embase and Web 
of Science literature up to April 2014, without using a psychology-related 
database. They identified 30 potentially relevant studies enrolling 893,850 
participants, becoming the largest meta-analysis on this topic to date. 
Methodological qualities of the eligible cohorts were assessed in accordance with 
the NOS tool. Their pooled RR demonstrated that depression was associated with 
a 30% increased risk of new onset CHD and MI (RR = 1.30, 95% CI, 1.22, 1.40; RR = 
1.33, 95% CI, 1.18, 1.44, correspondingly). Heterogeneity between studies was 
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substantial (p = .000, I2= 71.9). Further, they presented a cumulative meta-
analysis and showed that the risk estimate stabilised from 2013 and remained 
unchanged after adding more recent large cohorts (Brunner et al., 2014, Gustad 
et al., 2014a), suggesting that adding more studies in future even with thousands 
of participants would produce similar results. The number of included cohorts 
(n=30) also made it possible to explore the effect of depression more extensively 
in different subgroups, including type of depression measurements, gender, age, 
follow-up duration and study location. However, the Gan et al. (2014) review 
contains important methodological problems that limit their results. First, the 
reviewers stated that only studies that have measured depression as a binary 
variable were considered, but they included ineligible studies with RR from studies 
modelled depression as a continuous or ordinal variable (Barefoot John and 
Schroll, 1996, Hawkins et al., 2014). Second, they included multiple publications 
from the same study populations (Anda et al., 1993, Brown et al., 2011, Ferketich 
et al., 2000, Hawkins et al., 2014). Third, their primary meta-analysis 
incorporated all independent reports of CHD subtypes (i.e. MI and fatal CHD) 
derived from one study. Therefore, they treated each report as a separate study 
(i.e. double counting of studies). Statistically, according to Borenstein et al. 
(2009), this is problematic, mainly because when computing the summary effect 
across studies, studies with more than one report will be assigned more weight 
than studies with only a single report, which will consequently affect the overall 
risk estimates (Borenstein et al., 2009). The latest review was carried out by Wu 
and Kling (2016). The authors used five search engines – MEDLINE, EMBASE, 
PsycINFO, ISI Web of Science and Scopus – up to August 2015. They also reviewed 
the references of the eligible papers and related review articles. The eligible 
outcomes in this review were only hard CHD endpoints (i.e. MI or fatal CHD) 
excluding composite CHD events involving angina pectoris. Their search identified 
19 prospective cohorts with 323,709 participants. Because of the strict inclusion 
criteria in terms of the outcome of interest, several key studies in this area were 
omitted (Gump et al., 2005, Majed et al., 2012, Nabi et al., 2010a, Pequignot et 
al., 2013, Rahman et al., 2013, Scherrer et al., 2011). The methodological 
qualities of included cohorts were also assessed using the NOS tool. Compared to 
past reviews, Wu and Kling (2016) reported the lowest effect estimate of 
depression (RR = 1.22, 95% CI, 1.13, 1.32) but with a substantial amount of 
heterogeneity (p < .001, I2 = 78.5). 
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My review covers the period after 2004; thus, it overlaps the latest two systematic 
reviews (Gan et al., 2014, Wu and Kling, 2016). I employed a similar search 
strategy to Wu and Kling’s (2016) study, though I only used four databases 
(MEDLINE, EMBASE, PsycINFO, Web of Science) to retrieve potential studies. I also 
hand-searched the bibliography of related reviews (Gan et al., 2014, Smaardijk et 
al., 2019, Wulsin and Singal, 2003) and all relevant studies. I also extended the 
search to July 2020. The eligibility criteria for my review are stricter than all past 
reviews, as my research focused on participants who were free of CHD and stroke 
before study entry. Unlike Wu et al. (2016), I broadened the outcome to include 
various CHD and CHD related deaths following Gan et al.’s (2014) approach. I used 
a similar strategy to the last two reviews to assess the methodological quality of 
each included cohort. In comparison to Gan et al. (2014), I attempted to minimise 
the double counting of studies due to multiple reports of outcome by including 
only the HRs corresponding with the largest number of events and investigating 
the effect of depression on other independent reports of outcome within the same 
study by performing subgroup analyses. My search identified nine more recent 
cohorts, all of which were published after 2015. I also identified two major eligible 
studies (Mejia-Lancheros et al., 2014, Gafarov et al., 2013) that were omitted by 
the last two reviews. Nine cohorts (Ahto et al., 2007, Egede et al., 2005, Hawkins 
et al., 2014, Huang et al., 2013, Kamphuis et al., 2006, Marzari et al., 2005, Mittag 
and Meyer, 2012, Sun et al., 2013, Surtees et al., 2008a) that were published after 
2004 and were included in the last two reviews were excluded from my study for 
reasons described in Section 3.2.1. Eventually, my meta-analysis comprised a 
much higher number of participants than Wu and Kling’s (2016) review (> 10 times 
larger) and Gan et al.’s (2014) review (>3 times larger). Therefore, to the author’s 
knowledge, the present meta-analysis includes all qualified studies, including 
those omitted by previous meta-analyses and most recent studies assessing the 
effect of depression on risk of incident CHD. 
 Conclusion 
In conclusion, the results from this review provide strong evidence that baseline 
depression is independently associated with an increased risk of CHD, MI and 
angina, and it is unlikely to be influenced by the pre-existence of clinically 
apparent CHD and cerebrovascular diseases. The strong positive association was 
also evident between time-varying depressive symptoms and CHD incident. 
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Clinical depression was found to be a stronger predictor of CHD incident than 
depressive symptoms. However, on balance, this research was still unable to 
provide clear evidence of a linear association between depression and CHD risk, 
and further studies are warranted. 
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 Depression and risk of HF in CVD free patients: 
A systematic review and meta- analysis  
 Introduction 
 HF  
HF is a global pandemic affecting at least 26 million people worldwide and is 
increasing in prevalence and healthcare burden (Conrad et al., 2018, Savarese and 
Lund, 2017). A recent analysis of primary care data in the UK found that the 
absolute number of people living with HF increased by 23% between 2002 and 2014 
from 750,125 to 920,616 (Conrad et al., 2018). In Scotland, the overall incidence 
and mortality rate of HF fell between 2008/09 and 2017/18, while a 23% increase 
was found in the hospital discharge rate, from 276 per 100,000 people to 342 per 
100,000 people over the same period (Information Services Division, 2019). The 
health expenditure of HF accounts for approximately 1 million inpatient bed days, 
2% of the National Health Service inpatient bed days and 5% of all emergency 
medical admissions to hospital, costing around £2 billion, which is equivalent to 
2% of the total all National Health Service budget (National Institute for Health 
and Care Excellence, 2018). 
HF has a poor prognosis, and despite advances in medical therapies, survival or 
improvement after a HF diagnosis remains poor. This highlighting the importance 
of prevention strategies and the need to target potential risk factors to avoid 
mortality and morbidity from HF. Common factors that contribute to the 
development of HF involve population aging and other modifiable CVD risk factors, 
such as hypertension, CHD and arrhythmias (Dunlay et al., 2009). Since depression 
has evolved as an independent risk factor for the new onset of stroke and CHD, it 
is plausible that depression may also be a risk factor for HF, and ongoing 
surveillance is required to determine its impact on HF aetiology. 
  
234 
Chapter 6: Depression and risk of HF 
 
 Depression in patients with HF 
Several studies have shown that HF is associated with an increased risk of 
depression. According to DeJongh et al. (2015) patients with HF are two to three 
times more likely to develop depressive symptoms than the general population. A 
large population-based study with 5,769 participants found that HF was an 
independent risk factor for depression and is associated with a 41% (05% CI 1.03, 
1.94) increased risk of depressive symptoms and syndromes in this population 
(Luijendijk et al., 2010).  
Compared to HF patients with no depressive symptoms, HF patients with 
depressive symptoms have worse outcomes across a broad range of events, 
including cardiac mortality, all-cause mortality, and other clinical conditions and 
healthcare utilisation. Rutledge et al. (2006) performed a meta-analysis to 
investigate the impact of depression on HF outcomes and reported that depressed 
patients with HF are more likely to experience increased healthcare utilisation, 
such as emergency room visits, healthcare costs and short- and long-term medical 
encounters, compared to HF patients without depressive symptoms. They also 
reported a two-fold increased risk of CVD mortality and all-cause mortality among 
HF patients with depression (Rutledge et al., 2006).  
 HF in depressed patients  
In contrast to the large body of evidence supporting the detrimental effect of 
depression in HF populations, few studies have examined the association between 
depression and HF incidence in HF-free populations. The following section 
summarises these early studies and their main findings. Whooley et al. (1998) 
proposed that elderly women with six or more depressive symptoms have a three-
fold (HR = 3.2 95% CI 1.3, 8.0) increased risk of death from HF compared to women 
with five or fewer depressive symptoms. However, a subsequent study conducted 
by Chen et al. (1999) rejected that symptoms of depression can be considered as 
risk factor for HF based on p-values from 𝜒2 and t-statistics, which do not account 
for time to event. An epidemiological study conducted by Abramson et al. (2001) 
was the first cohort suggesting a strong association between depression and 
incidence of HF. This was a prospective cohort enrolling 4,538 individuals aged 60 
years and older with isolated systolic hypertension (ISH) but free of HF at baseline. 
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Over 4.5 years, depression was independently associated with a substantial 
increase in HF risk (HR = 2.59 95% CI 1.57,4.27). This strong association remained 
stable after excluding HF cases that occurred within the first year of follow-up 
and when depressive symptoms were modelled as a time-dependent variable 
(Abramson et al., 2001). However, the participants in this study may have already 
had a high baseline risk of HF as they were elderly and had established ISH, both 
of which are risk factors for HF (Chen et al., 1999, Ekundayo et al., 2009). In 
addition, the study did not exclude previous history of MI, which may lead to an 
overestimation of depression risk. In a subsequent cohort, Williams et al. (2002) 
examined the association between depression and incidence of HF in 2,501 elderly 
participants aged ≥ 65 years who were free of HF at baseline. In this study, the 
authors identified depressive symptoms using the CES-D with a high cut-off score 
of ≥ 21, which approximates a clinical diagnosis of depression. They found that 
depression was not significantly associated with increased risk of HF (HR = 1.52 
95% CI 0.94, 2.43). However, in a subsequent analysis, they showed that 
depression was an independent risk factor for HF in women but not in men. In 
view of these inconsistent study findings, I conducted a systematic review and 
meta-analysis to investigate the association between depression and the initial 
onset of HF in CVD free population at study entry. 
 Aim 
This chapter systematically reviews and reports a meta-analysis of prospective 
cohort studies that examined the association between depression and HF incidents 
in CVD-free patients. 
 Hypothesis  
1- Depression is associated with an increased risk of HF in CVD-free patients. 
2- Depression increases the risk of HF in a dose-response manner.  
 Method  
Full descriptions of the methods used for this review and meta-analysis were 
provided in Chapter 2, Section 2.1, Systematic review and meta-analysis. 
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The cohort conducted by White et al. (2015) is a population-based cohort that 
used an established data from the Veterans Aging Cohort Study. This cohort 
included data about individuals with or without HIV infection matched on age, 
sex, race/ethnicity and clinical site, extracted from the US Department of 
Veterans Affairs (VA) administration. White et al. (2015) performed a separate 
analysis to investigate the incidence of HF risk in HIV-infected participants and in 
HIV-uninfected participants. This review considered only data for HIV-uninfected 
participants, including cohort size, clinical characteristics and the calculated HR 
estimated risk of depression. 
 Results 
Overall, the analysis includes three studies comprising 2,200,308 participants and 
an average follow-up of 10.13 years. Chapter 3 provided a full description of the 
search and identification process of the included cohorts and a summary of the 
studies. Table 6-1 summarises the main characteristics of the included studies. In 
short, two studies were conducted with cohorts in European countries and had a 
long follow-up duration (≈ 13 years) (Daskalopoulou et al., 2016, Gustad et al., 
2014b). One study was performed in the US with a shorter follow-up duration (6 
years) (White et al., 2015) and one was an international study where participants 
recruited from 21 economically diverse countries with a follow-up duration of 14 
years. Two studies used the ICD codes with or without antidepressant prescriptions 
to identify patients with clinical depression (Daskalopoulou et al., 2016, White et 
al., 2015). Rajan et al. (2020) used the short form of the diagnostic interview and 
Gustad et al. (2014b) used a validated SRS to identify depression cases. Only one 
study investigated the dose-response relation between depressive symptoms and 
HF (Gustad et al., 2014b). The primary outcome, new-onset HF, was identified 
according to the ICD codes extracted from electronic medical records. The total 
number of HF cases from the four cohorts was 20,268. Three cohorts 
(Daskalopoulou et al., 2016, Rajan et al., 2020, Gustad et al., 2014b) included 
men and women, whereas the study by White et al. (2015) was almost entirely 
male (96%). Only one study reported a small loss to the follow-up proportion (0.3%) 
(Gustad et al., 2014b). All three studies estimated the effect size of depression 
using HRs, providing a consistent measure. 
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Table 6-1 Characteristics of the included cohort studies 

























according to the ICD 10 
(I50, I11.0, I13.0 and 
I13.2), death 
9397 
Age, sex, smoking, SBP, diabetes, 





Norway, EU 62,567 46.8 ≥18 
13 years 
1995-2008 
21-item HADS ≥11 HF 
Medical records 
according to ICD 9 (428) 
and ICD 10 (I50.0, I50.1 
and I50.9) 
1499 
Age, sex, marital status, education, 
smoking, physical activity, BMI, total 
cholesterol, diabetes mellitus, 
resting HR, SBP, alcohol, serum 
creatinine, time-dependent 





145,862 58 35-70 
14 years  
2005-2019 
CIDI-SF; cut-off 






medical records, death 
certificates, and other 
sources 
582 
Age, sex, urban/rural residence, 
educational attainment, use of 
statins, disabilities 
former and current smoking and 
alcohol use, HTN, diabetes, and 
social isolation index 
(White et 
al., 2015) 
USA 54519 96 48 
6 years 
2003-2009 
1 or 2 inpatient 
outpatients for 
CD of MDD 
according to ICD-




according to ICD-9 
(428.xx, 429.3, 402.11, 
402.91, 425.x)) 
8791 
Age, sex, race/ ethnicity, BMI, HTN, 
diabetes mellitus, LDL-c, HDL-c, 
triglycerides, statin use, 
hemoglobin, renal function, atrial 
fibrillation, atrial flutter, smoking 
status, alcohol abuse or 
dependence, cocaine abuse or 
dependence, 
Abbreviation: AD, antidepressants; BMI, body mass index; CD, clinical diagnosis; HADS, hospital anxiety depression scale; HDL-c, high density lipoprotein cholesterol; HF, heart failure; HTN; 
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Depression and risk of HF 
As shown in Figure 6-1, depression is associated with a 17% (HR = 1.17, 95% CI 
1.08, 1.28, P <0.0002) increased risk of HF incidence in CVD free participants, with 
no significant amount of heterogeneity (chi-square P = 0.77 and I2 statistics of 0%). 
In this analysis, out of four studies, two studies showed a positive association, 
while the other two have a null result. Notably, the pooled estimated risk was 
mostly driven by cohorts that reported a positive association conducted by White 
et al. (2015) and Daskalopoulou et al. (2016) as, altogether, they carried more 
than 80% of the overall weight.  
 
The interpretation of funnel plots (
 
Figure 6-2) to investigate risk of publication bias was limited due to the small 
number of pooled results in this analysis. The removal of each study in turn 
provided similar estimates of HR ranging between 1.16 and 1.19. 
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Figure 6-1 Forest plot showing the adjusted HR of HF incidence for depressed individuals 
compared with non-depressed individuals in 4 cohorts 
Abbreviations: HF; heart failure; SE, standard error 
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Figure 6-2 Funnel plot from 4 cohorts investigated the association between depressions and 
first-incidence of HF. SE, standard error 
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 Discussion 
This meta-analysis of four cohorts provides evidence supporting an association 
between depression and an increased risk of HF incident (HR = 1.17 95% CI 1.08, 
1.38) in CVD free participants. However, due to low power of this analysis (the 
total included number of studies is small), these results should be considered with 
caution. 
Only a few studies published between 2005 and 2020 investigated the relationship 
between depression and incidence of HF, plus their findings were conflicting. For 
example, Kamphuis et al. (2006) studied the relationship between depressive 
symptoms and CVD using data from Finland, Italy and the Netherlands. The 
researchers enrolled 799 men, aged 70–90 years, free of CVD at baseline and 
followed them for up to 10 years for the first CVD outcome. Their main findings 
showed that every five-point increase in depressive symptoms was associated with 
a 16% (HR = 1.16 95% CI 1.00, 1.35) increased risk of developing HF. By contrast, 
in a 10-year prospective study with 4,114 elderly participants who were free of 
HF at baseline, van den Broek et al. (2011) found no evidence that depression was 
associated with an increased risk of new-onset HF (HR = 1.08 95% CI 0.92–1.26). A 
subsequent large prospective study of 236,079 VA participants who had no 
previous history of CVD and were aged between 50 and 80 years demonstrated 
that individuals with MDD had a 56% (HR = 1.56 95% CI 1.45, 1.67) increased risk 
of HF incidence compared to those without MDD (Garfield et al., 2014). More 
recently, Khodneva et al. (2019) conducted a prospective cohort study to 
investigate the association between depressive symptoms and risk of first HF 
hospitalisation among community dwelling individuals (aged ≥45 years) who were 
free of HF and CHD at study baseline. The authors demonstrated that the risk 
differs by the type of HF based on ejection fraction: they found that depressive 
symptoms were independently associated with future risk of first hospitalization 
for HF preserved ejection fraction (HR= 1.54, 95% CI 1.06-2.22), but not for HF 
reduced ejection fraction. 
Table 6-2 summarises the studies that investigated the relationship between 
depression and incidence of HF. The table shows that the magnitude of the HRs 
varies considerably across the studies, which may be due to several reasons. One 
reason is the varied population between the studies, as some focused on elderly 
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populations (Abramson et al., 2001, Chen et al., 1999, Kamphuis et al., 2006, 
Khodneva et al., 2019, van den Broek et al., 2011), while others included only 
men (Kamphuis et al., 2006), only women (Whooley et al., 1998) or patients with 
specific health conditions (Abramson et al., 2001). In this meta-analysis, the 
population in the White et al. (2015) study was almost entirely men (96%), and 
evidence shows that the incidence of HF is generally higher in men than in women 
at all ages (Mehta and Cowie, 2006). Therefore, the pooled estimates of HRs may 
be affected by the unequal male/female proportion in this study. Another possible 
reason for discrepancies is the different diagnostic tools used to identify 
depression cases. As is known, the diagnosis of depression based on the gold 
standard method means that only cases with more severe depressive symptoms 
will be considered, while other screening tools such as the SRS are likely to capture 
severe symptoms as well as mild to moderate symptoms. This may be an important 
issue when examining the relationship between depression and HF. Unlike stroke 
and CHD, where the risk conferred by depression has been well documented in 
relation to moderate and more severe depressive symptoms, it is unclear whether 
the same applies to HF. 
Unfortunately, I was unable to examine whether a dose-response relationship 
existed between depression and HF, as only one of the included studies provided 
such information (Gustad et al., 2014b). Two other cohorts that had not met my 
inclusion criteria (Abramson et al., 2001, Kamphuis et al., 2006) also explored 
whether a dose-response relation exists. All three studies reported that depression 
increases the risk of HF in a dose-response manner, although evidence for 
significant association was only observed for high levels of depressive symptoms, 
which may indicate that depressive symptoms need to reach a clinical threshold 
to be considered a risk factor for HF. However, this finding was not replicated by 
other studies (Williams et al., 2002). Overall, it is still early to draw a firm 
conclusion as the effect of depression may differ substantially following addition 
of studies in the future. 
Because the results of my meta-analysis derived largely from cohorts that 
examined the risk of developing HF in relation to clinical depression (i.e. severe 
depressive symptoms), they cannot be applied to depression of mild to moderate 
severity. 
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 Conclusion 
This study found that depression was associated with an increased risk of HF 
incidence in a CVD-free population. The results from this review and meta-analysis 
add to the growing body of evidence suggesting that depression is a risk factor of 
HF independent of the main precursors for HF (i.e. CHD). However, because most 
studies relied on clinical diagnosis as a criterion to measure depression the finding 
is more likely to reflect the impact of clinical depression rather than depressive 
symptoms. Further research confirming this finding and investigating the role of 
depression in the pathological process underlying HF is warranted. 
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Table 6-2 summary of studies examined the association between depression and HF morbidity and mortality 
Study Study Design 
Study 
population 




Elderly free of 
HF with ISH 
4538 DS Incident HF 4.5 2.59 (1.57-4.27)  
(Chen et al., 
1999) 
Prospective cohort 
Elderly free of 
HF and CHD  
1749 DS Incident HF 10 NA 
Risk was measured by 𝜒2, 
P- = 0.65 









6 1.56 (1.45–1.67)  





94 DS HF symptoms 12 months  
Baseline DS strongly 







free of CVD  











11 1.54 (1.06-2.22) 
Risk was evident only for 
HFpEF but not for HFrEF 
(Luck-Sikorski 
et al., 2015) 




HR was calculated based 
on sex. Risk was 
significant for men but 
not for women 










90 day 0.99 (0.97–1.01)  
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Study Study Design 
Study 
population 
N Exp OC FU* HR (95%CI) Comments 
(van den Broek 
et al., 2011) 
Prospective cohort 
Elderly free of 
HF 
4,114 DS Incident HF 11 1.08 (0.92-1.26)  
(Whooley et 
al., 1998) 
Prospective cohort Elderly with CVD 7518 DS 
HF-related 
death 




Elderly free of 
HF 
2501 DS Incident HF 14 1.52 (0.94-2.43)  
Abbreviations: CHD, coronary heart diseases; CVD, cardiovascular diseases; DS, depressive symptoms; EXP, exposure; FU, follow-up; HF, heart failure; HFpEF; heart 
failure preserved ejection fraction; HFrEF; heart failure reduced ejection fraction; HR, hazard ratio; ISH, isolated systolic hypertension; MDD, major depressive 
disorders; NA, not applicable; OC, outcome; VA, Veterans Affairs; * follow-up demonstrated in years unless indicated; a Study was a conference abstract. 
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 Antihypertensive drugs and risk of depression 
 Introduction 
Evidently, all antihypertensive drug classes are deemed to be effective in 
controlling BP, thereby recommended by clinical guidelines as first- or second-line 
therapy to manage hypertension. Since hypertension is a chronic health problem, 
these drugs are intended for long-term use with the ultimate objective of 
preventing CVD and end organ damage. In the introduction of this thesis, I 
compiled evidence for a long-standing controversy, dating from as early as 1967 
(Waal, 1967), about a possible role of antihypertensive drugs in the pathogenesis 
of depression. Promising findings suggesting that antihypertensive drugs may 
protect against depressive symptoms co-exist with negative reports of increased 
risk of depression. Based on my findings in Chapters 4–6, one in five people who 
have experienced depression during their lifetime is likely to develop CVD. The 
same figure has been reported in CVD patients in relation to depression incidence. 
The data shows that for every five CVD patients, at least one will meet the criteria 
for MDD, which contributes to poor cardiovascular outcomes for such patients. 
Accordingly, it is reasonable to assume that factors associated with an increased 
risk of depression would indirectly heighten the risk of subsequent CVD and poor 
health outcomes. Given that antihypertensive drugs constitute one of the 
cornerstone therapies for patients at high risk of CVD and those with established 
CVD, it is crucial to understand the impact of this type of treatment on depression. 
I therefore aim to investigate the association between different antihypertensive 
drug classes and depression. 
Figure 7-1 provides a theoretical illustration of the role of four major classes of 
antihypertensive drugs in depression based on pre-clinical evidence. I 
hypothesised that BB and CCB are associated with an increased risk of depression, 
as they interfere with BDNF, neuronal survival and neuronal plasticity, while ACEI 
and ARB are associated with a reduced risk of depression, as they act as anti-
inflammatory agents at the circulatory and neuronal levels. In the absence of 
compelling evidence linking diuretics to depression, it is plausible to hypothesise 
that they have no effect on depression. 
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Figure 7-1 Illustrations of the main pathways linked to depression that are likely to be 
modulated by antihypertensive drugs 
Theoretically, ACEIs and ARBs may produce a beneficial effect in depression as they suppress the 
RAAS and AT1R respectively reducing the stress sensitivity of HPA-axis and therefore decrease 
HPA—axis hyperactivation during stress, which corresponds with the neuroendocrine dysfunction 
theory of depression (1). ACEIs and ARBs may also act as anti-inflammatory agents reducing 
neuronal inflammation associated with depression, corresponding with the inflammation theory of 
depression (2). By contrast, CCBs and BBs may disrupt the normal process of synaptic plasticity and 
neurogenesis, hence may increase risk of depression which corresponds with the down regulation 
of BDNF and nerve growth theory of depression (3). Abbreviations: ACEI, angiotensin converting 
enzyme inhibitors, ACTH, adrenocorticotropic hormone; AMPAR, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; Akt, protein kinase B; ARB, angiotensin receptor blocker; AT1R; 
angiotensin type-1 receptor, Ang II, angiotensin; βAR, beta-adrenergic receptor; BB, beta-blocker; 
BDNF, brain derived neurotrophic factor; Ca+2, calcium; cAMP, cyclic adenosine monophosphate, 
CaMK; Ca2+/calmodulin-dependent protein kinase; CCB, calcium channel blocker; CREB, cAMP-
responsive element-binding protein CRH, Corticotropin-releasing hormone; ERK, extracellular 
signal-regulated kinase; Glut, glutamate; L-VGCC, L-type voltage calcium channel; MAPK, mitogen-
activated protein kinase; MEK, mitogen-activated protein kinase; mTOR, mammalian target of 
rapamycin; NA, noradrenaline; PKA, protein kinase A; PI3K,phosphoinositide-3 kinase, RAAS, renin 
angiotensin aldosterone system; TrK, tropomyosin receptor kinase 
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 Aim 
The aim of the study is to test for association between antihypertensive drugs use 
and incident depression defined by a first-ever prescription of antidepressants 
after commencement of antihypertensive therapy. A secondary aim was to study 
the association between antihypertensive drug exposure defined by cumulative 
daily defined dose (cDDD) of the five anti-hypertensive classes and incident 
depression.  
 Hypothesis 
1- CCB and BB as monotherapy or as part of polytherapy are associated with 
an increased risk of incident depression compared to ACEI. 
2- There will be a dose–response relationship between the defined daily dose 
(DDD) of CCB and BB and the risk of depression.
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 Methodology 
 Study setting and population of the GBPC 
The study population includes all patients attending the GBPC between January 
2005 and March 2013. Further information on the study population and setting has 
been provided in Section 2.1.7  
 Study design 
This study was a retrospective cohort study of patients attending a specialist 
hypertension clinic who were newly prescribed antihypertensive drugs. All 
patients between the ages of 18 and 80 years at the time of their first prescription 
were included in the study. Two analyses were performed and described below. 
 Antihypertensive monotherapy and risk of depression 
In this analysis, the exposure period to antihypertensive monotherapy for all 
eligible patients was fixed at one year. This time window starts from the month 
of their first fill of an antihypertensive drug prescription at any time point 
between January 2005 and March 2012 and extends to 12 months. At the end of 
this period, follow-ups commence and continued until the first prescription of 
antidepressants (study outcome), the time of death or up to March 2013 (end of 
the study). A graphical chart of the monotherapy study design is represented 
below (Figure 7-2). 
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Figure 7-2 Graphical chart for the monotherapy study design 
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 Antihypertensive drugs as monotherapy or as part of polytherapy and 
risk of depression 
In this analysis, eligible patients were identified between January 2006 and March 
2013. The participants were newly commenced on antihypertensive drugs, which 
was defined as not having been prescribed any antihypertensive drugs for six 
months before the index date of the first prescription. The first six months after 
the index date was considered a treatment period. Patients who died or developed 
depression within this period were excluded. The cumulative number of 
antihypertensive drugs, either those had discontinued or changed to another drug 
class during the treatment period was calculated. They were also numbered in 
order based on their sequence. 
 Inclusion criteria  
For the monotherapy analysis, patients were eligible for inclusion if they were 
between 18 and 80 years of age at the time of the first prescription of 
antihypertensive medication, if they newly started antihypertensive monotherapy 
and if they continued to be on the same single medication over the exposure 
period. The patients should have had no previous history of an antidepressant 
prescription. I also excluded subjects with a recorded prescription of 
antihypertensives before January 2005, those who were on multiple 
antihypertensive medications at any point during the exposure period, patients 
who had developed depression (recorded first prescription of antidepressants), 
those who died during the antihypertensive exposure period and patients who 
started antihypertensive treatment after March 2012. As shown in Figure 7-3, of 
the 9070 patients screened, 2406 were eligible to be included in this analysis. 
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Figure 7-3 Flow charts for patient’s inclusion 
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For the monotherapy analysis, exposure was defined as a monotherapy 
prescription of any of the following antihypertensive medications: CCB, BB, ACEI, 
ARB and TZD. In the case of polytherapy, the definition of exposure was extended 
to include other classes of antihypertensive drugs, such as alpha blockers and 
centrally acting agents. CCBs were further devided into dihydropyridine and non-
dihydropyridine, while diuretics were also stratified into spironolactone and 
mineralocorticoids.  
 Outcome 
The main outcome in this study was depression defined by initiating 
antidepressant medication, including TCA, SSRI, MAOI and ‘other 
antidepressants’.  
 Assessemnt of study quality 
I applied the NOS tool to evaluste the quality of the present cohort in a similar 
way as descriped in section 2.1.5. 
 Statistical analysis 
Details on the statistical packages and tests were used to summarise and present 
data were previously described in section 2.2.3 For the monotherapy cohort 
analysis, Cox proportional hazards models were used to estimate the risk of 
developing depression among the five monotherapy drug classes of 
antihypertensive drugs. In this analysis, outcome was treated as a binary outcome 
(presence/ absence of depression). The time to event was calculated in years from 
the last month of the exposure period to either the first prescription date of 
antidepressant, date of death, or the last follow-up date for the study. Model 1 
was adjusted for age at first prescription and gender. Model 2 was further adjusted 
for the other covariates including BMI, smoking, SBP, CCI, cholesterol and eGFR. 
The ACEI group was the reference group. Proportionality assumptions was checked 
by inspection of log minus log plots and testing of Schoenfeld residuals. 
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If a causal relationship indeed exists between any antihypertensive drug and 
depression, a trend toward elevated risk of depression is expected to be observed 
with higher levels of antihypertensive drugs. I therefore investigated the dose-
response relationship between each antihypertensive drug class and depression 
using escalating levels of antihypertensive DDD. Because the DDD are likely to be 
changed over the exposure period, and there are likely to be short-term and long-
term users, I calculated the cumulative DDD (cDDD) for each patient, representing 
the total exposed DDD dispensed monthly during the exposure period. I chose to 
classify the cDDD into tertiles, approximately equal in sizes, instead of a 
continuous measure for two reasons. First, the DDD data was positively skewed in 
this study. Second, to enable a comparison between groups that had been exposed 
to low, moderate and high cDDD. In this contest, the referent group in Cox 
regression analysis was the lowest cDDD tertile within the drug class. I then used 
stepwise backward regression analysis to obtain the most parsimonious model. All 
variables were included in the ‘variable list’ and the significant levels for entry 
and removal were set at 0.15 and 0.2 respectively, as a conservative approach. In 
the next step, the algorithm attempts to drop one of the variables with p-value 
≥0.2, one at a time. The best final model includes all covariates with p-value ≤0.15 
at the chosen α significance level of 0.05. This stepwise procedure has been 
criticised on many counts. One of the most noted potential drawbacks is that it 
may not be guaranteed to reveal the best subset variables within a model. 
Additionally, models identified by stepwise methods have an inflated risk of 
capitalising on chance features of the data which may then fail when applied to 
new datasets. On the other hand, this is a commonly used procedure which is 
easily implemented and intuitive. 
For the polytherapy analysis, a similar analytical approach was used to examine 
the association between the index antihypertensive drug and depression 
incidence. Cox proportional hazard analysis was performed to estimate the 
depression incidence in comparison to the ACEI group. Models 1 and 2 were 
adjusted for the same covariates previously mentioned; however, in this context, 
the number of antihypertensive drugs was also added to Model 2 as a covariate. 
In order to conduct a more inclusive analysis that is relevant to real-life where 
patients tend to be prescribed multiple drugs a generalised estimating equations 
method was employed. This overcomes the correlation between patients who 
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appear in the data multiple times when they are prescribed a new 
antihypertensive drug. A sequence variable that indicates the order by which a 
new agent was prescribed was used to inform the model of the repeated measure. 
The GEE analysis in polytherapy study permits that examination of association 
between the index prescription of antihypertensive drug and risk of depression in 
the presence of other concomitant antihypertensive therapy. The GEE model was 
estimated with a binomial outcome (presence/absence of new-onset depression) 
distribution and a logit link. The univariate and multivariate models were adjusted 
for the same prespecified covariates. This type of analysis accounts for the within-
subject variable, in this context defined as repeated admission (as a proxy for 
each time a new antihypertensive drug class was introduced) and, therefore, 
allows the use of all available data for all eligible patients.  
 Results 
 Antihypertensive drugs and risk of depression: 
monotherapy analysis 
 General characteristics of the GBPC study population  
Table 7-1 summarises the clinical characteristics of the 2406 patients involved in 
the monotherapy analysis. The study population was middle aged at the initiation 
of their treatment (mean age 51 ± 14), hypertensive (SBP/DBP = 157 ± 24 
/93.79 ± 12 mm Hg), and overweight (BMI = 28.45 ± 5.4), with an approximately 
equal sex distribution (female, 50.9%). About 35% were smokers, 68% had at least 
stage 3 chronic kidney disease (CKD) and more than half (57%) had comorbid 
conditions at baseline. The average follow-up was 4.3 years. 
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Table 7-1 Baseline characteristic of the GBPC population on antihypertesive monotherapy 
during the first 12 months window (n=2406) 
Variable M (SD)/ N (%) 
Age at first prescription (years) 51.12 (14.00) 
SBP (mmHg) 157 (24.4) 
DBP (mmHg) 93.79 (12.52) 
BMI  28.45 (5.4) 
Cholesterol 5.78 (1.1) 
Gender  
Male 1181 (49.1) 
Female 1225 (50.9) 
Smoking  
Non-smoker 1553 (64.5) 
Smoker 853 (35.5) 
Kidney function  
eGFR (≥60ml/min) 394 (16.4) 
eGFR (<60ml/min) 1647 (68.5) 
Charlson comorbidity index score  
0 1034 (43) 
1 633 (26.3) 
>1 739 (30.7) 
N of prescriptions during the EP  
1-3 948 (39.4) 
4-6 866 (36) 
≥7 592 (24.6) 
BMI, body mass index; DBP, diastolic blood pressure; eGFR, Estimated glomular 
filtration rate; EP, exposure period; SBP, systolic blood pressure. Continuous data are 
presented in mean (M)/ slandered deviation (SD), Categorical data are presented in 
numbers (%). 
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 General characteristics of the study population grouped by 
antihypertensive drug class 
The baseline characteristics of the study population stratified by antihypertensive 
drug class are presented in Table 7-2. The mean age of the different 
antihypertensive treatment groups varied, with patients on ACEI having the 
youngest mean age (48.7 years), while those in the TZD group had the oldest mean 
age (53.3 years). Patients on CCB, BB and TZD were predominantly female, while 
those on ACEI and ARBs were mainly male. There were significant differences 
between the groups in terms of baseline SBP/DBP, with patients receiving ARB 
showing the highest SBP/DBP measures (160.5 ± 24.8/95.3 ± 12.6). About half of 
the patients (51%) who were treated with ACEI had a CCI score of zero reflecting 
no comorbidities, while 57% patients on other antihypertensives had a CCI score 
of at least 1. Patients receiving BB and ACEI were more likely to be on treatment 
for more than 6 months, as indicated by the number of prescriptions (30.2% and 
27.7%, respectively) compared to other antihypertensive groups (< 25%). 
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Age at first prescription 
(years) 52.6 (13.7) 50.48 (14.41) 48.73 (14.3) 51.64 (13.5) 53.3 (13.43) 
0.000 
Female sex 321 (52.5) 194 (53.7) 314 (46.4) 213 (49.3) 183 (56.3) 0.023 
SBP,mmHg 159.83 (25.13) 153.88 (24) 154.61 (24) 160.50 (24.86) 158.75 (22.7) 0.000 
DBP,mmHg 94.34 (13.21) 92.45 (12.52) 92.82 (11.96) 95.38 (12.69) 94.15 (11.79) 0.003 
BMI 28.37 (5.3) 28.64 (5.8) 27.73 (5.22) 28.75 (6) 28.7 (5.1) 0.36 
Cholesterol 5.82 (1.13) 5.68 (1) 5.78 (1.12) 5.8 (1.06) 5.8 (1.07) 0.45 
Smoking 230 (37.6) 138 (38.2) 244 (36.1) 137 (31.7) 104 (32) 0.14 
eGFR (< 60 ml/min) 403 (78.9) 250 (81.4) 463 (83.1) 305 (80.1) 226 (79.3) 0.44 
Charlson index score       
0 237 (38.7) 155 (42.9)  345 (51) 182 (42.1) 115 (35.4) 
0.000 1 166 (27.1) 101 (28) 149 (22) 115 (26.6) 102 (31.4) 
>1 209 (34.2) 105 (29.1) 182 (26.9) 136.3 (31.3) 108 (33.2) 
N of prescriptions during 
the EP        
 
1-3 226 (36.9) 141 (39.1) 257 (38.0) 166 (38.4) 158 (48.6) 
0.000 4-6 247 (40.4) 111 (30.7) 232 (34.3) 159 (36.8) 117 (36.0) 
≥7 139 (22.7) 109 (30.2) 187 (27.7) 107 (24.8) 50 (15.4) 
ACEI, Angiotensin converting enzyme inhibitor; ARBs, Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; CCB, calcium channel clocker; 
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EP, exposure period; N, number; SBP, systolic blood pressure; TZD, thiazide 
diuretics. X2 test and 1-way ANOVA test were used for categorical and continuous variables respectively. Continuous data are presented in mean (M)/ 
slandered deviation (SD), Categorical data are presented in numbers (%). 
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 General characteristics of the study population grouped by the 
presence or absence of new-onset depression  
Table 7-3 presents the clinical characteristics of the 2406 participants according 
to whether or not they developed depression. The baseline characteristics, such 
as age, SBP, DBP, CCI and eGFR, were comparable between the two outcome 
groups. However, other potential risk factors, such as BMI and smoking, were more 
frequent in patients who developed depression. As expected, females were over-
represented in the depressed patients group (60.4%, p < 0.000). Almost one-third 
of the participants who developed depression were on CCB, 21% on ACEI, 19% on 
ARBs, 15.5% on BB and 12.8% on TZD. 
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Table 7-3 Baseline characteristic of 2406 patients on antihypertensive monotherapy during 
the first 12 months window stratified by the main outcome 
Variable  Outcome p-value 
 No depression 
N=1865 (77.5) 
depressed 
 N=541 (22.5)  
Age at first prescription 
(years)  51.22 (14.08) 50.75 (13.87) 0.49 
SBP  157.54 (24.4) 157.14 (24.25) 0.73 
DBP  93.92 (12.4) 93.32 (12.72) 0.32 
BMI  28.26 (5.14) 29.13 (6.47) 0.004 
Cholesterol   5.7 (1.08) 5.8 (1.10) 0.59 
Gender  
Male  967 (51.8) 214 (39.6) 
0.000 
Female  898 (48.2) 327 (60.4) 
Smoking  
Non-smoker   1227 (65.8) 326 (60.3) 0.018 
Smoker  638 (34.2) 215 (39.7) 
Kidney function  
eGFR (>= 60ml/min)  297 (18.8) 97 (21) 0.31 
eGFR (< 60ml/min)  1281 (77.8) 366 (22.2) 
Charlson comorbidity index score  
0  788 (42.3) 246 (45.5) 
0.41 1  498 (26.7) 135 (25.0) 
>1  579 (31) 160 (29.6) 
N of prescriptions during the EP   
1-3  701 (37.4) 247 (46.6) 
0.000 4-6  686 (36.6) 180 (34.0) 
≥7  489 (26.1) 17.4 (19.4) 
Antihypertensive drug 
CCB  454 (24.3) 158 (29.2) 
0.039 
BB  277 (14.9) 84 (15.5) 
ACEI  549 (29.4) 127 (21.5) 
ARB  329 (17.6) 103 (19) 
TZD  256 (13.7) 69 (12.8) 
ACEI, Angiotensin converting enzyme inhibitor; AD, antidepressants medication; ARBs, 
Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; CCB, calcium channel 
clocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EP, exposure 
period; N, number SBP, systolic blood pressure; TZD, thiazide diuretics. X2 test and T-test were 
used for continuous and categorical data respectively. Continuous data are presented in mean 
(M)/ slandered deviation (SD), Categorical data are presented in numbers (%). 
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 Antihypertensive monotherapy and incidence of depression 
During a median of 4.4 (interquartile range 2.6–6.0) years of follow-up, there were 
541 incident depression events. The overall incidence rate of depression was 52 
per 1000 person-years among patients treated with antihypertensive monotherapy 
during the exposure period (Table 7-4). The crude depression rate per 1000 
person-years was significantly higher among participants who received CCB (62.7 
per 1000 persons-years) compared to the rates in the other four groups—i.e. ACEI, 
ARB, BB and TZD (Table 7-4). 
Figure 7-4 shows the Kaplan Meir plot for incident depression comparing the major 
five classes of antihypertensive drugs. The difference between groups tested by 
the log rank test was statistically significant (p=0.002). None of the groups reached 
median survival probabilities during the follow-up period, but as is evident from 
Figure 7-4, ARB and CCB show higher risk of incident depression compared to other 
groups.  
Table 7-4 presents the associations between the antihypertensive medication 
classes and subsequent depression events using multivariable Cox regression 
analysis. After adjustment for age and gender in model 1, CCB showed significant 
higher risk (HR = 1.42, 95% CI 1.13–1.81, p = 0.004) compared with the reference 
group (i.e. ACEI). Model 2 was adjusted for additional covariates (BMI, smoking, 
cholesterol, eGFR and CCI); the direct association between CCB and depression 
persisted with a slight attenuation of the risk magnitude (HR = 1.38, 95% CI 1.07–
1.80, p = 0.014). The point estimates for the other antihypertensive groups  were 
greater than 1 but the confidence intervals overlapped 1 and thus were not 
significantly different to the ACEI group. 
As expected, females were at higher risk of developing depression compared to 
males (HR = 1.50, 95% CI 1.24–1.82, p < 0.000). Both smoking and BMI were 
significantly associated with depression, with HRs of 1.34 (95% CI 1.11–1.61, 
p = 0.002) and 1.02 (95% CI 1.01–1.04, p = 0.004), respectively. An increasing 
number of prescriptions was associated with a lower risk of incident depression; 
however, non-statistically significant (HR=0.98 95%CI 0.91, 1.07). 
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 Sensitivity analysis 
To test the robustness of my findings, I repeated the analyses excluding the 
depression events that occurred within the first year of follow-up (Table 7-5). The 
results remained stable, showing a direct association between CCB and depression 
(HR =1.38, 95% CI 1.03–1.85). After restricting the analysis to include participants 
with a minimum of 3 prescriptions of antihypertensive medication during the 
exposure period, both CCB (HR =1.45 95%CI 1.05, 1.98; P-value= 0.02) and ARB 
(HR=1.42, 95%CI 1.01,1.99 p= 0.04) were significantly associated with incident 
depression in the fully adjusted model. 
The association between CCB and incident depression (HR = 1.45, 95% CI 1.06–
1.95, p = 0.02) persisted after I excluded patients with prevalent CVD and those 
who developed CVD within the 12 months of the exposure period (Table 7-5). 
Additionally, I used a strict criterion to define depression cases: the patients 
should have been on antidepressant therapy for at least six months within the first 
12 months since the index date prescription (Kennedy et al., 2016). The patterns 
of association were similar to those of the primary analysis, showing that CCB is a 
strong predictor of incident depression. The magnitude of the HR increases 
(HR = 1.63, 95% CI 1.01–2.63, p = 0.047) which may be due to  decreased events 
number and therefore reduced precision of the magnitude. (Table 7-5). 
Finally, I manually censored all patients survival time at 3.5 years, which is around 
the average period of the follow-up in the present study. This analysis was 
performed as patients were more likely to discontue medication with longer time 
of follow-up. The relationship between CCB and incident hyperension remained 
unchanged (HR= 1.39 95%CI 1.02, 1.91) (Table 7-5). 
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Figure 7-4 Unadjusted Kaplan Meier curves for onset of depression as indicated by receipt of 
antidepressants prescriptions, by antihypertensive classes in hypertensive patients newly 
treated with antihypertensive medication within first 12 months window 
*Patients censored at 6.5 years 
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Table 7-4 Cox PH model results for risk of depression and different antihypertensive medication classes among patients on antihypertensive monotherapy 
 
 
  Univarite   Model 1 Model 2 
Events/Total (%) Incident rate 
per 1000 
person-year 
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
Antihypertensive class      
ACEI  128/676 (18.93) 45 Ref (1) Ref (1) Ref (1) 
ARB  103/432 (23.84) 53.6 1.39 (1.07, 1.82) 0.01 1.22 (0.94,1.58) 0.14 1.24 (0.93,1.01) 0.13 
BB 84/361 (23.26) 53.3 0.99 (0.75, 1.32) 0.98 1.15 (0.87,1.52) 0.33 1.17 (0.86,1.59) 0.31 
CCB 158/612 (25.82) 62.71 1.30 (1.03, 1.65) 0.027 1.42 (1.13,1.81) 0.003 1.38 (1.07,1.80) 0.014 
TZD 69/325 (21.23) 44.12 0.83 (0.62, 1.12) 0.23 0.97 (0.72,1.31) 0.83 1.05 (0.76,1.44) 0.75 
Total 541/2406 (22.5) 52       
Variables         
Age   0.998 (0.992, 1.004) 0.43 0.99 (0.98,1.00) 0.13 0.99 (0.98,1.01) 0.82 
Female   1.49 (1.25, 1.77) 0.00 1.52 (1.28,1.81) 0.000 1.50 (1.24,1.82) 0.000 
BMI   1.02 (1.01, 1.04) 0.003 1.02 (1.01,1.04) 0.002 1.02 (1.01,1.04) 0.004 
Smoking   1.23 (1.03, 1.45) 0.022 1.25 (1.05,1.49) 0.01 1.34 (1.11,1.61) 0.002 
eGFR   0.86 (0.68, 1.08) 0.19 0.85 (0.66,1.08) 0.18 0.84 (0.65, 1.07) 0.17 
Cholesterol   1.03 (0.96, 1.12) 0.34 1.03 (0.95,1.11) 0.39 1.02 (0.94, 1.10) 0.62 
CCI   0.94 (0.85, 1.05) 0.29 0.86 (0.68,1.00) 0.23 0.88 (0.68,1.14) 0.33 
N of prescription during the EP 0.97 (0.89, 1.05) 0.45 0.97 (0.91, 1.05) 0.58 0.98 (0.91, 1.07) 0.75 
Model 1 adjusted for age and gender. Model 2 adjusted for age, gender, BMI, smoking, eGFR, cholesterol and Charlson comorbidity index. Abbreviations: ACEI, 
Angiotensin converting enzyme inhibitor; ARB, Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; CCB, calcium channel clocker; CI, 
confidence interval; EP; exposure period; N, number; HR, hazard ratio; TZD, thiazide diuretics. 
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Figure 7-5 Adjusted survival plot for onset of depression as indicated by receipt of 
antidepressants prescriptions, by antihypertensive classes in hypertensive patients newly 
treated with antihypertensive medication within first 12 months window 
This figure shows greatest hazard for patients treated with CCB compared with those patients with 
ACEI Abbreviations: ACEI, Angiotensin converting enzyme inhibitor; ARBs, Angiotensin II receptor 
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Table 7-5 Cox PH model results for risk of depression and different antihypertensive 
medication classes (sensitivity analysis) 




HR (95%CI) p-value HR (95%CI) p-
value 
Excluding cases occurring within the first year of follow-up (N= 2282) 
ACEI  95/647 Ref (1) Ref (1) 
ARB  79/409 1.20 (0.89,1.61) 0.23 1.17 (0.85,1.62) 0.32 
BB 55/336 1.01 (0.73,1.41) 0.93 0.99 (0.69,1.44) 0.99 
CCB 125/580 1.47 (1.12,1.92) 0.005 1.38 (1.03,1.85) 0.03 
TZD 52/310 0.94 (0.66,1.32) 0.71 0.99 (0.69,1.42) 0.96 
Excluding patients with antihypertesive presctreption of less than 3 months (N= 1757) 
ACEI  83/498 Ref (1) Ref (1) 
ARB  79/323 1.39 (1.02,1.89) 0.03 1.42 (1.01,1.99) 0.04 
BB 49/266 1.04 (0.73,1.49) 0.82 1.08 (0.73,1.61) 0.68 
CCB 108/457 1.46 (1.09,1.94) 0.01 1.45 (1.05,1.98) 0.02 
TZD 44/213 1.05 (0.72,1.52) 0.79 1.16 (0.78,1.73) 0.45 
Excluding patients with CVD before and during the exposure period (N= 1950) 
ACEI 93/547 Ref (1) Ref (1) 
ARB 85/368 1.26 (0.94,1.70) 0.12 1.33 (0.96,1.83) 0.08 
BB 62/265 1.23 (0.89,1.70) 0.20 1.27 (0.89,1.82) 0.19 
CCB 126/504 1.48 (1.13,1.94) 0.004 1.45 (1.06,1.95) 0.017 
TZD 54/266 1.02 (0.73,1.43) 0.91 1.11 (0.77,1.61) 0.56 
Outcome defined as receiving antidepressants for 6 months or more within 12 months 
window of the index date* (N=2406) 
ACEI 35/676 Ref (1) Ref (1) 
ARB 19/432 0.83 (0.47,1.46) 0.52 0.87 (0.477,1.58) 0.65 
BB 22/361 1.15 (0.67,1.96) 0.61 1.35 (0.77,2.37) 0.29 
CCB 50/612 1.68 (1.08,2.59) 0.02 1.63 (1.01,2.63) 0.047 
TZD 18/325 0.98 (0.55,1.73) 0.94 1.08 (0.58,1.97) 0.81 
Patients right censored at 3.5 years censoring point (N=2406) 
ACEI 87/676 Ref (1) Ref (1) 










CCB 105/612 1.39 (1.04, 
1.85) 
0.024 
1.39 (1.02, 1.91) 
0.037 





Model 1 adjusted for age and gender. Model 2 adjusted for age, gender, BMI, smoking, eGFR and 
Charlson comorbidity index. Abbreviations: ACEI, Angiotensin converting enzyme inhibitor; ARBs, 
Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; CCB, calcium channel 
clocker; CI, confidence interval; HR, hazard ratio., TZD; thiazide diuretics. *Patients considered 
having the outcome if they received antidepressants prescriptions for at least 6 months within the first 
12-month window starting from the incident date of depression. 
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 Dose-response relationship 
 CCB and risk of anti-depressants usage: subgroup analysis 
Table 7-6 presents the baseline characteristics for patients treated with CCB 
stratified based on whether or not they developed depression. Over a median of 
4.1 years of follow-up, 158 (25.8%) of these patients developed depression. 
Generally, there were no major differences between the two groups (p > 0.05); 
however, patients with depression were more likely to be female (p < 0.000). The 
cDDD also varied significantly between the two groups (p = 0.02). 
The baseline characteristics were further stratified according to the cDDD tertiles 
(Table 7-7). There were no differences between the groups except for gender and 
number of prescreption. The female proportion was higher in the first tertile 
compared to the second and third ones (p = 0.03). The patients in the first and 
second tertiles were more likely to be short-term users (i.e. used CCB for less than 
or equal to 6 months) (p < 0.000). 
From the Kaplan-Meier survival curve in Figure 7-6, it is clear that there are no 
significant differences in the estimated mean event-free survival times between 
the three tertiles of the cDDD of CCB. The log-rank test shows a p-value of 0.66. 
The adjusted survival plot for depression incidence stratified based on the cDDD 
tertiles of CCB are presented in Figure 7-7. 
Table 7-8 shows the Cox regression for incident depression across the cDDD tertiles 
of CCB. After adjusting for age and gender in Model 1, the patients in the second 
and third tertiles were not at increased risk of developing depression compared 
to those in the first tertile. The corresponding HRs are 0.93 (95% CI 0.63–1.36) and 
0.91 (95% CI 0.63–1.36). Similar results were obtained after adjusting for smoking 
in Model 2. The corresponding HRs for the second and third tertiles are 0.93 
(95% CI 0.63–1.36) and 0.91 (95% CI 0.60–1.37). 
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Table 7-6 Baseline characteristics of 612 patients on CCB monotherapy stratified by the 
main outcome 





Age (years) 52.66 (13.74) 52.44 (13.62) 0.86 
SBP, mmHg 160.23 (25.8) 158.71 (23.14) 0.515 
DBP, mmHg 94.90 (13.15) 92.72 (13.3) 0..075 
Cholesterol 5.81 (1.15) 5.83 (1.07) 0.85 
BMI 28.20 (4.79) 28.86 (6.5) 0.25 
Gender    
Male 235 (51.58) 56 (35.4) 
0.000 
Female 219 (48.2) 102 (64.6) 
Smoking    
Non-smoker  287 (63.2) 95 (60.1) 
0.49 
Smoker 167 (36.8) 63 (39.9) 
Kidney function    
eGFR (>60ml/min) 78 (20.4) 30 (23.3) 
0.49 
eGFR (<= 60ml/min) 304 (79.6) 99 (76.7) 
Charlson comorbidity 
index score    
0 175 (38.5) 62 (39.2) 
0.82 1 121 (26.7) 45 (28.5) 
>1 158 (34.8) 51 (32.3) 
N of prescriptions 
during the EP      
1-3 157 (34.5) 69 (43.9) 0.08 
4-6 188 (41.3) 59 (37.6) 
≥7 110 (24.2) 29 (20.9) 
cDDD tertiles    
T1 102 (22.4) 47 (29.9) 
0.02 T2 163 (25.8) 63 (40.1) 
T3 190 (41.8) 29.9 (19.8) 
BMI, body mass index; cDDD, cumulative defined daily dose; DBP, diastolic blood 
pressure; EP, exposure period; eGFR, estimated glomerular filtration rate; N, 
number; SBP, systolic blood pressure; T1, first tertile; T2, second tertile; T3, third 
tertile. X2 test and T-test were used for continuous and categorical data respectively; 
p-value for trend 
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Table 7-7 Baseline characteristics of 612 patients on CCB with and without depression 
stratified by the cDDD levels 
Variable 
First tertile 








Age (years) 54.66 (12.91) 51.86 (14.1) 52 (13.7)  0.11 
Female sex 92 (61.7) 115 (50.9) 114 (48.1)  0.03 







DBP,mmHg 93.36 (14.27) 94.23 (13.1) 95.06 (12.62)  0.47 
BMI 28.47 (5.1) 28.13 (5.4) 28.54 (5.37)  0.69 
Cholesterol 5.81 (1.06) 5.75 (1.10) 5.88 (1.2)  0.50 
Smoking 55 (36.9) 84 (37.2) 91 (38.4)  0.94 
eGFR (< 60ml/min) 98 (79) 158 (81.9) 147 (75.8)  0.34 
Charlson index 
score    
 
0.62 
0 50 (33.6) 88 (38.9) 99 (41.8)  
 
1 43 (28.9) 61 (27) 62 (26.2)  
>1 56 (37.6) 77 (34.1) 76 (32.1)  
N of prescriptions 
during the EP     
 
 
1-3 142 (95.3) 72 (31.9) 12 (5.1)   
4-6 7 (4.7) 123 (54.4) 117 (47.4)  0.000 
≥7 0 (0.0) 31 (13.7) 108 (45.6)   
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; 
EP, exposure period; N, number; SBP, systolic blood pressure.  X2 test and 1-way ANOVA test 
were used for categorical and continuous data respectively. 
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Figure 7-6 Unadjusted Kaplan Meier curves for onset of depression stratified by tertiles of the 
cDDD of CCB monotherapy received within the first 12 months window from the index date. 
Abbrevations: CCB, calcium channel blocker; cDDD, cumulative defined daily dose; T1, first tertile; 
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Table 7-8 Cox proportional hazards model results for risk of depression and cDDD tertiles 
 
 
Figure 7-7 Adjusted survival plot for onset of depression stratified by tertiles of the cDDD of 
CCB monotherapy received within the first 12 months window of the treatment 
This figure shows no difference in risk between the three groups. Abbreviations: CCB, calcium 















T1 48/149 (32.2) 71.04 ref (1) ref (1) 
T2 













Model 1 adjusted for age and gender.  Model 2 adjusted for age, gender and smoking. Abbreviations: 
CCB, calcium channel blocker; CI, confidence interval; DDD; defined daily dose; HR, hazard ratio;  
T1, first tertile; T2, second tertile; T3, third tertile. 
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 BB and risk of depression: subgroup analysis 
The characteristics of 361 patients treated with BB stratified based on whether 
they developed depression or not are presented in Table 7-9. Over a median of 
4.5 years of follow-up, 84 (23.3%) of these patients developed depression. These 
subjects were mainly female (p = 0.007), younger (p = 0.001), short-term users of 
BB (treated for less than or equal to 6 months) (p = 0.023) and had a lower burden 
of comorbidities at baseline (p = 0.005) compared to those who did not develop 
depression. 
The baseline characteristics of patients treated with BB stratified by the cDDD 
tertiles are presented in Table 7-10. Comparing the three groups, the patients in 
the first tertile were predominantly female (≈78%). The number of prescriptions 
varied considerably between the groups, with those in the higher tertile being 
more likely to be long-term users. 
Figure 7-8 displays the unadjusted Kaplan–Meier event-free survival curve, 
showing that the estimated mean event free-survival time is longer for the third 
tertile compared to the first tertile, although with borderline significance as 
indicated by the log-rank test (p = 0.05). 
Figure 7-9 shows the adjusted survival plot for depression incidence stratified 
based on the cDDD tertiles of BB. The corresponding associations calculated using 
the Cox model are displayed in Table 7-11. Model 1 was adjusted for age and 
gender, while Model 2 was additionally adjusted for BMI and CCI score. In Model 
1, there was no apparent difference in the risk of depression incidence between 
patients in the second cDDD tertile compared to those in the first tertile (HR = 
0.72, 95% CI 0.42–1.26, p = 0.26). The association between the second tertile of 
cDDD and depression incidence remained unchanged in Model 2 (HR = 0.70, 95% CI 
0.39–1.23, p = 0.21). On the other hand, the patients in the third tertile appeared 
to be at lower risk of developing depression compared to the first tertile, although 
this was not significant in the age-gender adjusted model (HR = 0.62, 95% CI 0.35–
1.09, p = 0.09). Similar to the results of the log-rank test, the relationship 
between the third tertile and depression incidence became marginally significant 
as the BMI and CCI covariates were added into the model (HR = 0.6, 95% CI 0.34–
1.06, p = 0.08).
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Table 7-9 Baseline characteristics of 361 patients on BB monotherapy stratified by the main 
outcome 
Variable No depression  




Age (years) 51.83 (13.99) 46.04 (14.94) 0.001 
SBP, mmHg 154.32 (23.9) 152.36 (24.06) 0.52 
DBP, mmHg 92.44 (12.115) 92.49 (13.88) 0.97 
Cholesterol 5.7 (0.99) 5.61 (1.02) 0.47 
BMI 28.52 (5.52) 29.04 (6.95) 0.48 
Gender    
Male 139 (50.2) 28 (33.3) 0.007 
Female 138 (49.8) 56 (66.7)  
Smoking    
Non-smoker  173 (62.5) 50 (59.5) 
0.63 
Smoker 104 (37.5) 34 (40.5) 
Kidney function    
eGFR (≥60ml/min) 47 (19.9) 10 (14.1) 
0.27 
eGFR (<60ml/min) 189 (80.1) 61 (85.9) 
Charlson comorbidity 
index score    
0 106 (38.3) 49 (58.3)  
1 84 (30) 17 (20.2) 0.005 
>1 87 (31.4) 18 (21.4)  
N of prescriptions during the 
EP    
1-3 100 (35.6) 41 (51.2) 
0.02 4-6 88 (31.3) 23 (28.7) 
≥7 93 (33.1) 16 (20.0) 
cDDD tertiles    
T1 44 (15.7) 24 (30.0) 
0.009 T2 103 (78) 29 (22) 
T3 134 (47.7) 27 (33.8) 
BMI, body mass index; cDDD, cumulative defined daily dose; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; EP, exposure period; N, number; SBP, systolic 
blood pressure; T1, first tertile; T2, second tertile; T3, third tertile. X2 test and T-test were used 
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N=161 (44.6) p-value 
Age (years) 48.24 (15.2) 51.02 (14.8) 50.99 (13.65) 0.36 
Female sex 53 (77.9) 64 (48.5) 77 (47.8) 0.000 
SBP,mmHg 151.24 (21.8) 152.32 (24.84) 156.27 (24.04) 0.23 
DBP,mmHg 93.23 (11.5) 91.7 (13.3) 92.73 (12.2) 0.66 
BMI 27.8 (5.57) 29.02 (6.43) 28.69 (5.51) 0.37 
Smoking 26 (39.2) 55 (41.7) 57 (35.4) 0.55 
Cholesterol  5.7 (1.07) 5.62 (1.04) 5.7 (0.92) 0.65 
eGFR (< 60ml/min) 43 (75.4) 91 (84.3) 116 (81.7) 0.38 
Charlson index score     
0 33 (48.5) 53 (40.2) 69 (42.9) 0.18 
1 22 (32.4) 32 (24.2) 47 (29.2)  
>1 13 (19.1) 47 (35.6) 45 (28.0)  
N of prescriptions during the EP     
0.000 
1-3 60 (88%) 64 (48.5) 17 (10.6) 
4-6 6 (8.8) 40 (30.3) 65 (40.4) 
≥7 2 (2.9) 28 (21.2) 79 (49.1) 
BMI, body mass index; cDDD, cumulative defined daily dose; DBP, diastolic blood pressure; eGFR, 
estimated glomerular filtration rate; EP, exposure period; N, number; SBP, systolic blood pressure.  
X2 test and 1-way ANOVA test were used for categorical and continues data respectively. 
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Figure 7-8 Unadjusted Kaplan Meier curves for onset of depression stratified by tertiles of the 
cDDD of BB monotherapy received within the first 12 months window from the BB 
prescription index date.  
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T1 25/68 (36.7) 82 ref (1) ref (1) 
T2 31/132 (23.5) 






T3 28/161 (17.4) 






Model 1 adjusted for age and gender.  Model 2 adjusted for age, gender, BMI and charlson 
comorbidity index score. Abbreviations: BB, β-blockers; CI, confidence interval; cDDD; cumulative 
defined daily dose; HR, hazard ratio; T1, first tertile; T2, second tertile; T3, third tertile. 
 
Figure 7-9 Adjusted survival plot for new-onset of depression stratified by tertiles of the cDDD 
of BB monotherapy received within the first 12 months window from the BB prescription index 
date.  
This figure shows no significant differences in risk of depression incident between the three groups. 
Abbreviations: BB, β-blockers; cDDD; cumulative defined daily dose; T1, first tertile; T2 second tertile; 
T3 third tertile.
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 ACEI and risk of depression: subgroup analysis  
The baseline characteristics of 676 patients treated with ACEI are shown in Table 
7-12. Overall, 127 (18.8%) of these patients developed depression over a median 
follow-up of 4.3 years. Comparing the groups with and without depression, 
subjects in the group with incident depression were significantly more likely to be 
overweight (p = 0.003). The other characteristics were comparable between the 
two groups.  
Table 7-13 shows the baseline characteristics stratified according to the cDDD of 
ACEI. There were no significant differences between the three groups except for 
the number of ACEI prescriptions. Patients in the first and second tertiles tended 
to be short-term users (six prescriptions or fewer). 
The unadjusted event-free Kaplan–Meier survival curve is presented in Figure 7-10. 
The log-rank test shows a non-statistically significant difference (p = 0.17) in the 
mean event-free survival time between the three tertiles of the cDDD of ACEI. 
Table 7-14 presents the association between the cDDD tertiles within the ACEI 
group and the risk for depression incidence. Model 1 was adjusted for age and 
gender, while Model 2 was further adjusted for BMI and smoking. In both models, 
the association between the second tertile and depression compared to the first 
tertile was not significant: HR = 1.08 (95% CI 0.72–1.62, p = 0.71) and HR = 1.09 
(95% CI 0.73–1.63, p = 0.67), respectively. On the other hand, the patients in the 
third tertile appeared to be at lower risk of incident depression compared to those 
in the first tertile, although this association was not statistically significant in 
either models (Model 1: HR = 0.68, 95% CI 0.42–1.09, p = 0.11; Model 2: HR = 0.69, 
95% CI 0.43–1.11, p = 0.12) (Figure 7-11). 
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Table 7-12 Baseline characteristics of 676 patients on ACEI monotherapy stratified by the 
main outcome 
Variable No depression  
N= 549 (81.2) 
Depressed 
N= 127 (18.8) 
p-value 
Age (years) 48.63 (14.55) 49.17 (13.12) 0.71 
SBP 154.95 (23.43) 153.19 (26.18) 0.46 
DBP 92.97 (12.08) 92.16 (11.45) 0.49 
Cholesterol 5.7 (1.11) 5.88 (1.15) 0.29 
BMI 27.8 (4.96) 29.54 (6.05) 0.003 
Gender    
Male 298 (54.3) 64 (50.4) 
0.43 
Female 251 (45.7) 63 (49.6) 
Smoking    
Non-smoker  359 (65.4) 73 (57.5) 
0.09 
Smoker 190 (34.6) 54 (42.5) 
Kidney function    
eGFR (>60ml/min) 73 (16.2) 21 (19.6) 
0.39 
eGFR (<= 60ml/min) 377 (83.8) 86 (80.4) 
Charlson comorbidity 
index score    
0 279 (50.8) 66 (52.0) 
0.76 1 124 (22.6) 25 (19.7) 
>1 146 (26.6) 36 (28.3) 
N of prescriptions during 
the EP      
1-3 124 (48.1) 34 (50.7) 
0.86 4-6 93 (36.0) 24 (20.5) 
≥7 41 (15.9) 9 (13.4) 
cDDD tertiles    
T1 147 (26.6) 43 (34.7) 
0.008 
T2 196 (35.3) 52 (41.9) 
T3 210 (28) 29 (23.4)  
BMI, body mass index; cDDD, cumulative defined daily dose; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; EP, exposure perioed; N, number; 
SBP, systolic blood pressure; T1, first tertile; T2, second tertile; T3, third tertile. X2 test 
and T-test were used for categorical and continuous data respectively 
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N=239 (35.4) p-value 
Age (years) 48.20 (15.04) 49.68 (13.99) 46.39 (13.97) 0.42 
Female sex 91 (47.9) 111 (44.9) 112 (46.9) 0.81 
SBP,mmHg 154.42 (25.46) 152.84 (22.58) 156.61 (24.08) 0.23 
DBP,mmHg 93.13 (11.79) 91.63 (11.95) 93..81 (12.04) 0.12 
BMI 28.4 (5.48) 28.18 (4.9) 27.85 (5.3) 0.55 
Smoking 70 (36.8) 87 (35.2) 87 (36.4) 0.93 
Choleserol     
eGFR (< 60ml/min) 131 (82.9) 166 (82.2) 166 (84.3) 0.85 
Charlson index 
score 
    
0 101 (53.2) 123 (49.8) 121 (50.6) 
0.63 
1 36 (18.9) 54 (21.9) 59 (24.7) 
>1 53 (27.9) 70 (28.3) 59 (24.7) 
N of prescriptions 
during the EP 
   
1-3 155 (81.6) 79 (32) 23 (8.9) 
0.000 4-6 29 (15.3) 95 (39.5) 108 (45.2) 
≥7 6 (3.2) 73(29.6) 108 (57.8) 
BMI, body mass index; cDDD; cumulative defined daily dose; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; EP, exposure period; N, number; SBP, systolic blood 
pressure. X2 test and 1-way ANOVA test were used for categorical and continues data 
respectively. 
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Figure 7-10 Unadjusted Kaplan Meier curves for onset of depression stratified by tertiles of 
the cDDD of ACEI monotherapy received within the first 12 months window from the index 
date. 
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; cDDD, cumulative defined daily 
dose; T1, first tertile; T2, second tertile; T3, third tertile 
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HR (95%CI) p-value HR (95%CI) p-value 
T1 46/190 (24.21) 50.3 ref (1) ref (1) 







T3 29/239 (12.1) 






 Model 1 adjusted for age and gender. Model 2 adjusted for age, gender, smoking 
and body mass index.Abbreviations: ACEI, Angiotensin converting enzyme 
inhibitor; CI, confidence interval; cDDD; cumulative defined daily dose; HR, hazard 
ratio; T1, first tertile; T2, second tertile; T3, third tertile. 
 
Figure 7-11 Adjusted survival plot for onset of depression stratified by tertiles of the cDDD of 
ACEI monotherapy received within the first 12 months window from the ACEI prescription 
index date.  
This figure shows that patients in the third tertile were at lower risk for onset of depression compared 
to patients in the lower tertile, though the association was marginally Abbreviations: ACEI, 
Angiotensin converting enzyme inhibitor; cDDD; cumulative defined daily dose; T1, first tertile; T2 
second tertile; T3 third tertile. 
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 ARB and risk of depression: subgroup analysis 
The characteristics of 432 patients treated with ARB categorised by depression 
outcome status are presented in Table 7-15. Over a median of 4.5 years of follow-
up, 103 (23.8%) ARB-treated patients developed depression. Comparing the groups 
with and without depression, the patients who did develop depression were 
predominantly female (p = 0.003). No other significant differences between the 
two groups were observed. 
As shown in Table 7-16, the distributions of baseline characteristics divided by the 
cDDD tertiles of ARB were comparable between the three groups, except for the 
number of prescriptions variable, as patients within the first and second tertiles 
were more likely to be short-term users. 
The unadjusted event-free Kaplan–Meier survival curve is presented in Figure 7-12 
showing a linear relationship with tertile 1 with the lowest risk and tertile 3 with 
higher risk but this did not reach statistical significance (log-rank p = 0.12). 
Table 7-17 provides the Cox proportional hazard ratios of the association between 
cDDD tertile and incident depression among patients receiving ARB. Model 1 was 
adjusted for age and gender, whereas Model 2 was further adjusted for SBP and 
number of prescriptions. Using the first tertile as the reference group, the HR for 
the second tertile was 1.49 (95% CI 0.90–2.47, p = 0.12) and 1.43 (95% CI 0.82–
2.50, p = 0.18) in Models 1 and 2, respectively. In the age-gender adjusted model, 
the patients in the third tertile were associated with an increased risk of 
developing depression (HR = 1.78, 95% CI 1.08–2.94, p = 0.02) compared to the 
first tertile. This association was attenuated after additional adjustments for SBP 
and number of prescriptions (HR = 1.77, 95% CI 0.97–3.22, p = 0.06). 
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Table 7-15 Baseline characteristics of 432 patients on ARB monotherapy stratified by the 
main outcome 
Variable No depression  
N= 329 (76.2) 
Depressed 
N= 103 (23.8) 
p-value 
Age (years) 51.92 (13.46) 50.74 (13.87) 0.44 
SBP 161.15 (25.41) 158.46 (23.1) 0.34 
DBP 95.73 (13.10) 94.28 (11.3) 0.28 
Cholesterol 5.7 (1.01) 5.87 (1.22) 0.45 
BMI 28.62 (5.5) 29.15 (7.2) 0.44 
Gender    
Male 180 (54.7) 39 (37.9) 
0.003 
Female 149 (45.3) 64 (62.1) 
Smoking    
Non-smoker  228 (69.3) 67 (65.0) 
0.42 
Smoker 101 (30.7) 36 (35.0) 
Kidney function    
eGFR (>=60ml/min) 53 (18.3) 23 (25.0) 
0.16 
eGFR (<60ml/min) 236 (81.7) 69 (75.0) 
Charlson comorbidity 
index score    
0 135 (41) 47 (45.6) 
0.66 1 88 (26.7) 27 (26.2) 
>1 106 (32.2) 29 (28.2) 
N of prescriptions 
during the EP      
1-3 128 (38.8) 38 (37.3) 
0.70 4-6 118 (35.8) 41 (40.2) 
≥7 84 (25.5) 23 (22.5) 
cDDD tertiles    
T1 102 (30.9) 26 (25.5)  
T2 109 (33) 36 (24.8) 0.57 
T3 119 (36.1) 40 (39.2)  
BMI, body mass index; cDDD; cumulative defined daily dose; DBP, diastolic 
blood pressure; eGFR, estimated glomerular filtration rate; EP, exposure 
period; N, number; SBP, systolic blood pressure; T1, first tertile; T2, second 
tertile; T3, third tertile. X2 test and T-test were used for categorical and 
continuous data respectively. 
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Table 7-16 Baseline characteristics of 432 patients on ARB monotherapy stratified by cDDD 
levels 
Variable 
First tertile  
N= 128 (29.6) 
Second tertile 
N= 145 (33.6) 
Third tertile 
N= 159 (36.8) p-value 
Age (years) 52.25 (14.36) 50.83 (13.22) 51.89 (13.24) 0.66 
Female sex 70 (54.7) 74 (51.0) 69 (43.4) 0.144 
SBP,mmHg 160.77 (25.5) 157.7 (26.43) 162.88 (22.6) 0.19 
DBP,mmHg 95.19 (12.68) 95.08 (12.63) 95.81 (12.83) 0.87 
BMI 28.61 (4.79) 29.34 (6.7) 28.31 (6.1) 0.31 
Smoking 39 (30.5) 49 (33.8) 49 (30.8) 0.80 
Cholesterol 5.82 (1.04) 5.8 (1.04) 5.76 (1.11) 0.86 
eGFR (< 60ml/min) 94 (80.3) 95 (79.8) 116 (80.0) 0.99 
Charlson index score     
0 54 (42.2) 64 (44.1) 64 (10.3) 0.61 
1 29 (22.7) 38 (26.2) 48 (30.2)  
>1 45 (35.2) 43 (29.7) 47 (29.6)  
N of prescriptions during 
the EP   
    
1-3 89 (69.5) 17 (11.7) 3 (2.8) 
0.000 4-6 26 (20.3) 49 (33.8) 38 (23.9) 
≥7 4 (3.1) 34 (23.4) 69 (43.4) 
; BMI, body mass index; cDDD; cumulative defined daily dose; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; EP, exposure period; N, number; SBP, systolic blood 
pressure. X2 test and 1-way ANOVA test were used for categorical and continuous data 
respectively. 
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Figure 7-12 Unadjusted Kaplan Meier curves for onset of depression stratified by tertiles of 
the cDDD of ARB monotherapy received within the first 12 months window from the ARB 
prescription index date 
Abbreviation: ARB, angiotensin receptor antagonist; cDDD, cumulative defined daily dose; T1, first 
tertile; T2, second tertile; T3, third tertile 
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T2 37/145 (25.5) 






T3 40/159 (25.1) 






Model 1 adjusted for age and gender.  Model 2 adjusted for age, gender, number of prescription 
and systolic blood pressure. Abbreviations: ARBs, Angiotensin II receptor blockers; cDDD; defined 




Figure 7-13 Adjusted survival plot for onset of depression as indicated by receipt of 
antidepressants prescriptions, by tertiles of cDDD of ARB in hypertensive patients newly 
treated with ARB within 12 months window.  
This figure shows greatest hazard for the third tertile compared to the first tertilr of the cDDD 
Abbreviations: ARBs, Angiotensin II receptor blockers; cDDD; cumulative defined daily dose; T1, 
first tertile; T2 second tertile; T3 third tertile. 
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 TZD and risk of depression: subgroup analysis 
Table 7-18 presents the baseline characteristics for 325 patients treated with TZD, 
based on whether they developed depression. Sixty-nine (21.2%) cases of 
depression occurred over a median follow-up of 5.5 years. The participants who 
developed depression were predominantly female (≈61%) and had higher SBP at 
baseline (p = 0.02) compared to those who did not develop depression. 
The baseline characteristics across the cDDD tertiles of TZD were comparable, 
except for the number of prescriptions, as the participants in the first and 
second tertiles were more often short-term users (p < 0.000) (Table 7-19). 
The unadjusted event-free Kaplan-Meier survival curves (Figure 7-14) shows no 
significant differences in the cumulative event-free survival rate between the 
cDDD tertiles of TZD. The estimated mean time to depression was comparable 
between the three groups, as indicated by the log-rank test (p = 0.95)  
Table 7-20 presents the HRs for the association between the cDDD tertiles of TZD 
and incidence of depression. Model 1 was adjusted for age and gender, while 
Model 2 was adjusted for SBP, smoking and CCI. In both models, there was no 
significant association between the second tertile of cDDD and risk of depression 
compared to the first tertile, and the HRs were almost identical (HR = 0.93 95% CI 
0.50–1.73, p = 0.94). Likewise, there were no apparent differences in the risk of 
depression between patients in the third tertile compared to those in the first 
tertile. The corresponding HRs for the third tertile in Models 1 and 2 were 1.02 
(95% CI 0.58–1.78, p = 0.95) and 0.98 (95% CI 0.55–1.74, p = 0.94), respectively. 
Figure 7-16 displays the adjusted HRs and CI overlaps for incident depression 
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Table 7-18 Baseline characteristics of 325 patients on TZD monotherapy stratified by the 
main outcome 
Variable No depression 
N= 256 (78.8) 
Depressed 
N= 69 (21.2) 
p-value 
Age at first prescription 
(years) 52.68 (13.63) 55.59 (12.5) 0.11 
SBP 157.22 (22.36) 164.58 (23.24) 0.02 
DBP 93.54 (11.11) 96.42 (13.93) 0.07 
Cholesterol 5.81 (1.1) 5.7 (0.98) 0.52 
BMI 28.58 (5.09) 29.12 (5.22) 0.44 
Gender    
Male 115 (44.9) 27 (39.1) 
0.039 
Female 141 (55.1) 42 (60.9) 
Smoking    
Non-smoker  180 (70.3) 41 (59.4) 
0.08 
Smoker 76 (29.7) 28 (40.6) 
Kidney function    
eGFR (>= 60ml/min) 46 (20.8) 13 (20.3) 
0.93 
eGFR (< 60ml/min) 175 (79.2) 51 (79.7) 
Charlson comorbidity index 
score    
0 93 (36.3) 22 (31.9) 
0.65 1 81 (31.6) 21 (30.4) 
>1 82 (32.0) 26 (37.7) 
N of prescriptions during the 
EP      
1-3 87 (34) 25 (36.2) 
0.001 4-6 66 (25.8) 19 (27.5) 
≥7 41 (16) 9 (13) 
cDDD tertiles    
T1 81 (31.4) 25 (37.3) 
0.59 T2 65 (25.2) 17 (25.4) 
T3 112 (43.4) 25 (37.3) 
BMI, body mass index; cDDD; cumulative defined daily dose; DBP, diastolic blood 
pressure; eGFR, estimated glomerular filtration rate; EP, exposure period; N, 
number; SBP, systolic blood pressure; T1, first tertile; T2, second tertile; T3, third 
tertile. X2 test and T-test were used for categorical and continues data 
respectively. 
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N= 82 (25.2) 
Third tertile 
N= 137 (42.2) P-value 
Age (years) 54.83 (14.28) 52.71 (13.9) 52.47 (12.3) 0.36 
Female sex 60 (56.6) 52 (63.4) 71 (51.8) 0.25 
SBP,mmHg 160 (21.41) 157 (22.6) 158 (23.8) 0.68 
DBP,mmHg 93.14 (11.9) 93.98 (11.2) 95.03 (12.03) 0.47 
BMI 28.9 (5.1) 28.67 (5.5) 28.55 (4.2) 0.87 
Smoking 34 (32.1) 30 (36.6) 40 (29.2) 0.52 
Choleserol 5.6 (1.1) 5.7 (1.08) 5.9 (1.03) 0.18 
eGFR(< 60ml/min) 76 (79.2) 63 (84.0) 87 (76.3) 0.44 
Charlson index score    0.59 
0 37 (34.9) 29 (35.4) 49 (35.8)  
1 28 (26.4) 29 (35.4) 45 (32.8)  
>1 41 (38.7) 24 (29.3) 43 (31.4)  
N of prescriptions during 
the EP 
    
1-3 100 (94.3) 51 (62.2) 7 (5.1) 
0.000 4-6 6 (5.7) 27 (32.9) 84 (71.8) 
≥7 0 (0.0) 4 (4.9) 46 (92.0) 
BMI, body mass index; cDDD; cumulative defined daily dose; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; EP, exposure period; N, number; SBP, systolic blood 
pressure.  X2 test and 1-way ANOVA test were used for categorical and continuous data 
respectively. 
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Figure 7-14 Unadjusted Kaplan Meier curves for onset of depression stratified by tertiles of 
the cDDD of TZD monotherapy received within the first 12 months window from the TZD 
prescription index date. 
Abbreviation: cDDD, cumulative defined daily dose; TZD, thiazide diuretics; T1, first tertile; T2, 
second tertile; T3, third tertile 
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Model 1 adjusted for age and gender.  Model 2 adjusted for age, gender, systolic blood pressure, 
smoking and Charlson comorbidity index score. Abbreviations: CI, confidence interval; DDD; 
defined daily dose; HR, hazard ratio; T1, first tertile; T2, second tertile; T3, third tertile. 
 
 
Figure 7-15 Adjusted survival plot for onset of depression as indicated by receipt of 
antidepressants prescriptions, by tertiles of cDDD of TZD in hypertensive patients newly 
treated with TZD within 12 months window.  
This figure shows no significant differences between the tertiles of the cDDD of TZD. Abbreviations: 
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Figure 7-16 Forest plot of adjusted hazard ratios for new onset depression as indicated by 
receipt of antidepressants prescriptions by the cDDD tertiles of the five major classes of 
antihypertensive monotherapy in hypertensive  
ACEI, Angiotensin converting enzyme inhibitor; ARBs, Angiotensin II receptor blockers; BB, β-
blockers;CCB, calcium channel clocker; T2, second tertile; T3, third tertile. 
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 Antihypertensive drugs and risk of depression: polytherapy 
analysis 
 General characteristics of patients on antihypertensive monotherapy 
or polytherapy grouped by baseline depression status and index 
antihypertensive drug class 
Table 7-21 presents the baseline clinical characteristics of 5060 patients who were 
either on antihypertensive monotherapy or polytherapy, categorised based on 
their depression status. Patients with prevalent depression (27%) were excluded 
from further analysis. Compared to individuals without depression, patients with 
prevalent depression tend to be younger (p < 0.00), predominantly female 
(p < 0.00) and more likely to be smokers (p = 0.03) and had higher BMIs (p = 0.00) 
and lower scores of CCI at presentation (p < 0.000). Of the patients without 
depression, 14% progressed to develop new-onset depression, defined by the first-
ever prescription of antidepressants. In comparison to patients with no 
depression, those with new-onset depression were predominantly female and 
more likely to be overweight and smokers.  
The baseline characteristics of the 3691 eligible patients are presented in Table 
7-22. They were further stratified based on the index antihypertensive drug, as 
presented in Table 7-23. As demonstrated, there were significant differences 
between drug groups in most of the baseline covariates except for cholesterol 
level.
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 Quality assessment  
The overall score on the NOS is 7 (Appendix 7), which indicated a good quality of 
the present cohort. However, taking into account the limitation of the tool (see 
2.1.5) as well as the poor guidance in the literature about the optimal measure 
of depression, the score may not be an accurate reflection of the study quality. 
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Table 7-21 Baseline characteristic of the GBPC population on antihypertensive polytherapy (N=5060) stratified based on their depression status 




N= 1369 (27.1) 
New onset depression 
 N=708 (14) 
P-valuea P-valueb 
Age at first prescription (years) 58.5 (13.4) 56.7 (13.2) 58.0 (13) 0.000 0.42 
BMI 28.6 (5.4) 29.4 (6.4) 29.1 (6.8) 0.000 0.01 
Cholesterol 5.7 (1.03) 5.79 (1.1) 5.7 (1.1) 0.01 0.92 
Gender    
Male 1619 (54.3) 464 (33.9) 291 (41.1) 
0.000 0.000 
Female 1364 (45.7) 904 (66.1) 417 (58.9) 
Smoking    
Non-smoker  1976 (66.2) 862 (63.0) 439 (62.0) 
0.035 
0.03 
Smoker 1007 (33.8) 507 (37.0) 269 (38)  
Kidney function    
eGFR (>= 60ml/min) 440 (18.3) 200 (18.6) 112 (19.4) 
0.81 
0.51 
eGFR (< 60ml/min) 1970 (81.7) 875 (81.4) 464 (80.6)  
CCI    
0 1310 (43.9) 705 (51.5) 324 (45.8) 
0.000 
 
1 805 (27) 358 (26.2) 169 (23.9) 0.24 
>1 868 (29.1) 306 (22.4) 215 (30.4)  
Number of antihypertensive 
drugs    
 
1 2238 (75) 1054 (77) 520 (73.4) 
0.06 
 
2 530 (17.8) 238 (17.4) 142 (20.1) 0.32 
>2 215 (7.2) 77 (5.6) 46 (6.5)  
BMI, body mass index; eGFR, estimated glomerular filtration rate. 
a Prevalent depression vs non-depressed patients 
b New-onset depression vs  non-depressed patients 
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Table 7-22 Baseline characteristic of eligible patients (N=3691)  
Variable M (SD)/ N (%) 
Age at first prescription (years) 58.40 (13.4) 
BMI  28.71 (5.7) 
Cholesterol 5.71 (1.04) 
Gender  
Male 1910 (51.7) 
Female 1781 (48.3) 
Smoking  
Non-smoker 2415 (65.4) 
Smoker 1276 (34.6) 
Kidney function  
eGFR (≥60ml/min) 552 (15) 
eGFR (<60ml/min) 2434 (65.9) 
Charlson comorbidity index score  
0 1634 (44.3) 
1 974 (26.4) 
>1 1083 (29.3) 
Number of antihypertensive drugs    
1 2758 (74.7) 
2 672 (18.2) 
>2 261 (7.1) 
BMI, body mass index; eGFR, estimated glomular filtration rate. Continuous data are 
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5.72 (1.15) 5.75 (1.10) 
5.81 
(1.12) 
5.62 (0.93) 5.72 (1.00) 5.70 (1.06) 
5.61 
(1.18) 
5.73 (1.05) 5.66 (1.09) 0.50 
Smoking 105 (41.7) 271 (36.6) 28 (35.9) 151 (34.2) 325 (30.7) 158 (32.8) 64 (46) 115 (33) 59 (39.1) 0.002 
eGFR (< 60 ml/min) 158 (74.5) 500 (82) 50 (76.9) 288 (81.4) 681 (85) 337 (83.2) 97 (77.6) 223 (78.2) 100 (77.5) 0.011 
Charlson index score          
0 
69 (27.4) 316 (42.6) 
233 
(29.5) 
213 (48.2) 582 (55) 198 (41.2) 39 (28.1) 124 (35.5) 70 (46.4) 
0.000 
1 87 (34.5) 184 (24.8) 26 (33.3) 99 (22.4) 245 (23.2) 138 (28.7) 44 (31.7 105 (30.1) 46 (30.5) 
>1 96 (38.1) 241 (32.5) 29 (37.2) 130 (29.4) 231 (21.8) 145 (30.1) 56 (40.3) 120 (34.4) 35 (23.2) 
Number of antihypertensive 
drugs   
         
1 
202 (80.2) 589 (79.5) 67 (85.9) 308 (69.7) 683 (64.6) 368 (76.5) 
128 
(92.1) 
280 (80.2) 133 (88.1) 
0.000 
2 35 (13.9) 120 (16.2) 8 (10.3) 102 (23.1) 244 (23.1) 88 (18.3) 10 (7.2) 52 (14.9) 13 (8.6) 
>2 15 (6.0) 32 (4.3) 3 (3.8) 32 (7.2) 131 (12.4) 25 (5.2) 1 (0.7) 17 (4.9) 5 (3.3) 
α-blocker, Alpha-blocker; ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; CCB, 
calcium channel clocker; DHP, dihydropyridine; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoids. X2 test and 1-way ANOVA test were used for 
categorical and continuous variables respectively 
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 Association between antihypertensive drugs used as monotherapy 
or as part of polytherapy and risk of incident depression 
The Cox proportional hazard method was used to calculate the risk of developing 
incident depression over the follow-up period based on the index antihypertensive 
drug. Figure 7-17 show the unadjusted Kaplan–Meier event-free survival curves. 
The log-rank test indicates that there were no statistically significant differences 
between antihypertensive drugs and depression rates (p = 0.081). 
The results of the univariate and multivariate Cox proportional hazard models are 
displayed in Table 7-24. The univariate results showed that compared to the ACEI 
group, BB, dihydropyridine CCB and diuretics were associated with a statistically 
significant increased risk of incident depression, with the corresponding HRs of 
1.45 (p = 0.013), 1.36 (p = 0.018) and 1.42 (p = 0.034). Although these trends were 
in the predicted direction in the multivariate model after adjusting the covariates 
in Model 2, the association with depression remained statistically significant only 
for the dihydropyridine CCB (HR = 1.38 95% CI 1.03–1.86, p = 0.03), while marginal 
associations between BB, diuretics and depression were observed (p = 0.07 and 
0.049, respectively). As shown in the adjusted survival plot (Figure 7-18) the non-
dihydropyridine CCB group shows the highest HR compared to ACEI, but this does 
not attain statistical significance and may be a reflection of the relatively small 
number of individuals among the non-dihydropyridine CCB group. Sensitivity 
analyses were performed where patients were censored at 3.5 years (Table 7-25). 
The results are very similar to those derived from the monotherapy analysis, 
showing that dihydropyridine CCB has a statistically significant relationship at 3.5 
years. Overall, these results are in line with the findings obtained from the 
multivariate Cox proportional hazard model of the monotherapy analysis, 
demonstrating that CCB, is associated with a higher risk compared to ACEI.  
The GEE analysis was used to account for the correlation between multiple 
antihypertensive drug classes prescribed subsequently to the index 
antihypertensive drug for each patient. The results of the GEE analysis showing 
the association between antihypertensive drug classes and the risk of depression 
are presented in Table 7-26. The findings are consistent with those of the Cox 
regression in the multivariate model, revealing that dihydropyridine CCB was 
associated with significantly greater odds of depression in the univariate model 
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(OR = 1.26, 95% CI 1.05–1.50, p = 0.02) and after controlling for other covariates 
in the multivariate model (OR = 1.32, 95% CI 1.06–1.64, p = 0.01). Diuretics also 
showed a statistically significant association in the univariate and multivariate 
models (OR = 1.45, 95% CI 1.12–1.87, p = 0.004). Regarding the other covariates, 
gender and smoking status at baseline were significant predictors for depression 
incidence in the multivariate model. The BMI showed a strong association in the 
univariate model, but after controlling for other covariates, the association lost 
significance (p = 0.06). Increasing number of antihypertensive drugs was not 
statistically significant (OR = 0.98, 95% CI 0.82–1.17, p = 0.85). The sequence of 
antihypertensive drugs was introduced in the model as a variable to explore 
whether prescription antihypertensive drugs subsequent to the index drug 
influence the association between the index antihypertensive drug and incidence 
of depression. As shown in Table 7-26 the sequence covariate has a statistically 
significant negative correlation with depression, which perhaps reflects that the 
risk of inducing depression is more likely related to the index antihypertensive 
drug or the duration of exposure to the antihypertensive drug. 
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Figure 7-17 Unadjusted Kaplan Meier curves for onset of depression as indicated by receipt 
of antidepressants prescriptions, by first/index antihypertensive classes in hypertensive 
patients newly treated with antihypertensive medication. 
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Table 7-24 Cox PH model results for risk of depression and different antihypertensive medication classes among patients on antihypertensive poly therapy 
 
  Univariate  Model 1 Model 2 
Events/Total (%) Incident rate 
per 1000 
person-year 
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
Antihypertensive class      
ACEI  173/1058 (16.3) 26.7 Ref (1)  Ref (1) Ref (1) 
Alpha blocker  51/252 (20.2) 34.5 1.12 (0.75, 1.66) 0.57 1.21 (0.81, 1.81) 0.34 1.31 (0.85,2.01) 0.21 
ARB   84/481 (17.4) 28.5 0.97 (0.71, 1.34) 0.88 1.01 (0.72, 1.39) 0.97 1.04 (0.73,1.49) 0.81 
BB  99/442 (22.3) 38.9 1.45 (1.08, 1.97) 0.013 1.41 (1.05, 1.89) 0.023 1.36 (0.96,1.91) 0.075 
DHP-CCB  161/741 (21.7) 36.7 1.36 (1.05, 1.76) 0.018 1.38 (1.06, 1.79) 0.015 1.38 (1.03,1.86) 0.03 
Diuretics  76/349 (21.7) 38.2 1.42 (1.03, 1.96) 0.034 1.45 (1.05, 2.00) 0.025 1.44 (1.00,2.09) 0.049 
MRA  20/139 (14.3) 24.7 0.91 (0.52, 1.57) 0.73 0.94 (0.54,1.65) 0.84 0.96 (0.54,1.71) 0.89 
NONDHP CCB  15/78 (19.2) 32.3 1.45 (0.82, 2.57) 0.20 1.51 (0.84, 2.68) 0.16 1.67 (0.91,3.09) 0.09 
Other antihypertensive 
drugs 
29/151 (19.2) 33.2 1.16 (0.72, 1.88) 0.54 
1.24 (0.76,2.01) 0.38 1.15 (0.67,1.96) 0.61 
Total 708/3691 (19.2) 32.25       
Variables         
Age   0.99 (0.98,1.00) 0.07 0.99 (0.97, 0.99) 0.03 0.99 (0.98, 1.00) 0.12 
Female   1.58 (1.32,1.90) 0.00 1.58 (1.32, 1.90) 0.000 1.62 (1.32, 1.99) 0.00 
BMI   1.02 (1.002,1.03) 0.03 1.02 (1.002,1.03) 0.03 1.01 (0.99,1.03) 0.08 
Smoking   1.25 (1.04, 1.50) 0.02 1.25 (1.04,1.50) 0.01 1.41 (1.15, 1.72) 0.001 
eGFR   0.87 (0.68,1.12) 0.28 0.87 (0.68,1.12) 0.28 0.88 (0.68,1.14) 0.35 
Cholesterol   0.97 (0.89, 1.06) 0.55 0.97 (0.89,1.06) 0.55  0.97 (0.81, 1.16) 0.52 
CCI   0.94 (0.85,1.05) 0.32 0.94 (0.85,1.05) 0.32 0.98 (0.83, 1.18) 0.91 
Number of 
antihypertensive drugs 





Model 1 adjusted for age and gender. Model 2 adjusted for age, gender, BMI, smoking, eGFR, cholesterol and Charlson comorbidity index. Abbreviations: ACEI, Angiotensin 
converting enzyme inhibitor; ARB, Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; CCB, calcium channel clocker; CCI, Charlson comorbidity index; 
CI, confidence interval; DHP, dihydropyridine; eGFR;  estimated glomerular filtration rate; HR, hazard ratio; MRA, mineralocorticoids. 
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Figure 7-18 Adjusted survival plot for onset of depression as indicated by receipt of 
antidepressants prescriptions, by index antihypertensive drug classes in newly treated 
hypertensive patients.
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Table 7-25 Sensitivity analysis patients right censored at 3.5 years censoring point 
 
 
  Univariate  Model 1 Model 2 
Events/Total 
(%) 
Incident rate per 
1000 person-
year 
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
Antihypertensive class       
ACEI  91/1058 (8.6) 31.3 Ref (1)  Ref (1) Ref (1) 
Alpha blocker 21/252 (8.3) 30.5 0.98 (0.61, 1.58) 0.95 1.07 (0.66, 1.73) 0.78 1.13 (0.67,1.89) 0.65 
ARB  34/481 (7.1) 25.4 0.82 (0.55, 1.22) 0.33 0.85 (0.57, 1.26) 0.42 0.85 (0.55, 1.33) 0.49 
BB 48/442 (10.9) 40.7 1.31 (0.93, 1.86) 0.12 1.27 (0.89, 1.81) 0.17 1.19 (0.79, 1.79) 0.38 
DHP-CCB 84/741 (11.3) 41.6 1.34 (1.00, 1.81) 0.049 1.36 (1.01, 1.84) 0.04 1.43 (1.03,2.01) 0.03 
Diuretics 43/349 (12.3) 46.7 1.49 (1.04, 2.15) 0.03 1.53 (1.06, 2.21) 0.02 1.61 (1.07, 2.42) 0.02 
MRA 10/139 (7.2) 26.3 0.83 (0.43, 1.61) 0.59 0.87 (0.45, 1.69) 0.68 0.91 (0.46, 1.78) 0.77 
NONDHP CCB 6/78 (7.7) 27.7 0.86 (0.38, 1.97) 0.73 0.90 (0.39, 2.07) 0.81 0.92 (0.36, 2.28) 0.85 
Other antihypertensive 
drugs 
17/151 (11.3) 42 1.35 (0.81, 2.27) 0.25 
1.44 (0.86, 2.43) 
0.16 1.29 (0.72,2.32) 0.38 
 Model 1 adjusted for age and gender. Model 2 adjusted for age, gender, BMI, smoking, eGFR, cholesterol and Charlson comorbidity index. 
Abbreviations: ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; 
CCB, calcium channel clocker; CI, confidence interval; DHP, dihydropyridine; eGFR;  estimated glomerular filtration rate; HR, hazard ratio; MRA, 
mineralocorticoids; 
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Table 7-26 Results of generalised estimating equation (GEE) models showing the association between antihypertensive drug classes and odds of 
having new-onset depression among patients on antihypertensive polytherapy 
 
Unadjusted   Model 1 Model 2 
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
Antihypertensive class     
ACEI  Ref (1)  Ref (1) Ref (1) 
Alpha blocker 1.31 (0.99,1.71) 0.05 1.34 (1.02, 1.77) 0.03 1.43 (1.04, 1.95) 0.03 
ARB  1.08 (0.87,1.35) 0.43 1.09 (0.88, 1.35) 0.42 1.17 (0.91, 1.51) 0.22 
BB 1.22 (0.98,1.52) 0.07 1.21 (0.97, 1.51) 0.09 1.15 (0.88, 1.50) 0.28 
DHP CCB 1.26 (1.05,1.50) 0.02 1.27 (1.06,1.52) 0.01 1.32 (1.06, 1.64) 0.01 
Diuretics 1.26 (1.03,1.55) 0.03 1.28 (1.04, 1.58) 0.02 1.45 (1.12, 1.87) 0.004 
MRA 0.87 (0.59,1.29) 0.49 0.92 (0.62, 1.37) 0.69 0.95 (0.61, 1.47) 0.82 
NONDHP CCB 1.41 (0.92,2.15) 0.18 1.42 (0.92, 2.18) 0.12 1.46 (0.88, 2.41) 0.13 
Other antihypertensive drugs 1.18 (0.82,1.71) 0.36 1.27 (0.88, 1.83) 0.00 1.02 (0.66, 1.56) 0.93 
Variables       
Age 0.998 (0.991,1.00) 0.47 0.99 (0.98, 1.00) 0.21 0.99 (0.98, 1.004) 0.17 
Female 1.74 (1.43,2.10) 0.00 1.75 (1.45, 2.12) 0.000 1.88 (1.53, 2.33) 0.00 
BMI 1.02 (1.003,1.04) 0.02 1.02 (1.00, 1.04) 0.02 1.02 (0.99, 1.04) 0.06 
Smoking 1.19 (0.98,1.44) 0.07 1.28 (1.05, 1.55) 0.014 1.38 (1.12, 1.71) 0.002 
eGFR 0.93 (0.72,1.21) 0.61 0.95 (0.73, 1.25) 0.75 0.99 (0.72, 1.26) 0.74 
Cholesterol 1.03 (0.94, 1.13) 0.51 1.03 (0.94, 1.13) 0.51 1.01 (0.92, 1.11) 0.79 
CCI 1.005 (0.89,1.13) 0.93 1.05 (0.88, 1.24) 0.58 1.00 (0.83, 1.21) 0.97 
Number of antihypertensive drugs 0.97 (0.84,1.12) 0.74 0.96 (0.83, 1.10) 0.54 0.98 (0.82, 1.17) 0.85 
Sequence of the antihypertensive 
drug 
0.90 (0.80, 1.01) 0.07 0.88 (0.78,0.99) 0.04 0.87 (0.78, 0.97) 0.012 
 α-blocker, Alpha-blocker; ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin II receptor blockers; BB, β-blockers; BMI, body mass index; CCB, 
calcium channel clocker; CCI, Charlson comorbidity index; CI; confidence interval; DHP, dihydropyridine; eGFR, estimated glomerular filtration rate; MRA, 
mineralocorticoids; OR, odd ratio 
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 Discussion 
The purpose of the current study was to investigate the relationship between 
antihypertensive drug classes and the risk of incident depression in a middle-aged 
hypertensive population attending to a secondary care hypertension clinic over a 
7-year period. This question was addressed in several ways. First, I examined the 
association between the five major classes of antihypertensive drugs as 
monotherapy and the risk of incident depression. If a causal relationship between 
an individual class and depression indeed exists, a dose-response relationship may 
be expected. Second, I therefore also investigated whether higher doses of 
antihypertensive drugs were associated with a higher risk of developing 
depression. Finally, to ensure consistency in the results and delineate the type of 
association between antihypertensive drug subclasses and depression, an 
additional analysis of antihypertensive polytherapy was conducted. In this 
analysis, the effect of individual major classes and subclasses of antihypertensive 
drugs, used as either monotherapies or as a part of antihypertensive 
polytherapies, on depression was investigated after adjusting for the baseline 
polytherapy of antihypertensive drugs and their prescription sequencing.  
 Antihypertensive monotherapy and risk of depression 
incidence 
In this cohort of 2406 newly treated hypertensive patients with no previous history 
of antihypertensive or antidepressant prescriptions followed for 7 years by the 
GBPC, my findings demonstrated that compared to the ACEI group, CCB 
monotherapy was significantly associated with increased risk of depression 
incidence (HR = 1.38; 95% CI 1.07–1.80; p = 0.014), which is consistent with my 
hypothesis. This association remained stable after conducting additional analysis 
excluding events that occurred within the first year of follow-up (HR = 1.38; 
95% CI 1.03–1.85; p = 0.03), excluding patients with a prevalent CVD and those 
who developed CVD during the exposure period (HR = 1.45; 95% CI 1.06–1.95; 
p = 0.017) and after restricting the analysis to patients who received six or more 
antidepressant prescriptions within the first 12 months from the index date 
(HR = 1.6;3; 95% CI 1.01–2.63; p = 0.047). This  finding is consistent with prior 
studies suggesting that CCB may be associated with an increased risk of mood 
disorders (Boal et al., 2016) and for developing depression and/or initiating 
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antidepressant treatment (Cao et al., 2019, Shaw et al., 2019). Nevertheless, it 
contrasts some other published studies. A cross-sectional study of 14,195 elderly 
patients with no previous history of CVD or HF found no association between CCB 
and depressive symptoms as measured by the CES-D scale (Agustini et al., 2020). 
Moreover, a cohort study conducted by Tully et al. (2018) suggested that CCB may 
be effective as adjunctive therapy for the treatment of depression and cognitive 
dysfunction. In line with these findings, (Kessing et al., 2020) showed that CCB as 
a general class is associated with a reduced incident rate of depression. The 
researchers further reported that among this drug class, amlodipine and verapamil 
in particular were associated with a lower rate of incident depression. 
Controversies also remains within findings derived from pre-clinical research 
(Nanou and Catterall, 2018, Clark et al., 2020, Korczak et al., 2020, Normann et 
al., 2018, Giansante et al., 2020). After the discovery of the risk gene within the 
L-VGCC variation (i.e. CACNA1C) as being involved in psychiatric diseased, calcium 
channel seems a promising target in modulating depressive disorders, though the 
exact role of L-VGCC blockades, hence their clinical effect in the context of 
depression remains to be elucidated. It is well known that L-VGCC is involved in 
several neurobiological functions which are differed based on the L-VGCC 
subtypes, isoforms and their brain localisation. Recently Clark et al. (2020) 
proposed that the CACNA1C in human brain is highly complex after identifying 38 
novel exons and 241 novel transcripts within this gene. Accordingly, we would 
expect that blockade of L-VGCC would not produce a unifying pharmacological 
effect on the brain level. Findings from the current study suggests a higher risk of 
depression incident within CCB therapy compared to ACEI therapy, However, until 
further investigations perhaps it will be unwise to draw a firm conclusion regarding 
the relationship between the currently available CCB and depression. 
Contrary to my hypothesis, the results from this study showed that BB was not 
associated with incident depression in comparison with the ACEI group (HR = 1.17; 
95% CI 0.86–1.59; p = 0.31). My findings are consistent with previous studies 
suggesting that BB in general has no effect on depression or that the effect might 
be trivial (Battes et al., 2012, Bright and Everitt, 1992, Carney et al., 1987, Ko et 
al., 2002, Luijendijk et al., 2011, Verbeek et al., 2011). By contrast, my results 
also contradict the conclusions of several recent studies providing evidence that 
points towards the involvement of BB in mood disorders, including depression 
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(Agustini et al., 2020, Boal et al., 2016, Cao et al., 2019, Shaw et al., 2019). Other 
studies have suggested that antidepressant activity is a specific feature to 
lipophilic BBs, such as propranolol (Johnell and Fastbom, 2008, Ringoir et al., 
2014, Shaw et al., 2019). Nevertheless, in a very large case-control study, Kessing 
et al. (2020) refuted the BB-induced depression theory and suggested that BB as 
a drug class is associated with a decreased risk of incident depression and that 
propranolol, carvedilol, bisoprolol and atenolol are the drugs within this class with 
the lowest statistically significant risk of incident depression (Kessing et al., 
2020). Notably, these drugs have varying lipid solubility; therefore, according to 
the authors, they may induce an antidepressogenic effect that is independent of 
their lipid solubility (Kessing et al., 2020). As previously noted, depression is 
correlated with poor cardiac prognosis and a high mortality rate, particularly in 
CVD patients. Thus, medications that are associated with an increased risk of 
depression might be an important consideration for physicians treating these 
patients. Indeed, Kim et al. (2019a) showed that even though BBs are 
recommended for patients with HF, the use of these medications was lower among 
those with co-morbid depression, resulting in a reduced survival rate in these 
patients. Although my findings do not support that BBs are associated with 
incident depression, confounding due to health improvement cannot be ruled out. 
On the other hand, my results may indicate that any benefit of BBs might outweigh 
the negative impact on mood. Since quality of life may be considered just as 
important as length of life, future studies could examine the extent to which BBs 
affect mental health and quality of life in CVD patients.  
Furthermore, the current study provides no evidence that TZD can induce 
depression (HR = 1.04; 95% CI 0.77–1.43; p = 0.77), in line with previous work (Boal 
et al., 2016, Johnell and Fastbom, 2008, Kessing et al., 2020, Shaw et al., 2019). 
Likewise, the ARB group showed no statistically significant differences in 
depression risk compared to the ACEI group (HR = 1.17; 95% CI 0.86–1.59; 
p = 0.31). Because my study design lacks an untreated control group, it is difficult 
to compare my results with those of previous studies in the literature. My findings 
do not provide clear evidence of whether ACEI/ARB have any favourable effect 
against depression; however, the dose-response analysis in the present study 
suggested that ACEI and ARB may each have a distinct effect on depression 
(Section 7.5.3). In the literature, observational studies have examined ACEI and 
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ARB as a combined group relative to a control group and have provided evidence 
that these antihypertensive classes may be associated with decreased incidence 
of depression (Kessing et al., 2019), decreased rates of antidepressant use (Nasr 
et al., 2011) and decreased risk of hospital admission due to mood disorders (Boal 
et al., 2016). In contrast, findings from a large and more recent prospective study 
of 1.8 million patients showed that RAS blockade was associated with increased 
risk of depression, although this association was relatively weak (Shaw et al., 
2019). Another study has reported a null association between RAS blockade and 
the use of antidepressants; however, the authors observed a significantly lower 
risk of antidepressant use among specific groups of patients, particularly those 
with diabetic nephropathy (Ahola et al., 2014). Kessing et al. (2020) showed that 
ACEI and ARB are generally associated with reduced risk of depression and out of 
these two classes, only enalapril and ramipril have shown a significant risk 
reduction of incident depression. 
 Antihypertensive polytherapy and risk of depression 
incidence 
This study aimed to expand my previous analysis to provide a better sense of the 
whole picture. This was a prospective cohort study enrolling 3691 treated 
hypertensive patients attending the GBPC and were followed up for 7 years. In 
this additional analysis CCB class were further stratified into dihydropyridine and 
non-dihydropyridine. Two types of analysis were performed including the GEE and 
survival analysis. Overall, findings from the current study do not support early 
evidence suggesting that dihydropyridine possess antidepressants effect 
(Casamassima et al., 2010). By contrast it showed that in comparison to ACEI, 
dihydropyridine subclass of CCB as a mono or part of antihypertensive poly therapy 
increase the risk of incident depression (HR= 1.38, 95%CI 1.03, 1.86 p-value=0.03), 
which is consistent with the results of the monotherapy analysis. The GEE analysis 
further reaffirms and bolsters my findings demonstrating that dihydropyridine CCB 
is associated with a significant increased risk of depression while controlling for 
demographic variables, baseline number of antihypertensive drugs and their 
sequencing (OR= 1.32 95%I 1.06, 1.64 p-value=.0.01).  
In the literature, studies investigating the effect of dihydropyridine, non-
dihydropyridine each separately in relation to depression has been scarce, making 
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the comparison of my findings to other a bit of challenging. However, the result 
is in line with recent evidence generated from preclinical studies proposing that 
dihydropyridine CCB is implicated in depression pathogenesis (Nanou and 
Catterall, 2018, Qian et al., 2017, Zhou et al., 2017). On balance, not all member 
of this subclass may have the same effect in human. In a pair of a double blind 
placebo RCT, Taragano et al., found that nimodipine was superior to placebo in 
reducing depression symptoms and lowering the rates of depression recurrence 
(Taragano et al., 2001, Taragano et al., 2005). Kessing et al., also showed that 
amlodipine may reduce the risk of new-onset depression. Altogether, these 
evidences present how data generated from animal and humans are varied 
complicating their interpretation and clinical implication.  
Unexpectedly, diuretics also showed a trend toward increased risk of depression 
in both survival and GEE analysis. As mentioned previously, most evidence 
reported a null association between diuretics and depression, though very few 
reported positive correlations(Cao et al., 2019, Okada, 1985). One explanation for 
this odd results is perhaps due to the underlying missing data. About 20% of the 
patient’s data related to eGFR variable was missing in this cohort. In the diuretic 
group, eGFR missing data represents 22%, whereas 80% of those patients did not 
develop depression. Thus, excluding those patients from the model would lead to 
overestimation of the diuretic effect. I re-run the GEE analysis and omit the eGFR 
variable. Result showed non statistically significant association with depression 
but a trend association between dihydropyridine and depression was observed (p-
value= 0.055, data not shown). 
 Dose-response realtionship 
The results of my dose-response relationship need to be considered in relation to 
the inherent limitations in the calculation of DDD from the available data. The 
prescription data available included only data on dispensed drugs – number 
dispensed and the tablet strength. There were no data on the prescribed dose. 
Hence one of the assumptions in calculating DDD was based on the defined average 
dose for each drug. Whilst this is not accurate and may over- or underestimate 
drug exposure, it gives a crude estimate of drug exposure. Another major 
limitation of the dose-response analysis is that there is no indicator of actual drug 
adherence. Whilst prescription encashment indicates that the patient has 
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received the drug, this does not imply that the patient has actually taken the drug 
as prescribed. Because my results from the primary analysis suggested that CCB is 
associated with a higher risk of depression, I expected a similar link pattern in the 
dose-response analysis. Contrary to my expectation, a higher level of cDDD of CCB 
did not show an association with an increased risk of depression. Similarly, BB 
dose-response analysis showed that depression incidence tended to be lower 
among patients in the higher tertile of the cDDD compared to the lower tertile in 
the subgroup analysis of BB users, although this did not attain statistical 
significance (HR = 0.6; 95% CI 0.34–1.04; p = 0.07). Participants in the lower 
tertile were predominantly female, representing around 80% of the patients; 
however, the association persisted after adjusting for this confounder in the 
multivariate model. In line with this result, Battes et al. (2012) examined the 
association between BB therapy and depressive symptoms in PCI patients. They 
demonstrated that after 12 months, the patients treated with BB were less likely 
to experience depressive symptoms compared to the control group and that there 
was a dose-response relationship between BB and depressive symptoms, with a 
higher dose providing a more pronounced protective effect. Altogether, these 
observations—including my findings—are consistent with those reported by Kessing 
et al. (2020). 
One of the most important conclusions of this chapter is that ACEI and ARB may 
not have the same effect on depression. The results of the dose–response analysis 
showed that the patients who received higher cDDD of ARB were at increased risk 
of subsequent depression compared to those who received low cDDD of ARB. This 
might indicate that depression is related only to high levels of the therapeutic 
dose of ARB. Although this finding slightly differs from those of Kessing et al., 
showing that none of the individual drugs within the ARB group is associated with 
depression risk, it can be argued that Kessing et al. measured the risk of 
depression in relation to the number of prescriptions. While the cDDD may simply 
reflect a patient’s compliance with their increasing number of prescriptions, they 
are two different measures of drug exposure. Additionally, my result was derived 
after having adjusted for the number of prescriptions during the exposure period. 
Both ACEI and ARB belong to the same class and have been shown to be equivalent 
in their blood pressure lowering effect (Yusuf et al., 2008). Thus, it is reasonable 
to study them as a combined group, but does this apply when assessing depression 
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as an outcome? The following section suggests a different perspective, based on 
findings from studies that evaluated the effect of ACEI and ARB separately on 
mental health outcomes. A previous nested case-control study showed an 
increased risk of suicide among ARB users but not ACEI users, although this study 
was limited by the very small number of patients receiving ARB and was not 
intended to investigate a priori the link between ACEI, ARB and suicide (Callréus 
et al., 2007). Nonetheless, this finding was supported by Mamdani et al. (2019), 
who conducted a nested case-control study matching 964 cases to 3856 controls 
aged 66 years and older, who were exposed to either an ACEI or ARB. They found 
that patients receiving ARB were at a greater risk of suicide (OR = 1.63; 
95% CI 1.33–2.00) than those receiving ACEI. Nonetheless, the notion that ARB may 
elevate suicide risk has been challenged recently, and evidence suggests that 
there are no significant differences between ACEI and AEB in this regard (Dent et 
al., 2020, Lin et al., 2020). Agustini and colleagues investigated the association of 
different antihypertensive drugs and their combinations with the presence of 
depressive symptoms in a cross-sectional study enrolling 14,195 older individuals 
(Agustini et al., 2020). They found that out of all possible combinations, only the 
combination of ARB and BB was significantly associated with depressive symptoms 
(OR = 1.62; 95% CI 1.18–2.22; p < 0.01) compared to non-medicated patients or 
those on diuretics. Other studies have suggested that among the RAS agents, ACEI 
may be the group most likely to be involved in the pathology of depression. A 
retrospective cohort enrolling 181,709 patients who were newly diagnosed with 
hypertension examined the associations of different classes of antihypertensives 
with the risk of depression over a median of 4.3 years of follow-up. In contrast to 
my results, they found that the incidence of depression among ACEI users was 
higher than among ARB users. Nasr et al. (2011) also observed that patients 
treated with ARB were at lower risk for subsequent antidepressant use compared 
to patients treated with ACEI. 
One explanation for these inconsistent findings might be that ACEI and/or ARB can 
act through a biological pathway that is independent of RAS. A preclinical study 
by Luo et al. (2020) demonstrated that unlike ARB and renin inhibitors, ACEI may 
function as an antidepressant via a non-RAS mechanism. The authors used chronic 
unpredictable stress and chronic social defeat stress to induce depressive-like 
behaviour in rodents. They found that ACEI initiated antidepressant activity by 
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activating bradykinin, a degraded substrate of ACE, which in turn activated the 
bradykinin 2 receptor and subsequently stimulated cell division cycle 42. The later 
is a protein kinase that regulates the activation of the mTORC1 signalling pathway, 
which is critical in the synaptic mechanisms underlying rapid-acting 
antidepressants. Consequently, this study concluded that ACEI may emerge as a 
novel fast-onset antidepressant. 
As aforementioned, most previous studies evaluated that the effects of ACEI and 
ARB as antihypertensive drugs belonged to the same class; their effects have 
rarely been considered separately. Therefore, it is important to keep in mind that, 
while my results indicating that the effect of ACEI and ARB may not be equivalent 
in the context of depression and that each could exert distinct effects on mental 
health agree with some of the literature, they should be interpreted as 
preliminary until future investigations are able to replicate the findings—with 
respect to the dose in particular, as the trend is only marginally significant.  
It should be noted that all the clinical studies described above, including my study, 
evaluated RAS agents as a potential preventive intervention for depression. The 
literature on the antidepressant activity of RAS agents in populations with 
depression is limited and reports inconsistent findings (Brownstein et al., 2017, 
Fujiwara et al., 2017, Köhler-Forsberg et al., 2020, Pavlatou et al., 2008). In a 
recent matched prospective cohort study, Köhler-Forsberg et al. (2020) 
investigated whether a combined treatment of RAS agents and SSRIs was 
associated with a reduced risk of psychiatric hospital contacts compared to the 
use of SSRIs alone. The main finding from this study showed that patients treated 
with RAS agents plus SSRIs were at lower risk for any psychiatric hospital contacts 
(HR = 0.91; 95% CI 0.84–0.98) compared to patients treated with SSRIs alone, and 
there was no apparent difference in the risk of suicide (HR = 1.06; 95% CI 0.79–
1.42) or risk of hospital contact due to depression (HR = 0.92; 95% CI 0.80–1.05). 
This study examined the combined effect of ACEI and ARB; thus, a clear picture 
of how each group might act on depression cannot be determined. Furthermore, 
the main outcome in most of the previously mentioned observational studies 
examining the effect of ACEI/ARBs was MDD (Boal et al., 2016, Cao et al., 2019, 
Kessing et al., 2019, Kessing et al., 2020, Köhler-Forsberg et al., 2020, Shaw et 
al., 2019). Regarding depressive symptoms, a meta-analysis of six RCTs showed 
that RAS blockade was associated with improved quality of life in terms of mental 
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health; however, there were no differences in terms of depressive symptoms 
(Brownstein et al., 2017). Some other studies have found that certain RAS agents 
were associated with improving depressive symptom scores (Fujiwara et al., 2017, 
Pavlatou et al., 2008). This improvement would have been undetectable in studies 
measuring depression as a clinical diagnosis and/or antidepressant initiation, 
which gives rise to the question of whether some RAS agents are effective as 
therapeutic and/or as preventive interventions for mild (but not for severe) cases 
of depression. 
It is important to note that while several studies have investigated the association 
between antihypertensive drug classes and depression, only a few have considered 
evaluating the dose response of antihypertensive drugs in relation to the 
occurrence of depression. Most comparable to the current investigation is the 
study conducted by Kessing et al. (2020). Because my work lacks an untreated 
comparison group, individuals with lower cDDD were set as the reference group, 
an approach similar, to some extent, to the one adopted by Kessing et al. (2020) 
where they set individuals with one or two prescriptions as the reference group. 
Nevertheless, this methodological approach is likely to be confounded by patient 
adherence. Table 7-27 presents the baseline characteristics of patients stratified 
according to the number of prescriptions received during the exposure period of 
the monotherapy analysis. As shown, the main variables that significantly varied 
across the three groups were age, SBP and CCI score. Patients with seven or more 
filled prescriptions were relatively older, predominantly stage 2-hypertensive 
patients and had higher CCI compared to the other two groups. I compiled the 
same table with the subgroups of the antihypertensive drug class, and the results 
were almost the same (data not shown). While the number of prescriptions does 
mirror the severity of elevated BP at baseline in my cohort, it may also be an 
indication of adherence during the exposure period. Perhaps the individuals 
diagnosed and labelled as stage-2 hypertensive were more committed to adhering 
to their medication than those with lower BP. Therefore, the reference group in 
Kessing et al. (2020), as well as the one in my study, may be confounded by 
adherence to medication. 
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Table 7-27 Baseline characteristics of 2406 patients based on number of prescriptions at 
baseline 
 Number of prescriptions  
Variable 1-3 4-6 ≥7 p-value 
Age (years) 51 (14.2) 50.36 (13.9) 52.29 (13.6) 0.036 
Female sex 504 (41.1) 425 (34.7) 296 (24.2) 0.2 
SBP,mmHg 156.37 (23.59) 156.84 (24.1) 160.1 (25.9) 0.01 
DBP,mmHg 109.41 (32.2) 112 (34.5) 110 (33) 0.23 
BMI 28.62 (5.6) 28.24 (5.3) 28 (50) 0.32 
Cholesterol 5.7 (1.08) 5.7 (1.1) 5.8 (1.1) 0.08 
Smoking 336 (39.4)) 299 (35.1) 218 (25.6) 0.67 
eGFR (< 60ml/min) 672 (40.8) 611 (37.1) 364 (22.1) 0.00 
Charlson index score     
0 417 (44) 395 (45.6) 222 (37.5) 
0.038 1 246 (25.9) 216 (24.9) 171 (28.9) 
>1 285 (30.1) 255 (29.4) 199 (33.6) 
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration 
rate; SBP, systolic blood pressure.  X2 test and 1-way ANOVA test were used for categorical 
and continuous data respectively. 
 
 Comparison with other studies 
Tremendous work has been done on this topic to elucidate the nature of the 
association between different classes of antihypertensive drugs and depression. I 
summarised the main studies in the literature focusing on one or multiple classes 
of antihypertensive drugs in the introductory chapter of this thesis, dedicating a 
section to each main drug class. I also compared my results with the main findings 
from these studies in the previous sections. Thus, in this sub-chapter, I shall only 
describe and discuss the studies that are similar to mine in terms of main 
objectives, outcomes and overall design. Altogether, two such cohorts published 
in recent years were found. Shaw et al. (2019) conducted a prospective cohort 
study enrolling 538,730 participants where new users of antihypertensive 
monotherapy were matched with an untreated comparator based on age, sex and 
area deprivation using a 1:1 ratio. Their study design was analogous to my 
monotherapy analysis. Eligible patients were free of antihypertensive 
prescriptions for six months, after which the antihypertensive treatment period 
started and lasted for up to 12 months, which is equivalent to the exposure period 
in my cohort. During this treatment window, the patients were on at least four 
prescriptions of antihypertensive drug monotherapy (each lasted for three 
months, so the four prescriptions covered a one-year period in total). This 
included any of the four major antihypertensive classes: CCB, BB, angiotensin 
antagonist and TZD. The patients on polytherapy were also eligible if during the 
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last 3 months of the treatment window, they received antihypertensive 
medication from two or more of the aforementioned antihypertensive drug 
classes. Patients with a prescription of psychiatric treatment during the 
antihypertensive treatment window or within the preceding 10 years were 
excluded from the cohort. The main outcome was treatment for new-onset 
depressive episodes, as indicated by the first prescription of antidepressants or 
hospital admission. The authors calculated the risk for incident depression based 
on five different time periods. Two of the most noticeable differences between 
the cohort design of Shaw et al. (2019) and mine is that my cohort lacked a control 
untreated group and the cumulative number of prescriptions during the exposure 
period in my study varied considerably between participants, with less than 25% 
having filled their prescriptions for more than 6 months and only 1.6% for the 
whole 12 months. On the other hand, as I mentioned above, Shaw et al. (2019) 
ensured that eligible participants received a consistent number of prescriptions 
covering all the antihypertensive treatment window (12 months), although this 
approach does not necessarily ensure better adherence. These methodological 
heterogeneities might create some discrepancies between my findings and those 
of Shaw et al. (2019) in several aspects. First, Shaw et al. (2019) showed that all 
monotherapy drugs were associated with a small elevated risk of incident 
depression—especially at the initial time of follow-up—a risk which declined over 
time, while I found that the risk of incident depression might be low during the 
initial period, in particular at the first two-year censoring point (data not shown), 
and might increase over time. However, this observation is likely due to the low 
number of events in my cohort during the first period, which translates to 
insufficient power to detect any statistical difference. Perhaps the low number of 
prescriptions in my cohort during the exposure period may indicate poor 
adherence, and consequently, the effect of antihypertensive drugs on depression 
was diluted. Nonetheless, the dose-response analysis showed no statistically 
significant differences in the depression incident rate for patients who had a 
higher level of cDDD compared to those who had a lower cDDD, suggesting that 
my findings are robust against this methodological approach. Second, the highest 
risk of incident depression in the study of Shaw et al. (2019) was observed among 
BB users at all time periods. This is perhaps unsurprising, knowing that the 
cardiovascular conditions of patients receiving BB as an initial drug are likely to 
be more complicated placing them at greater risk of depression than those of 
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patients newly started on CCB or RAS antagonist, the first-line therapy of 
hypertension. In the polytherapy analysis of my cohort, this problem was 
addressed by creating a sequence variable. The results showed that BB was 
associated with an elevated risk of depression; however, that was in comparison 
to ACEI, and it was only marginally significant. Finally, I also showed that 
antihypertensive polytherapy is not associated with an increased risk of 
developing depression, which also contradicts the findings of Shaw et al. (2019).  
The second investigation similar to mine consisted of a nested-case control 
population-based study conducted more recently by Kessing et al. (2020). The 
authors enrolled 5.4 million participants to investigate the association between 
41 individual antihypertensive drugs belonging to the five major classes (ACEI, 
ARB, CCB, BB and diuretics) and new-onset depression, defined as either a clinical 
diagnosis or the use of antidepressant drugs. This is the first study of its kind and 
of this size on this research subject. Kessing et al. (2020) adopted a 
methodological approach to minimise confounding by indication: they estimated 
the rate of depression during successive prescription periods of the drug, where 
the patients who had received a cumulative of three or more prescriptions of an 
antihypertensive drug were compared to a reference group, which included 
people who had only one or two prescriptions for the same drug. This method 
highlighted the bias related to confounding by indication, as patients who had one 
or two prescriptions showed increased HR of depression relative to individuals with 
a non-use period. Although this approach lowers this kind of bias to some extent, 
it can also increase other sources of bias, particularly those related to adherence 
(see Section 7.5.3). The main findings of this study revealed that neither the 5 
major classes nor the individual 41 antihypertensive drugs within these classes 
were associated with an increased risk of depression incidents. Kessing et al. 
(2020) further indicated that nine of these medications were associated with a 
reduced risk of developing depression, which were therefore suggested to be 
considered in patients at high risk of depression. It is important to note that 
Kessing et al. (2020) had only compared the risk of depression across different 
prescription periods within each individual drug. Overall, my findings generated 
from the dose-response analysis agree with these results. Nevertheless, 
antihypertensive treatment persistence and/or duration may be an important 
factor in achieving long-term benefits, which may explain the overall depression 
317 
Chapter 7: Antihypertensive drugs and risk of depression 
 
risk reduction in this study. Furthermore, given that the nine antihypertensive 
drugs recommended by Kessing et al. (2020) are from three different classes, it is 
possible that their global effect on depression was achieved through their common 
pharmacological effect on overall cardiovascular health rather than through an 
independent biological mechanism. The latter suggestion complements several 
other observations that have shown that the BP lowering effect is important in 
improving and/or reducing the risk of some neurological disorders, such as 
Alzheimer’s disease (Ding et al., 2020), dementia (Hughes et al., 2020) and 
cognitive dysfunction (Forte et al., 2019), signifying the importance of BP in 
modulating these disorders, although the role of BP in depression pathogenesis 
has been less consistent. Another possible source of discrepancy is the variation 
in the targeted population. In the Kissing et al. (2020) study, the median age the 
particpants was >60 years; however, the participants’ median age varied 
considerably across individual drugs. For example, the median age of the patients 
treated with propranolol, a candidate drug in this study, was 20 years. Those 
patients were very likely to be healthy individuals at baseline, with low severity 
or low chronicity of the treated illness. On top of that, even the type of illness 
being treated—and subsequently, the dosage regimen of propranolol—may differ 
from those in elderly patients on other antihypertensive drugs. By contrast, it 
should be stressed that the population in my study were participants attending 
hypertension clinic providing secondary and tertiary care service. From the 
clinical presentation of the participants data it can be anticipated that those 
patients are already at high risk of developing depression. They have complicated 
hypertension, multiple comorbidities, and family history of premature CVD which 
by it is self can trigger psychological stress (which is often associated with 
depressive symptoms). Altogether these complicated health condition can at least 
partly explain the higher incidence rate of depression in my cohort. Nevertheless, 
despite the potential source of bias in the current sample, given that several 
studies with different designs continued to publish contrasting results , this may 
raise the possibility that the relationship between antihypertensive drugs and 
depression may not be uniform across patients exposed to these drugs. One 
possible explanation is that the depression in CVD patients or those at high risk of 
CVD may represent a subtype of depression distinct from that in healthy 
individuals. CVD or high-risk CVD patients usually experience changes in normal 
cardiovascular function, whereby depression may stem from these pathological 
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roots. Accordingly, ameliorating and treating depressive symptoms in CVD and CVD 
high-risk populations may, in the first place, rely on controlling and effectively 
treating CVD and its potential risk factors. However, due to population 
heterogeneity across studies, it is unclear whether the reduced risk of depression 
noticed among patients receiving certain antihypertensive drug classes are due to 
an improvement in overall CVD health (such as BP, cardiac output, vascular 
resistance, cerebral perfusion, improvement of microvascular integrity and 
suppression of vascular atherosclerosis) or indeed due to a specific 
antidepressogenic activity related to the general class or to a particular 
medication within the drug class. Further investigation is required to elucidate 
the pharmacological role of different antihypertensive drugs in relation to 
depression in CVD- and CVD-free populations and whether cardiac conditions could 
evoke a distinct subtype of depression. Another reason may explain results 
discrepancies could be related to shared pathological origin between hypertension 
and depression that could facilitate or enhance the treatment of both conditions 
simultaneously. For example, extensive evidence has suggested that neuroimmune 
mechanisms, such as the hyperactivation of brain RAS and microglial neuronal 
cells, have a role in initiating and maintaining arterial hypertension (Calvillo et 
al., 2019, Hirooka, 2020, Llorens-Cortes and Touyz, 2020). In this case, agents 
acting on the RAS system may have a potential benefit over other antihypertensive 
drugs in managing hypertension. On the other hand, these neurobiological 
disruptions have been suggested to be linked to the pathogenesis of 
depression.Therefore, at least theoretically, it would be expected that patients 
with hypertension that involves the disruption of these neurobiological pathways 
are more likely to experience depressive symptoms, and therefore, 
antihypertensive agents targeting these pathways will also show some benefit 
against depression.  
 Conclusion 
Overall, my findings support the notion that different antihypertensive classes 
may have distinct effects on depression risk. The results revealed that, compared 
with ACEI, there is a class effect of other antihypertensives on the risk of 
depression and that the highest negative effect was for CCB—specifically, the 
dihydropyridine subclass. ACEI and ARB might not be equivalent in the context of 
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depression. It should be emphasised that these findings may not be generalisable 
to other more normotensive population or those who have less severe 
hypertension. Further, they should be considered as preliminary evidence and 
future research is needed. 
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 General discussion and prospects 
This chapter summarises the main findings and conclusions of this thesis, and 
addresses strengths and limitations, clinical implications and implications for 
future research. 
This thesis aimed to investigate the following: 
1- The association between depression and risk of major subtypes of CVD 
(including CHD, stroke and HF), and  
2- the association between exposure to antihypertensive drugs and risk of 
depression as indicated by the first-ever prescription of antidepressants. 
 Depression and risk of CVD 
The first objective of this thesis was to investigate the association between 
depression and three CVD subtypes: CHD, stroke and HF. I considered three 
hypotheses that potentially could further substantiate the principle that 
depression should be considered a major risk factor for CVD, similar to 
hypertension, hyperlipidaemia, diabetes and smoking: (1) depression increases 
the risk of different CVD outcomes independent of pre-existing CVD; (2) 
depression increases the risk of CVD in a dose-response manner; and (3) baseline 
depression predicts future CVD events as much as time-varying depression. The 
study design used in this thesis to test these hypotheses was based on a systematic 
review and a meta-analysis. 
 Summary of the main findings  
Figure 8-1 summarise main findings of the systematic review and meta-analysis 
study. 
Chapter 3 presented the methodological quality of the included studies and main 
methodological considerations relating to depressive symptoms screening tools 
and covariates selection. Overall, 60% of the included studies were evaluated as 
good, while the remaining were evaluated as fair. Section 8.1.1.1 discusses 
methodological issues of the included studies in more detail. 
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In Chapter 4, I examined the impact of depression on first-ever stroke in patients 
with no known history of stroke or CHD at baseline. I demonstrated that depression 
was associated with a 22% increased risk of first-ever stroke based on 19 studies. 
The estimated risk for time-varying depression was 27%, confirming the significant 
risk of baseline depressive symptoms. I also showed that age could be a potential 
modifier of the association linking depression to stroke. 
In Chapter 5, I examined 23 studies to evaluate the association between 
depression and CHD. I showed that patients who were depressed but had no CHD 
event or stroke before study initiation had a 22% increased risk of developing a 
first-ever CHD event, compared to patients who were not depressed. This 
estimated risk was slightly higher for patients with MI and angina (24% and 57%, 
respectively). Depression remains a strong predictor for future CHD events when 
it is modelled as a time-varying variable. I observed that the risk for future CHD 
was more pronounced for clinical depression than for depressive symptoms (26% 
vs 17%). There was some evidence that women with depression may have a higher 
risk of CHD than men with depression.  
In Chapter 6, I examined the association between depression and incident HF in 
patients with no known history of CVD at baseline. Only four studies were available 
to compute an effect size. I found that depression was associated with a 17% 
increased risk of HF. To my knowledge, this review is the first to assess whether 
depression is associated with increased risk of HF in the absence of other CVD 
history. The two other hypotheses, including the effect of time-varying depression 
and an assessment of dose-response relationships, could not be tested due to the 
small number of studies.  
Altogether, the current thesis provided evidence that depression associated with 
~20% increased risk of developing stroke, CHD and HF in apparently healthy 
individuals. 
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Figure 8-1 Summary of the systematic review key findings 
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 Methodological considerations 
In Chapter 3, I highlighted several methodological issues relating to depression 
screening and adjusting for covariates. Regarding depression screening, the 
various scales for depressive symptom screening differ in two important points. 
The first is that different screening scales capture depressive symptoms over 
different timeframes. Scales that asked about depressive symptoms experienced 
over the last month would obviously capture a greater duration of symptoms than 
those with a timeframe of one day, or one or two weeks, and it is unknown to 
what extent this could affect the magnitude or direction of the depression-CVD 
associations. The second point is that different screening scales differ in terms of 
the number of depressive symptoms representing each dimension of depression; 
some scales predominantly focus on specific dimensions of depression and exclude 
others. Evidence from epidemiological studies suggested that distinct type of 
depressive symptoms reflect the severity of depression status (Tolentino and 
Schmidt, 2018). Further, studies conducted among cardiac patients suggests that 
each dimension of depression is associated with a distinct effect on cardiac 
prognosis. A systematic review of 13 prospective studies with 11,128 subjects 
showed that the somatic symptom dimension, but not the cognitive symptom 
dimension, is independently associated with poor cardiac prognosis (HR = 1.19, 
95% CI, 1.10-1.29) (de Miranda Azevedo et al., 2014). More recently, Norton et al. 
(2020) found that both symptom dimensions (i.e. somatic and cognitive) are strong 
predictors of new cardiac events among heart disease patients. Norton et al. 
(2020) also suggested that specific symptoms within the somatic dimension, such 
as poor appetite/overeating and feeling like a failure for the cognitive dimension, 
are significantly associated with the main outcome. Whether the same cluster of 
symptoms can also be considered predictors for incident CVD in CVD-free 
participants has yet to be discovered. Overall, examining the association between 
n depression dimensions or specific depressive symptoms and a new-onset CVD 
event in CVD-free patients is a relatively new approach (compared to depression 
in a CVD population) that has rarely been considered in past studies. To the best 
of my knowledge, Li et al. (2019) was one of the first studies to prospectively 
investigate the impact of each individual’s depressive symptoms on CVD incidence 
among CVD-free patients. Li et al. (2019) assessed the association between 10 
depressive symptoms, identified using the 10-item CES-D scale, and incidence of 
CVD. Of the 10 symptoms, they found that restless sleep and loneliness were the 
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most significant predictors for future CVD events. However, given that the main 
outcomes were a composite endpoint and the targeted population in this study 
was elderly participants, their results may not fully generalise to individual CVD 
subtypes or to younger adults, and thus merit further investigation. Future studies 
should apply multiple measurements targeting the different dimensions of 
depression. Their findings will help clinical practice to assess depressive 
symptoms, giving special attention to specific symptoms to predict and prevent 
future CVD-related events (Norton et al., 2020). 
In Chapters 4 and 5, I identified other methodological challenges concerning the 
interpretation of inconsistent findings as a result of using different methods to 
measure depression. In the current review, depression cases were identified using 
different indicators, including SRS, clinical diagnosis and antidepressant 
prescriptions. It is plausible to expect that different depression indictors might 
give consistent results in terms of the direction of the associations in the context 
of depression and CVD incidence. A common measure of clinical depression 
involves combining participants receiving antidepressant treatment with those 
diagnosed with depression based on structured interviews to represent the 
depressed cohort. However, given that antidepressant medications have other 
clinical indications (plus the possibility that participants receiving antidepressants 
could have better treated depression), it is problematic to combine those patients 
in the depressed cohort; thus, a separate analysis to examine the impact of 
exposure to antidepressants on CVD incidence should be considered. 
The final methodological issue concerns examining a dose-response relationship 
between depression and CVD incidence. Researchers investigating the depression-
CVD field of research have been encouraged to investigate this aspect (Carney and 
Freedland, 2017, Rugulies, 2002). Although many studies have investigated a dose-
response relationship, two principal challenges hindered the practicality of 
conducting a meta-analysis. First, the cohorts used various 
parameters/indications for a ‘dose of depression’ which were dissimilar enough to 
reduce the consistency of their research findings and preclude drawing a general 
conclusion. The various indications/parameters for a dose of depression that were 
identified in this thesis include the following: number of depressive symptoms, 
level of depression severity, number of cumulative episodes, number of 
outpatients visits due to depression and responsiveness to antidepressant 
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treatment. Second, the cohorts tended to use different statistical approaches 
when generating levels of severity, for example, based on quintiles, tertiles, 
standardised cut-off scores or standard deviations. One potential reason for these 
methodological inconsistencies is that until recently there has been no clear 
consensus regarding the optimal approach to examining dose-response 
relationships. Guidance is lacking on how to evaluate and address this and provide 
a standardised strategy that directs researchers to a better application of 
different measures of depression severity. 
Table 8-1 summarises the methodological concerns and suggestions. 
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screening tools  
• Report the rationale of using the selected 
screening tool. 
• Describe the tool performance to measure 
depression, tool contents, such as type of 
symptoms, and the timeframe of the asked 
questions. 
• Standardise the timeframe of the asked 
question. 
• Consider using the optimal cut-off score 
(when depression is categorised as a binary 
variable) based on the best available 
evidence. 
• Apply multiple measurements targeting the 
different dimensions of depression and 
investigate the relation between each 





• Perform a sensitivity analysis excluding 
antidepressants users. 
• Calculate the risk estimate of a CVD event 
for each examined indicator. 
• Extract sufficient information when 
examining antidepressants as a proxy of 
depression, such as the type of 






A- Indication for 
a dose of 
depression 
• Apply multiple measurements to allow for 
direct empirical comparisons and enhance 
understanding of the fundamental 
differences between different measures of 
a dose-response relation with respect to 
CVD outcome.(a)  
• Different studies may consider adopting 
similar approaches based on previous 
compelling evidence and use of a 
comparable screening tool. 
• Measure depressive symptoms at multiple 
instants over the follow-up period and 
model depression as a time-varying 
variable 
• Consider analysing patterns of depressive 
symptoms over the follow-up period, such 
as previous history, new onset episode, 
duration of the depressive episode, 







• Consider multiple statistical approaches 
to derive increasing levels of severity (e.g. 
based on standard deviation and tertiles). 
• Consider analysing depression as a 
continuous variable and as a binary 
variable simultaneously. 
CVD, cardiovascular diseases; aModified from (Rutledge and Goulda, 2019) 
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 Strength of the review  
This review integrates study findings included in prior reviews with findings from 
the most recent prospective studies, resulting in an extremely large sample size 
and thus providing greater reliability (precision) of the estimated effects. This 
review was strict about including only studies that enrolled participants who were 
free of CHD and stroke histories at study initiation, which to some extent reduced 
the between-studies variation in terms of the baseline risk of developing CVD. This 
requirement implied that my results were unaffected by pre-existing clinically 
apparent CHD or stroke events and, therefore, findings are robust to conclude 
that depression is associated with an increased risk of CVD incidence, independent 
of previous or coexisting cardiac or stroke events. This review also examined the 
association between depression and three subtypes of CVD rather than focusing 
on a single CVD outcome. Further, I performed a meta-analysis from 14 studies 
that investigated the independent association between depression and CHD and 
depression and stroke simultaneously within the same population. Pooling of HR 
for CHD and stroke from these studies showed that depression raises the risk of 
developing CHD and stroke to approximately the same level (the corresponding 
HRs are 1.22 and 1.24), which supports the primary findings of the present review. 
Finally, unlike past reviews, I not only computed a summary effect size, but I also 
shed light on some methodological issues related to depression measures and 
provided suggestions that need to be considered in future epidemiological studies. 
 Limitation of the review  
Several limitations of this meta-analysis should be considered. First, the search 
strategy of my review covers four databases: MEDLINE, Embase, Web of Science 
and PsycINFO. However, despite Bramer et al. (2017) recommendation, I did not 
use Google Scholar in addition to these four databases to ensure an efficient 
coverage of systematic reviews. Additionally, due to the massive volume of 
citations generated from the four databases and time constraints, I did not search 
for grey literature. Nonetheless, my search covered all studies included in the 
latest reviews (Barlinn et al., 2015, Gan et al., 2014, Li et al., 2015a, Wu and 
Kling, 2016) that were published after 2004. Further, I used a wider variety of 
search terms compared to previous reviews. Moreover, where possible, I 
contacted the primary or secondary author of the respective studies, although not 
328 
Chapter 8: General discussion 
 
many responded. I also considered abstracts if they contained the required 
information. Although abstracts may affect the precision of the estimated effect, 
I performed a sensitivity analysis excluding abstract study and results were 
consistent with the primary analysis. Second, my eligibility criteria were limited 
to a particular period (i.e. after 2004) and to studies published in English. Third, 
I only included studies that measured depression as a binary variable where 
patients should be dichotomised as ‘with or without depression/depressive 
symptomatology’ and excluded studies that measured depression as a continuous 
variable. Although this is likely to generate more homogenous results, there are 
some caveats regarding a binary measure of depression. According to Zigmond and 
Snaith (1983), in general, psychiatric disorders cannot be considered as either 
‘present’ or ‘absent’ as the degree of distress is continuously distributed in the 
population. They proposed that measuring ‘how much depressive symptoms’ 
would be more relevant than measuring their presence or absence. Therefore, 
studies that measured depressive symptoms as a continuous variable may be closer 
to clinical reality than those that provided dichotomous measures. In addition, 
binary measures tend to conceal any linear relationship between the variable and 
the outcome (Altman and Royston, 2006). In the current context, this means that 
depression severity was not considered by studies that measured depression as a 
binary variable. Establishing a relationship between depression severity and CVD 
will provide a solid evidence base so that depression can be compared easily with 
the classical risk factors of CVD. Fourth, because in some cases there is no known 
recognised cut-off point for a certain SRS, one of the undesirable methodological 
consequences is that researchers are compelled to derive arbitrary cut-off points 
to dichotomise patients. In these cases, the results may not be generalisable to 
other populations. However, in the present review, relatively few studies (n = 2) 
adopted this approach, and the majority used a common or an optimal cut-off 
score to identify patients with depressive symptomatology. Fifth, the majority of 
studies included in this review were not designed to evaluate a dose-response 
relationship between depression and CVD outcomes. Additionally, even the few 
studies that provided such information used diverse methods to examine a dose-
response relationship, which hampered meta-analysis of their findings. Finally, 
the functional limitation of the software used for this review. RevMan, is not built 
to run certain analyses. For example, investigating the possible risk of publication 
bias in RevMan can only be done via a visual inspection of the funnel plot, since 
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other statistical methods such as Eager test or trim-fill method are not supported. 
Furthermore, meta-regression analysis, which enables the investigation of the 
influence of modifiers or covariates on the effect size, is not implemented in 
RevMan. However, in any case, this kind of test was not a good option for my 
analysis because meta-regression requires a minimum of 10 studies for each 
covariate to produce reliable results (Higgins and Green, 2011) and I included 
fewer studies for each possible modifier. On balance, the subgroup analyses that 
I conducted in this study should meet my requirements to assess the modifier 
variables. 
 Antihypertensive drugs and risk of depression 
 Summary of the main findings 
In Chapter 7, I investigated the association between antihypertensive drugs and 
the risk of incident depression by applying different study designs. Findings 
emerging from these studies were consistent, showing that among the five drug 
classes, CCB, in particular dihydropyridine, is associated with an increased risk of 
incident depression compared to ACEI. I also explored a dose-response relationship 
between the cDDD of antihypertensive drugs and depression and showed that 
higher doses of ARB therapy were marginally associated with the risk of incident 
depression.  
 Study strengths and limitations of the GBPC cohort 
The main strengths of the GBPC cohort study include the large cohort size 
conducted in real-life settings with global healthcare records obtained through 
the electronic linkage; long duration of follow-up; large number of events; and 
availability of refill prescription data. My study has further expanded the previous 
work based on recommendations from the latest research. It also gained an 
advantage over past studies in terms of the multiple study designs that were used 
to investigate the antihypertensive-depression relationship. The study’s main 
objectives were not limited to detecting the class of antihypertensive medications 
associated with depression, but also providing information on a dose-response 
relationship between antihypertensive medications and depression. Furthermore, 
the design of the monotherapy cohort study created a fixed period of exposure 
(i.e., one year), standardising the exposure duration for all study participants. I 
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also provided risk estimates for ARB and ACEI separately, which has rarely been 
considered in prior studies. Further, I limited the monotherapy analysis to 
participants without a history of CVD and excluded those who developed CVD 
during the exposure period and obtained a consistent risk estimate, suggesting 
that confounding due to CVD as an indication for antihypertensive treatment did 
not alter the aggregate findings. Finally, although the data were derived from one 
population, two different study designs and analyses were used and results were 
very similar serving to increase the internal and external validity of the findings. 
There are, however, several limitations that should be considered. The 
observational design precludes us from drawing conclusions regarding causality 
between antihypertensive medications and depression. A primary disadvantage of 
the GBPC cohort is that I was unable to examine an “antihypertensives-free” 
cohort and follow them up prospectively to compare depression outcomes 
between patients who were treated with antihypertensives and those who were 
not. Furthermore, patients in the GBPC cohort were confined to secondary and 
tertiary care hypertension clinic in the West of Scotland. Thus, my results may not 
be generalisable to other apparently healthy normotensive populations, or indeed 
less severely hypertensive patients. Residual confounders may provide an 
alternative explanation. For example, particpants in the GBPC are likely to have 
resistance hypertension, being multimorbid and have family history of CVD. 
Although I adjusted for the CCI, which has been widely used in clinical practice to 
adjust for comorbidities, it has been suggested that this confounding tool may be 
insufficient to control for comorbidities. As a result, relying solely on the CCI may 
result in considerable residual confounding (Renson and Bjurlin, 2019), and 
therefore biased results and conclusions. Another example is the socioeconomic 
status of particpants. The GBPC study has no data on the socioeconomic status of 
the included participants, so I was unable to adjust for this variable in the analysis. 
The association between socioeconomic status and depression is well documented 
by several studies (Freeman et al., 2016, Lorant et al., 2007, Lorant et al., 2003). 
Lockhart and Guthrie (2011) conducted a prospective cohort study to examine the 
prescribing pattern of antidepressants in a primary care facility in the Tayside 
region of Scotland. The study measured the socioeconomic status for patients 
using the postcode-assigned Scottish Index of Multiple Deprivation (SIMD), which 
was divided into quintiles, with the first quintile representing the least deprived 
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area and the fifth quantile representing the most deprived area. The study found 
no consistent gradient of either antidepressant use or increases in antidepressant 
use by the SIMD. Additionally, increased prescribed use of antidepressants was 
experienced by all socioeconomic groups. Perhaps this may indicate that the 
socioeconomic factors may explain only a small proportion of the association in 
this population, including the population of this study. 
It is important to emphasise that confounding by indication is difficult or even 
impossible to avoid in pharmaco-epidemiological work. This is one of the key 
confounders in this study for two reasons. First, my population is hypertensive, 
which could be the primary trigger of depression. Second, the diverse indications 
of antihypertensive medications include cardiac indications. This is problematic 
when investigating the association between antihypertensive medications and 
depression in a population with established CVD, as it is very likely that the result 
could be confounded by the cardiovascular indication of antihypertensive drugs. 
However, as aforementioned, I excluded patients with a history of CVD, and the 
results were unchanged. Further, in the monotherapy analysis, the mean age of 
patients started on CCB was 52 years, which is below the recommended age to 
initiate CCB (55 years) according to the hypertension guidelines. This may indicate 
that those patients treated with CCB had more severe cardiac conditions than 
patients treated with ACEI. As a consequence, the significant association observed 
between CCB and incident depression may reflect CVD severity at baseline. 
However, this problem of sequencing was overcome in the polytherapy analysis, 
and findings from both analyses were consistent. Nevertheless, given that  
In the monotherapy analysis, the main “exposure” (i.e., antihypertensive 
medication) was not measured as a time-varying variable. Patients with 
hypertension often require multiple medications, switching medications and 
titrating the doses to control their hypertension. Cox proportional analysis based 
only on baseline measures would mean that I used a very limited part of the 
information that is contained in the history of using certain antihypertensive drugs 
and thereby introduced a bias (Stricker and Stijnen, 2010). Moreover, the DDD was 
categorised into three groups based on tertiles and the comparison was performed 
between the lowest and the highest tertile of DDD. The cut-off points for these 
groups are statistically driven and may have little clinical meaning. 
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Depression cases were identified using prescription data of antidepressants from 
the ISD; however, additional information about what actual conditions 
antidepressants have been prescribed for was not available. Antidepressant 
medications are known to be used for other conditions with proven benefits, such 
as chronic pain.. The ISD annual report, “Prescribing in Mental Health,” provides 
summary information on antidepressant use in Scottish Health Boards during the 
period 2003/04 up to 2012/13 (Information Service Division, 2013), which is 
compatible with the follow-up period in the GBPC cohort. It was reported that the 
number of prescriptions dispensed for low doses of amitriptyline tablets (a TCA 
medication) increased from 26.4% of dispensed items in 2003/04 to 49.8% by 
2012/13, whereas prescription of higher doses of amitriptyline tablets declined 
from 46.9% to 31.2% of dispensed items. According to the prescribing guidance of 
the British National Formulary, lower doses of amitriptyline are not recommended 
for treating depression; instead, they are being used to treat a range of largely 
unlicensed but recommended indications, such as neuropathic pain and migraine 
prophylaxis (Information Service Division, 2013). Based on this information, it can 
be inferred that a change in practice has occurred with amitriptyline being used 
to treat indications other than depression (Information Service Division, 2013). 
Therefore, it is very likely that the current study suffers from bias due to 
misclassification of the outcome, although the extent to which it affects my 
results cannot be determined. Besides, I showed in the meta-analysis chapters (4 
and 5) that antidepressants may not be a reliable proxy to identify depressed cases 
and results could vary if depression measured using clinical diagnostic criteria. 
The aim of this cohort study was to investigate whether there was an association 
between exposure to different antihypertensive medications and depression. 
Approximately more than 75% of the population had received antihypertensive 
treatment for less than or equal to six months during the exposure period. This 
might indicate that those patients had poor adherence behaviour. Alternatively, 
given that the time window for the exposure duration in the current study is 
relatively short (i.e., only one year), the initial therapeutic plan for those patients 
might have been for short-term treatment only. Shaw et al. (2019) suggested that 
the effect of antihypertensive medications on MDD is likely to vary with time. 
Another cross-sectional study proposed that initiation of antihypertensive 
medication in newly diagnosed hypertensive patients significantly improved 
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depression and other psychological scores after three months of treatment (Korosi 
et al., 2017). These findings suggest that the effect of antihypertensives may 
indeed vary with time and, perhaps, that there is a therapeutic (or harmful) 
window, depending on the dose or the length of the exposure. Accordingly, the 
results obtained from this study may not be an accurate reflection of the actual 
effect of antihypertensive medication over a one-year period. 
 Clinical implications 
 Depression and CVD 
Patients with depression are at a considerable risk of developing CVD, particularly 
CHD, stroke and HF (likely 1 in 5 will develop CVD) in the absence of a known 
history of a CVD event. The risk imposed by depression on CVD might be similar to 
a transient episode of depression with minor symptoms and with cumulative 
severe episodes. Detecting depression is not as easy a task as identifying other 
major risk factors of CVD, such as hypertension or diabetes. Therefore, it is 
important that clinicians increase their efforts to detect depression in its early 
phase, as the impact and consequences of depression onset might be more severe 
in some groups of patients, including adults at young and middle ages (< 65 years) 
and women. 
 Hypertension, antihypertensive drugs and depression 
Elevated BP is the most important modifiable risk factor for premature death 
worldwide. There are multiple drugs available for the treatment of high BP and 
the effect of these drugs on mortality and incident CVD has been evaluated in 
numerous RCTs and summarised in several systematic reviews and meta-analyses. 
All major systematic reviews agree that antihypertensive treatment is associated 
with reduced risk of death and CVD for an SBP of 140 mm Hg or higher and all 
guidelines recommend commencing these patients on treatment. In this context, 
if antihypertensive therapy induces depression it will have an adverse impact on 
hypertension control as depression, especially unrecognised depression may have 
a major impact on antihypertensive drug adherence and BP control with a 
detrimental effect on cardiovascular risk and mortality. Thus, understanding the 
impact of antihypertensive therapy on depression is crucial both from a public 
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health perspective in reducing the population burden of CVD and also from the 
patient perspective with the adverse impact on depression on quality of life. 
My findings suggest that dihydropyridine CCB drugs may place hypertensive 
patients at a greater risk of developing depression compared to ACEI drugs, 
although the generalisability of this finding may be limited to a high-risk CVD 
population. As recommended by the current guidelines for hypertension treatment 
and CVD prevention, CCB is one of the initial drugs that should be used to manage 
hypertension, making the prescription of these medications highly prevalent. 
Therefore, despite the limited generalisability of the current findings, it is 
important that clinicians are aware of possible neuropsychiatric adverse events of 
CCBs. They may need to evaluate mental health while prescribing CCB to 
hypertensive patients, particularly those with established CVD. This is primarily 
because depression in such patients becomes an important factor that requires 
routine screening to prevent any negative impact on quality of life and possible 
gains in morbidity and mortality. Furthermore, the current study proposed that 
high doses of ARB may make patients more susceptible to developing depression. 
While this finding should be considered preliminary evidence that merits further 
investigation, it suggests that evaluation of the patient’s mental health at each 
stage of dose titration may have to be considered, and adjustment of the dosage 
regimen should be made if medication adverse effects in mood are suspected. 
Guidelines on hypertension management should also consider neuropsychiatric 
side effects of antihypertensive drugs and alternative treatments in those at high 
risk of depression. Lastly, as the diagnosis of depression may not be easy or 
straightforward in physically ill patients, patients treated with antihypertensive 
drugs should be encouraged to report depression-related symptoms even if they 
think, from their perspective, that they stem from physical discomfort. 
 Implication for future research 
It has been two decades since the first systematic review was published revealing 
a positive association between depression and a single CVD subtypes (Rugulies, 
2002). The first review was followed by 10 reviews, including my study. 
Nevertheless, despite the observed improvement in the precision of the estimated 
risk of depression, additional new science to the literature provided by these 
reviews does not go beyond quantifying an effect size of depression risk as a single 
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diagnostic entity. The inability of systematic reviews to further expand the 
knowledge base on depression-CVD relationships indicates a paucity of new 
primary research in this area. Future studies should examine the dynamic aspects 
of depressive symptoms over the follow-up period relating to CVD and subclinical 
CVD. In the following section, I outline some research gaps that need to be 
addressed by future studies based on the findings presented in this thesis and 
regarding what I have identified in the literature through reviewing studies for 
eligibility. 
 Remission/Previous history 
The majority of studies that established a relationship between depression and 
CVD incidence relied on a single baseline measurement of depression, which 
reflects an active (i.e. ongoing) or a new onset episode. In the current evidence 
base, it is not clear whether a previous history or a remitted depressive episode 
would carry the same risk on CVD outcomes as a baseline status of depressive 
symptoms. Few studies in the literature have examined such a possibility, and 
where this has been done the findings are inconsistent. For example, Pan et al. 
(2011a) in the Nurses’ Health Study cohort showed that women who reported a 
current depression episode had a 41% increased risk of developing a stroke (HR = 
1.41, 95% CI, 1.18, 1.67), while those who only had a past history of depression 
were at a non-significant elevated risk (HR = 1.23, 95% CI, 0.97–1.56). However, 
Daskalopoulou et al. (2016) found that the risk of developing CVD was similar for 
a previous history and new onset depression. Remission of depressive symptoms 
has been proposed as a potential predictor of lower incidents of second cardiac 
events and mortality in post hoc analyses of RCTs that investigated the impact of 
depression treatment on poor prognoses in cardiac patients (see Section 1.1.7). In 
light of this evidence, it would be expected that in a CVD-free patient, a past 
depressive episode that was completely remitted is not associated with an 
elevated risk of developing CVD. However, the opposite could be also possible 
where the pathological consequences stimulated by one depressive episode might 
persist regardless of the episode going into a remission status through treatment 
(Baune et al., 2012). However, limited evidence in the literature is available to 
support either notion.  
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Seldenrijk et al. (2015) investigated six-year associations between depression and 
newly developed CVD in 2,510 CVD-free participants in the Netherlands Study of 
Depression and Anxiety. The investigators found that compared to non-depressed 
participants, patients with current or remitted depression did not have an 
increased risk of developing a new CVD event. By contrast, Gilsanz et al. (2015) 
recruited 16,178 participants from the Health and Retirement Study, who were 
free from stroke at study entry and showed that a new-onset depressive episode 
is not associated with increased risk of developing stroke over a four year of 
follow-up, unlike a remitted episode which was associated with a 66% increased 
risk of stroke incident (HR = 1.66, 95% CI, 1.22, 2.26). More recently, Gilsanz et 
al. (2017) suggested that neither a new-onset nor a remitted depressive episode 
is associated with incident stroke during the year following two consecutive annual 
assessments of depressive symptoms. Notably, the two later studies examined 
stroke outcomes over a relatively short period, which restricted their findings. 
Further, other factors should be considered when studying depression remission. 
For example, whether the remitted episode was treated or untreated and, if it 
was treated, whether the intervention was introduced at an early phase or at an 
advanced phase of the episode, identifying how each could affect the 
development of CVD outcomes. It is not uncommon that participants may remit 
before receiving an intervention, and this period could last up to a year. In a 
systematic review of 19 studies, Whiteford et al. (2013) investigated the 
proportion of prevalent cases of untreated major depression that will remit 
without treatment in a year and examined whether remission rates vary by 
disorder severity. Untreated depressed cases were drawn from consenting wait-
list and primary-care samples. Depression in this study was identified based on 
either clinical diagnosis or cases that exceeded the thresholds score on a 
standardised SRS (Whiteford et al., 2013). The main findings were that 23% of 
untreated depressed patients remitted within three months, 32% within six months 
and 53% within 12 months. An inverse association between remission rate and 
severity was also reported (Whiteford et al., 2013). Another study showed that 
62% of patients with MDD were found to be still depressed after five months from 
the baseline assessment, suggesting that depression cannot in all cases be 
considered a self-limiting disorder (Penninx et al., 2001). The pathological damage 
that is imposed by depression if untreated could occur before symptoms are 
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completely remitted and is in some cases irreversible (e.g. early onset depression 
[patients ≤ 21 years]) (Schmaal et al., 2016). Another factor that may also be 
considered is the duration of an episode. Epidemiological data have shown that 
the probability of recovery from an episode declines with increasing episode 
duration (Patten, 2006). This factor might also be considered a possible measure 
to determine a dose-response relationship between depression and CVD.  
Future research on how changes in depressive symptoms influence CVD-related 
outcomes should consider whether any significant differences exist between 
different lengths of depressive episode duration, treated and untreated previous, 
but dormant, history of depressive episode and whether the timing of medical 
intervention modifies the relation. An RCT is the ideal study design to answer 
these questions; however, due to ethical constraints preventing randomising 
depressed participants to remain untreated, observational studies should be 
considered. 
 Relapse/Recurrence 
A relapse or recurrence of depression could be an important sign of a distinct 
biological profile of a MDD subtype. Patients experiencing recurrent depressive 
episodes may strongly deviate from healthy individuals in terms of the 
pathophysiological and genetic aspects (Lok, 2013). Schmaal et al. (2016) 
demonstrated that the morphological structures of the brain can be potentially 
changed in a detrimental way with depression recurrence, which may also be a 
sign of severity. In relation to CVD, few past studies have included this patient 
group, though findings from these studies were consistent, suggesting that a 
history of recurrent depression, but not a single lifetime of a depressive episode, 
is associated with increased risk of subclinical CVD and CVD events (Jones et al., 
2003, Seldenrijk et al., 2015, Wagner et al., 2009, Windle and Windle, 2013). 
However, most literature in this area is significantly limited by the paucity of 
prospective studies and by studies targeting a selected group of the population. 
Future studies aiming to investigate a dose-response relation could consider 
measuring recurrent depression as a proxy for depression severity. It would also 
be worth examining whether any pleiotropic genetic variants contribute to both 
major recurrent depression and CVD. 
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 Depression subtype and risk of incident CVD 
Most studies in the literature examined depression as a single diagnostic entity 
irrespective of its subtypes (Baune et al., 2012). However, it remains unclear 
whether there are any depression subtype-specific associations. In a 
comprehensive systematic review, Baune et al. (2012) examined possible 
biological mechanisms implicated in the association between depression and CVD. 
The authors suggested that different depression subtypes may increase the risk of 
developing CVD via distinct biological mechanisms such as immune activation and 
HPA axis hyperactivation, which could also explain the differences in the strength 
of the associations between specific subtypes of depression and CVD. To my 
knowledge, only two studies were published between 2005 and 2020 investigating 
the longitudinal association between depression subtypes and the incidence of 
CVD. The first study, which was carried out by Case et al. (2018), enrolled 28,726 
adults who were initially free of CVD. The authors examined the risk associated 
with MDD, typical depression, atypical depression, dysthymia and double 
depression (defined as a history of both lifetime dysthymic disorder and MDD) 
compared to a control group with no known history of depression. The findings 
showed that compared to the control group, all depression subtypes had a 
statistically significant association with incident CVD; however, the odds of 
incident CVD were more pronounced for atypical depression (OR = 2.19, 95% CI, 
1.71, 2.81) and double depression (OR = 2.17, 95% CI, 1.92, 2.45). Other studies 
in the literature examining the cross-sectional association between atypical 
depression and prevalent CVD reported inconsistent findings (Brailean et al., 2020, 
Niranjan et al., 2012, Vogelzangs et al., 2010), which merits further exploration.  
The second prospective study was conducted more recently by Rantanen et al. 
(2020a) among 2,522 patients with elevated CVD risk. The authors classified the 
patients into three groups, including subjects with and without non-melancholic 
depressive symptoms and a control group of subjects with no depressive 
symptoms. Compared to the control group, only non-melancholic depressive 
symptoms were found to be strong predictors of CVD incidents (IRR = 1.69, 95% CI, 
1.23, 2.31). The authors further stratified the analysis based on CVD subtypes, 
and the results remained statistically significant with CHD, stroke and PVD. This 
is a useful avenue for further research assessing depressive subtypes in relation to 
different CVD subtypes. Future research should thus take into consideration 
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possible biological and genetic mechanisms that might be involved in the 
pathological pathways to enhance clinical services to detect, treat and prevent 
premature CVD. 
 The effect of antidepressant treatment on incident/ complication of 
CVD 
As previously described in the introduction (see section 1.1.7), the effect of 
antidepressants on CVD is still a controversial issue. There is huge uncertainty 
about how antidepressant can influence CVD. Evidence are mixed showing both 
negative and positive results. Despite the optimistic findings that were recently 
published by Kim et al. (2018) and Lavoie et al. (2018), which showed that 
antidepressants may be cardio-protective, there are also several pre-clinical 
reports revealing that certain drugs within the SSRI, first-line antidepressants drug 
class, can promote the pathophysiological cascade of CVD development (Rami et 
al., 2018, Shively et al., 2015, Ungvari et al., 2019). The later could partly justify 
the failure of several RCTs to report any significant risk reduction toward CVD 
endpoint, despite the noticeable improvement in depressive symptoms as treated 
by antidepressants (Berkman et al., 2003, Glassman et al., 2002a, van Melle et 
al., 2007, Zuidersma et al., 2013). Future studies should prospectively evaluate 
the association between antidepressants drugs, particularly the first line 
medications, and subclinical endpoints of CVD. Further, because the association 
between depression and CVD is currently well established, discovery of new 
treatment that can target the complex interplay between these disorders might 
be valuable in clinical practice as a new therapeutic approach. 
 Antihypertensive drugs and depression 
At present, the available evidence examining iatrogenic depression as a 
consequence of antihypertensive drugs is limited to the incidence of depression. 
If depression is an adverse drug reaction of certain medications, then it is plausible 
to expect recurrent episodes of depression with the continuous use of these 
medications. Therefore, future studies with long-term follow-up exploring the 
trajectory of depressive symptoms among antihypertensive drug users are needed. 
These could also be done with the aid of technology, whereby patients can be 
advised to self-report depressive symptoms over scheduled secessions, which can 
enhance the number of observations over the follow-up period and ensure that 
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different levels of depressive symptom severity are captured. Moreover, most of 
the previous studies on the association between antihypertensive drugs and 
incident depression compared antihypertensive drug users with non-users (or with 
short-term users). This approach makes it difficult to separate the effect on 
depression risk of antihypertensive drugs from the effect of the chronic underlying 
CVD condition. Future studies can minimise bias due to confounding by indication 
and be more specific in investigating the effect of antihypertensive drugs based 
on baseline CVD conditions (i.e., antihypertensive users without CVD vs. 
antihypertensive users with CVD). This would enable researchers to evaluate the 
association of antihypertensive drugs and incident depression in a subgroup of 
patients with normal cardiovascular health and compare the effect of 
antihypertensive drugs to those of patients with cardiovascular problems, as 
evidence suggested that the effect of treatment might be only present in patients 
with the condition being treated (Agustini et al., 2020). It would also be beneficial 
to explore whether an improvement in cardiovascular functions by 
antihypertensive drugs would also contribute to a reduced risk of incident 
depression. Lastly, because clinical judgment should be based on medical 
evidence obtained through robust scientific research, a well-designed RCT will be 
the only solution that can provide a clear answer to whether repurposing 
antihypertensive drugs, particularly those that have strong support from the 
literature such as RAS agents, would bring any significant clinical benefit in the 
depression context.  
 Conclusion 
In conclusion, I investigated the association between baseline depression, time-
varying depression, and the incidence of CVD outcomes within a CVD-free 
population. Overall, I provided robust evidence that baseline depression imposes 
a similar level of risk across different CVD subtypes, including CHD, stroke, and 
HF, independent of other major risk factors of CVD. The strong contribution of 
depression to first-ever HF demonstrated here within a CVD-free population should 
encourage researchers to investigate the biological factors involved in 
pathological pathways linking the two conditions. Time-varying depression was 
also a strong predictor for CHD and stroke incidents, although further study is 
warranted to verify this finding and investigate its effects in relation to HF. I also 
identified several important methodological issues limiting the practicality of a 
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meta-analysis in investigating a dose-response relationship between depression 
and CVD, and I provided suggestions for future epidemiological studies. 
Furthermore, I investigated the association between antihypertensive drug classes 
and incident depression. Among the five major classes, dihydropyridine CCB 
therapy could carry a greater risk of incident depression compared to ACEI 
therapy. However, due to the overall limitation and the limited generalisability of 
the current study, these findings should be considered with caution and 
antihypertensive drugs should continue to be used by clinicians as recommended 
by the current guidelines for hypertension treatment and CVD prevention, bearing 
in mind the possible neuropsychiatric adverse effects of these drugs. 
Overall, this thesis further supports the bidirectional association notion between 
depression and CVD. Clinicians, including cardiologists, psychiatrists, and other 
relevant stakeholders, such as clinical guidelines and policy writers, should make 
a collaborative effort to ensure the adoption of the best clinical practice for 






Appendix 1: Systematic review protocol(1) 
Review title Depression associated with first incidence of cardiovascular disease (CVD): A systematic 
review and meta-analysis 
First reviewer Anwar Alnakhli 
Review team Prof Sandosh Padmanabhan 
Prof Daniel Smith 
Mohammed Ba-zuhair 
Nur Aishah Che Roos 
Search strategy • The search was applied to four databases: Medical Literature Analysis and Retrieval 
System Online (MEDLINE [OVID], from 2005 onwards), Excerpta Medica Database (EMBASE 
[OVID] from 2005 onwards), Web of Science (from 2005 onward) and Psychological 
Information Database (PsycINFO, from 2005 onwards). 
• The reference lists of the most relevant papers and reviews were searched manually to 
identify any relevant study not detected by the electronic search. 
• The search was limited to the period after 2004 and studies written in English. 
Inclusion criteria • Participants: Adult population of men and women aged 18 years old and over and with 
no history of ischemic heart disease (IHD) or cerebrovascular disease (CBVD) at the time 
of study initiation. 
• Exposure: Participants diagnosed with depression, which refers to major depression, 
clinical depression, depressive disorder, depressive mood and depressive symptoms. A 
screening or diagnosis strategy for measuring depression was prospectively performed at 
baseline and included a standard-self report questionnaire, a structured clinical 
diagnostic interview, and/or a physician/clinical diagnosis. 
• Comparator: Eligible studies are required to have a control group of participants with 
no depression at the time of the study initiation. 
• Outcome: First-ever CVD during the follow-up period divided into three groups, based 
on the 10th Revision of the International Classification of Diseases (ICD-10): (a) ischaemic 
heart diseases (ICD-10 code I20-I25); (b) cerebrovascular disease (stroke) (ICD-10 code 
I60-I69); (c) heart failure (ICD-code 150). 
• Study design: Prospective cohort studies. 
Exclusion criteria • Participants <18 years with history of CHD or stroke at study entry and participants 
diagnosed with bipolar depressive disorder. 
• Depression combined with other mood disorders, such as anxiety, screening or diagnostic 
strategy, non-specifically measured depression (e.g. measures anxiety alone or other 
generalised psychological distress). 
• CVD outcome was reported as a combined endpoint or not prespecified in the inclusion 
criteria. 
• The study had no control group of participants without depression. 
Review method • Study selection: The first reviewer (AA) conducted abstract screening and assessment of 
full texts. Two reviewers (MB & NC) checked 20% of the excluded studies. Uncertainty 
was resolved through discussions with supervisors (SP and DS). 
• Data extraction: Two reviewers (AA and MB) independently extracted data in detail from 
the eligible studies. 
• Data items: (1) name of the first author; (2) year of publication; (3) study location; (4) 
study design; (5) sample size; (6) characteristics of study population at baseline (i.e. 
mean age in years and percentage of males); (7) duration of follow-up; (8) definition of 
depression (cut-off point); (9) measurement of depression; (10) type of outcomes; (11) 
number of cases; (12) measurement method of the outcomes; (13) covariates that were 
adjusted in the multivariable analysis; and (14) most fully adjusted RR or HR with the 
corresponding 95% CI. 
• Assessment of risk of bias: AA assessed the methodological quality of potential studies 
by using the Newcastle-Ottawa scale for cohort studies. 
• Data synthesis: Statistical analysis using RevMan 5.3 for the outcomes. The model for 
the meta-analysis was a random-effect model or fixed-effect model if data are 
sufficiently homogenous. 
• Sensitivity and subgroup analyses: Based on previous reviews and data availability, 
subgroup analyses were done for the following:  
➢ Participant’s characteristics (i.e. age and sex) 
➢ Type of assessment of depression (clinical depression and depressive 
symptoms), depression measure, inclusion of antidepressants. 
➢ Definition of the outcome 
➢ Essential characteristics of the selected studies, including subgroups 
stratified by the length of follow-up, adjustments of confounders 




CVD, cardiovascular diseases; IHD, Ischemic heart diseases;  
(1) Systematic review registered in PROSPERO available at 
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=94605 
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of the exposed 
cohort 
Somewhat 
representative of the 
average in the 
community 
* 
The study focused on primary 
care elderly adults of men 
and women aged ≥60 years on 
urban public health 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
The study used medical 
records and NDI exclusion of 
participants with CVD 




Study controls for 
age/sex 
Yes * Age, sex race, diabetes, HTN, 
history of smoking, 
cholesterol, and ideal body 
weight 
2 
Study controls for at 









by secure records 
* 
Outcome were determined 
using data from the National 
Death Index (NDI) and medical 
records 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes 
* 
Follow-up period was for 15 
years 
3 
Adequacy of follow 
up of cohorts 
Follow up rate had not 
reported 
0 No statement about attrition 
rate 
Total     7  
 
(Brunner et al., 2014) 





of the exposed cohort 
Cohort was somewhat 
representative of the 
average population 
0 
Civil servants aged 35-55 years 
in 20 London based 
department 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







The study used GHQ-30 ≥ 5 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
No 0 
Data regarding baseline 
characteristics of included 
participants were extracted 




Study controls for 
age/sex 
Yes * 
Age, sex, and ethnicity 
2 
Study controls for at 









by secure records 
* 
Self-reported confirmed by 
using medical records, GP 
confirmation and death 
certificate 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 





Adequacy of follow up 
of cohorts 
Complete follow up - 
all subjects accounted 
for 
* Follow-up was completed for 
99.9% 
Total     5  
 
(Daskalopoulou et al., 2016) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* 
Cohort recruited participants 
from 225 general practices 
including men and women 
aged 30 years or older 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 






Depressed participants were 
identified by using medical 




outcome of interest 
was not present at 
start of study 
Yes * 
Study used participant’s 
medical record to exclude CVD 




Study controls for 
age/sex 
Yes * 
Age, sex, smoking, SBP, 
diabetes, cholesterol, and 
socio-economic status 
2 
Study controls for at 









by secure records * 
Cardiac events were identified 
using medical records or death 
certificates 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up period was for 13 
years 
3 
Adequacy of follow up 
of cohorts 
Not reported  0 No statement about attrition 
rate 
Total     8  
 
(Davidson et al., 2009) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* 
Targeted population consisted 
of all noninstitutionalized 
adult participants aged 
between 18-98 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







Exposure identified using 
20-item CES-D ≥10 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 





Study controls for 
age/sex 
Yes * 
Age, gender, and Framingham 
risk score 
2 
Study controls for at 













Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up was for 10 years 
3 
Adequacy of follow up 
of cohorts 
Complete follow up * 100% completed the follow-up 




(Everson-Rose et al., 2014) 





the exposed cohort 
Cohort was somewhat 
representative of the 
average population 
* 
Cohort was a population-based 
study men and women aged 
45-85 years recruited from 6 
fields centres 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
The cohort demonstrated that 
participants at baseline were 





Study controls for 
age/sex 
Yes * 
Age, race, sex, education and 
study site, systolic blood 
pressure, alcohol use, smoking 
status, moderate and vigorous 
physical activity, BMI, height, 
use of anti-hypertensives, 
diabetes/fasting blood glucose 
status, high density 
lipoprotein cholesterol, and 
triglycerides 
2 
Study controls for at 









by independent blind 
assessment * 
Incidence of the event was 
assessed by reviewing all 
medical records by two 
independent reviewers who 
were blinded to the study data 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up was for 12 years 
3 
Adequacy of follow up 
of cohorts 
Not reported  0 No statement about attrition 
rate 
Total     7  
 
(Gafarov et al., 2013) 





the exposed cohort 
Cohort was selected 
group of users 0 
Cohort was a random 
representative sample of 
women aged 25-64 years  
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







The study used 15-item MOPSY 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
The cohort demonstrated that 
participants at baseline were 
free of participants at baseline 
were free of HTN, CBVD, MI, 
CAD, MI and diabetes but not 
reported how they were 




Study controls for 
age/sex 
Yes * 
Age and sex 
2 
Study controls for at 









by secure records 
* 
Incidence of the event was 
confirmed by means of 
examination, reviewing 
medical records, card and 
death certificates 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * The follow-up was for 16 years  
3 
Adequacy of follow up 
of cohorts 
Complete follow-up * Almost 100% completed the 
follow-up 
Total     6  
 
(Gump et al., 2005) 
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the exposed cohort 
Cohort was selected 
group of users 
0 Men who had above average 
risk of CHD because of high 
blood pressure, elevated blood 
cholesterol levels, and/or 
cigarette smoking 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







Exposure identified using 20-
item CES-D ≥16 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Data regarding stroke at 





Study controls for 
age/sex 
Yes 
* Age, intervention group, race, 
educational attainment, 
smoking at baseline and visit 6, 
trial averaged SBP, alcohol 
consumption, and fasting 
cholesterol, as well as the 
occurrence of nonfatal 
cardiovascular events during 
the trial. 
2 
Study controls for at 










by secure records 
* 
National Death Index 
or Social Security 
Administration files. cause of 
death determined by 
death certificates 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up duration was for 18 
years 
3 
Adequacy of follow up 
of cohorts 
Subjects lost to follow 
up unlikely to introduce 
bias 
* follow-up was 
for >90%  
Total     7  
 
(Gustad et al., 2013) 





the exposed cohort 
Cohort was somewhat 
representative of the 
average population 
* 
Cohort was a population-based 
study including adult men and 
women 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
Only CVD free participants at 




Study controls for 
age/sex 
Yes * 
Age, sex, marital status, 
education, smoking, physical 
activity, BMI, total cholesterol, 
diabetes mellitus and systolic 
BP 
2 
Study controls for at 








Outcome ascertained by 
secure records * 




Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes 
* Follow-up was for 11.4 years 
3 
Adequacy of follow up 
of cohorts 
No 
0 lost to follow-up was <28% 
Total     7  
 
(Gustad et al., 2014b) 





the exposed cohort 
Cohort was somewhat 







Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
Authors carried additional 
analysis excluding patients 




Study controls for 
age/sex 
Yes * 
Age, sex, marital status, 
education, smoking, physical 
activity, BMI, total 
cholesterol, diabetes mellitus, 
resting HR, SBP, alcohol, 
serum creatinine, time-
dependent adjustment for AMI 
during follow-up. 
2 
Study controls for at 













Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up was for 13 years 
3 
Adequacy of follow up 
of cohorts 
No 0 lost to follow-up was <26 
Total     7  
 
(Hamieh et al., 2019) 





the exposed cohort 
Cohort was somewhat 
representative of the 
average population 
0 
Middle-aged worker population 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







Exposure identified using 20-
item CES-D  
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Only CVD free participants at 




Study controls for 
age/sex 
Yes * 
Age, sex, hypertension, 
diabetes, dyslipidemia, 
occupational grade, parental 
CHD history, obesity, smoking 
status and physical inactivity. 
2 
Study controls for at 








Outcome ascertained by 
secure records * 
Medical records or self-
reported confirmed by medical 
records 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up was for 20 years 
3 
Adequacy of follow up 
of cohorts 
No 0 No statement about attrition 
rate 
Total     6  
 
(Janszky et al., 2010) 





the exposed cohort 
Cohort was selected 
group of users 
0 
Participants were young men 
aged between 18 and 20 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 






Depressed patients were 
identified through a structured 
interview by a psychologist 
according to the (ICD-8) 
4 
Demonstration that 
outcome of interest 
Yes * 
Yes, the cohort recruted only 
healthy young population who 
348 
 
was not present at 
start of study 
were extensively examined for 




Study controls for 
age/sex 
Yes * 
Smoking, body length, 
diabetes, systolic blood 
pressure, alcohol consumption, 
physical activity, father’s 
occupation, family history of 
coronary heart disease (CHD), 
and geographic area 
2 
Study controls for at 
least 5 additional risk 






Outcome ascertained by 
secure records 
* 
Outcome information were 
obtained from medical records 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up was for 37 years 
3 
Adequacy of follow up 
of cohorts 
Not reported  0 Not provided a percentage for 
those who lost to follow-up 
Total     7  
 
(Jee et al., 2019) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* Population-based sub-sample 
of subjects who undertook 
national health screening 
programme provided by 
National Health Insurance 
System (NHIS) 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 




Medical records * 
Medical records at least one 
visit diagnosed according to 
ICD-10 or prescription of 
depression medication at more 
than three visit 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Participants were excluded 
from the analyses if they had a 
record of admission or 




Study controls for 
age/sex 
Yes 
* Age, smoking status, 
hypertension, 
hypercholesterolaemia, 
diabetes and chronic renal 
failure 
2 
Study controls for at 











Medical records  
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No * Follow-up duration was for a 
median of 8 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     8  
 
(Karlsen et al., 2020) 





the exposed cohort 
Cohort was selected 
group of users 
0 
Population were elderly men 
with osteoporosis 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







Exposure identified using 
9-item GADS ≥2 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Additional analysis was 
performed excluding patients 









antidepressant use, BMI, 
cholesterol/oxidised low-
density lipoprotein, smoking 
status, drinking habit, physical 
activity and sleep quality 
2 
Study controls for at 
least 5 additional risk 












and/or phone conformed by 
medical records. 
Fatal event adjudicated by 
death certificate, hospital 
record or next of kin interview 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up was for 12 years 
3 
Adequacy of follow up 
of cohorts 
No 0 No statement about attrition 
rate 
Total     6  
 
(Khambaty et al., 2016) 





the exposed cohort 
Cohort was selected 
group of users 
0 
Cohort enrolled HIV- infected 
population 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 






Exposure identified using 
electronic medical records 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Participants at baseline were 





Study controls for 
age/sex 
Yes * 
Age, sex, race/ethnicity, HTN, 
dyslipidaemia, diabetes, statin 
use, CD4 cell count, HIV-1 RNA 
level, antiretroviral therapy 
regimen, hepatitis C infection, 
renal disease, history of abuse 
or dependence of alcohol and 
cocaine, and haemoglobin 
level Smoking, BMI, anti-
depressants 
2 
Study controls for at 









by secure records * 
Outcome identified using 
medical records and death 
certificates 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * The follow-up was for 11 years  
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     7  
 
(Krishnan et al., 2005) 





the exposed cohort 
Cohort was somewhat 
representative of the 
average population 
0 
Men and women who are 
residents in a continuing care 
retirement community 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 








Exposure identified using GDS-
15 ≥6 evaluated by physician 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Participants at baseline were 
free of stroke and MI  




Study controls for 
age/sex 
Yes * 
Age, Sex, level of education, 
marital status, Mini-Mental 
State Examination, BMI, HTN, 
CHF, arterial fibrillation, 
diabetes, hyperlipidaemia , 
and smoking 
2 
Study controls for at 








Outcome ascertained by 
physical diagnosis 
* 





Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * The follow-up was for 10 years  
3 
Adequacy of follow up 
of cohorts 
Not reported  0 No statement about attrition 
rate 
Total     6  
 
(Ladwig et al., 2006b) 





the exposed cohort 
Cohort was selected 
group of users 
* 
The cohort was a population-
based study of men and women 
with a BMI > 18.5kg/m2 who 




Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
Participants at baseline were 
free of stroke and MI but not 
reported how they were 




Study controls for 
age/sex 
Yes * 
Age, total cholesterol, 
cigarette smoking and systolic 
BP, education, alcohol 
consumption and physical 
activity 
2 
Study controls for at 








Outcome ascertained by 
secure records * 
Outcome identified by Medical 
records and death certificates  
medical records  
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * The follow-up was for a 
maximum of 13.7 years 
3 
Adequacy of follow up 
of cohorts 
Not reported  0 No statement about attrition 
rate 
Total     7  
 
(Li et al., 2012) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* 
Patients were drawn from 
nationwide database  
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
All subjects who had major 
metabolic diseases or stroke 





Study controls for 
age/sex 
Yes * 




Study controls for at 













Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No * Follow-up was for 9 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 




(Li et al., 2019) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* 
Patients were drawn from 
nationwide database 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







Exposure identified using 
10-item CES-D ≥12 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Patient who reported stroke or 





Study controls for 
age/sex 
Yes * 
Age, sex, residence, marital 
status, educational level, 
smoking status, drinking status, 
BP,BMI; history of diabetes, 
hypertension, dyslipidaemia, 
chronic kidney disease; use 
hypertension medications, 
diabetes medications, and 
lipid-lowering therapy 
2 
Study controls for at 








Outcome ascertained by 
secure records 
* 
Self-reported of physician 
diagnosis 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No * Follow-up was for 4 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     7  
 
(Majed et al., 2012) 





the exposed cohort 
Cohort was selected 
group of users 0 
Cohort was a population-based 
study including only men aged 
50-59 years 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 







Exposure identified using 13-
item-modified CES-D scale 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
History of stroke and CHD 
were confirmed by a self-
administered health 





Study controls for 
age/sex 
Yes * 
Age, study centres, 
socioeconomic factors, 
including marital status, 
education level, employment 
status, physical activity, 
smoking status, daily alcohol 
intake, systolic BP, use of anti-
hypertensive drugs, BMI, total 
and high-density lipoprotein 
cholesterol, treatment for 
diabetes, and use of 
antidepressant 
2 
Study controls for at 








Outcome ascertained by 
secure records 
* 
Outcome identified by Medical 
records, death certificates and 
validated by 2 independent 
medical committees 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * The follow-up was for a 
median of 10 years 
3 
Adequacy of follow up 
of cohorts 
Complete follow up * 100% completed the follow-up 
Total     7  
 
(Mathur et al., 2016) 







the exposed cohort 
Cohort was selected 
group of users 
0 
The cohort drawn from 141 
general practices across the 
east London which is one of the 
most deprived in the UK 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 






Exposure identified by viewing 
medical records using the 




outcome of interest 
was not present at 
start of study 
Yes * 
Data were extracted from 
medical records considering 
patient only who were free of 




Study controls for 
age/sex 
Yes * 
Age, sex, and ethnic group, 
diabetes, hypertension, 
hyperlipidaemia, and smoking 
anti-depressant prescribing at 
baseline, obesity, and 
Townsend deprivation score, 
presence of co-morbid anxiety 
2 
Study controls for at 
least 5 additional risk 






Outcome ascertained by 
record linkage * 
Cardiac outcomes were defined 
according to the read code 
recorded in medical record 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * The follow-up was for 10 years 
3 
Adequacy of follow up 
of cohorts 
Complete follow up * 100% completed the follow-up 
Total     8  
 
(Mejia-Lancheros et al., 2014) 





the exposed cohort 
Cohort was selected 
group of users 0 
Participants were men and 
women aged 55-80 years at 
high cardiovascular risk 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 





by reviewing secure 
record 
* 
Exposure identified by self-
reported scale by participants 
during a face to face interview 
at the inclusion visit and 




outcome of interest 
was not present at 
start of study 
Yes * 
Participants were excluded if 
they had a documented history 




Study controls for 
age/sex 
Yes * 
Age, sex, smoking, alcohol 
consumption, BMI, HTN, type 2 
diabetes, dyslipidaemia and 
family history of premature 
CHD, and type Mediterranean 
diet intervention 
2 
Study controls for at 








Outcome ascertained by 
secure records * 
Cardiac outcomes were defined 
using medical records, data 
from GPs and death certificates 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 The follow-up was for 7 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     6  
 
(Moise et al., 2016) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* 
Cohort was a population-based 
study representative of black 
and white patients aged ≥45 




Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
Patient were free of any CVD 
at baseline confirmed by 





Study controls for 
age/sex 
Yes * 
Age, sex, region, income, 
health insurance, education, 
and traditional CHD risk factors 
(systolic  BP, total cholesterol, 
high-density lipoprotein 
cholesterol, and medication 
use [aspirin, statins, any 
antihypertensive medications], 
BMI, log of albumin: creatinine 
ratio, diabetes mellitus, pack-
years of cigarette smoking, 
self-reported alcohol use, 
physical inactivity, medication 
adherence, log of high-
sensitivity C-reactive protein, 
antidepressant use, QT interval 
corrected for heart rate, atrial 
fibrillation and left ventricular 
hypertrophy 
2 
Study controls for at 








Outcome ascertained by 
secure records * 
Endpoints ascertain by regular 
telephone contact with patients 
and retrieval of medical records 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 The follow-up was  
for 9 years 
3 
Adequacy of follow up 
of cohorts 
Subjects lost to follow 
up unlikely to introduce 
bias 
* Lost to follow-up was < 20% 
(1.6%) 
Total     7  
 
(Nabi et al., 2010a) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* 
Cohort was a population-based 
study representative of the 
Finnish population 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 











outcome of interest 
was not present at 
start of study 
Yes * 
Patient were free of any CVD 
at baseline confirmed by 




Study controls for 
age/sex 
Yes * 
Age, sex, education, alcohol 
consumption, sedentary 
lifestyle, smoking, obesity, 
hypertension or diabetes and 
incident CHD or incident CBVD 
2 
Study controls for at 








Outcome ascertained by 
record linkage * 
Endpoints ascertain by hospital 
discharge and mortality 
records 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 The follow-up was for 7 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     6  
 
(Pequignot et al., 2013) 







the exposed cohort 
Cohort was 
representative of the 
average population 
* Cohort was a population-based 
study, sample was non-
institutionalized, randomly 
selected from the 
electoral rolls of three large 
cities in Franc 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* The same cohort sample were 
screened for depression and 
then classified as depressed 




A self-reported scale 
0 
Exposure identified using 20-
item CES-D ≥16 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Participants enrolled in the 
study only if they had no 
history of CHD or stroke based 
on face-to-face interviews 





Study controls for 
age/sex 
Yes * Age, sex, study centre, 
smoking status, alcohol 
consumption, high BP, 
impaired fasting glycaemia or 
diabetes, 
hypercholesterolemia, living 
alone, education level, Mini 
mental state examination 
2 
Study controls for at 








Outcome ascertained by 
secure records 
* 
Information on the cardiac 
event was obtained from 
medical records, interviews 
with the patient's physician and 
death certificates 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 Follow-up was for a median of 
5.3 years 
3 
Adequacy of follow up 
of cohorts 
Subjects lost to follow 
up unlikely to introduce 
bias 
* < 20% were lost to follow-up 
(3.05) 
Total     7  
 
(Rahman et al., 2013) 





the exposed cohort 
Cohort was 
representative of the 
average population 
* 
The study participants were 
identified from the 
population- 
based Swedish Twin Registry  
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 






Exposure identified linkage to 
the national patient register 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Participants with any CVD at 
baseline were excluded based 





Study controls for 
age/sex 
Yes * 
Birth year, sex, smoking 
status, educational level, 
HTN, diabetes, alcohol intake 
and BMI 2 
Study controls for at 









by secure records * 
Diagnosis of CVD outcome 
obtained through linkage to the 
national patient register 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 The maximum follow-up time 
was 4 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     7  
 
(Rajan et al., 2020) 







the exposed cohort 
Cohort was truly 
representative of the 
average population 
* 
Cohort was a multicentre 
population-based study from 
21 countries 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 






Short form of the CIDI-SF; cut-




outcome of interest 
was not present at 
start of study 
Yes * 





Study controls for 
age/sex 
Yes * 
Age, sex, urban/rural 
residence, educational 
attainment, use of statins, 
disabilities  
former and current smoking 
and alcohol use, hypertension, 
diabetes, and social isolation 
index 
2 
Study controls for at 








Mixed of Self-reported 




standardised form, household 
interviews, medical records 
and death certificates 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up was for 14 years 
3 
Adequacy of follow up 
of cohorts 
Subjects lost to follow 
up unlikely to 
introduce bias 
* lost to follow-up was 2% 
Total     8  
 
(Scherrer et al., 2011) 





the exposed cohort 
Cohort was selected 
group of users 
0 
Cohort participants data were 






Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 





(identified through ICD 
codes 
* 




outcome of interest 
was not present at 
start of study 
Yes * 
Cohort used medical records to 
identify participants free of 




Study controls for 
age/sex 
Yes * 
Age, sex, race, marital status, 
and insurance type 
2 
Study controls for at 








Outcome ascertained by 
secure records * 
Outcome was assessed by 
medical records and register 
database 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 Follow-up time was for 7 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     5  
 
(Whang et al., 2009) 





the exposed cohort 
Cohort was selected 
group of users 
0 Cohort enrolled only female 




Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* The same cohort sample were 
screened for depression and 
then classified as depressed 




A self-reported scale 0 Exposure identified by 
administering 5-item-MHI <53, 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * Participants completed a 
questionnaire about their 
medical history and those with 





Study controls for 
age/sex 
Yes * Age, beginning year of follow-
up, smoking status, BMI, 
alcohol intake, menopausal 
status and postmenopausal 
hormone use, usual aspirin use, 
multivitamin use, vitamin E 
supplement use, 
hypercholesterolemia, family 
history of MI, history of stroke, 
n-3-fatty acid intake 
(quintiles), alpha linoleic acid 
intake (quintiles), and 
moderate/vigorous physical 
activity, non-fatal CHD during 
follow-up, HTN and diabetes  
2 
Study controls for at 








Outcome ascertained by 
medical records and 
some events were 
further confirmed by 
physician who were 
blinded to the exposure 
* Outcome confirmed by medical 
records and death certificate, 
further confirmation included 
physician blinded to the 
exposure 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 Follow-up time was 8 years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     5  
 
(Wouts et al., 2008) 





the exposed cohort 
Cohort was selected 
group of users 
* 
 Elderly population aged 55-85 
years drawn from the 
population registers of 11 
municipalities 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 




A self-reported scale 
0 
Exposure identified using 20-
item CES-D ≥16 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Cardiac event confirmed either 
by self-reported, GP 





Study controls for 
age/sex 
Yes * 
Age, sex, Mini-Mental State 
Examination score, smoking, 
functional limitations, HTN, 
diabetes mellitus, and obesity 2 
Study controls for at 








Outcome ascertained by 
record linkage 
* 
Cardiac event was ascertain by 
self-report confirmed by GP or a 
cardiac specialist confirming 
the GP diagnosis of stroke 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
Yes * Follow-up time was for 10 years  
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     7  
 
(White et al., 2015) 







the exposed cohort 
Cohort was selected 
group of users 0 
 Cohort enrolled HIV+ patients 
matched with HIV- 
 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 






Exposure identified using 
electronic medical records 
diagnosed according to ICD-9 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
participants at baseline were 





Study controls for 
age/sex 
Yes * 
Age, sex, race/ethnicity, BMI, 
HTN, diabetes mellitus, LDL-c, 
HDL-c, triglycerides, statin use, 
hemoglobin, renal function, 
atrial fibrillation, atrial flutter, 
smoking status, alcohol abuse 
or dependence, cocaine abuse 
or dependence, and HCV 
infection 
2 
Study controls for at 








Outcome ascertained by 
secure records  * 
Outcome determined by using 
medical health records and CVD 
diagnosed according to ICD-9 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 Follow-up time was for 5.8 
years 
3 
Adequacy of follow up 
of cohorts 
Not reported 0 No statement about attrition 
rate 
Total     6  
 
(Wulsin et al., 2005) 





the exposed cohort 
Cohort was somewhat 
representative of the 
average population 
* 
 Cohort randomly allocated 
sample of adult population 
ranged in age from 30 to 91 
years 
2 
Selection of the non-
exposed cohort 
Drawn from the same 
community as the 
exposed cohort 
* 
The same cohort sample were 
screened for depression and 
then classified as depressed 




A self-reported scale 
0 
Exposure identified using 20-
item CES-D ≥16 
4 
Demonstration that 
outcome of interest 
was not present at 
start of study 
Yes * 
Baseline cardiac disease 
identified by examination of 




Study controls for 
age/sex 
Yes * 
Age, sex stratified, smoking, 
HTN, diabetes, BMI, total 
cholesterol, and alcohol 
consumption 2 
Study controls for at 









by secure records and 
blind assessment * 
Events were reviewed using 
medical records and 
adjudicated by a panel of 3 
physician investigators, 
blinded to the exposure 
2 
Was follow-up long 
enough for outcomes 
to occur (≥10years) 
No 0 Follow-up time was for 6 years 
3 
Adequacy of follow up 
of cohorts 
Lost to follow-up 
unlikely to introduce 
bias  
* < 20% were lost to follow-up 








Assessment of the cohort study presented in chapter 7 by New-castle Ottawa scale tool 





of the exposed 
cohort 
Cohort was selected 
group of users 
* 
The study focused on 
hypertensive particpants 
attending secondary and 
tertiary health care centre  
2 
Selection of the non-
exposed cohort 




There was no non-user group 




Electronic records of 
prescription data 
* 
The present cohort relied on 
electronic records to extract 




outcome of interest 
was not present at 
start of study 
Yes * 
The present study relied on 
prescription data to ensure 
that participants were free of 
antidepressants prescriptions 
at least for 12 months before 
study entry. However, the 
measurement may not be an 





Study controls for 
age/sex 
Yes * 
Age, sex, SBP, history of 
smoking, cholesterol, body 
weight, CCI and eGFR 2 
Study controls for at 









by electronic records 
of prescription data 
* 
Outcome were determined 
using data from the (ISD). 
Again, antidepressants may 
not be a good proxy as a 
diagnostic criterion for 
depression 
2 
Was follow-up long 
enough for outcomes 
to occur (≥ one year) 
Yes 
* 
Follow-up period was for 
seven years 
3 
Adequacy of follow 
up of cohorts 
Complete follow up * 100% completed the follow-up 
Total     7  
359 
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